Hepatocellular Carcinoma: Epidemiology and Molecular

Gastroenterology
132, 2557-2576
DOI: 10.1053/j.gastro.2007.04.061

Citation Report

#	Article	IF	Citations
1	Hepatocellular Carcinoma Associated with Liver-Gender Disruption in Male Mice. Cancer Research, 2007, 67, 11536-11546.	0.4	90
2	Hepatocellular Carcinoma: The Role of the North American GI Steering Committee Hepatobiliary Task Force and the Advent of Effective Drug Therapy. Oncologist, 2007, 12, 1425-1432.	1.9	47
3	Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: Is it really different, and if so, why?. Journal of Hepatology, 2007, 47, 447-450.	1.8	11
4	Is interleukin-6 a gender-specific risk factor for liver cancer?. Hepatology, 2007, 46, 1304-1305.	3.6	24
5	Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology, 2008, 47, 511-520.	3.6	173
6	MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 2008, 47, 1223-1232.	3.6	384
7	Gene expression profiles of different stages of hepatocarcinogenesis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1-3.	1.4	0
8	Molecular pathogenesis of hepatocellular carcinoma. Liver International, 2008, 28, 160-174.	1.9	134
9	Palliation of hepatic tumors. Surgical Oncology, 2007, 16, 277-291.	0.8	44
10	Effects of o-aminoazotoluene on liver regeneration and p53 activation in mice susceptible and resistant to hepatocarcinogenesis. Toxicology, 2008, 254, 91-96.	2.0	6
11	Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. Cancer Causes and Control, 2008, 19, 1193-1200.	0.8	26
12	Pulmonary Resection for Nonâ€Small Cell Lung Cancer in Patients with Hepatocellular Carcinoma. World Journal of Surgery, 2008, 32, 2204-2212.	0.8	8
13	Rationale for targeted therapies in hepatocellular carcinoma. Targeted Oncology, 2008, 3, 81-85.	1.7	1
14	Surgical Management of Early-Stage Hepatocellular Carcinoma: Resection or Transplantation?. Journal of Gastrointestinal Surgery, 2008, 12, 1699-1708.	0.9	81
15	Liver transplantation for hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 124-130.	2.0	24
16	Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics, 2008, 8, 5108-5118.	1.3	45
17	Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer, 2008, 113, 1244-1255.	2.0	19
18	Cancer risk in people infected with human immunodeficiency virus in the United States. International Journal of Cancer, 2008, 123, 187-194.	2.3	713

#	Article	IF	Citations
19	Biology and pathobiology of gap junctional channels in hepatocytes. Hepatology, 2008, 47, 1077-1088.	3.6	88
20	The emergence of a new discipline, hepatobiliary oncology. Hepatology, 2008, 47, 365-366.	3.6	3
21	Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology, 2008, 47, 1211-1222.	3.6	170
22	Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin-6 signaling. Hepatology, 2008, 47, 2134-2136.	3.6	11
23	Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology, 2008, 48, 863-870.	3.6	167
24	Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology, 2008, 48, 1149-1156.	3.6	62
25	RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology, 2008, 48, 1118-1127.	3.6	146
26	Comprehensive analysis of the Î±-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology, 2008, 48, 1821-1833.	3.6	60
27	Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48, 2047-2063.	3.6	571
28	Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?. International Journal of Clinical Practice, 2008, 62, 1206-1211.	0.8	5
29	Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene, 2008, 27, 5578-5589.	2.6	179
30	Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter?. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e179-88.	1.4	12
31	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1259-1266.	1.4	32
32	Diabetes mellitus and prognosis after curative therapy for hepatocellular carcinoma: Alas, still grave for those who are hyperglycemic. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1633-1634.	1.4	11
33	The microenvironments of multistage carcinogenesis. Seminars in Cancer Biology, 2008, 18, 322-329.	4.3	49
34	Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 641, 27-35.	0.4	41
35	A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 643, 70-74.	0.4	20
36	Wnt/Î²-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncology, 2008, 4, 647-660.	1.1	83

#	Article	IF	Citations
37	Rho GTPase and Wnt Signaling Pathways in Hepatocarcinogenesis. Gastroenterology, 2008, 134, 875-878.	0.6	3
38	Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1752-1763.	0.6	994
39	Tetraspanin CD81-Regulated Cell Motility Plays a Critical Role in Intrahepatic Metastasis of Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 244-256.e1.	0.6	76
40	Moving Targets in Hepatocellular Carcinoma: Hepatic Progenitor Cells as Novel Targets for Tyrosine Kinase Inhibitors. Gastroenterology, 2008, 135, 733-735.	0.6	7
41	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2008, 68, 6698-6707.	0.4	109
42	Molecular Pathogenesis and Targeted Therapy of Hepatocellular Carcinoma. Onkologie, 2008, 31, 10-10.	1.1	26
43	The Effect of Doxorubicin on MEK-ERK Signaling Predicts Its Efficacy in HCC. Journal of Surgical Research, 2008, 150, 219-226.	0.8	38
44	Experimental models of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 858-879.	1.8	203
45	The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. Journal of Hepatology, 2008, 49, 373-383.	1.8	44
46	Sorafenib in advanced hepatocellular carcinoma â€“ We have won a battle not the war. Journal of Hepatology, 2008, 49, 871-873.	1.8	33
47	Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 653, 6-13.	0.9	50
48	Racial and Ethnic Variations in Hepatocellular Carcinoma Incidence within the United States. American Journal of Medicine, 2008, 121, 525-531.	0.6	85
49	Telomere dysfunction and stem cell ageing. Biochimie, 2008, 90, 24-32.	1.3	34
50	A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. Cancer Letters, 2008, 272, 268-276.	3.2	15
51	TGF-Î²1 genotypes in cirrhosis: Relationship with the occurrence of liver cancer. Cytokine, 2008, 44, 256-261.	1.4	35
52	A stringent dual control system overseeing transcription and activity of the Cre recombinase for the liver-specific conditional gene knock-out mouse model. Journal of Genetics and Genomics, 2008, 35, 431-439.	1.7	3
53	Liver Repopulation and Carcinogenesis: Two Sides of the Same Coin?. American Journal of Pathology, 2008, 172, 857-864.	1.9	53
55	Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatology Research, 2008, 38, 980-986.	1.8	34

#	Article	IF	Citations
56	Expression of galectinâ€3 involved in prognosis of patients with hepatocellular carcinoma. Hepatology Research, 2008, 38, 1098-1111.	1.8	65
57	Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Current Medical Research and Opinion, 2008, 24, 3559-3569.	0.9	26
59	Hepatitis C Virus Infection and Hepatocellular Carcinoma. Clinics in Liver Disease, 2008, 12, 661-674.	1.0	34
60	Sorafenib in Liver Cancer â€" Just the Beginning. New England Journal of Medicine, 2008, 359, 420-422.	13.9	103
61	Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1139-1165.	1.5	125
64	Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 2008, 26, 2992-2998.	0.8	478
65	Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection. Clinical Cancer Research, 2008, 14, 3850-3859.	3.2	143
66	ESMO Handbook of Cancer Prevention. , 0, , .		4
67	Recent Advances in Tumor Markers of Human Hepatocellular Carcinoma. Intervirology, 2008, 51, 34-41.	1.2	20
68	Heat Shock Protein A1B 1267 Polymorphism Is Highly Associated With Risk and Prognosis of Hepatocellular Carcinoma. Medicine (United States), 2008, 87, 87-98.	0.4	20
69	Trim24 (Tif1Î±): An essential â€˜brakeâ€™ for retinoic acid-induced transcription to prevent liver cancer. Cell Cycle, 2008, 7, 3647-3652.	1.3	30
70	Fighting Fire With Fire: Effects of Oncolytic Virotherapy on Underlying Viral Hepatitis in Hepatocellular Carcinoma. Molecular Therapy, 2008, 16, 1521-1523.	3.7	0
71	Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2008, 2, 425-433.	1.4	10
72	Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival. Clinical Cancer Research, 2008, 14, 419-427.	3.2	486
73	Treatment options for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2008, 2, 81-92.	1.4	29
74	Epigenetic down-regulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Cell Cycle, 2008, 7, 3202-3210.	1.3	36
75	Predictive Factors for Hepatocellular Carcinoma in Type 1 Autoimmune Hepatitis. American Journal of Gastroenterology, 2008, 103, 1944-1951.	0.2	85
76	Lack of Association between the Functional Polymorphisms in the Estrogen-Metabolizing Genes and Risk for Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3621-3627.	1.1	26

#	Article	IF	Citations
77	Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma. Molecular Cancer Therapeutics, 2008, 7, 2476-2485.	1.9	111
78	Institutional guidelines and ongoing studies in management of liver tumours: The experience of the European Institute of Oncology. Ecancermedicalscience, 2008, 2, 64.	0.6	0
79	Loss of Androgen Receptor in Aging and Oxidative Stress through Myb Protooncoprotein-regulated Reciprocal Chromatin Dynamics of p53 and Poly(ADP-ribose) Polymerase PARP-1. Journal of Biological Chemistry, 2008, 283, 36474-36485.	1.6	28
80	A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis, 2008, 29, 2126-2131.	1.3	326
81	Sex Hormone Influence on Hepatitis in Young Male A/JCr Mice Infected withHelicobacter hepaticus. Infection and Immunity, 2008, 76, 4071-4078.	1.0	16
82	Role of Estrogen in Liver Cancer. Women's Health, 2008, 4, 41-50.	0.7	51
83	Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene. Clinical Cancer Research, 2008, 14, 2450-2457.	3.2	44
84	Re-Expression of Transcription FactorATF5in Hepatocellular Carcinoma Induces G2-M Arrest. Cancer Research, 2008, 68, 6743-6751.	0.4	38
85	Analysis of the Mechanisms Mediating Tumor-Specific Changes in Gene Expression in Human Liver Tumors. Cancer Research, 2008, 68, 2641-2651.	0.4	47
86	Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncology, 2008, 4, 803-814.	1.1	49
87	Efficient Inhibition of Hepatitis B Virus Replication In Vivo, Using Polyethylene Glycol-Modified Adenovirus Vectors. Human Gene Therapy, 2008, 19, 1325-1332.	1.4	38
88	HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice. International Journal of Oncology, 0, , .	1.4	12
89	Targeting vessels to treat hepatocellular carcinoma. Clinical Science, 2008, 114, 467-477.	1.8	12
91	Hepatobiliary pathology. Current Opinion in Gastroenterology, 2008, 24, 269-277.	1.0	4
92	Liver Transplantation for Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2008, 14, 95-99.	1.0	5
93	Wnt Signaling in Liver Cancer. Current Drug Targets, 2008, 9, 1013-1024.	1.0	145
94	Evolving therapies in the treatment of hepatocellular carcinoma. Biologics: Targets and Therapy, 2008, Volume 2, 453-462.	3.0	17
96	Oncolytic virotherapy. Annals of Hepatology, 2008, 7, 34-45.	0.6	19

#	Article	IF	Citations
97	Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology. Ecancermedicalscience, 0, 2, .	0.6	0
98	Systemic therapies for advanced hepatocellular carcinoma. , 0, , 97-121.		0
99	A role of functional T-type Ca2+ channel in hepatocellular carcinoma cell proliferation. Oncology Reports, 2009, 22, 1229-35.	1.2	22
100	Hepatocellular Carcinoma in Keio Affiliated Hospitals â€" Diagnosis, Treatment, and Prognosis of this Disease â€". Keio Journal of Medicine, 2009, 58, 161-175.	0.5	9
101	Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. Pathology, 2009, 41, 626-629.	0.3	19
102	Emerging role of microRNAs in liver diseases. World Journal of Gastroenterology, 2009, 15, 5633.	1.4	140
103	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of Clinical Oncology, 2009, 27, 3027-3035.	0.8	467
104	Current and future treatments of autoimmune hepatitis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 269-291.	1.4	53
105	Alcohol-related and hepatocellular cancer deaths by country of birth in England and Wales: analysis of mortality and census data. Journal of Public Health, 2009, 31, 250-257.	1.0	19
106	Identification of Replication-competent HSV-1 Cgal+ Strain Signaling Targets in Human Hepatoma Cells by Functional Organelle Proteomics. Molecular and Cellular Proteomics, 2009, 8, 805-815.	2.5	19
107	Wnt-1 Protein as a Prognostic Biomarker for Hepatitis Bâ€"Related and Hepatitis Câ€"Related Hepatocellular Carcinoma after Surgery. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1562-1569.	1.1	33
108	The Impact of Type 2 Diabetes on the Development of Hepatocellular Carcinoma in Different Viral Hepatitis Statuses. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2054-2060.	1.1	90
109	Anti-Proliferative Efficacy of Icariin on HepG2 Hepatoma and Its Possible Mechanism of Action. The American Journal of Chinese Medicine, 2009, 37, 1153-1165.	1.5	23
110	Identification of genes conferring resistance to 5-fluorouracil. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12938-12943.	3.3	136
111	The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation. Carcinogenesis, 2009, 30, 671-681.	1.3	42
112	JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut, 2009, 58, 688-698.	6.1	52
113	Factors Associated with Awareness of Infection Status among Chronic Hepatitis B and C Carriers in Korea. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1894-1898.	1.1	29
114	Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle, 2009, 8, 2802-2809.	1.3	36

#	Article	IF	Citations
115	Sex Disparities in Cancer Incidence by Period and Age. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1174-1182.	1.1	355
116	Is the Search for a Single Comprehensive Staging System for Hepatocellular Carcinoma an Elusive One?. Journal of Clinical Gastroenterology, 2009, 43, 697-698.	1.1	1
117	Independent and Additive Interactive Effects Among Tumor Necrosis Factor-Î± Polymorphisms, Substance Use Habits, and Chronic Hepatitis B and Hepatitis C Virus Infection on Risk for Hepatocellular Carcinoma. Medicine (United States), 2009, 88, 349-357.	0.4	34
118	Hepatitis B Virus and Hepatocellular Carcinogenesis. , 2009, , 41-91.		0
119	Laparoscopic Liver Resection for Hepatocellular Carcinoma. Archives of Surgery, 2009, 144, 143.	2.3	110
120	Interleukin-6 Polymorphisms and Gender: Relationship with the Occurrence of Hepatocellular Carcinoma in Patients with End-Stage Liver Disease. Oncology, 2009, 77, 304-313.	0.9	38
121	Hepatocellular carcinoma: prevalence and molecular pathogenesis ofHelicobacterspp.. Future Microbiology, 2009, 4, 1283-1301.	1.0	16
122	Early development of sunitinib in hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 143-150.	1.1	28
123	Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 2009, 14, 633-648.	1.0	33
124	Role of Alcohol in Liver Carcinogenesis. Seminars in Liver Disease, 2009, 29, 222-232.	1.8	96
125	Chronic hepatitis B and C: update on therapy. Future Virology, 2009, 4, 437-452.	0.9	3
126	Association between hepatitis C and hepatocellular carcinoma. Journal of Global Infectious Diseases, 2009, 1, 33.	0.2	136
127	Hepatocarcinogenesis following pancreatic islet transplantation in streptozotocin- and autoimmune-diabetic rats. Archives of Physiology and Biochemistry, 2009, 115, 97-104.	1.0	1
128	New Utility of an Old Marker: Serial Î±-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. Journal of Clinical Oncology, 2009, 27, 446-452.	0.8	241
129	Sex-Modified Effect of Hepatitis B Virus Infection on Mortality From Primary Liver Cancer. American Journal of Epidemiology, 2009, 169, 990-995.	1.6	22
130	IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis, 2009, 30, 1916-1922.	1.3	61
131	Supplementation with Branched-chain Amino Acids Inhibits Azoxymethane-induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Mice. Clinical Cancer Research, 2009, 15, 3068-3075.	3.2	60
133	Hepatocellular Carcinoma â€“ Epidemiological Trends and Risk Factors. Digestive Diseases, 2009, 27, 80-92.	0.8	406

#	Article	IF	Citations
134	Targeting of the Akt-Nuclear Factor-Î²B Signaling Network by [1-(4-Chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a Novel Indole-3-Carbinol Derivative, in a Mouse Model of Hepatocellular Carcinoma. Molecular Pharmacology, 2009, 76, 957-968.	1.0	57
135	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2009, 284, 11121-11133.	1.6	79
136	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009, 69, 7385-7392.	0.4	978
137	CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. Clinical Cancer Research, 2009, 15, 5518-5527.	3.2	122
138	249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC Cancer, 2009, 9, 204.	1.1	35
139	Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer, 2009, 9, 208.	1.1	71
140	Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer, 2009, 9, 240.	1.1	103
141	Rho GTPases in hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 137-151.	3.3	60
144	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 295-308.	7.7	345
145	MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology, 2009, 49, 1194-1202.	3.6	155
146	MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 2009, 49, 1571-1582.	3.6	531
147	Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology, 2009, 49, 1935-1943.	3.6	65
148	Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology, 2009, 49, 1944-1953.	3.6	85
149	Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology, 2009, 50, 102-112.	3.6	68
150	Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology, 2009, 50, 1152-1161.	3.6	274
151	Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug. International Journal of Cancer, 2009, 124, 2520-2527.	2.3	58
152	Serum ILâ€6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: An analysis based on gender differences. International Journal of Cancer, 2009, 125, 2264-2269.	2.3	160
153	Meta-analysis: Reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. International Journal of Cancer, 2009, 127, NA-NA.	2.3	24

#	Article	IF	Citations
154	A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer, 2009, 115, 5000-5006.	2.0	18
155	Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transplantation, 2009, 15, 1861-1866.	1.3	90
156	Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Journal of Gastroenterology, 2009, 44, 89-95.	2.3	262
157	Survival Differences by Race/Ethnicity and Treatment for Localized Hepatocellular Carcinoma Within the United States. Digestive Diseases and Sciences, 2009, 54, 2031-2039.	1.1	45
158	Adherence to Screening for Hepatocellular Carcinoma Among Patients with Cirrhosis or Chronic HepatitisÂB in a Community Setting. Digestive Diseases and Sciences, 2009, 54, 2712-2721.	1.1	61
159	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology International, 2009, 3, 480-489.	1.9	22
160	Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatment. Current Hepatitis Reports, 2009, 8, 59-65.	0.3	0
163	RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum Î±-fetoprotein level. Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29, 309-312.	1.0	10
164	Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdominal Imaging, 2009, 34, 566-581.	2.0	88
165	Minimally Invasive Surgical Treatment of Hepatocellular Carcinoma: Longâ€Term Outcome. World Journal of Surgery, 2009, 33, 2150-2154.	0.8	35
166	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 777-783.	1.1	261
167	Lectin of Concanavalin A as an anti-hepatoma therapeutic agent. Journal of Biomedical Science, 2009, 16, 10.	2.6	98
168	Strategy and mechanism for the prevention of hepatocellular carcinoma: Phosphorylated retinoid X receptor Î± is a critical target for hepatocellular carcinoma chemoprevention. Cancer Science, 2009, 100, 369-374.	1.7	63
169	(â€“)â€Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factorâ€“vascular endothelial growth factor receptor axis. Cancer Science, 2009, 100, 1957-1962.	1.7	101
170	Metaâ€analysis: surveillance with ultrasound for earlyâ€stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2009, 30, 37-47.	1.9	703
171	Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Proliferation, 2009, 42, 229-240.	2.4	74
172	Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. Journal of Viral Hepatitis, 2009, 17, 668-74.	1.0	16
173	Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. European Journal of Human Genetics, 2009, 17, 1250-1259.	1.4	17

#	Article	IF	Citations
174	A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine, 2009, 15, 1016-1022.	15.2	1,426
175	o-Aminoazotoluene suppresses hepatocyte proliferation in inbred mice susceptible to hepatocarcinogenesis. Doklady Biological Sciences, 2009, 428, 479-483.	0.2	1
176	ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene, 2009, 28, 638-650.	2.6	78
177	Molecular therapy for the treatment of hepatocellular carcinoma. British Journal of Cancer, 2009, 100, 19-23.	2.9	69
178	Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. British Journal of Cancer, 2009, 100, 1765-1770.	2.9	124
179	Prevention of hepatocellular carcinoma in nonviralâ€related liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 712-719.	1.4	35
180	The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transplant International, 2009, 22, 869-875.	0.8	43
181	Inflammation and Liver Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 206-221.	1.8	329
182	MTHFR C677T Polymorphism and Risk of HCC in Patients With Liver Cirrhosis: Role of Male Gender and Alcohol Consumption. Alcoholism: Clinical and Experimental Research, 2009, 33, 102-107.	1.4	46
183	Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft. Journal of Proteomics, 2009, 73, 153-160.	1.2	7
184	Synthesis and antiproliferative evaluation of 6-arylindeno[1,2-c]quinoline derivatives. Bioorganic and Medicinal Chemistry, 2009, 17, 7465-7476.	1.4	52
185	Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population. Annals of Surgical Oncology, 2009, 16, 413-422.	0.7	178
186	Autophagy Inhibition Enhances Apoptosis Induced by Ginsenoside Rk1 in Hepatocellular Carcinoma Cells. Bioscience, Biotechnology and Biochemistry, 2009, 73, 2183-2189.	0.6	60
187	Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis. Journal of the National Cancer Institute, 2009, 101, 1066-1082.	3.0	366
188	Targeted therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 423-432.	8.2	106
189	Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Letters, 2009, 286, 9-14.	3.2	285
190	Senescence and immortality in hepatocellular carcinoma. Cancer Letters, 2009, 286, 103-113.	3.2	72
191	Human hepatocellular carcinoma: Expression profiles-based molecular interpretations and clinical applications. Cancer Letters, 2009, 286, 96-102.	3.2	18

#	Article	IF	Citations
192	Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochemical and Biophysical Research Communications, 2009, 387, 239-244.	1.0	30
193	AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Molecular Genetics and Metabolism, 2009, 98, 289-299.	0.5	44
194	A Pilot Study of Proteomic Profiles of Human Hepatocellular Carcinoma in the United States. Journal of Surgical Research, 2009, 155, 237-243.	0.8	42
195	Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Human Pathology, 2009, 40, 1384-1390.	1.1	27
196	Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. Journal of Hepatology, 2009, 50, 388-393.	1.8	72
197	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Journal of Hepatology, 2009, 51, 725-733.	1.8	206
198	Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence. Journal of Hepatology, 2009, 51, 842-844.	1.8	33
199	Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy, 2009, 9, 503-509.	1.1	96
200	Role of Î±-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. Future Oncology, 2009, 5, 889-899.	1.1	30
201	MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer. New England Journal of Medicine, 2009, 361, 1437-1447.	13.9	778
202	The natural history of chronic HBV infection. Current Hepatitis Reports, 2009, 8, 10-17.	0.3	1
204	Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology, 2009, 136, 138-148.	0.6	570
205	Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes. Gastroenterology, 2009, 136, 1601-1608.	0.6	247
206	In Vitro Recapitulating of TP53 Mutagenesis in Hepatocellular Carcinoma Associated With Dietary Aflatoxin B1 Exposure. Gastroenterology, 2009, 137, 1127-1137.e5.	0.6	69
207	Deciphering Hepatocellular Carcinoma: From Bench to Bedside and Back. Gastroenterology, 2009, 137, 786-788.	0.6	4
208	Telomere Dysfunction and DNA Damage Checkpoints in Diseases and Cancer of the Gastrointestinal Tract. Gastroenterology, 2009, 137, 754-762.	0.6	25
209	Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform Î”Ex2p73 in Human Hepatocellular Tumors. Gastroenterology, 2009, 137, 1805-1815.e4.	0.6	64
210	Sorafenib. Drugs, 2009, 69, 223-240.	4.9	430

#	Article	IF	Citations
211	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology and Hepatology, 2009, 3, 353-367.	1.4	259
212	Epithelialâ€“mesenchymal transition in hepatocellular carcinoma. Future Oncology, 2009, 5, 1169-1179.	1.1	287
213	The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer. Experimental Biology and Medicine, 2009, 234, 713-725.	1.1	107
214	NASH and HCC. Clinics in Liver Disease, 2009, 13, 631-647.	1.0	121
215	Inflammation and Cancer. Methods in Molecular Biology, 2009, 511, v-viii.	0.4	5
216	MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib. Journal of Biological Chemistry, 2009, 284, 32015-32027.	1.6	441
217	PDGFRÎ±: a new therapeutic target in the treatment of hepatocellular carcinoma?. Expert Opinion on Therapeutic Targets, 2009, 13, 443-454.	1.5	42
218	Molecular profiling to predict hepatocellular carcinoma outcome. Expert Review of Gastroenterology and Hepatology, 2009, 3, 101-103.	1.4	37
219	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2009, 10, 25-34.	5.1	5,104
220	Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncology, The, 2009, 10, 794-800.	5.1	287
221	Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Review of Anticancer Therapy, 2009, 9, 739-745.	1.1	116
222	Overexpression of EphA2, MMPâ€9, and MVDâ€CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatology Research, 2009, 39, 1169-1177.	1.8	67
223	Does Postembolization Fever after Chemoembolization Have Prognostic Significance for Survival in Patients with Unresectable Hepatocellular Carcinoma?. Journal of Vascular and Interventional Radiology, 2009, 20, 209-216.	0.2	36
224	Current Management of Hepatocellular Carcinoma. Medical Clinics of North America, 2009, 93, 885-900.	1.1	53
225	Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model. Neoplasia, 2009, 11, 934-944.	2.3	60
226	Dynamic Contrast-Enhanced MR Imaging of the Liver: Current Status and Future Directions. Magnetic Resonance Imaging Clinics of North America, 2009, 17, 339-349.	0.6	59
227	Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited. European Journal of Gastroenterology and Hepatology, 2009, 21, 447-451.	0.8	4
228	Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2009, 15, 526-532.	1.0	121

#	Article	IF	Citations
229	Hepatocellular Carcinoma and Crohn's Disease: A Case Report and Review. Internal Medicine, 2009, 48, 815-819.	0.3	9
230	Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncology Reports, 2009, 23, .	1.2	2
231	Strategies for Successful Vaccination against Hepatocellular Carcinoma. International Journal of Immunopathology and Pharmacology, 2009, 22, 269-277.	1.0	13
232	Imaging for Radiotherapy Treatment Planning. , 2009, , 1201-1225.		0
234	Hepatic Delivery of RNA Interference Activators for Therapeutic Application. Current Gene Therapy, 2009, 9, 91-103.	0.9	17
235	Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma. Current Cancer Drug Targets, 2009, 9, 738-747.	0.8	32
236	Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anti-Cancer Drugs, 2009, 20, 389-395.	0.7	50
237	Therapeutics Based on microRNA: A New Approach for Liver Cancer. Current Genomics, 2010, 11, 311-325.	0.7	38
238	Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncology Reports, 2010, 23, 1037-43.	1.2	57
239	Recent advances in the treatment of hepatocellular carcinoma. Current Opinion in Gastroenterology, 2010, 26, 189-195.	1.0	79
240	Celecoxib activates Stat5 and restores or increases the expression of growth hormone-regulated genes in hepatocarcinogenesis. Anti-Cancer Drugs, 2010, 21, 411-422.	0.7	7
241	Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2010, 22, 1106-1110.	0.8	65
242	Survival in Asian Americans After Treatments for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2010, 44, e63-e70.	1.1	35
244	Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16, 3521.	1.4	32
245	Methylation ofDickkopf-3as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16, 755.	1.4	35
248	Interventional Radiological Treatment of Hepatocellular Carcinoma. Cancer Control, 2010, 17, 87-99.	0.7	20
249	A Comparative Study of Antiviral Therapy After Resection of Hepatocellular Carcinoma in the Immune-Active Phase of Hepatitis B Virus Infection. Annals of Surgical Oncology, 2010, 17, 179-185.	0.7	96
250	Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection. Annals of Surgical Oncology, 2010, 17, 869-877.	0.7	53

#	Article	IF	Citations
251	Hepatocellular Carcinomas in Cirrhotic and Noncirrhotic Human Livers Share Angiogenic Characteristics. Annals of Surgical Oncology, 2010, 17, 1564-1571.	0.7	18
252	Glucose-Regulated Protein 78 (GRP78) Silencing Enhances Cell Migration but Does Not Influence Cell Proliferation in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17, 1703-1709.	0.7	40
253	CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumorâ€"Nodeâ€"Metastasis Stage I Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17, 1917-1926.	0.7	42
254	Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?. Annals of Surgical Oncology, 2010, 17, 1247-1256.	0.7	52
255	Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma. Frontiers of Medicine in China, 2010, 4, 419-429.	0.1	13
256	Signal Transduction Pathways Involved in Hepatocarcinogenesis and Metastasis of Hepatoma. Cancer Metastasis - Biology and Treatment, 2010, , 265-282.	0.1	0
257	Laparoscopic Liver Resection for Hepatocellular Carcinoma in the Left Liver: Pringle Maneuver Versus Tourniquet Method. World Journal of Surgery, 2010, 34, 314-319.	0.8	18
258	Prognostic Factors and Outcome of 438 Chinese Patients with Hepatocellular Carcinoma Underwent Partial Hepatectomy in a Single Center. World Journal of Surgery, 2010, 34, 2434-2441.	0.8	24
259	Percutaneous Radiofrequency Ablation versus Partial Hepatectomy for Multicentric Small Hepatocellular Carcinomas: A Nonrandomized Comparative Study. World Journal of Surgery, 2010, 34, 2671-2676.	0.8	15
262	MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiology, 2010, 34, 448-452.	0.8	24
263	Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy. Journal of Medical Ultrasonics (2001), 2010, 37, 137-141.	0.6	1
264	Use of the Resection Map system as guidance during hepatectomy. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2327-2337.	1.3	55
265	Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. Journal of Gastroenterology, 2010, 45, 105-112.	2.3	29
266	Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. Journal of Gastroenterology, 2010, 45, 960-967.	2.3	64
267	Expression of Protein Kinase C Family in Human Hepatocellular Carcinoma. Pathology and Oncology Research, 2010, 16, 385-391.	0.9	11
268	Insulin resistance and hepatocarcinogenesis. Clinical Journal of Gastroenterology, 2010, 3, 271-278.	0.4	10
269	The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Medical Oncology, 2010, 27, 255-261.	1.2	186
270	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatology International, 2010, 4, 396-405.	1.9	36

#	Article	IF	Citations
271	Stem Cell Origins and Animal Models of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2010, 55, 1241-1250.	1.1	13
272	Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic. Digestive Diseases and Sciences, 2010, 55, 826-835.	1.1	43
273	Rates of Surveillance and Management of Hepatocellular Carcinoma in Patients Evaluated at a Liver Transplant Center. Digestive Diseases and Sciences, 2010, 55, 3591-3596.	1.1	18
274	Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory Data. Digestive Diseases and Sciences, 2010, 55, 3241-3251.	1.1	18
275	Vitamin Analogues in Chemoprevention of Hepatocellular Carcinoma After Resection or Ablationâ€"A Systematic Review and Meta-analysis. Asian Journal of Surgery, 2010, 33, 120-126.	0.2	29
276	Network-Based Analysis of Survival for Unresectable Hepatocellular Carcinoma. Seminars in Oncology, 2010, 37, 170-181.	0.8	13
277	Metabolic syndrome and risk of death from cancers of the digestive system. Metabolism: Clinical and Experimental, 2010, 59, 1231-1239.	1.5	44
278	Tropomyosin3 overexpression and a potential link to epithelial-mesenchymal transition in human hepatocellular carcinoma. BMC Cancer, 2010, 10, 122.	1.1	46
279	Anti-proliferative effect of extremely low frequency electromagnetic field on preneoplastic lesions formation in the rat liver. BMC Cancer, 2010, 10, 159.	1.1	40
280	miR-183 inhibits TGF-Î²1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer, 2010, 10, 354.	1.1	135
281	Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation. BMC Cancer, 2010, 10, 399.	1.1	25
282	Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer, 2010, 10, 461.	1.1	104
283	Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?. BMC Cancer, 2010, 10, 535.	1.1	8
284	Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genetics and Cytogenetics, 2010, 197, 54-59.	1.0	58
285	Hepatocyte IKKÎ²/NF-ÎºB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation. Cancer Cell, 2010, 17, 286-297.	7.7	405
286	Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Experimental and Molecular Pathology, 2010, 88, 107-111.	0.9	71
287	Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Experimental and Molecular Pathology, 2010, 89, 27-35.	0.9	100
288	Hepatitis B virusXprotein promotes hypermethylation of p16INK4A promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis. Experimental and Molecular Pathology, 2010, 89, 268-275.	0.9	34

#	Article	IF	Citations
289	Knowledge of hepatitis C virus screening in longâ€term pediatric cancer survivors. Cancer, 2010, 116, 974-982.	2.0	7
290	MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology, 2010, 51, NA-NA.	3.6	195
291	Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology, 2010, 51, NA-NA.	3.6	139
292	The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology, 2010, 51, 1972-1978.	3.6	1,083
293	Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology, 2010, 51, 1820-1832.	3.6	1,140
294	Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology, 2010, 52, 142-154.	3.6	69
295	Sorafenib: Where do we go from here?. Hepatology, 2010, 52, 360-369.	3.6	92
296	Overexpression of aspartyl-(asparaginyl)-Î²-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology, 2010, 52, 164-173.	3.6	90
297	A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology, 2010, 52, 1702-1712.	3.6	133
298	MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology, 2010, 52, 1731-1740.	3.6	225
299	Chemotherapyâ€induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. International Journal of Cancer, 2010, 126, 2049-2066.	2.3	78
300	Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. International Journal of Cancer, 2010, 126, 1291-1301.	2.3	87
301	Vitamin K enhancement of sorafenibâ€mediated HCC cell growth inhibition in vitro and in vivo. International Journal of Cancer, 2010, 127, 2949-2958.	2.3	47
302	LAPTM4Bâ€35 is a novel prognostic factor of hepatocellular carcinoma. Journal of Surgical Oncology, 2010, 101, 363-369.	0.8	49
303	Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). Journal of Surgical Oncology, 2010, 101, 476-480.	0.8	196
304	Tumor recurrence following liver transplantation for hepatocellular carcinoma: Role of tumor proliferation status. Liver Transplantation, 2010, 16, 279-288.	1.3	25
305	Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation, 2010, 16, 503-512.	1.3	41
306	Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today, 2010, 5, 296-312.	6.2	98

#	Article	IF	Citations
307	Inherited hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 725-734.	1.0	28
308	Spatial analysis of hepatocellular carcinoma and socioeconomic status in China from a Population-based Cancer Registry. Cancer Epidemiology, 2010, 34, 29-33.	0.8	16
309	Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Caseâ€“control study. Cancer Epidemiology, 2010, 34, 298-302.	0.8	31
310	Current Problems with Systemic Treatment of Advanced Hepatocellular Cancer. Current Problems in Cancer, 2010, 34, 131-149.	1.0	3
311	Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis. BMC Gastroenterology, 2010, 10, 145.	0.8	31
312	Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterology, 2010, 10, 79.	0.8	151
313	The impact of sex, gender and pregnancy on 2009 H1N1 disease. Biology of Sex Differences, 2010, 1, 5.	1.8	91
314	Subâ€proteome approach to the knowledge of liver. Proteomics - Clinical Applications, 2010, 4, 407-415.	0.8	9
315	The impact of miRâ€34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics, 2010, 10, 1557-1572.	1.3	65
316	Gas chromatography/timeâ€ofâ€flight mass spectrometryâ€based metabonomics of hepatocarcinoma in rats with lung metastasis: elucidation of the metabolic characteristics of hepatocarcinoma at formation and metastasis. Rapid Communications in Mass Spectrometry, 2010, 24, 2765-2775.	0.7	24
317	Threeâ€dimensional ultrasound imageâ€guided robotic system for accurate microwave coagulation of malignant liver tumours. International Journal of Medical Robotics and Computer Assisted Surgery, 2010, 6, 256-268.	1.2	44
318	Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis. Journal of Pathology, 2010, 220, 348-360.	2.1	22
319	Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. Hpb, 2010, 12, 174-180.	0.1	43
320	Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver International, 2010, 30, 112-118.	1.9	30
321	dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma. Liver International, 2010, 30, 438-446.	1.9	22
322	Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver International, 2010, 30, 479-486.	1.9	75
323	Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. International Journal of Clinical Practice, 2010, 64, 1034-1041.	0.8	66
324	Dietary supplementation with branchedâ€chain amino acids suppresses diethylnitrosamineâ€induced liver tumorigenesis in obese and diabetic C57BL/KsJâ€db/db mice. Cancer Science, 2010, 101, 460-467.	1.7	82

#	Article	IF	Citations
325	Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology and Therapeutics, 2010, 31, 407-414.	1.9	20
326	Review article: the management of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2010, 31, 461-476.	1.9	174
327	Pilot study: rapamycin in advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2010, 32, 763-768.	1.9	18
328	Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis, 2010, 17, 287-292.	1.0	90
329	TGFÎ²-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene, 2010, 29, 1787-1797.	2.6	338
330	Viral hepatocarcinogenesis. Oncogene, 2010, 29, 2309-2324.	2.6	227
331	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2010, 102, 981-986.	2.9	127
332	A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. British Journal of Cancer, 2010, 103, 954-960.	2.9	138
333	Induction of liver fibrosis in a murine hepatoma model by thioacetamide is associated with enhanced tumor growth and suppressed antitumor immunity. Laboratory Investigation, 2010, 90, 1782-1793.	1.7	28
334	Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nature Cell Biology, 2010, 12, 390-399.	4.6	290
335	Favorable Î±â€fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 605-612.	1.4	36
336	Prevention of hepatocellular carcinoma in the Asiaâ€"Pacific region: Consensus statements. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 657-663.	1.4	134
337	Optimal management of hepatocellular carcinoma: Challenges and opportunities. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1336-1338.	1.4	10
338	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transplant International, 2010, 23, 712-722.	0.8	45
339	Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World Journal of Gastroenterology, 2010, 16, 5766.	1.4	14
340	Hepatitis C and hepatocellular carcinoma. Annals of Hepatology, 2010, 9, S119-S122.	0.6	33
341	System biology analysis of cell cycle pathway involved in hepatocellular carcinoma. Frontiers in Bioscience - Scholar, 2010, S2, 1127-1144.	0.8	8
342	Genotype f prevails in Venezuelan urban patients with chronic hepatitis B. Annals of Hepatology, 2010, 9, 172-176.	0.6	5

#	Article	IF	Citations
343	The Clinical Presentation of Chronic Hepatitis B Virus Infection in Asian Americans. Journal of Clinical Gastroenterology, 2010, 44, 364-370.	1.1	12
344	Transarterial Radioembolization with Yttrium-90 for Regional Management of Hepatocellular Cancer: The Early Results of a Nontransplant Center. American Surgeon, 2010, 76, 1079-1083.	0.4	1
345	Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncology Reports, 2010, 23, 1317-23.	1.2	17
346	Progress in stem cell-derived technologies for hepatocellular carcinoma. Stem Cells and Cloning: Advances and Applications, 2010, 3, 81.	2.3	2
347	Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent. Biologics: Targets and Therapy, 2010, 4, 199.	3.0	7
348	Male-biased genes of Drosophila melanogaster that are conserved in mammalian testis. Frontiers in Bioscience - Elite, 2010, E2, 668.	0.9	0
349	Augmented Reality for Minimally Invasive Surgery: Overview and Some Recent Advances. , 0, , .		18
350	Molecular and functional genetics of hepatocellular carcinoma. Frontiers in Bioscience - Scholar, 2010, S2, 117-134.	0.8	18
351	Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness. Molecular Medicine, 2010, 16, 102-115.	1.9	69
352	Influence of Transforming Growth Factor-Î²1 Gene Polymorphism at Codon 10 on the Development of Cirrhosis in Chronic Hepatitis B Virus Carriers. Journal of Korean Medical Science, 2010, 25, 564.	1.1	14
353	Modulation of Mitochondrial Permeability Transition Pore Affects Multidrug Resistance in Human Hepatocellular Carcinoma Cells. International Journal of Biological Sciences, 2010, 6, 773-783.	2.6	27
354	Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World Journal of Gastroenterology, 2010, 16, 3016.	1.4	81
355	Non-viral causes of hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16, 3603.	1.4	149
356	Association of Meat and Fat Intake With Liver Disease and Hepatocellular Carcinoma in the NIH-AARP Cohort. Journal of the National Cancer Institute, 2010, 102, 1354-1365.	3.0	128
357	Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Experimental Biology and Medicine, 2010, 235, 32-39.	1.1	32
358	A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines In vitro and In vivo. Molecular Cancer Therapeutics, 2010, 9, 1809-1819.	1.9	39
359	Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma. Clinical Cancer Research, 2010, 16, 5529-5538.	3.2	44
360	BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma. Molecular Cancer Research, 2010, 8, 1116-1125.	1.5	50

#	Article	IF	Citations
361	Spectrum of Cancer Risk Late After AIDS Onset in the United States. Archives of Internal Medicine, 2010, 170, 1337.	4.3	114
362	Sorafenib Therapy for Hepatocellular Carcinoma in an HIVâ€“HCV Coinfected Patient: A Case Report. Oncologist, 2010, 15, 142-145.	1.9	17
363	The Phosphoinositide 3-Kinase Regulatory Subunit p85Î± Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling. Cancer Research, 2010, 70, 5305-5315.	0.4	140
364	Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?. Clinical Cancer Research, 2010, 16, 390-397.	3.2	98
365	Oncogenic Potential of Retinoic Acid Receptor-Î³ in Hepatocellular Carcinoma. Cancer Research, 2010, 70, 2285-2295.	0.4	64
366	Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8357-8362.	3.3	68
367	Cancer as a Cause of Death among People with AIDS in the United States. Clinical Infectious Diseases, 2010, 51, 957-962.	2.9	140
368	Palliative Chemoradiation in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2010, 28, e231-e232.	0.8	0
369	Distribution and Hepatocellular Carcinomaâ€“Related Viral Properties of Hepatitis B Virus Genotypes in Mainland China: A Community-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 777-786.	1.1	90
370	A Single-Institute Experience with Sorafenib in Untreated and Previously Treated Patients with Advanced Hepatocellular Carcinoma. Oncology, 2010, 78, 210-212.	0.9	6
371	Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut, 2010, 59, 88-97.	6.1	208
372	Tumour Necrosis Factor-Î± Polymorphisms and Hepatocellular Carcinoma: A Meta-analysis. Journal of International Medical Research, 2010, 38, 760-768.	0.4	19
373	Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis, 2010, 31, 1516-1522.	1.3	93
374	Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study. Journal of Clinical Oncology, 2010, 28, 4587-4593.	0.8	150
375	Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results. HPB Surgery, 2010, 2010, 1-8.	2.2	51
376	miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 2010, 31, 766-776.	1.3	538
378	PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis, 2010, 31, 1211-1219.	1.3	71
379	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut, 2010, 59, 387-396.	6.1	145

#	Article	IF	Citations
380	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Seminars in Liver Disease, 2010, 30, 035-051.	1.8	267
381	Suicide Rates and Risk Factors among Korean Cancer Patients, 1993-2005. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2097-2105.	1.1	72
382	Oncostatin M Renders Epithelial Cell Adhesion Moleculeâ€"Positive Liver Cancer Stem Cells Sensitive to 5-Fluorouracil by Inducing Hepatocytic Differentiation. Cancer Research, 2010, 70, 4687-4697.	0.4	88
383	Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma. Clinical Cancer Research, 2010, 16, 2518-2528.	3.2	149
384	Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1785-1791.	1.4	21
385	Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut, 2010, 59, 1303-1307.	6.1	149
387	Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2207-2212.	3.3	111
388	Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics, 2010, 10, 883-895.	1.5	8
389	CT and MRI of hepatocellular carcinoma: an update. Expert Review of Anticancer Therapy, 2010, 10, 507-519.	1.1	31
390	A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients. Cancer Research, 2010, 70, 10202-10212.	0.4	846
391	Glutamine Synthetase Immunostaining Correlates with Pathologic Features of Hepatocellular Carcinoma and Better Survival after Radiofrequency Thermal Ablation. Clinical Cancer Research, 2010, 16, 2157-2166.	3.2	67
392	An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. Science Translational Medicine, 2010, 2, 54ra77.	5.8	92
393	The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. Oncologist, 2010, 15, 14-22.	1.9	437
394	Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes. Clinical Cancer Research, 2010, 16, 957-966.	3.2	108
395	Î”Np73Î² is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle, 2010, 9, 2629-2639.	1.3	25
396	Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. American Journal of Physiology - Renal Physiology, 2010, 298, G126-G132.	1.6	27
397	Molecular Mechanism of Chemoresistance by Astrocyte Elevated Gene-1. Cancer Research, 2010, 70, 3249-3258.	0.4	188
398	Hepatitis B and C Viruses and Hepatocellular Carcinoma. Viruses, 2010, 2, 1504-1509.	1.5	39

#	Article	IF	Citations
399	Oxidative stress and antioxidants in hepatic pathogenesis. World Journal of Gastroenterology, 2010, 16, 6035.	1.4	196
400	Sexually Dimorphic Actions of Glucocorticoids Provide a Link to Inflammatory Diseases with Gender Differences in Prevalence. Science Signaling, 2010, 3, ra74.	1.6	152
401	Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. International Journal of Oncology, 2010, 37, .	1.4	13
402	Positioning and Indication of Sorafenib in the Treatment Algorithm and Real Practice Setting: Western and Eastern Approach â€“ Asian Perspective. Oncology, 2010, 78, 167-171.	0.9	12
403	Significance of DNA Polymerase Delta Catalytic Subunit p125 Induced by Mutant p53 in the Invasive Potential of Human Hepatocellular Carcinoma. Oncology, 2010, 79, 229-237.	0.9	16
404	Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association. Current Pharmaceutical Design, 2010, 16, 741-752.	0.9	61
405	NF-Î²B in Liver Cancer: The Plot Thickens. Current Topics in Microbiology and Immunology, 2010, 349, 185-196.	0.7	8
406	Stem Cells in Hepatocarcinogenesis: Evidence from Genomic Data. Seminars in Liver Disease, 2010, 30, 026-034.	1.8	50
407	Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics, 2010, 2, 233-243.	1.0	23
408	Fibrosis in the Liver. Progress in Molecular Biology and Translational Science, 2010, 97, 151-200.	0.9	29
409	Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. Expert Review of Gastroenterology and Hepatology, 2010, 4, 535-539.	1.4	12
410	Percutaneous Ablation of Hepatic Tumors. Seminars in Interventional Radiology, 2010, 27, 255-260.	0.3	34
411	Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Upsala Journal of Medical Sciences, 2010, 115, 232-237.	0.4	19
412	HNE-protein adducts formation in different pre-carcinogenic stages of hepatitis in LEC rats. Free Radical Research, 2010, 44, 119-127.	1.5	35
413	Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. Artificial DNA, PNA & XNA, 2010, 1, 17-26.	1.4	28
414	Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 2010, 15, 203-223.	1.0	54
415	Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men. Clinical Gastroenterology and Hepatology, 2010, 8, 891-898.e2.	2.4	76
416	Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States. Clinical Gastroenterology and Hepatology, 2010, 8, 718-723.	2.4	35

#	Article	IF	Citations
417	Percutaneous Ablation of Hepatocellular Carcinoma: Current Status. Journal of Vascular and Interventional Radiology, 2010, 21, S204-S213.	0.2	99
418	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 1197-1204.	0.2	16
419	MR Imaging of Hepatocellular Carcinoma. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 421-450.	0.6	33
420	Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacologica Sinica, 2010, 31, 1409-1420.	2.8	150
421	Chemoprevention of Hepatocellular Carcinoma in Chronic Hepatitis C. Recent Results in Cancer Research, 2010, 188, 85-99.	1.8	25
422	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 2010, 59, 953-962.	6.1	238
423	Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Molecular Cancer, 2010, 9, 146.	7.9	30
424	Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Molecular Cancer, 2010, 9, 256.	7.9	42
425	Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Molecular Cancer, 2010, 9, 81.	7.9	116
426	Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. Journal of Translational Medicine, 2010, 8, 109.	1.8	27
427	The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S206-S214.	0.4	465
428	Molecular approaches to treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S264-S272.	0.4	75
429	Future perspectives in hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S302-S309.	0.4	62
430	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental and Clinical Medicine, 2010, 2, 93-103.	0.2	21
431	Induction of p53 Renders ATM-Deficient Mice Refractory to Hepatocarcinogenesis. Gastroenterology, 2010, 138, 1155-1165.e2.	0.6	30
432	C/EBPÎ± Is Up-regulated in a Subset of Hepatocellular Carcinomas and Plays a Role in Cell Growth and Proliferation. Gastroenterology, 2010, 139, 632-643.e4.	0.6	45
433	Increased Expression of iASPP, Regulated by Hepatitis B Virus X Protein-Mediated NF-ÎºB Activation, in Hepatocellular Carcinoma. Gastroenterology, 2010, 139, 2183-2194.e5.	0.6	45
434	Up-regulation of KrÃ¼ppel-Like Factor 8 Promotes Tumor Invasion and Indicates Poor Prognosis for Hepatocellular Carcinoma. Gastroenterology, 2010, 139, 2146-2157.e12.	0.6	88

#	Article	IF	Citations
435	A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology, 2010, 42, 674-680.	0.3	38
436	Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma. Journal of Clinical Oncology, 2010, 28, 2220-2226.	0.8	163
437	Hepatocellular carcinoma: a global view. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 448-458.	8.2	1,159
438	Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Human Pathology, 2010, 41, 1310-1319.	1.1	23
439	LCSGJ-T Classification, 6th or 5th Edition TNM Staging Did Not Independently Predict the Long-Term Prognosis of HBV-Related Hepatocellular Carcinoma After Radical Hepatectomy. Journal of Surgical Research, 2010, 159, 538-544.	0.8	19
440	Comparative in vitro bioactivities of tea extracts from six species of Ardisia and their effect on growth inhibition of HepG2 cells. Journal of Ethnopharmacology, 2010, 130, 536-544.	2.0	56
441	EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. Journal of Hepatology, 2010, 52, 280-281.	1.8	187
442	Identification and expression analysis of the aldoâ€“ketoreductase1-B10 gene in primary malignant liver tumours. Journal of Hepatology, 2010, 52, 220-227.	1.8	85
443	Risk of HCC: Genetic heterogeneity and complex genetics. Journal of Hepatology, 2010, 52, 252-257.	1.8	194
444	MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 98-107.	1.8	151
445	Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. Journal of Hepatology, 2010, 53, 118-125.	1.8	114
446	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. Journal of Hepatology, 2010, 53, 348-356.	1.8	397
447	Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: Evidence from an updated meta-analysis. Journal of Hepatology, 2010, 53, 508-518.	1.8	110
448	PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. Journal of Hepatology, 2010, 53, 872-879.	1.8	88
449	Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Letters, 2010, 291, 120-129.	3.2	44
450	Transcriptional down-regulation of IGFBP-3 in human hepatocellular carcinoma cells is mediated by the binding of TIA-1 to its AT-rich element in the 3â€²-untranslated region. Cancer Letters, 2010, 297, 259-268.	3.2	21
451	Activated Notch signaling is required for hepatitis B virus X protein to promote proliferation and survival of human hepatic cells. Cancer Letters, 2010, 298, 64-73.	3.2	38
452	Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. European Journal of Cancer, 2010, 46, 1056-1061.	1.3	89

#	Article	IF	Citations
453	Hepatocellular carcinoma: Comparison of two different periods at the same center. European Journal of Internal Medicine, 2010, 21, 127-130.	1.0	11
454	Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell, 2010, 140, 197-208.	13.5	1,490
455	Comprehensive gene expression analysis of 5â€²-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. Genomics, 2010, 95, 217-223.	1.3	17
456	Glutathione S-transferases: an overview in cancer research. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 153-170.	1.5	190
457	Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca²⁺. Hepatology Research, 2010, 40, 424-431.	1.8	10
458	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatology Research, 2010, 40, 870-877.	1.8	65
459	Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology, 2010, 52, 2034-2043.	3.6	124
460	Apoptosis, Stem Cells, and Tissue Regeneration. Science Signaling, 2010, 3, re8.	1.6	258
461	Pigment Epithelium-Derived Factor Inhibits Lysosomal Degradation of Bcl-xL and Apoptosis in HepG2 cells. American Journal of Pathology, 2010, 176, 168-176.	1.9	21
462	Reduced Expression of Fibroblast Growth Factor Receptor 2IIIb in Hepatocellular Carcinoma Induces a More Aggressive Growth. American Journal of Pathology, 2010, 176, 1433-1442.	1.9	52
463	Novel inhibitors in development for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2010, 19, 615-629.	1.9	30
464	Epidemiology and Management of Hepatocellular Carcinoma. Infectious Disease Clinics of North America, 2010, 24, 899-919.	1.9	166
465	Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. Journal of Experimental and Clinical Cancer Research, 2010, 29, 145.	3.5	49
466	IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-Induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle, 2010, 9, 3423-3427.	1.3	65
467	Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy. Clinical Cancer Research, 2011, 17, 3783-3793.	3.2	142
468	Role of cancer stem cells in hepatocarcinogenesis. Genome Medicine, 2011, 3, 11.	3.6	26
469	Nano-LC-MS/MS based proteomics of hepatocellular carcinoma cells compared to Chang liver cells and tanshinone IIA induction. Molecular BioSystems, 2011, 7, 1728.	2.9	17
470	Global Gene Profiling of Spontaneous Hepatocellular Carcinoma in B6C3F1 Mice. Toxicologic Pathology, 2011, 39, 678-699.	0.9	35

#	Article	IF	Citations
471	EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Î²-Cateninâ€“Dependent Hepatocarcinogenesis. Cancer Research, 2011, 71, 4028-4039.	0.4	199
472	Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study. Journal of Proteome Research, 2011, 10, 1828-1836.	1.8	88
473	Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut, 2011, 60, 1109-1116.	6.1	159
474	Subcellular Tissue Proteomics of Hepatocellular Carcinoma for Molecular Signature Discovery. Journal of Proteome Research, 2011, 10, 5070-5083.	1.8	36
475	Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics, 2011, 43, 828-829.	9.4	392
476	Vascular Profile Characterization of Liver Tumors by Magnetic Resonance Imaging Using Hemodynamic Response Imaging in Mice. Neoplasia, 2011, 13, 244-IN5.	2.3	19
477	Hypomethylation of the hsa-miR-191 Locus Causes High Expression of hsa-miR-191 and Promotes the Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. Neoplasia, 2011, 13, 841-IN23.	2.3	105
478	Increased Risk for Malignant Neoplasms Among Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2011, 9, 168-174.	2.4	77
479	HBV-related HCC, clinical issues and therapy. Digestive and Liver Disease, 2011, 43, S32-S39.	0.4	14
480	Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S21-S30.	0.7	18
481	Aplasia Ras homologue member I overexpression induces apoptosis through inhibition of survival pathways in human hepatocellular carcinoma cells in culture and in xenograft. Cell Biology International, 2011, 35, 1019-1024.	1.4	6
482	Granulin-Epithelin Precursor and ATP-Dependent Binding Cassette (ABC)B5 Regulate Liver Cancer Cell Chemoresistance. Gastroenterology, 2011, 140, 344-355.e2.	0.6	130
483	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology, 2011, 140, 1618-1628.e16.	0.6	205
484	Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology, 2011, 141, 1572-1585.	0.6	1,544
485	The Wnt/Î²-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 709-713.	0.7	80
486	Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 905-911.	0.4	8
487	Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Digestive and Liver Disease, 2011, 43, 1001-1005.	0.4	22
488	Effects of E2F1â€“cyclin E1â€“E2 circuit down regulation in hepatocellular carcinoma cells. Digestive and Liver Disease, 2011, 43, 1006-1014.	0.4	42

#	Article	IF	Citations
489	Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers, 2011, 3, 2444-2461.	1.7	65
490	Pathogenesis of Liver Fibrosis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 425-456.	9.6	1,382
492	Primary Hepatocellular Carcinoma. Molecular Pathology Library, 2011, , 831-848.	0.1	0
493	Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician. Clinics in Liver Disease, 2011, 15, 307-321.	1.0	16
494	Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1410-1426.	0.6	408
495	The Promoter of Human Telomerase Reverse Transcriptase Is Activated During Liver Regeneration and Hepatocyte Proliferation. Gastroenterology, 2011, 141, 326-337.e3.	0.6	33
496	Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis. BMC Cancer, 2011, 11, 271.	1.1	49
497	Controlling liver cancer internationally: A qualitative study of clinicians' perceptions of current public policy needs. Health Research Policy and Systems, 2011, 9, 32.	1.1	12
499	Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2011, 9, 428-433.	2.4	358
500	Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib. Academic Radiology, 2011, 18, 89-96.	1.3	25
501	Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008. Clinical Gastroenterology and Hepatology, 2011, 9, 524-530.e1.	2.4	933
502	Gastrointestinal Oncology. , 2011, , .		2
503	Stem and progenitor cells in liver regeneration and repair. Cytotherapy, 2011, 13, 135-144.	0.3	44
504	RB and p53 Cooperate to Prevent Liver Tumorigenesis in Response to Tissue Damage. Gastroenterology, 2011, 141, 1439-1450.	0.6	28
505	Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 2011, 1, 73-79.	5.7	4
506	Hepatoprotective versus Oncogenic Functions of STAT3 in Liver Tumorigenesis. American Journal of Pathology, 2011, 179, 714-724.	1.9	58
507	Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clinica Chimica Acta, 2011, 412, 2310-2315.	0.5	18
508	An HNF4Î±-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis. Cell, 2011, 147, 1233-1247.	13.5	445

#	Article	IF	Citations
509	Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome. Cell Metabolism, 2011, 14, 91-103.	7.2	125
511	Subcellular proteomics: Determination of specific location and expression levels of lymphatic metastasis associated proteins in hepatocellular carcinoma by subcellular fractionation. Biomedicine and Pharmacotherapy, 2011, 65, 407-416.	2.5	23
512	The association between the survivin â˜'31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiology, 2011, 35, 555-559.	0.8	22
513	Mechanisms linking pathogens-associated inflammation and cancer. Cancer Letters, 2011, 305, 250-262.	3.2	97
514	Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: Role of Akt and nuclear factor-ÎºB. Cancer Letters, 2011, 301, 75-84.	3.2	99
515	Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Letters, 2011, 305, 123-143.	3.2	132
516	Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Letters, 2011, 312, 55-61.	3.2	95
519	Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochemical and Biophysical Research Communications, 2011, 406, 70-73.	1.0	203
520	Steatosis induced by the accumulation of apolipoprotein A-I and elevated ROS levels in H-ras12V transgenic mice contributes to hepatic lesions. Biochemical and Biophysical Research Communications, 2011, 409, 532-538.	1.0	9
521	Hepatitis B virus X protein reduces starvation-induced cell death through activation of autophagy and inhibition of mitochondrial apoptotic pathway. Biochemical and Biophysical Research Communications, 2011, 415, 68-74.	1.0	36
522	Signaling Pathways in Hepatocellular Carcinoma. Oncology, 2011, 81, 18-23.	0.9	39
523	Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver International, 2012, 32, 457-466.	1.9	12
524	Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. Gut, 2011, 60, 156-165.	6.1	21
525	Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. Journal of Clinical Oncology, 2011, 29, 3960-3967.	0.8	279
526	Tumor Promotion via Injury- and Death-Induced Inflammation. Immunity, 2011, 35, 467-477.	6.6	235
527	Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation. Human Immunology, 2011, 72, 687-698.	1.2	14
528	Involvement of 14-3-3Î³ overexpression in extrahepatic metastasis of hepatocellular carcinoma. Human Pathology, 2011, 42, 129-135.	1.1	29
529	Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Human Pathology, 2011, 42, 1391-1400.	1.1	60

#	Article	IF	Citations
530	Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. Journal of Hepatology, 2011, 54, 300-305.	1.8	58
531	IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC. Journal of Hepatology, 2011, 54, 716-722.	1.8	163
532	Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 948-955.	1.8	410
533	The inflammatory microenvironment of HCC â€“ The plot becomes complex. Journal of Hepatology, 2011, 54, 853-855.	1.8	27
534	Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. Journal of Hepatology, 2011, 55, 838-845.	1.8	180
535	Criteria for liver transplantation for HCC: What should the limits be?. Journal of Hepatology, 2011, 55, 1137-1147.	1.8	66
536	Hepatocellular Carcinoma. New England Journal of Medicine, 2011, 365, 1118-1127.	13.9	3,427
537	Iodine-131-Lipiodol therapy in hepatic tumours. Methods, 2011, 55, 246-252.	1.9	21
538	Cytotoxic constituents of propolis inducing anticancer effects: a review. Journal of Pharmacy and Pharmacology, 2011, 63, 1378-1386.	1.2	163
539	Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology, 2011, 54, 2149-2158.	3.6	108
540	Synthesis and antiproliferative evaluation of 2,3-diarylquinoline derivatives. Organic and Biomolecular Chemistry, 2011, 9, 3205.	1.5	26
541	Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma. Molecular and Cellular Proteomics, 2011, 10, M110.004945.	2.5	267
542	Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. International Journal of Surgery, 2011, 9, 188-191.	1.1	42
543	MicroRNAs, SNPs and Cancer. Journal of Nucleic Acids Investigation, 2011, 2, 6.	0.5	440
544	ARID2: A new tumor suppressor gene in hepatocellular carcinoma. Oncotarget, 2011, 2, 886-891.	0.8	48
545	Liver Regeneration Associated Protein (ALR) Exhibits Antimetastatic Potential in Hepatocellular Carcinoma. Molecular Medicine, 2011, 17, 221-228.	1.9	35
547	Hepatitis B virus infection and the risk of hepatocellular carcinoma. World Journal of Gastroenterology, 2011, 17, 4853.	1.4	73
548	Integrating Palliative Care with Chronic Liver Disease Care. Journal of Palliative Care, 2011, 27, 20-27.	0.4	25

#	Article	IF	Citations
549	Viruses and Cancer. African Journal of Clinical and Experimental Microbiology, 2011, 13, .	0.1	0
550	Non-Cirrhotic Hepatocellular Carcinoma in a Young Active Duty Male. Military Medicine, 2011, 176, 475-476.	0.4	5
551	Chemoprevention of hepatocellular carcinoma by acyclic retinoid. Frontiers in Bioscience - Landmark, 2011, 16, 759.	3.0	17
552	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Current Oncology, 2011, 18, 228-240.	0.9	55
553	Survival of patients with primary liver cancer in central and northern Denmark, 1998–2009. Clinical Epidemiology, 2011, 3 Suppl 1, 3.	1.5	16
554	Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy. Frontiers in Bioscience - Landmark, 2011, 16, 225.	3.0	26
555	Clinical Utility of Alpha Fetoprotein and HCCR-1, Alone or in Combination, in Patients with Chronic Hepatitis, Liver Cirrhosis and Hepatocellular Carcinoma. Disease Markers, 2011, 30, 307-315.	0.6	12
556	Regulation of TGF-?1-Induced Pro-Apoptotic Signaling by Growth Factor Receptors and Extracellular Matrix Receptor Integrins in the Liver. Frontiers in Physiology, 2011, 2, 78.	1.3	40
558	Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target. International Journal of Biological Sciences, 2011, 7, 536-550.	2.6	208
559	Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile. International Journal of Oncology, 2011, 38, 745-53.	1.4	9
560	Insulin resistance and chronic liver disease. World Journal of Hepatology, 2011, 3, 99.	0.8	80
561	Single Nucleotide Polymorphisms of Toll-Like Receptor 4 Decrease the Risk of Development of Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e19466.	1.1	59
562	Interferon-Î±/Î² and Anti-Fibroblast Growth Factor Receptor 1 Monoclonal Antibody Suppress Hepatic Cancer Cells In Vitro and In Vivo. PLoS ONE, 2011, 6, e19618.	1.1	11
563	Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68. PLoS ONE, 2011, 6, e22069.	1.1	36
564	Male Germ Cell-Specific RNA Binding Protein RBMY: A New Oncogene Explaining Male Predominance in Liver Cancer. PLoS ONE, 2011, 6, e26948.	1.1	38
565	Granulin-Epithelin Precursor Is an Oncofetal Protein Defining Hepatic Cancer Stem Cells. PLoS ONE, 2011, 6, e28246.	1.1	45
566	RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: Its application as a therapeutic agent. International Journal of Oncology, 2011, 39, 853-61.	1.4	9
567	Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2011, 45, 355-360.	1.1	236

#	Article	IF	Citations
568	A single center experience of sorafenib in advanced hepatocellular carcinoma patients. European Journal of Gastroenterology and Hepatology, 2011, 23, 1233-1238.	0.8	44
569	Hepatocellular Carcinoma Metastatic to the Scalp. Journal of Craniofacial Surgery, 2011, 22, 720-721.	0.3	5
570	Targeting Hepatitis B Virus and Human Papillomavirus Induced Carcinogenesis: Novel Patented Therapeutics. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 158-174.	0.5	11
571	Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. The Cochrane Library, 2011, , CD004787.	1.5	173
572	Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2011, 45, 727-732.	1.1	83
574	Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncology Reports, 2011, 26, 523-31.	1.2	49
575	Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncology Reports, 2011, 26, 1273-9.	1.2	28
576	A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. International Journal of Oncology, 2011, 39, 1511-9.	1.4	20
577	Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clinical Science, 2011, 121, 159-168.	1.8	73
578	Growth Inhibition and Apoptosis Induced by Lupeol, a Dietary Triterpene, in Human Hepatocellular Carcinoma Cells. Biological and Pharmaceutical Bulletin, 2011, 34, 517-522.	0.6	33
579	Screening SNPs residing in the microRNA-binding sites of Hepatocellular Carcinoma related genes. International Journal of Data Mining and Bioinformatics, 2011, 5, 1.	0.1	3
580	Ubiquitinâ€proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 751-758.	1.4	10
581	Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 960-964.	1.4	30
582	Biology of hepatic cancer stem cells. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1229-1237.	1.4	49
583	Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, no-no.	1.4	23
584	Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1757-1764.	1.4	44
585	Safety and efficacy of trisectionectomy for hepatocellular carcinoma. ANZ Journal of Surgery, 2011, 81, 895-899.	0.3	10
586	Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Alimentary Pharmacology and Therapeutics, 2011, 34, 83-91.	1.9	21

#	Article	IF	Citations
587	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2011, 34, 205-213.	1.9	88
588	A functional polymorphism in preâ€microRNAâ€196aâ€2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a caseâ€"control study. Journal of Viral Hepatitis, 2011, 18, e399-407.	1.0	95
589	Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a populationâ€based cohort study, 1992â€"2007. Journal of Viral Hepatitis, 2011, 18, e232-41.	1.0	28
590	Î³â€Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, proâ€apoptotic and chemosensitizing agent. British Journal of Pharmacology, 2011, 163, 283-298.	2.7	125
591	Leptin inhibits hepatocellular carcinoma proliferation via p38-MAPK-dependent signalling. Hpb, 2011, 13, 225-233.	0.1	23
592	Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?. Liver International, 2011, 31, 377-385.	1.9	16
593	PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver International, 2011, 31, 1137-1143.	1.9	102
594	Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver International, 2011, 31, 1542-1553.	1.9	12
595	Molecular Pathogenesis of Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 2011, 35, 821-825.	1.4	47
596	Alcohol Induces Liver Neoplasia in a Novel Alcoholâ€Preferring Rat Model. Alcoholism: Clinical and Experimental Research, 2011, 35, 2216-2225.	1.4	20
597	High-resolution characterization of a hepatocellular carcinoma genome. Nature Genetics, 2011, 43, 464-469.	9.4	265
598	Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene, 2011, 30, 1773-1783.	2.6	25
599	p53-paralog DNp73 oncogene is repressed by IFNÎ±/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene, 2011, 30, 2670-2678.	2.6	26
600	The role of microRNAs in liver cancer progression. British Journal of Cancer, 2011, 104, 235-240.	2.9	208
601	NF-ÎºB and STAT3 â€" key players in liver inflammation and cancer. Cell Research, 2011, 21, 159-168.	5.7	975
602	Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector. Gene Therapy, 2011, 18, 606-612.	2.3	28
603	Increased risk of hepatocellular carcinoma after cholecystectomy. British Journal of Cancer, 2011, 105, 154-156.	2.9	30
604	Inhibin/activin expression in human and rodent liver: subunits Î± and Î²B as new players in human hepatocellular carcinoma?. British Journal of Cancer, 2011, 104, 1303-1312.	2.9	6

#	Article	IF	Citations
605	In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma. Cancer Gene Therapy, 2011, 18, 196-205.	2.2	12
606	Overexpression of 14-3-3Îµ predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology, 2011, 58, 705-711.	1.6	45
607	Desâ€gammaâ€carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. Journal of Digestive Diseases, 2011, 12, 481-488.	0.7	11
608	Can the Dropout Risk of Candidates with Hepatocellular Carcinoma Predict Survival after Liver Transplantation?. American Journal of Transplantation, 2011, 11, 1696-1704.	2.6	27
609	Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria. Transplantation Proceedings, 2011, 43, 3813-3818.	0.3	24
610	MicroRNA response to environmental mutagens in liver. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 67-76.	0.4	24
611	Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in Cancer Biology, 2011, 21, 10-20.	4.3	165
612	Liver cancer epidemic in China: Past, present and future. Seminars in Cancer Biology, 2011, 21, 59-69.	4.3	201
613	Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Experimental and Molecular Pathology, 2011, 90, 66-73.	0.9	42
614	Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Experimental and Molecular Pathology, 2011, 91, 695-701.	0.9	25
615	IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Molecular Cancer, 2011, 10, 150.	7.9	176
616	MDM2 SNP309T>G Polymorphism with Hepatocellular Carcinoma Risk: A Meta-analysis. Archives of Medical Research, 2011, 42, 149-155.	1.5	23
617	microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Letters, 2011, 585, 1828-1834.	1.3	53
618	miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Letters, 2011, 585, 2229-2234.	1.3	97
619	Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach. Biochimica Et Biophysica Acta - Bioenergetics, 2011, 1807, 664-678.	0.5	126
620	Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives. Bioorganic and Medicinal Chemistry, 2011, 19, 7653-7663.	1.4	10
621	Tumor-specific Expression of MicroRNA-26a Suppresses Human Hepatocellular Carcinoma Growth via Cyclin-dependent and -independent Pathways. Molecular Therapy, 2011, 19, 1521-1528.	3.7	108
622	Gender and oncology: Pathological observations. Memo - Magazine of European Medical Oncology, 2011, 4, 236-240.	0.3	0

#	Article	IF	Citations
623	Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Medical Molecular Morphology, 2011, 44, 183-189.	0.4	29
624	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. Annals of Surgical Oncology, 2011, 18, 413-420.	0.7	305
625	Overexpression of Long Non-coding RNA HOTAIR Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Following Liver Transplantation. Annals of Surgical Oncology, 2011, 18, 1243-1250.	0.7	670
626	Clinicopathological Characteristics of 20 Cases of Hepatocellular Carcinoma with Bile Duct Tumor Thrombi. Digestive Diseases and Sciences, 2011, 56, 252-259.	1.1	60
627	Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series. Digestive Diseases and Sciences, 2011, 56, 578-585.	1.1	66
628	Differential Effects of Vitamin K1 on AFP and DCP Levels in Patients with Unresectable HCC and in HCC Cell Lines. Digestive Diseases and Sciences, 2011, 56, 1876-1883.	1.1	14
629	Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis. Digestive Diseases and Sciences, 2011, 56, 1853-1861.	1.1	44
630	Small HCCs Identified by Screening. Digestive Diseases and Sciences, 2011, 56, 3078-3085.	1.1	8
631	The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Molecular Biology Reports, 2011, 38, 163-169.	1.0	29
632	Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. Journal of Gastroenterology, 2011, 46, 92-100.	2.3	75
633	Prevalence, gender, ethnic variations, and prognosis of NASH. Journal of Gastroenterology, 2011, 46, 63-69.	2.3	207
634	Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Medical Molecular Morphology, 2011, 44, 117-124.	0.4	19
635	A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Functional and Integrative Genomics, 2011, 11, 419-429.	1.4	19
636	The status of Chinese medicine in reversing multi-drug resistance of hepatocellular carcinoma. Chinese-German Journal of Clinical Oncology, 2011, 10, 541-546.	0.1	3
637	Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4Âyears experience at the Ghent University Hospital. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2117-2124.	3.3	26
638	A Primer on a Hepatocellular Carcinoma Bioresource Bank Using the Cancer Genome Atlas Guidelines: Practical Issues and Pitfalls. World Journal of Surgery, 2011, 35, 1732-1737.	0.8	4
639	Building a Comprehensive Genomic Program for Hepatocellular Carcinoma. World Journal of Surgery, 2011, 35, 1746-1750.	0.8	15
640	Transcatheter Arterial Chemoembolization with Epirubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience. CardioVascular and Interventional Radiology, 2011, 34, 557-565.	0.9	54

#	Article	IF	Citations
642	Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma. Medical Oncology, 2011, 28, 239-245.	1.2	12
643	Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma. Journal of Biosciences, 2011, 36, 659-668.	0.5	16
644	Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatology International, 2011, 5, 559-566.	1.9	13
645	Long-term surviving patient with inferior vena cava tumor thrombus and extrahepatic metastasis after spontaneous ruptured hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2011, 4, 123-128.	0.4	3
646	Chemoprevention against hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2011, 4, 185-197.	0.4	14
647	Gene therapy of liver cancer: an update. Journal Africain Du Cancer, 2011, 3, 180-192.	0.1	0
648	NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biology, 2011, 32, 1173-1182.	0.8	27
649	Evolution of proinflammatory cytokines in hepatocellular carcinoma patients undergoing orthotopic liver transplantation. Clinical Oncology and Cancer Research, 2011, 8, 38-41.	0.1	0
650	Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011, 10, 147-152.	0.3	0
651	Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. BMC Gastroenterology, 2011, 11, 53.	0.8	18
652	Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterology, 2011, 11, 71.	0.8	235
653	Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/dbobese mice. BMC Cancer, 2011, 11, 281.	1.1	45
654	Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer, 2011, 11, 3.	1.1	23
655	STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer, 2011, 11, 506.	1.1	64
656	A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complementary and Alternative Medicine, 2011, 11, 39.	3.7	25
657	Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine, 2011, 9, 166.	1.8	74
658	Combined logical and data-driven models for linking signalling pathways to cellular response. BMC Systems Biology, 2011, 5, 107.	3.0	26
659	Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?. Cell and Bioscience, 2011, 1, 5.	2.1	78

#	Article	IF	Citations
660	A Î”Raf1â€“ERâ€inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. Journal of Pathology, 2011, 225, 19-28.	2.1	18
661	Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transplantation, 2011, 17, S6-S13.	1.3	53
662	A matched caseâ€“control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. Journal of Medical Virology, 2011, 83, 45-53.	2.5	40
663	Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. Journal of Medical Virology, 2011, 83, 989-995.	2.5	60
664	Number of mutations within CTLâ€defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. Journal of Medical Virology, 2011, 83, 2082-2087.	2.5	24
665	Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Molecular Nutrition and Food Research, 2011, 55, 832-843.	1.5	105
666	Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1Î± pre-mRNA in mice and in vitro. Hepatology, 2011, 53, 171-180.	3.6	51
667	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology, 2011, 53, 483-492.	3.6	97
668	Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology, 2011, 53, 493-503.	3.6	75
669	Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology, 2011, 53, 854-864.	3.6	112
670	Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology, 2011, 53, 1137-1147.	3.6	51
671	Of mice and men: The nonrandom genomic instability in hepatocarcinogenesis. Hepatology, 2011, 53, 723-725.	3.6	0
672	Telomerase gene mutations are associated with cirrhosis formation. Hepatology, 2011, 53, 1608-1617.	3.6	143
673	Detection of acetaminophen-cysteine adducts in cases of indeterminate liver failure is not diagnostic of intentional overdose. Hepatology, 2011, 54, 746-747.	3.6	0
674	Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure. Hepatology, 2011, 54, 747-748.	3.6	3
675	Genetic background of hepatocyte cell lines: Are in vitro hepatitis C virus research data reliable?. Hepatology, 2011, 54, 748-748.	3.6	8
676	Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved. Hepatology, 2011, 54, 749-749.	3.6	8
677	Strategies for hepatocellular carcinoma therapy and diagnostics: Lessons learned from high throughput and profiling approaches. Hepatology, 2011, 53, 2112-2121.	3.6	49

#	Article	IF	Citations
678	Liver biopsy interpretation in liver cancer. Hepatology, 2011, 54, 750-750.	3.6	0
679	No transfats. Hepatology, 2011, 54, 750-751.	3.6	1
680	Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated mitogen-activated protein kinase. Hepatology, 2011, 54, 185-195.	3.6	74
681	Hepatocellular carcinoma and gene profiling: Back from perspective to reality. Hepatology, 2011, 54, 738-738.	3.6	5
682	Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition. Hepatology, 2011, 54, 307-318.	3.6	62
683	Apply sound scientific methodology to the evaluation of new medical treatments. Hepatology, 2011, 54, 739-739.	3.6	1
684	The ethics of placebo treatment for patients with acute exacerbation of chronic hepatitis B. Hepatology, 2011, 54, 740-740.	3.6	0
685	Mechanisms by which TLR4 and endotoxin promote hepatocellular carcinoma require further investigation. Hepatology, 2011, 54, 745-745.	3.6	1
686	Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?. Hepatology, 2011, 54, 742-742.	3.6	1
687	Bacterial translocation attenuates the systemic hemodynamic improvement produced by terlipressin in patients with cirrhosis. Hepatology, 2011, 54, 743-744.	3.6	2
694	Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology, 2011, 54, 910-919.	3.6	144
695	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. Hepatology, 2011, 54, 1167-1178.	3.6	36
696	Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatology, 2011, 54, 1259-1272.	3.6	53
697	The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology, 2011, 54, 2025-2035.	3.6	160
698	Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer, 2011, 117, 1089-1096.	2.0	159
699	Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer, 2011, 117, 1019-1026.	2.0	70
700	¹⁸Fâ€fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer, 2011, 117, 4779-4787.	2.0	47
701	Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer, 2011, 117, 4890-4904.	2.0	139

#	Article	IF	Citations
702	dbHCCvar: A comprehensive database of human genetic variations in hepatocellular carcinoma. Human Mutation, 2011, 32, E2308-E2316.	1.1	11
703	Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. International Journal of Cancer, 2011, 129, 2226-2235.	2.3	70
704	Loss of runtâ€related transcription factor 3 causes development and progression of hepatocellular carcinoma. Journal of Cellular Biochemistry, 2011, 112, 745-749.	1.2	32
705	Tumor necrosis factorâ€Î± treatment of HepG2 cells mobilizes a cytoplasmic pool of ERp57/1,25D₃â€MARRS to the nucleus. Journal of Cellular Biochemistry, 2011, 112, 2606-2615.	1.2	25
706	Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique. Journal of Clinical Laboratory Analysis, 2011, 25, 402-408.	0.9	13
707	Risk factors for survival and local recurrence after particle radiotherapy for single small hepatocellular carcinoma. British Journal of Surgery, 2011, 98, 558-564.	0.1	26
708	Upregulation of LAPTM4Bâ€35 Promotes Malignant Transformation and Tumorigenesis in L02 Human Liver Cell Line. Anatomical Record, 2011, 294, 1135-1142.	0.8	23
709	Liver development and cancer formation in zebrafish. Birth Defects Research Part C: Embryo Today Reviews, 2011, 93, 157-172.	3.6	30
710	Sonic Hedgehog Signaling Protects Human Hepatocellular Carcinoma Cells Against Ionizing Radiation in an Autocrine Manner. International Journal of Radiation Oncology Biology Physics, 2011, 80, 851-859.	0.4	57
711	The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI. Biomaterials, 2011, 32, 5187-5194.	5.7	68
712	The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2011, 103, 1696-1712.	3.0	67
713	Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. Expert Review of Gastroenterology and Hepatology, 2011, 5, 539-552.	1.4	15
714	Quantitative 4D Transcatheter Intraarterial Perfusion MRI for Standardizing Angiographic Chemoembolization Endpoints. American Journal of Roentgenology, 2011, 197, 1237-1243.	1.0	15
715	Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology, 2011, 258, 627-634.	3.6	264
716	Role of Class II Nuclear Receptors in Liver Carcinogenesis. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 529-542.	0.9	10
717	Genetics of Hepatobiliary Carcinogenesis. Seminars in Liver Disease, 2011, 31, 173-187.	1.8	138
718	Arterially Directed Therapies for Hepatocellular Carcinoma. American Journal of Roentgenology, 2011, 197, W590-W602.	1.0	21
720	Chemoembolization Endpoints: Effect on Survival Among Patients With Hepatocellular Carcinoma. American Journal of Roentgenology, 2011, 196, 919-928.	1.0	61

#	Article	IF	Citations
721	FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2512-2517.	1.1	37
722	Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma. Clinical Cancer Research, 2011, 17, 6040-6051.	3.2	122
723	Histological characteristics predisposing to development of hepatocellular carcinoma in patients with chronic hepatitis B. Journal of Clinical Pathology, 2011, 64, 599-604.	1.0	9
724	Preventive Effects of (â^')-Epigallocatechin Gallate on Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-db/db Mice. Cancer Prevention Research, 2011, 4, 396-403.	0.7	76
725	Chemopreventive Effect of Curcuma longa Linn on Liver Pathology in HBx Transgenic Mice. Integrative Cancer Therapies, 2011, 10, 168-177.	0.8	20
726	HSV-1 Cgal+ Infection Promotes Quaking RNA Binding Protein Production and Induces Nuclear-Cytoplasmic Shuttling of Quaking I-5 Isoform in Human Hepatoma Cells. Molecular and Cellular Proteomics, 2011, 10, M111.009126.	2.5	22
727	Acyclic Retinoid Inhibits Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BLKS/J- +Leprdb/+Leprdb Mice. Cancer Prevention Research, 2011, 4, 128-136.	0.7	54
728	Investigating the Potential for Toxicity from Long-Term Use of the Herbal Products, Goldenseal and Milk Thistle. Toxicologic Pathology, 2011, 39, 398-409.	0.9	29
729	Ibulocydine Is a Novel Prodrug Cdk Inhibitor That Effectively Induces Apoptosis in Hepatocellular Carcinoma Cells. Journal of Biological Chemistry, 2011, 286, 19662-19671.	1.6	27
730	Genetic polymorphisms in DNA double-strand break repair genes XRCC5 , XRCC6 and susceptibility to hepatocellular carcinoma. Carcinogenesis, 2011, 32, 530-536.	1.3	33
731	Combined inhibitors of angiogenesis and histone deacetylase: Efficacy in rat hepatoma. World Journal of Gastroenterology, 2011, 17, 3623.	1.4	3
732	Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth. Cancer Research, 2011, 71, 4138-4149.	0.4	189
733	Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis, 2011, 32, 1122-1132.	1.3	77
734	The Missing Link between Obesity and Hepatocellular Carcinoma: IL-6-Mediated STAT-3 Activation as a Key Player in Hepatocarcinogenesis. Digestion, 2011, 84, 185-186.	1.2	1
735	Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection. International Journal of Hepatology, 2011, 2011, 1-7.	0.4	26
736	Thyroid Hormone Receptor Mutations in Cancer and Resistance to Thyroid Hormone: Perspective and Prognosis. Journal of Thyroid Research, 2011, 2011, 1-20.	0.5	23
737	The Molecular Pathogenesis and Clinical Implications of Hepatocellular Carcinoma. International Journal of Hepatology, 2011, 2011, 1-8.	0.4	20
738	Chemokine RANTES Promoter Dimorphisms and Hepatocellular Carcinoma Occurrence in Patients with Alcoholic or Hepatitis C Virusâ€"Related Cirrhosis. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1439-1446.	1.1	19

#	Article	IF	Citations
739	Insulin-like Growth Factorâ€"Binding Protein-7 Functions as a Potential Tumor Suppressor in Hepatocellular Carcinoma. Clinical Cancer Research, 2011, 17, 6693-6701.	3.2	77
740	MicroRNA-423 promotes cell growth and regulates G 1 /S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis, 2011, 32, 1641-1647.	1.3	107
741	Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. North American Journal of Medical Sciences, 2011, 3, 167-175.	1.7	27
742	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study. Digestion, 2011, 84, 43-49.	1.2	22
743	FLNA and PGK1 are Two Potential Markers for Progression in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2011, 27, 207-216.	1.1	80
744	Future Treatment Option for Hepatocellular Carcinoma: A Focus on Brivanib. Digestive Diseases, 2011, 29, 316-320.	0.8	9
745	Living Donor Liver Transplantation for Hepatocellular Carcinoma: The Japanese Experience. Oncology, 2011, 81, 111-115.	0.9	17
746	Current Situation of Hepatocellular Carcinoma in Mongolia. Oncology, 2011, 81, 148-151.	0.9	25
747	Molecular Mechanisms of Liver Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 493-499.	0.9	38
748	MicroRNA-99a Inhibits Hepatocellular Carcinoma Growth and Correlates with Prognosis of Patients with Hepatocellular Carcinoma. Journal of Biological Chemistry, 2011, 286, 36677-36685.	1.6	218
749	Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. Cancer Prevention Research, 2011, 4, 2092-2100.	0.7	54
750	Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. British Journal of Cancer, 2011, 105, 146-153.	2.9	79
751	Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. British Journal of Cancer, 2011, 105, 945-952.	2.9	39
752	GABA-B receptor activation inhibits the in vitro migration of malignant hepatocytes. Canadian Journal of Physiology and Pharmacology, 2011, 89, 393-400.	0.7	13
753	Association ofPTENPolymorphisms with Susceptibility to Hepatocellular Carcinoma in a Han Chinese Population. DNA and Cell Biology, 2011, 30, 229-234.	0.9	16
754	Exposure to organochlorine pesticides is independent risk factor of hepatocellular carcinoma: A caseâ€"control study. Journal of Exposure Science and Environmental Epidemiology, 2011, 21, 601-608.	1.8	11
755	Quality of Care for Gastrointestinal Conditions: A Primer for Gastroenterologists. American Journal of Gastroenterology, 2011, 106, 1182-1187.	0.2	22
756	Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-Î±, and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma. OMICS A Journal of Integrative Biology, 2011, 15, 193-196.	1.0	18

#	Article	IF	Citations
757	Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut, 2011, 60, 992-997.	6.1	84
758	Blocking the IL-6â€“STAT3 signaling pathway: potential liver cancer therapy. Future Oncology, 2011, 7, 161-164.	1.1	6
760	Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis, 2011, 32, 1897-1904.	1.3	31
761	Extracellular Matrix Dynamics in Hepatocarcinogenesis: a Comparative Proteomics Study of PDGFC Transgenic and Pten Null Mouse Models. PLoS Genetics, 2011, 7, e1002147.	1.5	82
762	Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-Â. Carcinogenesis, 2011, 32, 897-903.	1.3	121
763	Surveillance for hepatocellular carcinoma: in whom and how?. Therapeutic Advances in Gastroenterology, 2011, 4, 5-10.	1.4	111
764	Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma. Canadian Journal of Surgery, 2011, 54, 89-94.	0.5	17
765	Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia. Hepatitis Research and Treatment, 2011, 2011, 1-10.	2.0	6
766	Results of en bloc resection for hepatocellular carcinoma extending to adjacent organs. Canadian Journal of Surgery, 2012, 55, 222-226.	0.5	11
767	Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-Î± for prevention of liver carcinogenesis. Journal of Carcinogenesis, 2012, 11, 11.	2.5	23
768	Effects of Antiviral Therapy on the Recurrence of Hepatocellular Carcinoma After Curative Resection or Liver Transplantation. Hepatitis Monthly, 2012, 12, e6031.	0.1	25
769	Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis, 2012, 33, 209-219.	1.3	51
770	Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis. American Journal of Physiology - Renal Physiology, 2012, 302, G1016-G1024.	1.6	18
771	Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers, 2012, 17, 422-429.	0.9	15
772	Resveratrol Helps Recovery from Fatty Liver and Protects against Hepatocellular Carcinoma Induced by Hepatitis B Virus X Protein in a Mouse Model. Cancer Prevention Research, 2012, 5, 952-962.	0.7	54
773	Pharmacological Effects of Ginseng on Liver Functions and Diseases: A Minireview. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-7.	0.5	38
774	Nutraceutical Approach for Preventing Obesity-Related Colorectal and Liver Carcinogenesis. International Journal of Molecular Sciences, 2012, 13, 579-595.	1.8	37
775	Risk of Hepatocellular Carcinoma in Workers Exposed to Chemicals. Hepatitis Monthly, 2012, 12, e5943.	0.1	23

#	Article	IF	Citations
776	MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis. International Journal of Molecular Sciences, 2012, 13, 1347-1379.	1.8	53
777	An Overview of Biomarkers for the Diagnosis of Hepatocellular Carcinoma. Hepatitis Monthly, 2012, 12, e6122.	0.1	26
778	Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Carcinogenesis, 2012, 33, 2499-2506.	1.3	47
779	Hepatocellular Carcinoma As Unusual Cause for Paraplegia. Journal of Clinical Oncology, 2012, 30, e303-e305.	0.8	3
780	A Single Neonatal Exposure to Aflatoxin B1 Induces Prolonged Genetic Damage in Two Loci of Mouse Liver. Toxicological Sciences, 2012, 128, 326-333.	1.4	12
781	Body Mass Index and Risk of Primary Liver Cancer: A Meta-Analysis of Prospective Studies. Oncologist, 2012, 17, 1461-1468.	1.9	54
782	Hepatocyteâ€“Stellate Cell Cross-Talk in the Liver Engenders a Permissive Inflammatory Microenvironment That Drives Progression in Hepatocellular Carcinoma. Cancer Research, 2012, 72, 2533-2542.	0.4	174
783	Reduced Expression of Argininosuccinate Lyase is Closely Associated With Postresectional Survival in Hepatocellular Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 602-606.	0.6	3
784	Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 345-350.	0.6	13
785	Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Therapeutic Advances in Gastroenterology, 2012, 5, 179-188.	1.4	10
786	PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Research, 2012, 40, 9738-9749.	6.5	49
787	Guardian and Selective Killer: The Versatile Functions of TLR3 in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2012, 104, 1780-1782.	3.0	2
788	Hepatitis C virus and hepatocarcinogenesis. Clinical and Molecular Hepatology, 2012, 18, 347.	4.5	81
789	Impact of comorbidities on the severity of chronic hepatitis B at presentation. World Journal of Gastroenterology, 2012, 18, 1616.	1.4	44
790	Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. International Journal of Nanomedicine, 2012, 7, 5465.	3.3	59
791	Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology, 2012, 22, 400-410.	1.3	91
792	Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis. Cancer Prevention Research, 2012, 5, 544-552.	0.7	128
793	Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. Oncologist, 2012, 17, 359-366.	1.9	142

#	Article	IF	Citations
795	Curcumin and Liver Cancer: A Review. Current Pharmaceutical Biotechnology, 2012, 13, 218-228.	0.9	218
796	FINGER SKIN METASTASIS FROM HEPATOCELLULAR CARCINOMA: A CASE REPORT. Hand Surgery, 2012, 17, 131-134.	0.6	4
797	Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy. Current Medicinal Chemistry, 2012, 19, 3722-3729.	1.2	22
798	Research Highlights: Highlights from the latest articles on epigenetics in tumorigenesis. Epigenomics, 2012, 4, 367-368.	1.0	2
799	The Multiple Functions of Heme Oxygenase-1 in the Liver. Zeitschrift Fur Gastroenterologie, 2012, 50, 34-40.	0.2	66
800	Immunotherapy of hepatocellular carcinoma. OncoImmunology, 2012, 1, 48-55.	2.1	146
801	Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors. Current Topics in Medicinal Chemistry, 2012, 12, 625-636.	1.0	2
802	Tumours and tumour-like lesions of the liver. , 2012, , 761-851.		22
803	Molecular biology of liver carcinogenesis and hepatitis. , 2012, , 142-152.e3.		1
804	Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut, 2012, 61, 1733-1743.	6.1	159
805	Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis, 2012, 33, 268-274.	1.3	59
806	miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma. Oncogenesis, 2012, 1, e15-e15.	2.1	29
807	Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice. Cancer Gene Therapy, 2012, 19, 77-83.	2.2	24
808	Editorial: Hepatocellular Carcinoma in Type 2 Diabetes: More Than Meets the Eye. American Journal of Gastroenterology, 2012, 107, 53-55.	0.2	24
809	Exposure to organochlorine pesticides is an independent risk factor of hepatocellular carcinoma: A caseâ€“control study. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 541-548.	1.8	29
810	Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scandinavian Journal of Gastroenterology, 2012, 47, 718-728.	0.6	38
811	Failure Rates in the Hepatocellular Carcinoma Surveillance Process. Cancer Prevention Research, 2012, 5, 1124-1130.	0.7	175
812	Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4503-4508.	3.3	37

#	Article	IF	Citations
813	Contemporary Strategies in the Management of Hepatocellular Carcinoma. HPB Surgery, 2012, 2012, 1-8.	2.2	4
814	Molecular Mechanisms of Liver Injury and Hepatocarcinogenesis: Focusing on the Role of Stress-Activated MAPK. Pathology Research International, 2012, 2012, 1-14.	1.4	64
815	Regulation of T Helper 17 by Bacteria: An Approach for the Treatment of Hepatocellular Carcinoma. International Journal of Hepatology, 2012, 2012, 1-8.	0.4	8
816	Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. Molecular Biology International, 2012, 2012, 1-8.	1.7	14
817	An Aspirin a Day: The Allure (and Distraction) of Chemoprevention. Journal of the National Cancer Institute, 2012, 104, 1782-1784.	3.0	4
818	Late SV40 Factor (LSF) Enhances Angiogenesis by Transcriptionally Up-regulating Matrix Metalloproteinase-9 (MMP-9). Journal of Biological Chemistry, 2012, 287, 3425-3432.	1.6	36
819	Expression and functional role of vacuolar H+-ATPase in human hepatocellular carcinoma. Carcinogenesis, 2012, 33, 2432-2440.	1.3	61
820	Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncology Reports, 2012, 28, 1406-1412.	1.2	48
821	TGF-Î² in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma. Current Pharmaceutical Design, 2012, 18, 4135-4147.	0.9	95
822	Transforming Growth Factor Beta 1 Overexpression Is Closely Related to Invasiveness of Hepatocellular Carcinoma. Oncology, 2012, 82, 11-18.	0.9	46
823	Epidemiology and Surveillance of Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 2-14.	4.2	144
824	Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer, 2012, 1, 257-266.	4.2	48
825	Clinical Implications of Arrest-Defective Protein 1 Expression in Hepatocellular Carcinoma: A Novel Predictor of Microvascular Invasion. Digestive Diseases, 2012, 30, 603-608.	0.8	24
826	Synthesis and Anticancer Activity of Novel Benzimidazole and Benzothiazole Derivatives against HepG2 Liver Cancer Cells. Medicinal Chemistry, 2012, 8, 151-162.	0.7	30
827	Therapeutically Targeting MicroRNAs in Liver Cancer. Current Pharmaceutical Design, 2012, 19, 1180-1191.	0.9	27
828	Preventive effect of caffeine and curcumin on hepatoÃ¯Â¿Â½carcinogenesis in diethylnitrosamine-induced rats. International Journal of Oncology, 2012, 40, 1779-88.	1.4	8
829	Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma. Oncology Reports, 2012, 27, 2073-9.	1.2	25
830	Epigenetic Deregulation of MicroRNAs: New Opportunities to Target Oncogenic Signaling Pathways in Hepatocellular Carcinoma. Current Pharmaceutical Design, 2012, 19, 1192-1200.	0.9	11

#	Article	IF	Citations
831	Role of Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Basic Aspects, Clinical Applications, and Future Prospects. Current Cancer Drug Targets, 2012, 12, 1119-1128.	0.8	5
832	Normal Hepatocyte Transplantation Delays the Emergence of Chemically Induced Preneoplastic Nodules in Rat Liver. Cell Transplantation, 2012, 21, 671-677.	1.2	2
833	The TGF-Î² Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma. Current Pharmaceutical Design, 2012, 18, 4148-4154.	0.9	16
834	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. Oncology Reports, 2012, 28, 701-706.	1.2	64
835	Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 840-848.	0.8	32
836	Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2012, 12, 1081-1094.	0.8	34
837	Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed. Current Drug Targets, 2012, 13, 1842-1857.	1.0	56
838	Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 575-582.	0.8	8
839	Differential expression profiles of sense and antisense transcripts between HCV-associated hepatocellular carcinoma and corresponding non-cancerous liver tissue. International Journal of Oncology, 2012, 40, 1813-20.	1.4	7
840	High HBV-DNA Titer in Surrounding Liver Rather Than in Hepatocellular Carcinoma Tissue Predisposes to Recurrence After Curative Surgical Resection. Journal of Clinical Gastroenterology, 2012, 46, 413-419.	1.1	5
841	African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection. Journal of Clinical Gastroenterology, 2012, 46, e62-e65.	1.1	15
842	Angiogenesis in Hepatocellular Carcinoma: A Potential Target for Chemoprevention and Therapy. Current Cancer Drug Targets, 2012, 12, 1095-1118.	0.8	3
843	Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. Antiviral Therapy, 2012, 17, 1397-1401.	0.6	12
844	Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncology Letters, 2012, 4, 817-823.	0.8	65
845	HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility. Oncology Letters, 2012, 4, 358-364.	0.8	6
846	Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules. International Journal of Molecular Medicine, 2012, 29, 1158-64.	1.8	20
847	Relationship of Î±-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Experimental and Therapeutic Medicine, 2012, 4, 972-976.	0.8	10
848	Multi-pathway network analysis of mammalian epithelial cell responses in inflammatory environments. Biochemical Society Transactions, 2012, 40, 133-138.	1.6	3

#	Article	IF	Citations
849	Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium. Oncology Reports, 2012, 27, 1090-1096.	1.2	36
850	Two-Stage Model of Chemically Induced Hepatocellular Carcinoma in Mouse. Oncology Research, 2012, 20, 517-528.	0.6	15
851	Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer. Oncology Reports, 2012, 28, 1263-1268.	1.2	40
852	Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo. International Journal of Molecular Medicine, 2012, 29, 1045-52.	1.8	9
853	Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Oncology Reports, 2012, 27, 1443-50.	1.2	11
854	Anticancer Effects of Residual Powder from Barley-<i>Shochu</i> Distillation Remnants against the Orthotopic Xenograft Mouse Models of Hepatocellular Carcinoma <i>in Vivo</i>. Biological and Pharmaceutical Bulletin, 2012, 35, 984-987.	0.6	5
855	Caffeine Increases the Antitumor Effect of Cisplatin in Human Hepatocellular Carcinoma Cells. Biological and Pharmaceutical Bulletin, 2012, 35, 400-407.	0.6	25
856	285 DOWNREGULATION OF ORGANIC CATION TRANSPORTERS OCT1 (SLC22A1) AND OCT3 (SLC22A3) IN HUMAN HEPATOCELLULAR CARCINOMA AND THEIR PROGNOSTIC SIGNIFICANCE. Journal of Hepatology, 2012, 56, S118.	1.8	0
857	Targeting autophagy for the treatment of liver diseases. Pharmacological Research, 2012, 66, 463-474.	3.1	63
858	MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of Î²-catenin. Biochemical and Biophysical Research Communications, 2012, 428, 525-531.	1.0	95
859	Daily Aspirin Use and Cancer Mortality in a Large US Cohort. Journal of the National Cancer Institute, 2012, 104, 1208-1217.	3.0	79
860	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virusâ€related advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1528-1534.	1.4	13
861	Desâ€Îˆâ€carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1602-1608.	1.4	31
862	Association Between Two Genetic Variants in miRNA and Primary Liver Cancer Risk in the Chinese Population. DNA and Cell Biology, 2012, 31, 524-530.	0.9	61
863	MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sciences, 2012, 91, 440-447.	2.0	62
864	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology, 2012, 142, 1021-1031.e15.	0.6	443
865	Hepatocellualar Carcinoma Serum Markers. Seminars in Oncology, 2012, 39, 410-433.	0.8	147
866	Hepatocellular carcinoma in nonâ€alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatology Research, 2012, 42, 1-14.	1.8	106

#	Article	IF	Citations
867	Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatology Research, 2012, 42, 22-32.	1.8	7
868	Serum miR-18a: A Potential Marker for Hepatitis B Virus-Related Hepatocellular Carcinoma Screening. Digestive Diseases and Sciences, 2012, 57, 2910-2916.	1.1	98
869	(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9. Investigational New Drugs, 2012, 30, 2087-2095.	1.2	14
870	Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 51-59.	0.6	13
871	Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 177-184.	0.6	17
872	Potential for statins in the chemoprevention and management of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1654-1664.	1.4	58
873	Risk factors for hepatocellular carcinoma. Clinical Liver Disease, 2012, 1, 180-182.	1.0	52
874	Current issues and future trends in surveillance for hepatocellular carcinoma. Clinical Liver Disease, 2012, 1, 186-189.	1.0	2
875	Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology, 2012, 56, 1651-1660.	3.6	98
876	Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. Hepatology, 2012, 56, 2231-2241.	3.6	347
877	Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha. Journal of Molecular Medicine, 2012, 90, 1069-1077.	1.7	33
878	Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2012, 61, 1433-1439.	2.0	39
879	Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunology, Immunotherapy, 2012, 61, 1977-1987.	2.0	63
880	Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 600-605.	1.4	27
881	Novel Lens culinaris agglutinin-reactive fraction of Î±-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low Î±-fetoprotein concentrations. International Journal of Clinical Oncology, 2012, 17, 373-379.	1.0	24
882	Antihyperlipidemic and Antitumor Effects of Chickpea Albumin Hydrolysate. Plant Foods for Human Nutrition, 2012, 67, 393-400.	1.4	38
883	Transcriptional repression of TWIST1 gene by Prosperoâ€related homeobox 1 inhibits invasiveness of hepatocellular carcinoma cells. FEBS Letters, 2012, 586, 3746-3752.	1.3	25
884	Liver Resection for Hepatocellular Carcinoma â‰¤3 cm: Results of an Italian Multicenter Study on 588 Patients. Journal of the American College of Surgeons, 2012, 215, 244-254.	0.2	51

#	Article	IF	Citations
885	Underuse of curative surgery for early stage upper gastrointestinal cancers in the United States. Journal of Surgical Research, 2012, 177, 55-62.	0.8	14
886	Heterogeneity of Microbubble Accumulation: A Novel Approach to Discriminate Between Well-Differentiated Hepatocellular Carcinomas and Regenerative Nodules. Ultrasound in Medicine and Biology, 2012, 38, 383-388.	0.7	11
887	Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumor Biology, 2012, 33, 2401-2409.	0.8	58
888	Novel Neo Glycolipid: Formulation into Pegylated Cationic Liposomes and Targeting of DNA Lipoplexes to the Hepatocyte-Derived Cell Line HepG2. Nucleosides, Nucleotides and Nucleic Acids, 2012, 31, 206-223.	0.4	8
889	Elevation of Highly Up-regulated in Liver Cancer (HULC) by Hepatitis B Virus X Protein Promotes Hepatoma Cell Proliferation via Down-regulating p18. Journal of Biological Chemistry, 2012, 287, 26302-26311.	1.6	332
891	Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature Genetics, 2012, 44, 760-764.	9.4	781
893	Analysis of Urinary Metabolic Signatures of Early Hepatocellular Carcinoma Recurrence after Surgical Removal Using Gas Chromatographyâ€“Mass Spectrometry. Journal of Proteome Research, 2012, 11, 4361-4372.	1.8	62
894	Considerations in the significance of Dickkopfâ€1 levels in human hepatocellular carcinoma. Liver International, 2012, 32, 1460-1460.	1.9	1
895	Micro<scp>RNA</scp>â€122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting <scp>Wnt/Î²</scp>â€catenin pathway. Liver International, 2012, 32, 752-760.	1.9	188
896	Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver International, 2012, 32, 1217-1221.	1.9	109
897	The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver International, 2012, 32, 1053-1063.	1.9	101
898	Applicability of <scp>BCLC</scp> stage for prognostic stratification in comparison with other staging systems: single centre experience from longâ€term clinical outcomes of 1717 treatmentâ€naÃ¯ve patients with hepatocellular carcinoma. Liver International, 2012, 32, 1120-1127.	1.9	91
899	Upâ€regulated aldoâ€keto reductase family 1 member B10 in chronic hepatitis C: association with serum alphaâ€fetoprotein and hepatocellular carcinoma. Liver International, 2012, 32, 1382-1390.	1.9	30
900	A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. American Journal of Surgery, 2012, 203, 182-190.	0.9	7
901	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. Journal of Hepatology, 2012, 56, 267-275.	1.8	150
902	Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. Journal of Hepatology, 2012, 56, 419-425.	1.8	101
903	Genomic risk of hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 729-730.	1.8	15
904	Obesity, inflammation, and liver cancer. Journal of Hepatology, 2012, 56, 704-713.	1.8	428

#	Article	IF	Citations
905	Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. Journal of Hepatology, 2012, 56, 1384-1391.	1.8	735
906	A dual role for hypoxia inducible factor-1Î± in the hepatitis C virus lifecycle and hepatoma migration. Journal of Hepatology, 2012, 56, 803-809.	1.8	74
907	Deregulation of microRNAs expression occurs in stages of multistep hepatocarcinogenesis: Why is it different?. Journal of Hepatology, 2012, 56, 1425-1426.	1.8	0
908	Reply to: â€œDeregulation of microRNAs expression occurs in stages of multistep hepatocarcinogenesis: Why is it different?â€. Journal of Hepatology, 2012, 56, 1426-1427.	1.8	0
909	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology, 2012, 56, 1343-1350.	1.8	181
910	Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. Journal of Hepatology, 2012, 57, 663-674.	1.8	140
911	Why men are at higher risk for hepatocellular carcinoma?. Journal of Hepatology, 2012, 57, 453-454.	1.8	38
912	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 2012, 57, 821-829.	1.8	736
914	Alterations in microRNA expression linked to microcystin-LR-induced tumorigenicity in human WRL-68 Cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 743, 75-82.	0.9	40
915	Residual powders from Shochu distillation remnants induce apoptosis in human hepatoma cells via the caspase-independent pathway. Journal of Bioscience and Bioengineering, 2012, 114, 104-109.	1.1	5
916	New natural variants of hepatitis B virus among Amerindians from Argentina with mainly occult infections. Journal of Clinical Virology, 2012, 54, 174-179.	1.6	22
917	Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2012, 418, 433-438.	1.0	40
918	SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated chemotherapeutic drugs induced apoptosis in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2012, 420, 651-655.	1.0	12
919	Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2012, 421, 355-360.	1.0	16
920	Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2012, 421, 837-843.	1.0	30
921	Gambogenic acid induced mitochondrial-dependent apoptosis and referred to Phospho-Erk1/2 and Phospho-p38 MAPK in human hepatoma HepG2 cells. Environmental Toxicology and Pharmacology, 2012, 33, 181-190.	2.0	62
922	Alantolactone induces activation of apoptosis in human hepatoma cells. Food and Chemical Toxicology, 2012, 50, 3313-3319.	1.8	56
923	miRâ€376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Letters, 2012, 586, 2396-2403.	1.3	70

#	Article	IF	Citations
924	In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. International Journal of Biochemistry and Cell Biology, 2012, 44, 1351-1360.	1.2	28
925	Thieno[3,2-c]pyran-4-one based novel small molecules: Their synthesis, crystal structure analysis and in vitro evaluation as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4418-4427.	1.0	34
926	HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. Cancer Letters, 2012, 316, 187-195.	3.2	34
927	Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Letters, 2012, 319, 98-108.	3.2	30
928	CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. European Journal of Cancer, 2012, 48, 138-148.	1.3	68
929	Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies. European Journal of Cancer, 2012, 48, 2137-2145.	1.3	192
930	Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection â€“ Results from a clinic-based longitudinal cohort. European Journal of Cancer, 2012, 48, 2319-2327.	1.3	21
931	Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes. European Journal of Internal Medicine, 2012, 23, 34-36.	1.0	7
933	RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene, 2012, 498, 264-269.	1.0	11
934	Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice. Science Signaling, 2012, 5, ra24.	1.6	157
935	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics, 2012, 44, 694-698.	9.4	1,229
936	Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. BioEssays, 2012, 34, 1050-1059.	1.2	227
937	Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology, 2012, 56, 1380-1390.	3.6	71
938	Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer, 2012, 12, 386.	1.1	41
939	Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Molecular Cancer, 2012, 11, 64.	7.9	61
940	Haematogenous abdominal wall metastasis of differentiated, alpha-fetoprotein-negative hepatocellular carcinoma after previous antiandrogen therapy within a site of lipoma manifestation since childhood. World Journal of Surgical Oncology, 2012, 10, 98.	0.8	4
941	Liver and Pancreas. , 2012, , 433-535.		20
942	Recent advances in metabolomics in oncology. Bioanalysis, 2012, 4, 431-451.	0.6	50

#	Article	IF	Citations
943	Multimodality Treatment for Early-Stage Hepatocellular Carcinoma: A Bridging Therapy for Liver Transplantation. Digestion, 2012, 86, 338-348.	1.2	27
944	The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC). Cellular and Molecular Immunology, 2012, 9, 103-104.	4.8	8
945	Effects of swim training on liver carcinogenesis in male Wistar rats fed a low-fat or high-fat diet. Applied Physiology, Nutrition and Metabolism, 2012, 37, 1101-1109.	0.9	14
946	Evidence-based Anticancer Materia Medica for Hepatocellular Carcinoma. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , 89-102.	0.1	0
947	Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 2012, 142, 1264-1273.e1.	0.6	2,753
948	Disruption of Trp53 in Livers of Mice Induces Formation of Carcinomas With Bilineal Differentiation. Gastroenterology, 2012, 142, 1229-1239.e3.	0.6	74
949	Hepatitis B Virus X Protein Confers Resistance of Hepatoma Cells to Anoikis by Up-regulating and Activating p21-Activated Kinase 1. Gastroenterology, 2012, 143, 199-212.e4.	0.6	70
950	MicroRNAs in Liver Disease. Gastroenterology, 2012, 142, 1431-1443.	0.6	248
951	Can Dietary Fish Intake Prevent Liver Cancer?. Gastroenterology, 2012, 142, 1411-1413.	0.6	4
952	Clinical Dilemmas in Primary Liver Cancer. Gastroenterology, 2012, 143, 1396-1397.	0.6	0
953	High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Human Pathology, 2012, 43, 1425-1435.	1.1	105
954	Expression of Yes-associated protein modulates Survivin expression in primary liver malignancies. Human Pathology, 2012, 43, 1376-1385.	1.1	41
955	Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: A caseâ€“control study. Alcohol, 2012, 46, 537-541.	0.8	19
956	Chemotherapeutic efficacy of limonin against Aflatoxin B1 induced primary hepatocarcinogenesis in Wistar albino rats. Biomedicine and Aging Pathology, 2012, 2, 206-211.	0.8	12
957	NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiology, 2012, 36, e294-e299.	0.8	40
958	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Critical Reviews in Oncology/Hematology, 2012, 83, 216-224.	2.0	42
959	Vinyl chloride exposure and cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease, 2012, 44, 775-779.	0.4	16
960	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. Digestive and Liver Disease, 2012, 44, 674-680.	0.4	17

#	Article	IF	Citations
961	A miR-1231 binding site polymorphism in the 3â€²UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene, 2012, 507, 95-98.	1.0	32
962	Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A caseâ€“control study. Gene, 2012, 511, 308-313.	1.0	23
963	Clinical Profile and Liver Explant Findings in Patients With and Without Pretransplant Downstaging for Hepatocellular Carcinoma. Transplantation Proceedings, 2012, 44, 2399-2402.	0.3	2
964	Why are East Asians more susceptible to several infection-associated cancers (carcinomas of the) Tj ETQq1 1 0.784314 rgBT /Overloc Hypotheses, 2012, 79, 833-842.	0.8	17
965	Identification of recurrenceâ€related microRNAs in hepatocellular carcinoma following liver transplantation. Molecular Oncology, 2012, 6, 445-457.	2.1	105
966	DEHP: Genotoxicity and potential carcinogenic mechanismsâ€”A review. Mutation Research - Reviews in Mutation Research, 2012, 751, 82-157.	2.4	175
967	MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-ÎºB-inducing kinase (NIK). Oncogene, 2012, 31, 3607-3620.	2.6	110
968	Clinical Implications of Cancer Stem Cell Biology in Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 461-472.	0.8	179
969	Concomitant lung metastasis in patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 2533.	1.4	15
970	The Role of Interferon Therapy in Patients with Hepatocellular Carcinoma. Current Hepatitis Reports, 2012, 11, 279-285.	0.3	0
971	The role of RhoC in the proliferation and apoptosis of hepatocellular carcinoma cells. Medical Oncology, 2012, 29, 1802-1809.	1.2	16
972	miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Medical Oncology, 2012, 29, 1859-1865.	1.2	52
973	Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Medical Oncology, 2012, 29, 2744-2749.	1.2	19
974	Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma. Medical Oncology, 2012, 29, 3063-3069.	1.2	9
975	Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatology International, 2012, 6, 735-743.	1.9	31
976	Inflammatory Immune Responses in Tumor Microenvironment and Metastasis of Hepatocellular Carcinoma. Cancer Microenvironment, 2012, 5, 203-209.	3.1	55
977	Medical Care Costs and Survival Associated With Hepatocellular Carcinoma Among the Elderly. Clinical Gastroenterology and Hepatology, 2012, 10, 547-554.	2.4	24
978	Phase I/II Multicenter Study of Transarterial Chemoembolization with a Cisplatin Fine Powder and Porous Gelatin Particles for Unresectable Hepatocellular Carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401. Journal of Vascular and Interventional Radiology, 2012, 23, 1278-1285.	0.2	15

#	Article	IF	Citations
979	The Significance of MMP-9 Over MMP-2 in HCC Invasiveness and Recurrence of Hepatocellular Carcinoma After Curative Resection. Annals of Surgical Oncology, 2012, 19, 375-384.	0.7	83
980	Liver Cancer. , 2012, , 95-119.		0
981	Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 793-799.	1.1	227
982	Sorafenib Use in Hepatocellular Carcinoma in Japan: Early Experience and Impact on Clinical Practice. Clinical Drug Investigation, 2012, 32, 1-2.	1.1	14
983	Survivin-mediated Therapeutic Efficacy of Gemcitabine through Glucose-regulated Protein 78 in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2012, 19, 2744-2752.	0.7	11
984	The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection. Annals of Surgical Oncology, 2012, 19, 3556-3565.	0.7	37
985	Construction and development of a mammalian cell-based full-length antibody display library for targeting hepatocellular carcinoma. Applied Microbiology and Biotechnology, 2012, 96, 1233-1241.	1.7	7
987	Sex and Gender Differences in Pharmacology. Handbook of Experimental Pharmacology, 2012, , .	0.9	36
988	Metabonomic Profiles Discriminate Hepatocellular Carcinoma from Liver Cirrhosis by Ultraperformance Liquid Chromatographyâ€“Mass Spectrometry. Journal of Proteome Research, 2012, 11, 1217-1227.	1.8	122
989	Knockdown of glucose-regulated protein 78 decreases the invasion, metalloproteinase expression and ECM degradation in hepatocellular carcinoma cells. Journal of Experimental and Clinical Cancer Research, 2012, 31, 39.	3.5	37
990	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e32493.	1.1	61
991	Effect of RECK Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathologic Features. PLoS ONE, 2012, 7, e33517.	1.1	21
992	LAPTM4B Allele *2 Is a Marker of Poor Prognosis Following Hepatic Tumor Resection for Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e34984.	1.1	18
993	Precore Mutation of Hepatitis B Virus May Contribute to Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis. PLoS ONE, 2012, 7, e38394.	1.1	51
994	Lack of Association of Two Common Polymorphisms rs2910164 and rs11614913 with Susceptibility to Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2012, 7, e40039.	1.1	42
995	Identification and Characterization of Tropomyosin 3 Associated with Granulin-Epithelin Precursor in Human Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e40324.	1.1	23
996	Dyskerin Overexpression in Human Hepatocellular Carcinoma Is Associated with Advanced Clinical Stage and Poor Patient Prognosis. PLoS ONE, 2012, 7, e43147.	1.1	60
997	Regulation of Amphiregulin Gene Expression by Î²-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS ONE, 2012, 7, e52711.	1.1	45

#	Article	IF	Citations
998	The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas, 2012, 104, 298-304.	0.1	40
999	Sequential analysis of diethylnitrosamine-induced hepatocarcinogenesis in rats. Experimental and Therapeutic Medicine, 2012, 3, 371-378.	0.8	14
1000	Pharmacological Unmasking Microarray Approach-Based Discovery of Novel DNA Methylation Markers for Hepatocellular Carcinoma. Journal of Korean Medical Science, 2012, 27, 594.	1.1	11
1001	Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Annals of Hepatology, 2012, 11, 899-906.	0.6	20
1002	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology, 2012, 11, 284-293.	0.6	22
1003	Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Annals of Hepatology, 2012, 11, 487-494.	0.6	45
1004	Modulation of Cell Proliferation Pathways by the Hepatitis B Virus X Protein: A Potential Contributor to the Development of Hepatocellular Carcinoma. , 2012, , .		1
1005	Meta-analysis of laparoscopicvsopen liver resection for hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 6657.	1.4	137
1006	Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma. Molecular Medicine, 2012, 18, 286-296.	1.9	54
1007	Target Therapy for Hepatocellular Carcinoma. Hanyang Medical Reviews, 2012, 32, 118.	0.4	0
1008	An Appraisal of Radiofrequency Ablation and Surgical Resection for Hepatocellular Carcinoma: Results from the Surveillance, Epidemiology, and End Results Registry. American Surgeon, 2012, 78, 1091-1095.	0.4	5
1009	Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report. Journal of Cancer, 2012, 3, 158-165.	1.2	22
1010	Targeted p21^{WAF1/CIP1} Activation by RNAa Inhibits Hepatocellular Carcinoma Cells. Nucleic Acid Therapeutics, 2012, 22, 335-343.	2.0	43
1011	Deficiency in Galectin-3 Promotes Hepatic Injury in CDAA Diet-Induced Nonalcoholic Fatty Liver Disease. Scientific World Journal, The, 2012, 2012, 1-9.	0.8	23
1012	Hepatocellular Carcinoma: Epidemiology and Etiology. , 2012, , .		0
1013	Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. , 2012, , 142-156.		2
1015	Effects of STAT3 Gene Silencing and Rapamycin on Apoptosis in Hepatocarcinoma Cells. International Journal of Medical Sciences, 2012, 9, 216-224.	1.1	19
1016	Embelin-induced apoptosis of HepG2 human hepatocellular carcinoma cells and blockade of HepG2 cells in the G2/M phase via the mitochondrial pathway. Experimental and Therapeutic Medicine, 2012, 4, 649-654.	0.8	12

#	Article	IF	Citations
1017	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget, 2012, 3, 236-260.	0.8	152
1018	The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virusâ€related hepatocellular carcinoma. Journal of Surgical Oncology, 2012, 105, 606-611.	0.8	16
1019	The promoting effect of adiponectin in hepatocellular carcinoma. Journal of Surgical Oncology, 2012, 106, 181-187.	0.8	39
1020	Oestrogen attenuates tumour progression in hepatocellular carcinoma. Journal of Pathology, 2012, 228, 216-229.	2.1	46
1021	AFB₁â€induced mutagenesis of the gpt gene in AS52 cells. Environmental and Molecular Mutagenesis, 2012, 53, 567-573.	0.9	4
1022	Zinc finger transcription factor 191, directly binding to Î²-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. Hepatology, 2012, 55, 1830-1839.	3.6	51
1023	V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology, 2012, 55, 1473-1484.	3.6	50
1024	Hepatitis B virus X protein modulates oncogene yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology, 2012, 56, 2051-2059.	3.6	159
1025	Prognostic significance of osteopontin in hepatocellular carcinoma: A metaâ€analysis. International Journal of Cancer, 2012, 130, 2685-2692.	2.3	36
1026	Type 2 diabetes and hepatocellular carcinoma: A caseâ€“control study in patients with chronic hepatitis B. International Journal of Cancer, 2012, 131, 1197-1202.	2.3	39
1027	Nuclear accumulation of seven in absentia homologueâ€2 supports motility and proliferation of liver cancer cells. International Journal of Cancer, 2012, 131, 2016-2026.	2.3	21
1028	Runtâ€related transcription factor 3 reverses epithelialâ€“mesenchymal transition in hepatocellular carcinoma. International Journal of Cancer, 2012, 131, 2537-2546.	2.3	46
1029	mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. Science Translational Medicine, 2012, 4, 139ra84.	5.8	88
1030	1,4â€Bis[2â€(3,5â€dichloropyridyloxy)]benzene induces substantial hyperplasia in fibrotic mouse liver. International Journal of Experimental Pathology, 2012, 93, 125-129.	0.6	3
1031	Demographics of hepatitis C virus today. Clinical Liver Disease, 2012, 1, 2-5.	1.0	1
1032	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer, 2012, 118, 3984-3992.	2.0	53
1033	Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer, 2012, 118, 5560-5571.	2.0	58
1034	Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. Annual Review of Genomics and Human Genetics, 2012, 13, 171-205.	2.5	86

#	Article	IF	Citations
1035	Management of Hepatocellular Carcinoma: Beyond Sorafenib. Current Oncology Reports, 2012, 14, 257-266.	1.8	27
1036	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486, 395-399.	13.7	1,778
1037	Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C. Digestive Diseases and Sciences, 2012, 57, 832-834.	1.1	2
1038	The Value of Thioredoxin Family Proteins and Proliferation Markers in Dysplastic and Malignant Gallbladders in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2012, 57, 1163-1170.	1.1	7
1039	Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 1768-1772.	1.2	7
1040	The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a caseâ€“control study. Molecular Biology Reports, 2012, 39, 5943-5951.	1.0	31
1041	Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Molecular Biology Reports, 2012, 39, 7019-7023.	1.0	117
1042	High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection. Journal of Gastrointestinal Surgery, 2012, 16, 828-836.	0.9	38
1043	Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review. Journal of General Internal Medicine, 2012, 27, 861-867.	1.3	245
1044	Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 36-43.	0.7	27
1045	O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Medical Oncology, 2012, 29, 985-993.	1.2	126
1046	Quantitation of Plasma Circulating DNA Using Quantitative PCR for the Detection of Hepatocellular Carcinoma. Pathology and Oncology Research, 2012, 18, 271-276.	0.9	71
1047	High-mobility Group Box 1 is Associated with Clinicopathologic Features in Patients with Hepatocellular Carcinoma. Pathology and Oncology Research, 2012, 18, 293-298.	0.9	28
1048	Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches. Abdominal Imaging, 2012, 37, 164-179.	2.0	25
1049	Switching the Loaded Agent from Epirubicin to Cisplatin: Salvage Transcatheter Arterial Chemoembolization with Drug-eluting Microspheres for Unresectable Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2012, 35, 555-562.	0.9	24
1050	Immunobiology of hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2012, 397, 673-680.	0.8	18
1051	Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. Journal of Gastroenterology, 2012, 47, 569-576.	2.3	36
1053	Use of antiviral therapy in surveillance: impact on outcome of hepatitis Bâ€related hepatocellular carcinoma. Liver International, 2012, 32, 271-278.	1.9	16

#	Article	IF	Citations
1054	Sphingosine kinase 1 promotes tumour cell migration and invasion via the <scp>S1P</scp>/<scp>EDG</scp>1 axis in hepatocellular carcinoma. Liver International, 2012, 32, 331-338.	1.9	89
1055	Insulinâ€like growth factor II mRNAâ€binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology, 2012, 60, 278-286.	1.6	35
1056	Anti-cancer activity and mutagenic potential of novel copper(II) quinolinone Schiff base complexes in hepatocarcinoma cells. European Journal of Pharmacology, 2012, 689, 45-55.	1.7	75
1057	The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 129-169.	3.3	338
1058	Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials, 2012, 33, 2187-2196.	5.7	247
1059	Hepatocellular carcinoma: diagnostics and screening. Journal of Evaluation in Clinical Practice, 2012, 18, 335-342.	0.9	46
1060	Chronic Ethanol Feeding Accelerates Hepatocellular Carcinoma Progression in a Sexâ€Dependent Manner in a Mouse Model of Hepatocarcinogenesis. Alcoholism: Clinical and Experimental Research, 2012, 36, 641-653.	1.4	69
1061	First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular) Tj ETQq1 1 0.784314 rgBT /Overlock Clinical Practice, 2012, 66, 675-683.	0.8	102
1062	Association Between Viral Hepatitis and Erectile Dysfunction: A Populationâ€Based Caseâ€Control Analysis. Journal of Sexual Medicine, 2012, 9, 1295-1302.	0.3	21
1063	Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 156-163.	0.7	14
1064	Integrated approach toward the discovery of glycoâ€biomarkers of inflammationâ€related diseases. Annals of the New York Academy of Sciences, 2012, 1253, 159-169.	1.8	36
1065	Green tea polyphenol epigallocatechinâ€3â€gallate enhances 5â€fluorouracilâ€induced cell growth inhibition of hepatocellular carcinoma cells. Hepatology Research, 2012, 42, 494-501.	1.8	35
1066	Lateâ€evening snack with branchedâ€chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. Hepatology Research, 2012, 42, 658-667.	1.8	34
1067	Clinical and pathological progression of nonâ€alcoholic steatohepatitis to hepatocellular carcinoma. Hepatology Research, 2012, 42, 767-773.	1.8	49
1068	Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatology Research, 2012, 42, 879-886.	1.8	86
1069	Do hepatitis B virus and hepatitis C virus coâ€infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression?. Hepatology Research, 2012, 42, 733-740.	1.8	13
1070	Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 2012, 42, 1175-1186.	1.8	6
1071	Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis. Journal of Nutritional Biochemistry, 2012, 23, 860-866.	1.9	20

#	Article	IF	Citations
1072	Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III. Journal of Proteomics, 2012, 75, 2855-2868.	1.2	11
1073	Anti-metastatic effects of ginsenoside Rd via inactivation of MAPK signaling and induction of focal adhesion formation. Phytomedicine, 2012, 19, 284-292.	2.3	54
1074	Potentially curative treatment in patients with hepatocellular cancerâ€"results from the liver cancer research network. Alimentary Pharmacology and Therapeutics, 2012, 36, 257-265.	1.9	35
1075	Hepatocellular carcinoma screening practices and impact on survival among hepatitis Bâ€infected Asian Americans. Journal of Viral Hepatitis, 2012, 19, 594-600.	1.0	41
1076	Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 10-14.	1.4	41
1077	Targeted therapy of hepatocellular carcinoma: Present and future. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 862-872.	1.4	72
1078	Overexpression of galectinâ€1 is associated with poor prognosis in human hepatocellular carcinoma following resection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1312-1319.	1.4	52
1079	Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer, 2012, 12, 109.	1.1	94
1080	Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer, 2012, 12, 56.	1.1	166
1081	Clinicopathological Significance of ZEB1 Protein in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2012, 19, 1700-1706.	0.7	85
1082	High Serum Hyaluronic Acid and HBV Viral Load are Main Prognostic Factors of Local Recurrence after Complete Radiofrequency Ablation of Hepatitis B-Related Small Hepatocellular Carcinoma. Annals of Surgical Oncology, 2012, 19, 1284-1291.	0.7	38
1083	SIRT1 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma and its Expression Predicts Poor Prognosis. Annals of Surgical Oncology, 2012, 19, 2011-2019.	0.7	150
1084	Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology, 2012, 55, 141-152.	3.6	39
1085	Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. Hepatology, 2012, 55, 800-806.	3.6	130
1086	Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. International Journal of Cancer, 2012, 130, 1319-1328.	2.3	80
1087	Increased incidence of aflatoxin B1â€induced liver tumors in hepatitis virus C transgenic mice. International Journal of Cancer, 2012, 130, 1347-1356.	2.3	30
1088	Depletion of GRIMâ€19 accelerates hepatocellular carcinoma invasion via inducing EMT and loss of contact inhibition. Journal of Cellular Physiology, 2012, 227, 1212-1219.	2.0	32
1089	Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus mâ€TOR inhibitors monotherapy?. Journal of Surgical Oncology, 2012, 105, 111-112.	0.8	9

#	Article	IF	Citations
1090	Mutations within enhancer II and BCP regions of hepatitis B virus in relation to advanced liver diseases in patients infected with subgenotype B3 in Indonesia. Journal of Medical Virology, 2012, 84, 44-51.	2.5	15
1091	HCV and Chemotherapy: Does Infection Change Management?. Current Hepatitis Reports, 2012, 11, 34-40.	0.3	0
1092	Comparing the Detectability of Hepatocellular Carcinoma by C-Arm Dual-Phase Cone-Beam Computed Tomography During Hepatic Arteriography With Conventional Contrast-Enhanced Magnetic Resonance Imaging. CardioVascular and Interventional Radiology, 2012, 35, 97-104.	0.9	66
1093	ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemotherapy and Pharmacology, 2012, 69, 799-805.	1.1	30
1094	Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a caseâ€“control study. Cancer Causes and Control, 2012, 23, 455-462.	0.8	31
1095	Estrogen Suppresses Metastasis in Rat Hepatocellular Carcinoma through Decreasing Interleukin-6 and Hepatocyte Growth Factor Expression. Inflammation, 2012, 35, 143-149.	1.7	39
1096	Predictors of Liver Transplant Eligibility for Patients with Hepatocellular Carcinoma in a Safety Net Hospital. Digestive Diseases and Sciences, 2012, 57, 580-586.	1.1	15
1097	Reduced High-Mobility Group Box 1 Expression Induced by RNA Interference Inhibits the Bioactivity of Hepatocellular Carcinoma Cell Line HCCLM3. Digestive Diseases and Sciences, 2012, 57, 92-98.	1.1	16
1098	Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Molecular and Cellular Biochemistry, 2012, 361, 337-343.	1.4	19
1099	p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a caseâ€“control study. Molecular Biology Reports, 2012, 39, 1639-1647.	1.0	30
1100	Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. Journal of Cancer Research and Clinical Oncology, 2012, 138, 153-161.	1.2	117
1101	Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell and Tissue Research, 2012, 347, 225-243.	1.5	74
1102	Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. International Journal of Cancer, 2013, 132, 645-657.	2.3	158
1103	Human O⁶â€methylguanineâ€DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice. Molecular Carcinogenesis, 2013, 52, 275-285.	1.3	1
1104	Black currant phytoconstituents exert chemoprevention of diethylnitrosamineâ€initiated hepatocarcinogenesis by suppression of the inflammatory response. Molecular Carcinogenesis, 2013, 52, 304-317.	1.3	30
1105	Expression of microRNAs, miRâ€21, miRâ€31, miRâ€122, miRâ€145, miRâ€146a, miRâ€200c, miRâ€221, miRâ€222, and miRâ€223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Molecular Carcinogenesis, 2013, 52, 297-303.	1.3	306
1106	The prolyl isomerase Pin1 interacts with and downregulates the activity of AMPK leading to induction of tumorigenicity of hepatocarcinoma cells. Molecular Carcinogenesis, 2013, 52, 813-823.	1.3	15
1107	Phase 2 trial of linifanib (ABTâ€869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer, 2013, 119, 380-387.	2.0	93

#	Article	IF	Citations
1108	Reduced expression of DACT2 promotes hepatocellular carcinoma progression: involvement of methylation-mediated gene silencing. World Journal of Surgical Oncology, 2013, 11, 57.	0.8	9
1109	Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2013, 32, 21.	3.5	75
1110	Expression and prognostic value of VEGFR-2, PDGFR-Î², and c-Met in advanced hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2013, 32, 16.	3.5	86
1111	Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Molecular and Cellular Biochemistry, 2013, 378, 99-106.	1.4	62
1112	Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein and Cell, 2013, 4, 71-81.	4.8	30
1113	The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma. Tumor Biology, 2013, 34, 2977-2981.	0.8	23
1114	Thyroid hormone actions in liver cancer. Cellular and Molecular Life Sciences, 2013, 70, 1915-1936.	2.4	26
1115	Advances in MALDI Mass Spectrometry in Clinical Diagnostic Applications. Topics in Current Chemistry, 2013, 336, 139-175.	4.0	33
1116	Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 553-562.	8.2	833
1117	Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer, 2013, 13, 335.	1.1	45
1118	UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer, 2013, 13, 167.	1.1	35
1119	MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell International, 2013, 13, 3.	1.8	21
1120	Operative Microwave Ablation for Hepatocellular Carcinoma: Complications, Recurrence, and Long-Term Outcomes. Journal of Gastrointestinal Surgery, 2013, 17, 719-729.	0.9	75
1121	AEG-1/MTDH/LYRIC in Liver Cancer. Advances in Cancer Research, 2013, 120, 193-221.	1.9	51
1122	From Phage lambda to human cancer: endogenous molecularâ€cellular network hypothesis. Quantitative Biology, 2013, 1, 32-49.	0.3	27
1123	Risk Profile of Hepatocellular Carcinoma Reveals Dichotomy among US Veterans. Journal of Gastrointestinal Cancer, 2013, 44, 318-324.	0.6	7
1124	High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Medical Oncology, 2013, 30, 537.	1.2	10
1125	Human genetic variation and the risk of hepatocellular carcinoma development. Hepatology International, 2013, 7, 820-831.	1.9	7

#	Article	IF	Citations
1126	Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asiaâ€“Pacific region. Journal of Gastroenterology, 2013, 48, 681-688.	2.3	47
1127	Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. Journal of Gastroenterology, 2013, 48, 515-525.	2.3	23
1128	Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients. Journal of Gastroenterology, 2013, 48, 366-373.	2.3	9
1129	Le carcinome hÃ©patocellulaire : difficultÃ©s diagnostiques et thÃ©rapeutiques. Journal Africain D'Hepato-Gastroenterologie, 2013, 7, 62-63.	0.0	0
1130	Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress and Chaperones, 2013, 18, 235-241.	1.2	26
1131	General Transcription Factor IIB Overexpression and a Potential Link to Proliferation in Human Hepatocellular Carcinoma. Pathology and Oncology Research, 2013, 19, 195-203.	0.9	11
1132	Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC. Pathology and Oncology Research, 2013, 19, 251-258.	0.9	10
1133	Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis. Digestive Diseases and Sciences, 2013, 58, 1459-1476.	1.1	47
1134	Analysis of the Risk Factors of Untransplantable Recurrence After Primary Curative Resection for Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2013, 20, 2526-2533.	0.7	13
1135	Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. Journal of Hepatology, 2013, 59, 999-1006.	1.8	79
1136	Presence of EpCAMâ€positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. International Journal of Cancer, 2013, 133, 2165-2171.	2.3	200
1137	Increase in CD14+HLA-DRâ^'/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunology, Immunotherapy, 2013, 62, 1421-1430.	2.0	231
1138	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 1417-1425.	1.1	12
1139	Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Seminars in Immunopathology, 2013, 35, 191-202.	2.8	48
1141	Postoperative outcomes of patients with hepatocellular carcinoma negative for all virus-related markers. Surgery Today, 2013, 43, 865-870.	0.7	1
1142	The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity. Cellular and Molecular Biology Letters, 2013, 18, 447-58.	2.7	3
1143	Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery, 2013, 154, 536-544.	1.0	76
1144	Carcinoma hepatocelular: epidemiologia, biologia, diagnÃ³stico e terapias. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2013, 59, 514-524.	0.3	81

#	Article	IF	Citations
1145	Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection. Clinica Chimica Acta, 2013, 421, 126-131.	0.5	24
1146	Referral Patterns and Treatment Choices for Patients with Hepatocellular Carcinoma: A United States Population-Based Study. Journal of the American College of Surgeons, 2013, 217, 896-906.	0.2	47
1147	Alterations in the redox state and liver damage: Hints from the EASL Basic School of Hepatology. Journal of Hepatology, 2013, 58, 365-374.	1.8	51
1148	Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma. Meta Gene, 2013, 1, 93-101.	0.3	13
1149	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (<scp>EPOIHCC</scp>). Liver International, 2013, 33, 327-337.	1.9	70
1150	Male-Specific W4P/R Mutation in the Pre-S1 Region of Hepatitis B Virus, Increasing the Risk of Progression of Liver Diseases in Chronic Patients. Journal of Clinical Microbiology, 2013, 51, 3928-3936.	1.8	34
1151	Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma. Hepatology, 2013, 57, 2369-2377.	3.6	52
1152	Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study. Journal of Hepatology, 2013, 58, 81-88.	1.8	95
1153	Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. Journal of Controlled Release, 2013, 172, 690-698.	4.8	76
1154	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. Journal of Hepatology, 2013, 59, 1014-1021.	1.8	75
1155	Elevated expression of complement C3 protein in chemically induced hepatotumorogenesis in Wistar rats: A correlative proteomics and histopathological study. Experimental and Toxicologic Pathology, 2013, 65, 767-773.	2.1	5
1156	The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. British Journal of Cancer, 2013, 109, 1344-1351.	2.9	58
1157	Double-negative feedback loop between Wnt/Î²-catenin signaling and HNF4Î± regulates epithelial-mesenchymal transition in hepatocellular carcinoma. Journal of Cell Science, 2013, 126, 5692-703.	1.2	61
1158	Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Surgical Oncology, 2013, 20, 923-928.	0.7	61
1159	MicroRNA-regulated non-viral vectors with improved tumor specificity in an orthotopic rat model of hepatocellular carcinoma. Gene Therapy, 2013, 20, 1006-1013.	2.3	6
1160	Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma. Cancer Research, 2013, 73, 4722-4731.	0.4	134
1161	Creation of a Six-fingered Artificial Transcription Factor That Represses the Hepatitis B Virus HBx Gene Integrated into a Human Hepatocellular Carcinoma Cell Line. Journal of Biomolecular Screening, 2013, 18, 378-387.	2.6	14
1162	Deregulation of Epigenetic Mechanisms by the Hepatitis B Virus X Protein in Hepatocarcinogenesis. Viruses, 2013, 5, 858-872.	1.5	29

#	Article	IF	Citations
1163	Molecular Mechanisms of Fibrosis-Associated Promotion of Liver Carcinogenesis. Toxicological Sciences, 2013, 132, 53-63.	1.4	84
1164	Management of Hepatocellular Carcinoma. Surgical Clinics of North America, 2013, 93, 1423-1450.	0.5	34
1165	Molecular Pathways: The Complex Roles of Inflammation Pathways in the Development and Treatment of Liver Cancer. Clinical Cancer Research, 2013, 19, 2810-2816.	3.2	64
1167	NCOA5 Haploinsufficiency Results in Glucose Intolerance and Subsequent Hepatocellular Carcinoma. Cancer Cell, 2013, 24, 725-737.	7.7	61
1168	Elk1 and AP-1 sites in the TBP promoter mediate alcohol-induced deregulation of Pol III-dependent genes. Gene, 2013, 526, 54-60.	1.0	6
1169	Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?. American Journal of Gastroenterology, 2013, 108, 425-432.	0.2	193
1170	Hepatocellular carcinoma: Transcriptome diversity regulated by RNA editing. International Journal of Biochemistry and Cell Biology, 2013, 45, 1843-1848.	1.2	17
1171	The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB. Investigational New Drugs, 2013, 31, 452-457.	1.2	16
1172	Endothelial cells do not arise from tumor-initiating cells in human hepatocellular carcinoma. BMC Cancer, 2013, 13, 485.	1.1	11
1173	A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World Journal of Surgical Oncology, 2013, 11, 240.	0.8	18
1174	MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer, 2013, 13, 448.	1.1	86
1175	Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2013, 11, 190.	0.8	60
1176	Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. Journal of Experimental and Clinical Cancer Research, 2013, 32, 65.	3.5	16
1177	MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. Journal of Translational Medicine, 2013, 11, 195.	1.8	73
1178	Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: A phase II-study (NCT00356161). BMC Gastroenterology, 2013, 13, 125.	0.8	13
1179	Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis. Diagnostic Pathology, 2013, 8, 130.	0.9	8
1180	Value of Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein for Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment. Digestive Diseases and Sciences, 2013, 58, 2406-2412.	1.1	15
1181	Association between Helicobacter pylori infection and liver cancer mortality in 67 rural Chinese counties. Cancer Causes and Control, 2013, 24, 1331-1337.	0.8	17

#	Article	IF	Citations
1182	Sustained Remission Over 36 Months of Advanced Hepatocellular Carcinoma After Short-Term Sorafenib Therapy. Digestive Diseases and Sciences, 2013, 58, 1428-1432.	1.1	8
1183	Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Medical Oncology, 2013, 30, 721.	1.2	44
1184	Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Medical Oncology, 2013, 30, 730.	1.2	14
1186	Gene expression signature of human HepG2 cell line. Gene, 2013, 518, 335-345.	1.0	77
1187	Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology and Metabolism, 2013, 24, 469-480.	3.1	245
1188	Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. Journal of Viral Hepatitis, 2013, 20, 669-677.	1.0	60
1189	Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1765-1775.	1.8	67
1190	Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. Journal of Controlled Release, 2013, 171, 1-10.	4.8	25
1191	Radiofrequency-Assisted Versus Clamp-Crushing Parenchyma Transection in Cirrhotic Patients with Hepatocellular Carcinoma: A Randomized Clinical Trial. Digestive Diseases and Sciences, 2013, 58, 835-840.	1.1	30
1192	Association analysis betweenMDR1gene polymorphisms and risk of hepatocellular carcinoma in Chinese population. Biomarkers, 2013, 18, 236-241.	0.9	8
1193	Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma. American Journal of Gastroenterology, 2013, 108, 1723-1730.	0.2	233
1194	Enhanced binding to and killing of hepatocellular carcinoma cells in vitro by melittin when linked with a novel targeting peptide screened from phage display. Journal of Peptide Science, 2013, 19, 639-650.	0.8	10
1195	Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. Journal of Pathology, 2013, 230, 441-452.	2.1	38
1196	Myofibroblasts are important contributors to human hepatocellular carcinoma: Evidence for tumor promotion by proteome profiling. Electrophoresis, 2013, 34, 3315-3325.	1.3	19
1197	Antitumor efficacy of <scp>C</scp>â€<scp>X</scp>â€<scp>C</scp> motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Science, 2013, 104, 1523-1531.	1.7	42
1198	Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology, 2013, 58, 1703-1712.	3.6	208
1199	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology, 2013, 58, 1054-1064.	3.6	138
1200	A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumor Biology, 2013, 34, 47-53.	0.8	12

#	Article	IF	Citations
1201	Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Human Molecular Genetics, 2013, 22, 1262-1269.	1.4	52
1202	Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics, 2013, 8, 34-43.	1.3	144
1203	Effects of hepatitis B eâ€antigen on recurrence of hepatitis Bâ€related hepatocellular carcinoma after curative resection: A metaâ€analysis. Hepatology Research, 2013, 43, 347-354.	1.8	8
1204	Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Archives of Toxicology, 2013, 87, 227-247.	1.9	195
1205	Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sciences, 2013, 92, 3-9.	2.0	64
1206	Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2013, 375, 23-30.	1.4	53
1207	Lactosylated poly(ethylene oxide)â€“poly(propylene oxide) block copolymers for potential active targeting: synthesis and physicochemical and self-aggregation characterization. Journal of Nanoparticle Research, 2013, 15, 1.	0.8	11
1208	Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nature Reviews Cancer, 2013, 13, 123-135.	12.8	688
1209	The human sulfatase 2 inhibitor 2,4â€disulfonylphenylâ€tertâ€butylnitrone (OKNâ€007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes and Cancer, 2013, 52, 225-236.	1.5	50
1210	Pathophysiological relevance of neutrophils in acetaminophen hepatotoxicity. Hepatology, 2013, 57, 419-419.	3.6	9
1211	Reply. Hepatology, 2013, 57, 418-419.	3.6	1
1212	Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Hepatology, 2013, 57, 171-182.	3.6	90
1213	Telomeraseâ€specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. International Journal of Cancer, 2013, 132, 1451-1462.	2.3	21
1214	The stem cell <scp>E3</scp>â€ligase Linâ€41 promotes liver cancer progression through inhibition of <scp>microRNA</scp>â€mediated gene silencing. Journal of Pathology, 2013, 229, 486-496.	2.1	31
1215	The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemporary Clinical Trials, 2013, 36, 605-615.	0.8	7
1216	hTERT rs2736098 genetic variants and susceptibility of hepatocellular carcinoma in the Chinese population: a case-control study. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 74-79.	0.6	22
1217	An X-chromosomal association study identifies a susceptibility locus at Xq22.1 for hepatitis B virus-related hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 586-595.	0.7	6
1218	Serotonin: is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients?. Alexandria Journal of Medicine, 2013, 49, 369-378.	0.4	3

#	Article	IF	Citations
1219	Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira (English Edition), 2013, 59, 514-524.	0.1	2
1220	Association of IL27 gene polymorphisms and HBV-related hepatocellular carcinoma risk in a Chinese population. Infection, Genetics and Evolution, 2013, 16, 1-4.	1.0	33
1221	A phase II study of sunitinib in advanced hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 692-698.	0.4	21
1222	Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magnetic Resonance Imaging, 2013, 31, 748-754.	1.0	34
1223	Improving Screening for Hepatocellular Carcinoma by Incorporating Data on Levels of Î±-Fetoprotein, Over Time. Clinical Gastroenterology and Hepatology, 2013, 11, 437-440.	2.4	87
1224	Induction of hepatocellular carcinoma in mice and the role of melatonin. Journal of Basic and Applied Zoology, 2013, 66, 206-222.	0.4	7
1225	Hepatitis B virus core protein enhances human telomerase reverse transcriptase expression and hepatocellular carcinoma cell proliferation in a c-Ets2-dependent manner. International Journal of Biochemistry and Cell Biology, 2013, 45, 1174-1185.	1.2	21
1226	Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. Journal of Hepatology, 2013, 58, 1147-1156.	1.8	26
1227	Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities. Gastroenterology, 2013, 144, 687-690.	0.6	18
1228	Sorafenib prolongs liver regeneration after hepatic resection in rats. Journal of Surgical Research, 2013, 184, 847-854.	0.8	6
1229	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 753-761.	1.8	82
1230	A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery, 2013, 154, 545-555.	1.0	27
1231	MUC15 Inhibits Dimerization of EGFR and PI3Kâ€“AKT Signaling and Is Associated With Aggressive Hepatocellular Carcinomas in Patients. Gastroenterology, 2013, 145, 1436-1448.e12.	0.6	111
1232	Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2013, 436, 711-718.	1.0	61
1233	Multivariate Analysis of Prognostic Factors for Survival following Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2013, 24, 647-654.	0.2	15
1234	Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene, 2013, 524, 156-160.	1.0	62
1235	Smad phospho-isoforms direct context-dependent TGF-Î² signaling. Cytokine and Growth Factor Reviews, 2013, 24, 385-399.	3.2	105
1236	The SxxSS motif of T-cell factor-4 isoforms modulates Wnt/Î²-catenin signal activation in hepatocellular carcinoma cells. Cancer Letters, 2013, 336, 359-369.	3.2	4

#	Article	IF	Citations
1237	HBV Infection and Hepatocellular Carcinoma. Clinics in Liver Disease, 2013, 17, 375-397.	1.0	34
1238	Obesity, cancer and acetyl-CoA metabolism. Drug Discovery Today Disease Mechanisms, 2013, 10, e55-e61.	0.8	23
1239	C/EBPÎ± inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades. Digestive and Liver Disease, 2013, 45, 844-851.	0.4	9
1240	Improving Hepatocellular Carcinoma Screening: Applying Lessons From Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2013, 11, 472-477.	2.4	49
1241	Transplantation for Hepatocellular Carcinoma in Younger Patients Has an Equivocal Survival Advantage as Compared With Resection. Transplantation Proceedings, 2013, 45, 265-271.	0.3	11
1243	Early fibrosis inhibits hepatocellular carcinoma mediated by free radical effects. Mitochondrion, 2013, 13, 391-398.	1.6	1
1244	Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma. Medical Oncology, 2013, 30, 379.	1.2	51
1245	Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Medical Oncology, 2013, 30, 446.	1.2	30
1246	Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clinical and Translational Oncology, 2013, 15, 146-153.	1.2	14
1247	Electrochemical identification of hepatocellular carcinoma based on the assay of human cervical cancer oncoprotein-1 in serum. Electrochemistry Communications, 2013, 27, 38-41.	2.3	14
1248	Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology, 2013, 57, 2338-2345.	3.6	54
1249	Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2013, 37, 62-73.	1.9	60
1250	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 330-344.	8.2	1,381
1251	miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncology Reports, 2013, 29, 2019-2024.	1.2	155
1252	Liver Injury and Disease Pathogenesis in Chronic Hepatitis C. Current Topics in Microbiology and Immunology, 2013, 369, 263-288.	0.7	58
1253	The hepatitis B virus X protein downregulates NF-Î°B signaling pathways through decreasing the Notch signaling pathway in HBx-transformed L02 cells. International Journal of Oncology, 2013, 42, 1636-1643.	1.4	25
1254	HBx and HBs regulate RhoC expression by upregulating transcription factor Ets-1. Archives of Virology, 2013, 158, 1773-1781.	0.9	11
1255	mTOR in aging, metabolism, and cancer. Current Opinion in Genetics and Development, 2013, 23, 53-62.	1.5	402

#	Article	IF	Citations
1256	Sex Differences in Prophylaxis and Therapeutic Treatments for Viral Diseases. Handbook of Experimental Pharmacology, 2013, , 499-522.	0.9	21
1257	Nonâ€alcoholic fatty liver disease contributes to hepatocarcinogenesis in nonâ€cirrhotic liver: A clinical and pathological study. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 848-854.	1.4	101
1258	Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. Journal of Hepatology, 2013, 58, 730-735.	1.8	131
1259	Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Hepatology, 2013, 57, 1869-1881.	3.6	59
1260	Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Life Sciences, 2013, 92, 555-561.	2.0	30
1261	Early Viral Suppression Predicts Good Postoperative Survivals in Patients with Hepatocellular Carcinoma with a High Baseline HBV-DNA Load. Annals of Surgical Oncology, 2013, 20, 1482-1490.	0.7	35
1262	Antiviral therapy decreases viral reactivation in patients with hepatitis B virusâ€"related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. Journal of Viral Hepatitis, 2013, 20, 336-342.	1.0	41
1263	Health care costs associated with hepatocellular carcinoma: A population-based study. Hepatology, 2013, 58, 1375-1384.	3.6	64
1264	Desâ€gammaâ€carboxy prothrombin identified by <scp>P</scp>â€11 and <scp>P</scp>â€16 antibodies reflects prognosis for patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 671-677.	1.4	10
1265	Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma. Hepatology, 2013, 58, 239-250.	3.6	44
1266	Etiological and molecular profile of hepatocellular cancer from India. International Journal of Cancer, 2013, 133, 437-445.	2.3	19
1267	Human leukocyte antigen class I alleles and haplotypes associated with primary hepatocellular carcinoma in persistent HBV-infected patients. Human Immunology, 2013, 74, 758-763.	1.2	8
1268	Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics, 2013, 7, 319-329.	1.6	22
1269	Hepatitis B virus X antigen and aflatoxin B1 synergistically cause hepatitis, steatosis and liver hyperplasia in transgenic zebrafish. Acta Histochemica, 2013, 115, 728-739.	0.9	37
1270	Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virusâ€"related hepatocellular carcinoma. Nature Genetics, 2013, 45, 72-75.	9.4	259
1271	Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology, 2013, 58, 1681-1692.	3.6	119
1272	Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clinical and Experimental Metastasis, 2013, 30, 651-658.	1.7	39
1273	A rare point mutation in the Ras oncogene in hepatocellular carcinoma. Surgery Today, 2013, 43, 289-292.	0.7	23

#	Article	IF	Citations
1274	Upregulation of Tâ€cell factorâ€4 isoformâ€responsive target genes in hepatocellular carcinoma. Liver International, 2013, 33, 1100-1112.	1.9	42
1275	Loss of exon 4 in a human Tâ€cell factorâ€4 isoform promotes hepatic tumourigenicity. Liver International, 2013, 33, 1536-1548.	1.9	8
1276	Expression Profiling of Hepatocellular Carcinoma. , 2013, , 163-184.		0
1277	Serum lipid profiling of patients with chronic hepatitis <scp>B</scp>, cirrhosis, and hepatocellular carcinoma by ultra fast <scp>LC</scp>/<scp>IT</scp>â€<scp>TOF MS</scp>. Electrophoresis, 2013, 34, 2848-2856.	1.3	41
1278	Size- and pathotropism-driven targeting and washout-resistant effects of boronic acid-rich protein nanoparticles for liver cancer regression. Journal of Controlled Release, 2013, 168, 1-9.	4.8	45
1279	Somatic changes in primary liver cancer in Russia: A pilot study. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2013, 755, 90-99.	0.9	11
1280	Influence of Angiotensin I-Converting Enzyme Gene Polymorphism on Hepatocellular Carcinoma Risk in China. DNA and Cell Biology, 2013, 32, 268-273.	0.9	20
1281	Robot-assisted laparoscopic liver resection for hepatocellular carcinoma: short-term outcome. American Journal of Surgery, 2013, 205, 697-702.	0.9	120
1282	Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study. Journal of Digestive Diseases, 2013, 14, 181-190.	0.7	79
1283	Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1169-1180.	1.7	125
1284	Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells. Stem Cells and Development, 2013, 22, 2655-2664.	1.1	41
1285	Overexpression of MMSET is Correlation with Poor Prognosis in Hepatocellular Carcinoma. Pathology and Oncology Research, 2013, 19, 303-309.	0.9	31
1286	Quantitative therapy response assessment by volumetric iodine-uptake measurement: Initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Radiology, 2013, 82, 327-334.	1.2	71
1287	CHK2 1100delC, IVS2+1G>A and I157T mutations are not present in hepatocellular cancer cases from a Turkish population. Gene, 2013, 512, 232-236.	1.0	3
1288	Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. European Journal of Medical Research, 2013, 18, 35.	0.9	11
1289	Shikonin Suppresses the Migratory Ability of Hepatocellular Carcinoma Cells. Journal of Agricultural and Food Chemistry, 2013, 61, 8191-8197.	2.4	34
1290	Nuclear Receptor CAR Specifically Activates the Two-Pore K+ Channel Kcnk1 Gene in Male Mouse Livers, Which Attenuates Phenobarbital-Induced Hepatic Hyperplasia. Toxicological Sciences, 2013, 132, 151-161.	1.4	12
1291	Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Digestive and Liver Disease, 2013, 45, 510-515.	0.4	24

#	Article	IF	Citations
1292	Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients. Digestive and Liver Disease, 2013, 45, 336-341.	0.4	44
1293	Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells. Biochemical Pharmacology, 2013, 85, 1761-1769.	2.0	57
1294	Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling. Annals of Surgical Oncology, 2013, 20, 3747-3753.	0.7	130
1295	Trends and Patterns of Utilization in Post-treatment Surveillance Imaging Among Patients Treated for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 1774-1783.	0.9	23
1296	Long-Term Ethanol Exposure-Induced Hepatocellular Carcinoma Cell Migration and Invasion through Lysyl Oxidase Activation Are Attenuated by Combined Treatment with Pterostilbene and Curcumin Analogues. Journal of Agricultural and Food Chemistry, 2013, 61, 4326-4335.	2.4	21
1297	Thioredoxin and Thioredoxin Target Proteins: From Molecular Mechanisms to Functional Significance. Antioxidants and Redox Signaling, 2013, 18, 1165-1207.	2.5	311
1298	Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: A novel in vitro model to study tumor-stroma interactions. Oncology Reports, 2013, 30, 1143-1148.	1.2	33
1299	Expression and significance of PTEN and miR-92 in hepatocellular carcinoma. Molecular Medicine Reports, 2013, 7, 1413-1416.	1.1	14
1300	Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma. Oncology, 2013, 84, 6-13.	0.9	54
1301	Intraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma?. Radiology, 2013, 266, 636-648.	3.6	99
1302	Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model. Molecular Cancer Therapeutics, 2013, 12, 1651-1664.	1.9	9
1303	Association Study of Single Nucleotide Polymorphisms inXRCC1Gene with Risk of Hepatocellular Carcinoma in Chinese Han Population. BioMed Research International, 2013, 2013, 1-6.	0.9	11
1304	Molecular Functions of Thyroid Hormones and Their Clinical Significance in Liver-Related Diseases. BioMed Research International, 2013, 2013, 1-16.	0.9	39
1305	Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation. Gastroenterology Research and Practice, 2013, 2013, 1-8.	0.7	19
1306	Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepatitis Monthly, 2013, 13, e8351.	0.1	28
1307	N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation. Glycobiology, 2013, 23, 1097-1109.	1.3	32
1308	Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors: A Study From India. Archives of Pathology and Laboratory Medicine, 2013, 137, 961-966.	1.2	54
1309	hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors. Carcinogenesis, 2013, 34, 1458-1467.	1.3	42

#	Article	IF	Citations
1310	Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study. Oncology Letters, 2013, 6, 1319-1322.	0.8	1
1311	Progesterone and Related Compounds in Hepatocellular Carcinoma: Basic and Clinical Aspects. BioMed Research International, 2013, 2013, 1-9.	0.9	31
1312	Role of phosphorylated histone H3 serine 10 in DEN-induced deregulation of Pol III genes and cell proliferation and transformation. Carcinogenesis, 2013, 34, 2460-2469.	1.3	24
1313	HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level. BioMed Research International, 2013, 2013, 1-14.	0.9	49
1314	The Stress-Regulated Transcription Factor CHOP Promotes Hepatic Inflammatory Gene Expression, Fibrosis, and Oncogenesis. PLoS Genetics, 2013, 9, e1003937.	1.5	64
1315	Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	30
1316	Clinical Characteristics of Patients with Hepatocellular Carcinoma in a Middle Eastern Population. Hepatitis Monthly, 2013, 13, e7612.	0.1	21
1317	Identification of Recurrence Related microRNAs in Hepatocellular Carcinoma after Surgical Resection. International Journal of Molecular Sciences, 2013, 14, 1105-1118.	1.8	23
1318	Crosstalk between Beta-Catenin and Snail in the Induction of Epithelial to Mesenchymal Transition in Hepatocarcinoma: Role of the ERK1/2 Pathway. International Journal of Molecular Sciences, 2013, 14, 20768-20792.	1.8	48
1319	Differential Expression of Wnt Pathway Genes in Sporadic Hepatocellular Carcinomas Infected With Hepatitis B Virus Identified With OligoGE Arrays. Hepatitis Monthly, 2013, 13, e6192.	0.1	4
1320	Targeted therapy for hepatocellular carcinoma: current status and future direction. Clinical Investigation, 2013, 3, 83-93.	0.0	0
1321	The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Review of Gastroenterology and Hepatology, 2013, 7, 749-757.	1.4	7
1322	Recent advances in the treatment of hepatocellular carcinoma. Current Opinion in Gastroenterology, 2013, 29, 285-292.	1.0	93
1323	Exploration of Genome-Wide Circulating MicroRNA in Hepatocellular Carcinoma: MiR-483-5p as a Potential Biomarker. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2364-2373.	1.1	97
1324	Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2013, 47, 861-870.	1.1	213
1325	Surveillance for Hepatocellular Carcinoma in a Medicaid Cirrhotic Population. Journal of Clinical Gastroenterology, 2013, 47, 713-718.	1.1	39
1326	The value of PIVKA-II and AFP-L3% in the diagnosis of hepatocellular carcinoma with normal and abnormal AFP levels. Egyptian Liver Journal, 2013, 3, 1-5.	0.3	3
1327	Surveillance for Hepatocellular Carcinoma: How Can We Do Better?. American Journal of the Medical Sciences, 2013, 346, 308-313.	0.4	9

#	Article	IF	Citations
1328	Retinoic Acid Decorated Albumin-Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma. Journal of Nanomaterials, 2013, 2013, 1-12.	1.5	13
1329	Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17480-17485.	3.3	61
1330	Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology, 2013, 58, 150-157.	3.6	73
1331	Increasing Hepatitis B Screening for Hmong Adults: Results from a Randomized Controlled Community-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 782-791.	1.1	51
1332	Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1083-91.	3.3	156
1333	Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 3944-3954.	3.2	108
1334	Hepatocellular Carcinomas in B6C3F1 Mice Treated with Ginkgo biloba Extract for Two Years Differ from Spontaneous Liver Tumors in Cancer Gene Mutations and Genomic Pathways. Toxicologic Pathology, 2013, 41, 826-841.	0.9	38
1335	Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines. PLoS ONE, 2013, 8, e54111.	1.1	32
1336	Overexpression of CTHRC1 in Hepatocellular Carcinoma Promotes Tumor Invasion and Predicts Poor Prognosis. PLoS ONE, 2013, 8, e70324.	1.1	73
1337	Comparative Analysis of TGF-Î²/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines. PLoS ONE, 2013, 8, e72252.	1.1	59
1338	Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma. Oncologist, 2013, 18, 430-438.	1.9	43
1339	Diagnostic Value of Immunohistochemical Staining of GP73, GPC3, DCP, CD34, CD31, and Reticulin Staining in Hepatocellular Carcinoma. Journal of Histochemistry and Cytochemistry, 2013, 61, 639-648.	1.3	33
1340	Hepatocarcinogenesis Driven by GSNOR Deficiency Is Prevented by iNOS Inhibition. Cancer Research, 2013, 73, 2897-2904.	0.4	38
1341	Biomarker Discovery for Early Detection of Hepatocellular Carcinoma in Hepatitis Câ€“infected Patients. Molecular and Cellular Proteomics, 2013, 12, 3640-3652.	2.5	44
1342	Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatology Research, 2013, 43, 147-154.	1.8	173
1343	Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma. Korean Journal of Physiology and Pharmacology, 2013, 17, 375.	0.6	15
1344	Low RIN1 Expression in HCC Is Associated With Tumor Invasion and Unfavorable Prognosis. American Journal of Clinical Pathology, 2013, 140, 73-81.	0.4	6
1345	LEPREL1 Expression in Human Hepatocellular Carcinoma and Its Suppressor Role on Cell Proliferation. Gastroenterology Research and Practice, 2013, 2013, 1-7.	0.7	9

#	Article	IF	Citations
1346	Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. Seminars in Liver Disease, 2013, 33, 147-156.	1.8	96
1347	Multitargeting and Antimetastatic Potentials of Silibinin in Human HepG-2 and PLC/PRF/5 Hepatoma Cells. Nutrition and Cancer, 2013, 65, 590-599.	0.9	25
1348	<scp>NC</scp>â€6300, an epirubicinâ€incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Science, 2013, 104, 920-925.	1.7	114
1349	Rise and fall of <scp>HCV</scp>â€related hepatocellular carcinoma in Italy: a longâ€term survey from the <scp>ITA</scp>.<scp>LI</scp>.<scp>CA</scp> centres. Liver International, 2013, 33, 1420-1427.	1.9	13
1350	Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Alimentary Pharmacology and Therapeutics, 2013, 38, 703-712.	1.9	92
1352	<scp>G</scp>enetic variants of heat shock protein A1L2437 and A1B1267 as possible risk factors for hepatocellular carcinoma in <scp>I</scp>ndia. Journal of Viral Hepatitis, 2013, 20, e141-7.	1.0	11
1353	Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. Journal of Digestive Diseases, 2013, 14, 552-558.	0.7	12
1354	Longâ€term outcome of hepatitis <scp>B</scp> virusâ€related <scp>C</scp>hronic <scp>H</scp>epatitis under protracted nucleos(t)ide analogues. Journal of Viral Hepatitis, 2013, 20, 502-509.	1.0	16
1355	Role of oxidative stress in the pathogenesis of alcohol-induced liver disease. Free Radical Research, 2013, 47, 894-904.	1.5	82
1356	Phosphorylated <scp>S</scp>mad2 and <scp>S</scp>mad3 signaling: Shifting between tumor suppression and fibroâ€carcinogenesis in chronic hepatitis <scp>C</scp>. Hepatology Research, 2013, 43, 1327-1342.	1.8	25
1357	CaracterÃsticas demogrÃ¡ficas actuales del virus de la hepatitis C. Clinical Liver Disease, 2013, 2, S12Å-S15Å.	1.0	0
1358	Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogeneâ€induced senescence. EMBO Molecular Medicine, 2013, 5, 1367-1382.	3.3	45
1359	Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism. International Journal of Cancer, 2013, 133, 1867-1875.	2.3	31
1361	The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescence-like phenotype. Cancer Biology and Therapy, 2013, 14, 222-229.	1.5	16
1362	Neuroglobin, a Novel Intracellular Hexa-Coordinated Globin, Functions as a Tumor Suppressor in Hepatocellular Carcinoma via Raf/MAPK/Erk. Molecular Pharmacology, 2013, 83, 1109-1119.	1.0	42
1363	Helicobacter pyloriinfection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis. Gut Microbes, 2013, 4, 577-590.	4.3	13
1364	The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma cells. Cell Death and Disease, 2013, 4, e489-e489.	2.7	78
1365	Epithelialâ€“mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death and Disease, 2013, 4, e831-e831.	2.7	126

#	Article	IF	Citations
1366	Role of lymphocytes in liver cancer. OncoImmunology, 2013, 2, e26468.	2.1	66
1367	Recent advances in developing nucleic acid-based HBV therapy. Future Microbiology, 2013, 8, 1489-1504.	1.0	6
1368	A novel taspine derivative suppresses human liver tumor growth and invasion in vitro and in vivo. Oncology Letters, 2013, 6, 855-859.	0.8	4
1369	Supplementation of Branched-Chain Amino Acids Maintains the Serum Albumin Level in the Course of Hepatocellular Carcinoma Recurrence. Tohoku Journal of Experimental Medicine, 2013, 230, 191-196.	0.5	10
1370	A standardized extract from Paeonia lactiflora and Astragalus membranaceus induces apoptosis and inhibits the proliferation, migration and invasion of human hepatoma cell lines. International Journal of Oncology, 2013, 43, 1643-1651.	1.4	26
1371	In vivo and in vitro inhibition of human liver cancer progress by downregulation of the Î¼-opioid receptor and relevant mechanisms. Oncology Reports, 2013, 30, 1731-1738.	1.2	27
1372	Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. International Journal of Oncology, 2013, 43, 88-94.	1.4	81
1373	Human hepatocyte carcinogenesis. International Journal of Oncology, 2013, 42, 1133-1138.	1.4	105
1374	Mulberry (æ¡‘è‘šå•Sang ShÃ¨n ZÇ) and its Bioactive Compounds, the Chemoprevention Effects and Molecular Mechanisms In Vitro and In Vivo. Journal of Traditional and Complementary Medicine, 2013, 3, 7-15.	1.5	61
1375	Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth. Oncology Reports, 2013, 29, 903-910.	1.2	16
1376	Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. International Journal of Molecular Medicine, 2013, 31, 1449-1456.	1.8	52
1377	Investigation of Pokemon-Regulated Proteins in Hepatocellular Carcinoma Using Mass Spectrometry-Based Multiplex Quantitative Proteomics. European Journal of Mass Spectrometry, 2013, 19, 111-121.	0.5	3
1378	Cytohesin-2 as a novel prognostic marker for hepatocellular carcinoma. Oncology Reports, 2013, 29, 2211-2218.	1.2	11
1379	Therapeutic Delays Lead to Worse Survival Among Patients With Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1101-1108.	2.3	69
1380	The Expression of Egfl7 in Human Normal Tissues and Epithelial Tumors. International Journal of Biological Markers, 2013, 28, 71-83.	0.7	43
1381	Oxidative stress-induced 1, N6-ethenodeoxyadenosine adduct formation contributes to hepatocarcinogenesis. Oncology Reports, 2013, 29, 875-884.	1.2	21
1382	Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis. Oncology Reports, 2013, 30, 1906-1912.	1.2	22
1383	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. Oncology, 2013, 85, 44-52.	0.9	46

#	Article	IF	Citations
1384	Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice. European Journal of Gastroenterology and Hepatology, 2013, 25, 338-343.	0.8	19
1385	Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncology Letters, 2013, 5, 1087-1092.	0.8	222
1386	Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. The Cochrane Library, 2013, , CD003046.	1.5	73
1387	SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3Î²/Î²-catenin signaling. Hepatology, 2013, 57, 2287-2298.	3.6	179
1388	Upregulation of the Î´ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo. International Journal of Oncology, 2013, 43, 1281-1290.	1.4	30
1389	Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily. Journal of Clinical Gastroenterology, 2013, 47, 461-465.	1.1	10
1390	DNMT3A â^'448A>G polymorphism and the risk for hepatocellular carcinoma. Biomedical Reports, 2013, 1, 664-668.	0.9	12
1391	Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Molecular Medicine Reports, 2013, 7, 969-974.	1.1	25
1392	Clinical and Epidemiological Aspects of Hepatocellular Carcinoma in Brazil. Antiviral Therapy, 2013, 18, 445-449.	0.6	16
1393	Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncology Reports, 2013, 29, 2163-2168.	1.2	18
1394	Potential therapeutic value of dendritic cells loaded with NY-ESO-1 protein for the immunotherapy of advanced hepatocellular carcinoma. International Journal of Molecular Medicine, 2013, 32, 1366-1372.	1.8	10
1395	Whole-body Insulin Resistance is Associated with Elevated Serum Î±-fetoprotein Levels in Patients with Chronic Hepatitis C. Internal Medicine, 2013, 52, 2393-2400.	0.3	11
1396	The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma. Biomedical Reports, 2013, 1, 604-608.	0.9	11
1397	Hepatitis B virus X protein in the proliferation of hepatocellular carcinoma cells. Frontiers in Bioscience - Landmark, 2013, 18, 1256.	3.0	13
1398	Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Management and Research, 2013, 5, 337.	0.9	16
1399	Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter. Neoplasma, 2013, 60, 469-479.	0.7	9
1400	Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. OncoTargets and Therapy, 2013, 6, 1417.	1.0	32
1401	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. OncoTargets and Therapy, 2013, 6, 1463.	1.0	22

#	Article	IF	Citations
1402	Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma. Yonsei Medical Journal, 2013, 54, 1178.	0.9	27
1403	EPIGENETIC MECHANISMS IN HEPATITIS C VIRUS-ASSOCIATED HEPATOCELLULAR CARCINOMA: A POTENTIAL NEW LINK BETWEEN STEM CELLS, VIROLOGY AND CANCER. American Medical Journal, 2013, 4, 21-35.	1.0	5
1404	Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. Journal of Ginseng Research, 2013, 37, 45-53.	3.0	56
1405	EPIDEMIOLOGICAL ASPECTS OF HEPATOCELLULAR CARCINOMA IN A REFERRAL CENTER OF MINAS GERAIS, BRAZIL. Arquivos De Gastroenterologia, 2013, 50, 97-100.	0.3	9
1406	Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases. Molecular Medicine, 2013, 19, 357-366.	1.9	98
1407	Overexpression of p42.3 promotes cell growth and tumorigenicity in hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 2913-2920.	1.4	11
1408	The Association between Two Common Polymorphisms in MicroRNAs and Hepatocellular Carcinoma Risk in Asian Population. PLoS ONE, 2013, 8, e57012.	1.1	23
1409	Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma Marker. PLoS ONE, 2013, 8, e59459.	1.1	67
1410	Role of a Novel Functional Variant in the PPP2R1A Promoter on the Regulation of PP2A-Aalpha and the Risk of Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e59574.	1.1	16
1411	Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging. PLoS ONE, 2013, 8, e59869.	1.1	32
1412	Genome-Wide Transcriptional Reorganization Associated with Senescence-to-Immortality Switch during Human Hepatocellular Carcinogenesis. PLoS ONE, 2013, 8, e64016.	1.1	61
1413	MACC1 as a Prognostic Biomarker for Early-Stage and AFP-Normal Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e64235.	1.1	30
1414	ERManI Is a Target of miR-125b and Promotes Transformation Phenotypes in Hepatocellular Carcinoma (HCC). PLoS ONE, 2013, 8, e72829.	1.1	20
1415	The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e76830.	1.1	70
1416	Branched-Chain Amino Acids Ameliorate Fibrosis and Suppress Tumor Growth in a Rat Model of Hepatocellular Carcinoma with Liver Cirrhosis. PLoS ONE, 2013, 8, e77899.	1.1	39
1417	miR-122 Regulates Tumorigenesis in Hepatocellular Carcinoma by Targeting AKT3. PLoS ONE, 2013, 8, e79655.	1.1	74
1418	Combined Adenovirus-Mediated Artificial microRNAs Targeting mfgl2, mFas, and mTNFR1 Protect against Fulminant Hepatic Failure in Mice. PLoS ONE, 2013, 8, e82330.	1.1	16
1419	TP53 and MDM2 Gene Polymorphisms, Gene-Gene Interaction, and Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis. PLoS ONE, 2013, 8, e82773.	1.1	26

#	Article	IF	Citations
1420	EGFRvIII Mediates Hepatocellular Carcinoma Cell Invasion by Promoting S100 Calcium Binding Protein A11 Expression. PLoS ONE, 2013, 8, e83332.	1.1	26
1421	Hyperthermia-Induced NDRG2 Upregulation Inhibits the Invasion of Human Hepatocellular Carcinoma via Suppressing ERK1/2 Signaling Pathway. PLoS ONE, 2013, 8, e61079.	1.1	20
1422	Liver-Specific Expressions of HBx and src in the p53 Mutant Trigger Hepatocarcinogenesis in Zebrafish. PLoS ONE, 2013, 8, e76951.	1.1	51
1423	FGFR4 and TGF-Î²1 Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Prognosis. International Journal of Medical Sciences, 2013, 10, 1868-1875.	1.1	29
1425	Association between the C.1161G>A and C.1779C>G Genetic Variants of XRCC1 Gene and Hepatocellular Carcinoma Risk in Chinese Population. International Journal of Biological Sciences, 2013, 9, 289-294.	2.6	8
1426	Sinulariolide Induced Hepatocellular Carcinoma Apoptosis through Activation of Mitochondrial-Related Apoptotic and PERK/eIF2Î±/ATF4/CHOP Pathway. Molecules, 2013, 18, 10146-10161.	1.7	44
1427	Non-viral factors contributing to hepatocellular carcinoma. World Journal of Hepatology, 2013, 5, 311.	0.8	51
1428	Role of the Nrf2-ARE Pathway in Liver Diseases. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-9.	1.9	155
1429	SCD1 Expression Is Dispensable for Hepatocarcinogenesis Induced by AKT and Ras Oncogenes in Mice. PLoS ONE, 2013, 8, e75104.	1.1	17
1430	Combination of Human Leukocyte Antigen and Killer Cell Immunoglobulin-Like Receptor Genetic Background Influences the Onset Age of Hepatocellular Carcinoma in Male Patients with Hepatitis B Virus Infection. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	11
1431	Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection. Scientific World Journal, The, 2013, 2013, 1-6.	0.8	12
1432	MicroRNAs and liver cancer associated with iron overload: Therapeutic targets unravelled. World Journal of Gastroenterology, 2013, 19, 5212.	1.4	52
1433	Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. Journal of Cancer, 2013, 4, 635-643.	1.2	90
1434	An IL-6 link between obesity and cancer. Frontiers in Bioscience - Elite, 2013, E5, 461-478.	0.9	36
1435	Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2013, 13, 300-312.	0.8	37
1436	Hepatocellular carcinoma and food contamination: Ochratoxin A as a great prompter. World Journal of Gastroenterology, 2013, 19, 3723.	1.4	30
1437	What Is the Clinical Course of Advanced Liver Disease and What Symptoms Are Associated With It?. , 2013, , 300-307.		1
1438	Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 2449.	1.4	53

#	Article	IF	Citations
1439	Unveiling the Intricacies of Helicobacter pylori-Induced Gastric Inflammation: T Helper Cells and Matrix Metalloproteinases at a Crossroad. , 2013, , .		4
1440	Epidemiology and Risk Factors. , 0, , .		1
1441	Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori, 2013, 99, 100-107.	0.6	11
1442	Neoadjuvant Chemotherapy for Hepatocellular Carcinoma. , 2013, , .		3
1443	Sorafenib in the Continuum of Care for Hepatocellular Carcinoma: Challenges in Defining Optimal Practice. , 0, , .		0
1444	How Do Mechanisms of Hepatocarcinogenesis (HBV, HCV, and NASH) Affect Our Understanding and Approach to HCC?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e132-e136.	1.8	5
1445	Curative Effect of Amorphophallus campanulatus (Roxb.) Blume. Tuber On N-Nitrosodiethylamine-Induced Hepatocellular Carcinoma in Rats. Journal of Environmental Pathology, Toxicology and Oncology, 2014, 33, 205-218.	0.6	7
1446	Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 43.	1.8	7
1447	Experimental Hepatocarcinogenesis. , 2014, , 1866-1880.		0
1448	Hypermethylation Leads to Bone Morphogenetic Protein 6 Downregulation in Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e87994.	1.1	11
1449	MiR-525-3p Enhances the Migration and Invasion of Liver Cancer Cells by Downregulating ZNF395. PLoS ONE, 2014, 9, e90867.	1.1	33
1450	Maotai Ameliorates Diethylnitrosamine-Initiated Hepatocellular Carcinoma Formation in Mice. PLoS ONE, 2014, 9, e93599.	1.1	21
1451	Positive Lymph Node Metastasis Has a Marked Impact on the Long-Term Survival of Patients with Hepatocellular Carcinoma with Extrahepatic Metastasis. PLoS ONE, 2014, 9, e95889.	1.1	34
1452	Stabilization and Augmentation of Circulating AIM in Mice by Synthesized IgM-Fc. PLoS ONE, 2014, 9, e97037.	1.1	27
1453	Comparing Outcomes of Two Vascular Inflow Occlusion Techniques and Treatment without Vascular Occlusion during Major Hepatectomy in Patients with Hepatitis B-Related Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e107303.	1.1	13
1454	ROCK Is Involved in Vasculogenic Mimicry Formation in Hepatocellular Carcinoma Cell Line. PLoS ONE, 2014, 9, e107661.	1.1	34
1455	Familial Correlations of Onset Age of Hepatocellular Carcinoma: A Population-Based Case-Control Family Study. PLoS ONE, 2014, 9, e108391.	1.1	10
1456	Association of Single Nucleotide Polymorphisms in VDR and DBP Genes with HBV-Related Hepatocellular Carcinoma Risk in a Chinese Population. PLoS ONE, 2014, 9, e116026.	1.1	52

#	Article	IF	Citations
1457	Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	15
1458	Expression of Serum Exosomal MicroRNA-21 in Human Hepatocellular Carcinoma. BioMed Research International, 2014, 2014, 1-5.	0.9	217
1459	Relationship between RUNX3 methylation and hepatocellular carcinoma in Asian populations: a systematic review. Genetics and Molecular Research, 2014, 13, 5182-5189.	0.3	4
1460	A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. Journal of Hepatocellular Carcinoma, 2014, 1, 1.	1.8	9
1461	The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. Diagnostic and Interventional Radiology, 2014, 20, 323-329.	0.7	15
1462	Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma: Implications for Lycopene Intervention. Nutrients, 2014, 6, 124-162.	1.7	46
1463	Spatial Analysis of the Home Addresses of Hospital Patients with Hepatitis B Infection or Hepatoma in Shenzhen, China from 2010 to 2012. International Journal of Environmental Research and Public Health, 2014, 11, 3143-3155.	1.2	10
1464	High expression of 23 kDa protein of augmenter of liver regeneration (ALR) in human hepatocellular carcinoma. OncoTargets and Therapy, 2014, 7, 887.	1.0	4
1465	Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evidence, 2014, 9, 81.	4.7	20
1466	Liver cancer stem cells are selectively enriched by low-dose cisplatin. Brazilian Journal of Medical and Biological Research, 2014, 47, 478-482.	0.7	11
1467	Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 9.	1.8	5
1468	Association study of c.910A>G and c.1686C>G polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in the Chinese population. Genetics and Molecular Research, 2014, 13, 1314-1322.	0.3	4
1469	Hepatitis virus and hepatocellular carcinoma in Brazil: a report from the State of EspÃ‹rito Santo. Revista Da Sociedade Brasileira De Medicina Tropical, 2014, 47, 559-563.	0.4	6
1470	Is the Indication of Liver Resection for Hepatocellular Carcinoma Expanding with the Application of Laparoscopic Approach?. , 2014, 04, .		0
1471	Metabolic Syndromeâ€"Related Hepatocellular Carcinoma Treated by Volumetric Modulated Arc Therapy. Current Oncology, 2014, 21, 340-344.	0.9	4
1472	Decreased expression of Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) correlated with prognosis of Hepatocellular carcinoma. Neoplasma, 2014, 61, 83-89.	0.7	6
1473	Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models. Journal of Hepatocellular Carcinoma, 2014, 1, 149.	1.8	8
1474	Inhibition of autophagy signï¬¬cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World Journal of Gastroenterology, 2014, 20, 4953.	1.4	59

#	Article	IF	Citations
1475	Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 21.	1.8	2
1476	Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World Journal of Diabetes, 2014, 5, 586.	1.3	83
1477	Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression. Oncotarget, 2014, 5, 6716-6733.	0.8	22
1478	Laparoscopic liver resections for hepatocellular carcinoma: Current role and limitations. World Journal of Gastroenterology, 2014, 20, 4892.	1.4	45
1479	Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World Journal of Gastroenterology, 2014, 20, 17756-17772.	1.4	372
1480	Geranylgeranoic Acid Induces Incomplete Autophagy but Leads to the Accumulation of Autophagosomes in Human Hepatoma Cells. , 2014, , 173-185.		1
1481	Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 15018.	1.4	19
1482	Safety of hepatectomy for elderly patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 15028.	1.4	44
1483	Role of SERPINB3 in hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 722-727.	0.6	29
1484	FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget, 2014, 5, 5113-5124.	0.8	106
1485	The role of Interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 788-795.	0.6	14
1486	Water Extract fromPleurotus pulmonariuswith Antioxidant Activity Exerts In Vivo Chemoprophylaxis and Chemosensitization for Liver Cancer. Nutrition and Cancer, 2014, 66, 989-998.	0.9	26
1487	Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis, 2014, 35, 769-775.	1.3	103
1488	MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Translational Oncology, 2014, 7, 672-680.	1.7	11
1489	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncology, 2014, 10, 285-304.	1.1	13
1490	High ATF5 expression is a favorable prognostic indicator in patients with hepatocellular carcinoma after hepatectomy. Medical Oncology, 2014, 31, 269.	1.2	6
1491	Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumor Biology, 2014, 35, 11473-11481.	0.8	13
1492	Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials, 2014, 15, 438.	0.7	29

#	Article	IF	Citations
1493	p53 in liver pathologiesâ€"taking the good with the bad. Journal of Molecular Medicine, 2014, 92, 1229-1234.	1.7	18
1494	Abrus agglutinin suppresses human hepatocellular carcinoma in vitro and in vivo by inducing caspase-mediated cell death. Acta Pharmacologica Sinica, 2014, 35, 814-824.	2.8	44
1495	Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria. Cell Death and Disease, 2014, 5, e1078-e1078.	2.7	34
1496	Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells. Cell Death and Disease, 2014, 5, e1400-e1400.	2.7	31
1497	Characterization of Inflammatory (Lymphoepithelioma-like) Hepatocellular Carcinoma: A Study of 8 Cases. Archives of Pathology and Laboratory Medicine, 2014, 138, 1193-1202.	1.2	38
1498	Considerations for Applying Metabolomics to the Analysis of Extracellular Vesicles. Frontiers in Immunology, 2014, 5, 651.	2.2	21
1499	Correlation between plasma miR-122 expression and liver injury induced by hepatectomy. Journal of International Medical Research, 2014, 42, 77-84.	0.4	11
1500	Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6418-6428.	3.2	233
1501	Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression. Hepatitis Monthly, 2014, 14, e23552.	0.1	3
1502	Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. Clinical Science, 2014, 126, 243-252.	1.8	23
1503	Remarkable Anticancer Activity ofTeucrium poliumon Hepatocellular Carcinogenic Rats. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-9.	0.5	17
1504	Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. PLoS Medicine, 2014, 11, e1001770.	3.9	117
1505	Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma. Oncology Letters, 2014, 7, 641-646.	0.8	6
1506	The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers, 2014, 6, 79-111.	1.7	82
1507	Long Non-Coding RNA HOTAIR Promotes Cell Migration and Invasion via Down-Regulation of RNA Binding Motif Protein 38 in Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2014, 15, 4060-4076.	1.8	150
1508	SREBP-1 Has a Prognostic Role and Contributes to Invasion and Metastasis in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2014, 15, 7124-7138.	1.8	98
1509	Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity. Oncology Letters, 2014, 8, 2333-2339.	0.8	29
1510	Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma. Oncology Letters, 2014, 8, 2436-2442.	0.8	8

#	Article	IF	Citations
1511	Expression of Aldo-Keto Reductase Family 1 Member B10 in the Early Stages of Human Hepatocarcinogenesis. International Journal of Molecular Sciences, 2014, 15, 6556-6568.	1.8	34
1512	The Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines. International Journal of Proteomics, 2014, 2014, 1-9.	2.0	12
1513	Diagnosis System for Hepatocellular Carcinoma Based on Fractal Dimension of Morphometric Elements Integrated in an Artificial Neural Network. BioMed Research International, 2014, 2014, 1-10.	0.9	16
1514	Association between Two Common Polymorphisms and Risk of Hepatocellular Carcinoma: Evidence from an Updated Meta-Analysis. BioMed Research International, 2014, 2014, 1-8.	0.9	7
1515	Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. Carcinogenesis, 2014, 35, 2485-2494.	1.3	14
1516	Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways. BioMed Research International, 2014, 2014, 1-10.	0.9	44
1517	A Critical Role for ZDHHC2 in Metastasis and Recurrence in Human Hepatocellular Carcinoma. BioMed Research International, 2014, 2014, 1-9.	0.9	22
1518	Albumin Suppresses Human Hepatocellular Carcinoma Proliferation and the Cell Cycle. International Journal of Molecular Sciences, 2014, 15, 5163-5174.	1.8	76
1519	Downregulation of Rap1 promotes 5-fluorouracil-induced apoptosis in hepatocellular carcinoma cell line HepG2. Oncology Reports, 2014, 31, 1691-1698.	1.2	30
1520	Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor Î± and Wnt pathways in vitro and in patients. Molecular Medicine Reports, 2014, 10, 3125-3131.	1.1	13
1521	Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer, 2014, 3, 428-438.	4.2	5
1522	Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma. Oncology Reports, 2014, 31, 933-939.	1.2	24
1523	Nucleolin identified by comparative mass-spectra analysis is a potential marker for invasive progression of hepatocellular carcinoma. Molecular Medicine Reports, 2014, 10, 1489-1494.	1.1	4
1524	Expression of Thioredoxins and Glutaredoxins in Human Hepatocellular Carcinoma: Correlation to Cell Proliferation, Tumor Size and Metabolic Syndrome. International Journal of Immunopathology and Pharmacology, 2014, 27, 169-183.	1.0	36
1525	Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation. Cell Reports, 2014, 9, 61-74.	2.9	60
1527	The effect of chemokine CC motif ligand 19 on the proliferation and migration of hepatocellular carcinoma. Tumor Biology, 2014, 35, 12575-12581.	0.8	5
1528	Sexually dimorphic actions of glucocorticoids: beyond chromosomes and sex hormones. Annals of the New York Academy of Sciences, 2014, 1317, 1-6.	1.8	48
1529	Impact of <scp>HBV</scp> therapy on the incidence of hepatocellular carcinoma. Liver International, 2014, 34, 139-145.	1.9	31

#	Article	IF	Citations
1530	Comparing different sterol containing solid lipid nanoparticles for targeted delivery of quercetin in hepatocellular carcinoma. Journal of Liposome Research, 2014, 24, 191-203.	1.5	40
1531	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 5976-5985.	3.2	95
1532	Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intraprocedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma. Radiology, 2014, 272, 587-597.	3.6	17
1533	Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Sorafenibâ€"A Retrospective Controlled Study. Radiology, 2014, 272, 284-293.	3.6	139
1534	Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology, 2014, 60, 588-597.	3.6	79
1535	Prediagnostic plasma testosterone, sex hormoneâ€binding globulin, IGFâ€I and hepatocellular carcinoma: Etiological factors or risk markers?. International Journal of Cancer, 2014, 134, 164-173.	2.3	33
1536	The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2. Journal of Molecular Histology, 2014, 45, 689-696.	1.0	31
1537	A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival. Pathology Research and Practice, 2014, 210, 885-892.	1.0	28
1538	Temporal trends in populationâ€based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer, 2014, 120, 3058-3065.	2.0	55
1539	Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis <scp>B</scp> surface antigen and hepatitis <scp>C</scp> virus antibody. Hepatology Research, 2014, 44, 1039-1046.	1.8	12
1540	Systematic review with metaâ€analysis: meat consumption and the risk of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2014, 39, 913-922.	1.9	55
1541	The DEN and CCl₄â€Induced Mouse Model of Fibrosis and Inflammationâ€Associated Hepatocellular Carcinoma. Current Protocols in Pharmacology, 2014, 66, 14.30.1-10.	4.0	109
1542	Identification of Zinc Finger, MYMâ€type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 633-639.	1.4	0
1543	Time and deprivation trends in incidence of primary liver cancer subtypes in <scp>E</scp>ngland. Journal of Evaluation in Clinical Practice, 2014, 20, 498-504.	0.9	20
1544	Multiple Infections and Cancer: Implications in Epidemiology. Technology in Cancer Research and Treatment, 2014, 13, 177-194.	0.8	38
1545	Transcriptomic analysis of a transgenic zebrafish hepatocellular carcinoma model reveals a prominent role of immune responses in tumour progression and regression. International Journal of Cancer, 2014, 135, 1564-1573.	2.3	18
1546	Prognostic Values of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 in Hepatocellular Carcinoma after Radiotherapy. Digestive Diseases, 2014, 32, 725-732.	0.8	18
1547	Significance of viral status on recurrence of hepatitis <scp>B</scp>â€related hepatocellular carcinoma after curative therapy: A metaâ€analysis. Hepatology Research, 2014, 44, 750-760.	1.8	14

#	Article	IF	Citations
1548	A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologistâ€™s perspective. Medical Oncology, 2014, 31, 282.	1.2	32
1549	Association between thePNPLA3(rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2014, 59, 2170-2177.	3.6	193
1550	High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. International Journal of Cancer, 2014, 134, 2189-2198.	2.3	27
1551	Performance of serum Î±-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. Hpb, 2014, 16, 366-372.	0.1	48
1552	The Role of Telomeres in Liver Disease. Progress in Molecular Biology and Translational Science, 2014, 125, 159-172.	0.9	3
1553	Dynamic multidetector computed tomography findings of hepatocellular carcinoma of hepatitis B virus-positive and -negative patients. Cancer Imaging, 2014, 14, 9.	1.2	2
1554	Survival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC. American Journal of Roentgenology, 2014, 203, W706-W714.	1.0	66
1555	A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. Journal of International Medical Research, 2014, 42, 611-618.	0.4	28
1556	High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma. BMC Gastroenterology, 2014, 14, 195.	0.8	25
1557	Chronic Hepatitis B and Liver Cancer Risks among Asian Immigrants in New York City: Results from a Large, Community-Based Screening, Evaluation, and Treatment Program. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2229-2239.	1.1	41
1558	Association of IL-2 polymorphisms and IL-2 serum levels with susceptibility to HBV-related hepatocellular carcinoma in a Chinese Zhuang population. Infection, Genetics and Evolution, 2014, 27, 375-381.	1.0	16
1559	Microbiome, Inflammation, and Cancer. Cancer Journal (Sudbury, Mass), 2014, 20, 181-189.	1.0	193
1560	miRNAs: new tools for molecular classification, diagnosis and prognosis of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 323-329.	4.2	4
1561	Ablation therapy for hepatocellular carcinoma: past, present and future perspectives. Hepatic Oncology, 2014, 1, 67-79.	4.2	11
1562	Hepatocellular Carcinoma Incidence in Noncirrhotic Patients With Chronic Hepatitis B and Patients With Cirrhosis of All Etiologies. Journal of Clinical Gastroenterology, 2014, 48, 644-649.	1.1	22
1563	Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009. Journal of Clinical Gastroenterology, 2014, 48, 279-289.	1.1	80
1564	Mechanisms of hepatitis B virus-induced hepatocellular carcinoma. Reviews in Medical Microbiology, 2014, 25, 20-25.	0.4	1
1565	Age, Arterial Stiffness, and Components of Blood Pressure in Chinese Adults. Medicine (United States), 2014, 93, e262.	0.4	19

#	Article	IF	Citations
1566	Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. European Journal of Gastroenterology and Hepatology, 2014, 26, 1039-1046.	0.8	10
1567	Recombinant Newcastle Disease Virus Anhinga Strain (NDV/Anh-EGFP) for Hepatoma Therapy. Technology in Cancer Research and Treatment, 2014, 13, 169-175.	0.8	10
1568	A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepatic Oncology, 2014, 1, 143-157.	4.2	16
1569	The Inflammation and Liver Cancer. Advances in Experimental Medicine and Biology, 2014, 816, 401-435.	0.8	237
1570	Hepatitis C Virus and Liver Transplantation. , 2014, , .		1
1571	Massive gene amplification drives paediatric hepatocellular carcinoma caused by bile salt export pump deficiency. Nature Communications, 2014, 5, 3850.	5.8	49
1573	Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA Journal, 2014, 5, 16.	3.3	12
1574	Prophylactic Role ofAverrhoa carambola(Star Fruit) Extract against Chemically Induced Hepatocellular Carcinoma in Swiss Albino Mice. Advances in Pharmacological Sciences, 2014, 2014, 1-8.	3.7	22
1575	HIF-1a Plays a Role in the Chemotactic Migration of Hepatocarcinoma Cells Through the Modulation of CXCL6 Expression. Cellular Physiology and Biochemistry, 2014, 34, 1536-1546.	1.1	46
1576	Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA). Microarrays (Basel, Switzerland), 2014, 3, 91-102.	1.4	10
1577	Advances in the study of molecularly targeted agents to treat hepatocellular carcinoma. Drug Discoveries and Therapeutics, 2014, 8, 154-164.	0.6	13
1578	Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Experimental and Therapeutic Medicine, 2014, 7, 31-38.	0.8	19
1579	Viral Carcinogenesis: Factors Inducing DNA Damage and Virus Integration. Cancers, 2014, 6, 2155-2186.	1.7	105
1580	Analysis of hepatocellular carcinoma and metastatic hepatic carcinoma via functional modules in a protein-protein interaction network. Journal of Cancer Research and Therapeutics, 2014, 10, 186.	0.3	5
1581	Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research, 2014, 74, 1845-1856.	0.4	34
1582	Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1a. Cellular Physiology and Biochemistry, 2014, 33, 37-51.	1.1	39
1583	Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis <scp>C</scp> patients on interferonâ€based antiâ€viral therapy. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 137-143.	1.4	20
1584	Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology, 2014, 59, 911-923.	3.6	382

#	Article	IF	Citations
1585	microRNA Biomarkers as Potential Diagnostic Markers for Cancer. , 2014, , 95-126.		0
1586	Synthesis of new N,Nâ€²-bis[1-aryl-3-(piperidine-1-yl)propylidene]hydrazine dihydrochlorides and evaluation of their cytotoxicity against human hepatoma and breast cancer cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 420-426.	2.5	11
1587	LINE(1)s of Evidence in HBV-Driven Liver Cancer. Cell Host and Microbe, 2014, 15, 249-250.	5.1	13
1588	Decorin deficiency promotes hepatic carcinogenesis. Matrix Biology, 2014, 35, 194-205.	1.5	71
1589	Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology, 2014, 146, 1691-1700.e3.	0.6	576
1590	SH2D4A is frequently downregulated in hepatocellular carcinoma and cirrhotic nodules. European Journal of Cancer, 2014, 50, 731-738.	1.3	9
1591	Regulation of microRNAs and their role in liver development, regeneration and disease. International Journal of Biochemistry and Cell Biology, 2014, 54, 288-303.	1.2	62
1592	The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. Journal of Surgical Research, 2014, 187, 377-385.	0.8	42
1593	Hepatic RIG-I Predicts Survival and Interferon-Î± Therapeutic Response in Hepatocellular Carcinoma. Cancer Cell, 2014, 25, 49-63.	7.7	182
1594	Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT. Journal of Hepatology, 2014, 61, 82-88.	1.8	271
1595	Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma. Clinica Chimica Acta, 2014, 433, 128-134.	0.5	34
1596	Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: Efficacy and outcomes. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 352-357.	1.4	31
1597	Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene, 2014, 33, 3225-3234.	2.6	172
1598	Mitochondria protection with ginkgolide B-loaded polymeric nanocapsules prevents diethylnitrosamine-induced hepatocarcinoma in rats. Nanomedicine, 2014, 9, 441-456.	1.7	14
1599	Fatty acid composition and biological activities of Isochrysis galbana T-ISO, Tetraselmis sp. and Scenedesmus sp.: possible application in the pharmaceutical and functional food industries. Journal of Applied Phycology, 2014, 26, 151-161.	1.5	66
1600	Overexpression of retinoic acid-induced protein 3 predicts poor prognosis for hepatocellular carcinoma. Clinical and Translational Oncology, 2014, 16, 57-63.	1.2	21
1601	New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. Journal of Gastroenterology, 2014, 49, 755-763.	2.3	39
1602	IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Journal of Gastroenterology, 2014, 49, 748-754.	2.3	13

#	Article	IF	Citations
1603	Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation. Biotechnology Letters, 2014, 36, 257-263.	1.1	37
1604	Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas. BMC Medical Genomics, 2014, 7, 2.	0.7	31
1605	Glycine inhibits angiogenic signaling in human hepatocellular carcinoma cells. Amino Acids, 2014, 46, 969-976.	1.2	14
1606	Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy. Journal of Cancer Research and Clinical Oncology, 2014, 140, 109-116.	1.2	18
1607	Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma. Abdominal Imaging, 2014, 39, 262-268.	2.0	19
1608	Mechanisms of alcohol-induced hepatocellular carcinoma. Hepatology International, 2014, 8, 452-457.	1.9	27
1609	miR-612 suppresses the stemness of liver cancer via Wnt/Î²-catenin signaling. Biochemical and Biophysical Research Communications, 2014, 447, 210-215.	1.0	77
1610	Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma. Hepatology International, 2014, 8, 260-5.	1.9	15
1611	Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases. Metabolomics, 2014, 10, 1026-1035.	1.4	7
1612	Steatohepatitic Hepatocellular Carcinomaâ€"A Case Report with Literature Review. Indian Journal of Surgical Oncology, 2014, 5, 161-163.	0.3	10
1613	Genetic polymorphisms of XRCC1 gene and susceptibility to hepatocellular carcinoma in Chinese population. Medical Oncology, 2014, 31, 887.	1.2	1
1614	Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues. Hormones and Cancer, 2014, 5, 61-71.	4.9	60
1615	Association of interleukin-8 gene polymorphisms with the risk of hepatocellular carcinoma. Molecular Biology Reports, 2014, 41, 1483-1489.	1.0	11
1616	Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?. Annals of Surgical Oncology, 2014, 21, 1010-1015.	0.7	15
1617	Expressions of Hypoxia-Inducible Factor-1 and Epithelial Cell Adhesion Molecule are Linked with Aggressive Local Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy. Annals of Surgical Oncology, 2014, 21, 436-442.	0.7	53
1618	Association analysis between the c.1804C>A genetic polymorphism of XRCC1 gene and risk of hepatocellular carcinoma in Chinese population. Medical Oncology, 2014, 31, 854.	1.2	4
1619	Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice. Tumor Biology, 2014, 35, 5459-5466.	0.8	19
1620	Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. Journal of Gastroenterology, 2014, 49, 1578-1587.	2.3	37

#	Article	IF	Citations
1621	Lack of association of EPHX1 gene polymorphisms with risk of hepatocellular carcinoma: a meta-analysis. Tumor Biology, 2014, 35, 659-666.	0.8	9
1622	Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma. BMC Genomics, 2014, 15, S13.	1.2	54
1623	Awareness of Biologically Confirmed HCV Among a Community Residing Sample of Drug Users in Baltimore City. Journal of Community Health, 2014, 39, 487-493.	1.9	2
1624	Sensitization of Hepatocellular Carcinoma Cells to <scp>A</scp>po2<scp>L</scp>/<scp>TRAIL</scp> by a Novel Akt/<scp>NF</scp>â€ºscp>B</scp> Signalling Inhibitor. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 464-471.	1.2	29
1625	NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. International Journal of Cancer, 2014, 135, 658-668.	2.3	108
1626	Synthesis and in vitro anticancer evaluation of 2-isopropyl-5-methylphenol Loaded PLGA based iron oxide nanoparticles. Biomedicine and Preventive Nutrition, 2014, 4, 137-141.	0.9	6
1627	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. Cancer Cell, 2014, 25, 335-349.	7.7	254
1628	Cell surface protein glycosylation in cancer. Proteomics, 2014, 14, 525-546.	1.3	436
1630	IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology, 2014, 26, 54-74.	2.7	532
1631	Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver International, 2014, 34, 834-843.	1.9	132
1632	Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2014, 23, 171-188.	0.6	39
1633	Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2014, 23, 289-311.	0.6	58
1634	Determining the Involvement and Therapeutic Implications of Host Cellular Factors in Hepatitis C Virus Cell-to-Cell Spread. Journal of Virology, 2014, 88, 5050-5061.	1.5	38
1635	Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. Journal of Hepatology, 2014, 60, 39-45.	1.8	52
1636	Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatology Research, 2014, 44, 523-531.	1.8	73
1637	Rare Benign Tumors of the Liver: Still Rare?. Journal of Gastrointestinal Cancer, 2014, 45, 202-217.	0.6	13
1638	Adult Stem Cells. Pancreatic Islet Biology, 2014, , .	0.1	2
1639	HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROSâ€“JNKâ€“autophagy pathway. Free Radical Biology and Medicine, 2014, 70, 194-203.	1.3	76

#	Article	IF	Citations
1640	Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology, 2014, 60, 1972-1982.	3.6	345
1641	An aptasensor using DNA aptamer and white light common-path SPR spectral interferometry to detect cytochrome-c for anti-cancer drug screening. Sensors and Actuators B: Chemical, 2014, 198, 416-423.	4.0	56
1642	Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology, 2014, 59, 1998-2009.	3.6	103
1643	Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatology Research, 2014, 44, 1329-1338.	1.8	33
1644	MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis, 2014, 3, e97-e97.	2.1	56
1645	Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. Liver Transplantation, 2014, 20, 912-921.	1.3	35
1646	Comparative analysis of viral protein interaction networks in Hepatitis B Virus and Hepatitis C Virus infected HCC. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 271-279.	1.1	8
1647	Prosurvival function of the cellular apoptosis susceptibility/importin-Î±1 transport cycle is repressed by p53 in liver cancer. Hepatology, 2014, 60, 884-895.	3.6	29
1648	Increased expression of glycinamide ribonucleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma, and it promotes liver cancer cell proliferation. Human Pathology, 2014, 45, 1370-1378.	1.1	24
1649	The pharmaceuticalization of sexual risk: Vaccine development and the new politics of cancer prevention. Social Science and Medicine, 2014, 101, 155-165.	1.8	49
1650	Hepatitis B virus and hepatitis D virus in blood donors from Argentina: circulation of HBsAg and reverse transcriptase mutants. Archives of Virology, 2014, 159, 1109-1117.	0.9	10
1651	Downregulation of microRNAâ€15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2â€induced Globo H expression. International Journal of Cancer, 2014, 134, 1638-1647.	2.3	62
1652	Viruses and Human Cancer. Recent Results in Cancer Research, 2014, , .	1.8	1
1653	Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis, 2014, 35, 507-514.	1.3	174
1654	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients. , 2014, , 77-93.		0
1655	Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America, 2014, 98, 103-118.	1.1	14
1656	MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2014, 443, 1078-1084.	1.0	99
1657	Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cellular and Molecular Immunology, 2014, 11, 184-196.	4.8	50

#	Article	IF	Citations
1658	Bio-responsive chitin-poly(l-lactic acid) composite nanogels for liver cancer. Colloids and Surfaces B: Biointerfaces, 2014, 113, 394-402.	2.5	35
1659	Cbx4 Governs HIF-1Î± to Potentiate Angiogenesis of Hepatocellular Carcinoma by Its SUMO E3 Ligase Activity. Cancer Cell, 2014, 25, 118-131.	7.7	180
1660	Reassessing Hepatocellular Carcinoma Staging in a Changing Patient Population. Oncology, 2014, 86, 63-71.	0.9	3
1661	Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis, 2014, 35, 537-545.	1.3	63
1662	Non-coding RNAs and Cancer. , 2014, , .		6
1663	Glypicanâ€3 antibodies: A new therapeutic target for liver cancer. FEBS Letters, 2014, 588, 377-382.	1.3	88
1664	Micro<scp>RNA</scp>â€520câ€3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypicanâ€3. Hepatology Research, 2014, 44, 338-348.	1.8	46
1665	The association between diabetes and liver disease: The need for a consensus. Arab Journal of Gastroenterology, 2014, 15, 166-168.	0.4	1
1666	Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. Journal of Gastrointestinal Surgery, 2014, 18, 2136-2148.	0.9	90
1667	SERPINB3 is associated with TGF-Î²1 and cytoplasmic Î²-catenin expression in hepatocellular carcinomas with poor prognosis. British Journal of Cancer, 2014, 110, 2708-2715.	2.9	57
1668	Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Digestive Diseases, 2014, 32, 705-710.	0.8	17
1669	Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: Chemoprevention of hepatocellular carcinoma using acyclic retinoid and branchedâ€chain amino acids. Molecular Nutrition and Food Research, 2014, 58, 124-135.	1.5	8
1670	Prognostic significance of receptor for advanced glycation end products expression in hepatocellular carcinoma after hepatectomy. Journal of Surgical Research, 2014, 192, 503-508.	0.8	11
1671	Association of microRNA-3144 variant with the susceptibility to hepatocellular carcinoma. Genes and Genomics, 2014, 36, 771-776.	0.5	0
1672	Sorafenib relieves cellâ€intrinsic and cellâ€extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. International Journal of Cancer, 2014, 134, 319-331.	2.3	102
1673	Chemical Diagnostics. Topics in Current Chemistry, 2014, , .	4.0	2
1674	Identification of miR-423 and miR-499 Polymorphisms on Affecting the Risk of Hepatocellular Carcinoma in a Large-Scale Population. Genetic Testing and Molecular Biomarkers, 2014, 18, 516-524.	0.3	37
1675	Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology, 2014, 60, 1291-1301.	3.6	67

#	Article	IF	Citations
1676	MicroRNAs: Key Regulators of Oncogenesis. , 2014, , .		14
1677	Inflammatory cytokines promote the retrodifferentiation of tumorâ€derived hepatocyteâ€like cells to progenitor cells. Hepatology, 2014, 60, 2077-2090.	3.6	75
1678	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
1679	Diagnostic value of circulating microRNAs for hepatocellular carcinoma. Molecular Biology Reports, 2014, 41, 6919-6929.	1.0	15
1680	Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1092-1101.	1.4	8
1681	Liposomes for targeting hepatocellular carcinoma: Use of conjugated arabinogalactan as targeting ligand. International Journal of Pharmaceutics, 2014, 477, 128-139.	2.6	39
1682	Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells. Experimental Cell Research, 2014, 328, 379-387.	1.2	27
1683	DNA Methylation-mediated Repression of miR-941 Enhances Lysine (K)-specific Demethylase 6B Expression in Hepatoma Cells. Journal of Biological Chemistry, 2014, 289, 24724-24735.	1.6	44
1684	Specific and efficient gene delivery mediated by an asialofetuin-associated nanosystem. International Journal of Pharmaceutics, 2014, 473, 366-374.	2.6	8
1685	Quantification of Hepatic Fat and Iron with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2014, 22, 397-416.	0.6	15
1686	Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Letters, 2014, 351, 232-241.	3.2	39
1687	Hepatocellular carcinoma. Wiener Medizinische Wochenschrift, 2014, 164, 450-455.	0.5	24
1688	Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. European Journal of Cancer, 2014, 50, 2560-2569.	1.3	61
1689	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene, 2014, 33, 1468-1474.	2.6	132
1690	The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Medical Oncology, 2014, 31, 209.	1.2	22
1691	n-butanol fraction of Uncaria rhynchophylla induces apoptosis in human hepatoma cancer cells through activation of PARP. Biotechnology and Bioprocess Engineering, 2014, 19, 411-418.	1.4	2
1692	MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X. BMC Cancer, 2014, 14, 393.	1.1	77
1693	Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer, 2014, 14, 621.	1.1	47

#	Article	IF	Citations
1694	The role of p21-activated kinases in hepatocellular carcinoma metastasis. Journal of Molecular Signaling, 2014, 9, 7.	0.5	16
1695	The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model. Journal of Experimental and Clinical Cancer Research, 2014, 33, 57.	3.5	30
1696	Expressions of heparanase and upstream stimulatory factor in hepatocellular carcinoma. European Journal of Medical Research, 2014, 19, 45.	0.9	12
1697	Pathogenesis of hepatocellular carcinoma according to aetiology. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 937-947.	1.0	59
1698	Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-Î¹B-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids, 2014, 46, 2809-2822.	1.2	70
1699	Methylation patterns of estrogen receptor Î± promoter correlate with estrogen receptor Î± expression and clinicopathological factors in hepatocellular carcinoma. Experimental Biology and Medicine, 2014, 239, 883-890.	1.1	18
1701	Preliminary experience of a new perspective view technology for the detection of portal vein thrombus in hepatocellular carcinoma patients. Abdominal Imaging, 2014, 39, 1145-1152.	2.0	2
1702	Preoperative Hepatitis B Virus DNA Level is a Risk Factor for Postoperative Liver Failure in Patients Who Underwent Partial Hepatectomy for Hepatitis Bâ€Related Hepatocellular Carcinoma. World Journal of Surgery, 2014, 38, 2370-2376.	0.8	11
1703	Antiviral Therapy Decreases Recurrence of Hepatitis B Virusâ€related Hepatocellular Carcinoma after Curative Resection: A Metaâ€analysis. World Journal of Surgery, 2014, 38, 2395-2402.	0.8	36
1704	Increased adiponectin associated with poor survival in hepatocellular carcinoma. Journal of Gastroenterology, 2014, 49, 1342-1351.	2.3	21
1705	Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. Journal of Gastroenterology, 2014, 49, 1105-1110.	2.3	40
1706	miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. Molecular and Cellular Biochemistry, 2014, 392, 289-296.	1.4	74
1707	Carvacrol modulates instability of xenobiotic metabolizing enzymes and downregulates the expressions of PCNA, MMP-2, and MMP-9 during diethylnitrosamine-induced hepatocarcinogenesis in rats. Molecular and Cellular Biochemistry, 2014, 395, 65-76.	1.4	18
1708	The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Molecular and Cellular Biochemistry, 2014, 395, 99-107.	1.4	37
1709	Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. Journal of Diabetes and Metabolic Disorders, 2014, 13, 57.	0.8	25
1710	Diabetes Mellitus and Increased Postoperative Risk of Acute Renal Failure After Hepatectomy for Hepatocellular Carcinoma: A Nationwide Population-Based Study. Annals of Surgical Oncology, 2014, 21, 3810-3816.	0.7	20
1711	Tollâ€like receptors and liver disease. Liver International, 2014, 34, 184-196.	1.9	77
1712	Physical and chemical insults induce inflammation and gastrointestinal cancers. Cancer Letters, 2014, 345, 190-195.	3.2	11

#	Article	IF	Citations
1713	Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism: Clinical and Experimental, 2014, 63, 607-617.	1.5	146
1714	Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution, 2014, 26, 327-339.	1.0	24
1715	Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population. Infection, Genetics and Evolution, 2014, 27, 77-82.	1.0	20
1716	Advances in managing hepatocellular carcinoma. Frontiers of Medicine, 2014, 8, 175-189.	1.5	8
1717	Molecular Targeted Therapy in Hepatocellular Carcinoma: From Biology to Clinical Practice and Future. Current Treatment Options in Oncology, 2014, 15, 380-394.	1.3	21
1718	Neutrophilâ€“lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Medical Oncology, 2014, 31, 969.	1.2	34
1719	The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein and Cell, 2014, 5, 673-691.	4.8	141
1720	Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis. Tumor Biology, 2014, 35, 3551-3561.	0.8	15
1721	Type 2 diabetes mellitus is a risk factor for hepatocellular carcinoma in Egyptian patients with HCV-related cirrhosis. International Journal of Diabetes in Developing Countries, 2014, 34, 210-214.	0.3	0
1722	Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma. BMC Complementary and Alternative Medicine, 2014, 14, 141.	3.7	17
1723	The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Molecular Cancer, 2014, 13, 98.	7.9	61
1724	Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Science, 2014, 12, 22.	0.7	36
1725	Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. Journal of Translational Medicine, 2014, 12, 86.	1.8	45
1726	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut, 2014, 63, 1943-1950.	6.1	149
1727	Factors predictive of readmission after hepatic resection for hepatocellular carcinoma. Surgery, 2014, 156, 1039-1048.	1.0	23
1728	Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis, 2014, 35, 2283-2290.	1.3	23
1729	AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells. Biochemical Pharmacology, 2014, 91, 168-180.	2.0	38
1731	In vitro regulation of hepatocellular carcinoma cell viability, apoptosis, invasion, and AEG-1 expression by LY294002. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 73-80.	0.7	21

#	Article	IF	Citations
1732	Positive association of long telomeres with the invasive capacity of hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2014, 447, 358-363.	1.0	17
1733	Impaired autophagy response in human hepatocellular carcinoma. Experimental and Molecular Pathology, 2014, 96, 149-154.	0.9	74
1734	The evaluation of p,pâ€²-DDT exposure on cell adhesion of hepatocellular carcinoma. Toxicology, 2014, 322, 99-108.	2.0	28
1735	Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population. Human Immunology, 2014, 75, 297-301.	1.2	31
1736	Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis Bâ€"A Nationwide Cohort Study. Gastroenterology, 2014, 147, 143-151.e5.	0.6	267
1737	Down-regulation of ribosomal protein S15A mRNA with a short hairpin RNA inhibits human hepatic cancer cell growth in vitro. Gene, 2014, 536, 84-89.	1.0	34
1738	MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochemical and Biophysical Research Communications, 2014, 446, 1255-1260.	1.0	79
1739	Allele-Specific Imbalance of Oxidative Stress-Induced Growth Inhibitor 1 Associates With Progression of Hepatocellular Carcinoma. Gastroenterology, 2014, 146, 1084-1096.e5.	0.6	33
1740	The Changing Landscape of Hepatocellular Carcinoma. American Journal of Pathology, 2014, 184, 574-583.	1.9	82
1741	Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Experimental and Molecular Pathology, 2014, 96, 375-381.	0.9	20
1742	Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 75-81.	1.8	431
1743	Extracellular vesicleâ€mediated transfer of long nonâ€coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio, 2014, 4, 458-467.	1.0	383
1744	NCOA5, IL-6, Type 2 Diabetes, and HCC: The Deadly Quartet. Cell Metabolism, 2014, 19, 6-7.	7.2	20
1745	RNA Identity Crisis: Hepatitis B Walks the LINE. Cancer Cell, 2014, 25, 259-260.	7.7	6
1746	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. American Journal of Gastroenterology, 2014, 109, 325-334.	0.2	270
1747	Positron Emission Tomography Diagnostic Imaging in Multidrug-Resistant Hepatocellular Carcinoma: Focus on 2-Deoxy-2-(18F)Fluoro-d-Glucose. Molecular Diagnosis and Therapy, 2014, 18, 495-504.	1.6	16
1748	Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing. Hepatology, 2014, 59, 2216-2227.	3.6	45
1749	TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infection. International Journal of Surgery, 2014, 12, 659-665.	1.1	58

#	Article	IF	Citations
1750	Efficient generation of highly immunocompetent dendritic cells from peripheral blood of patients with hepatitis C virus-related hepatocellular carcinoma. International Immunopharmacology, 2014, 21, 346-353.	1.7	7
1751	Manipulating hepatocellular carcinoma cell fate in orthogonally cross-linked hydrogels. Biomaterials, 2014, 35, 6898-6906.	5.7	34
1752	Tetraspanin-enriched microdomains and hepatocellular carcinoma progression. Cancer Letters, 2014, 351, 23-29.	3.2	16
1753	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: TheÂPuri Recommendations. Journal of Clinical and Experimental Hepatology, 2014, 4, S3-S26.	0.4	50
1754	Impact of insulin-like growth factor 2, insulin-like growth factor receptor 2, insulin receptor substrate 2 genes polymorphisms on susceptibility and clinicopathological features of hepatocellular carcinoma. Cytokine, 2014, 68, 50-58.	1.4	9
1755	A practical data processing workflow for multi-OMICS projects. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 52-62.	1.1	48
1756	Functional polymorphisms in microRNAs and susceptibility to liver cancer: a meta-analysis and meta-regression. Genetics and Molecular Research, 2014, 13, 5426-5440.	0.3	13
1757	Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations. World Journal of Gastroenterology, 2014, 20, 7525.	1.4	50
1758	Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives. World Journal of Gastroenterology, 2014, 20, 333.	1.4	90
1759	Role of mitochondria in alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 2136.	1.4	107
1760	Expression of the lysyl oxidase propeptide in hepatocellular carcinoma and its clinical relevance. Oncology Reports, 2014, 31, 1669-1676.	1.2	23
1761	Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. International Journal of Oncology, 2014, 44, 769-780.	1.4	42
1762	Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. International Journal of Oncology, 2014, 45, 1547-1555.	1.4	132
1763	Fatty acid metabolic enzyme acyl-CoA thioesterase 8 promotes the development of hepatocellular carcinoma. Oncology Reports, 2014, 31, 2797-2803.	1.2	31
1764	Celecoxib induces apoptosis via a mitochondria-dependent pathway in the H22 mouse hepatoma cell line. Molecular Medicine Reports, 2014, 10, 2093-2098.	1.1	12
1765	Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF-1Î± expression in vivo. Molecular Medicine Reports, 2014, 10, 585-592.	1.1	8
1766	Association study of miR-149 rs2292832 and miR-608 rs4919510 and the risk of hepatocellular carcinoma in a large-scale population. Molecular Medicine Reports, 2014, 10, 2736-2744.	1.1	34
1767	Development of a Simple Miniature Thermochemical Ablation Device Suitable for Tumor Ablation Research in Rodent Models. Journal of Medical Devices, Transactions of the ASME, 2014, 8, .	0.4	0

#	Article	IF	Citations
1768	Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma. Oncology Reports, 2014, 31, 2569-2578.	1.2	19
1769	Synergistic effects of co-expression plasmid-based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo. Oncology Reports, 2014, 32, 2501-2510.	1.2	8
1770	MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. International Journal of Oncology, 2014, 44, 1915-1922.	1.4	74
1771	Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo. Oncology Reports, 2014, 32, 1913-1922.	1.2	20
1772	Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines. International Journal of Oncology, 2014, 45, 1450-1456.	1.4	8
1773	Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?. Hepatic Oncology, 2014, 1, 309-321.	4.2	1
1774	Latexin exhibits tumor suppressor potential in hepatocellular carcinoma. Oncology Reports, 2014, 31, 1364-1372.	1.2	17
1775	Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal-regulated kinase signaling pathway. Molecular Medicine Reports, 2014, 9, 882-888.	1.1	55
1776	Stereotactic Body Radiation Therapy as a Bridge to Transplantation and for Recurrent Disease in the Transplanted Liver of a Patient with Hepatocellular Carcinoma. Case Reports in Oncology, 2014, 7, 18-22.	0.3	7
1777	Hepatitis B Virus-Related Hepatocellular Carcinoma: Pathogenic Mechanisms and Novel Therapeutic Interventions. Gastrointestinal Tumors, 2014, 1, 135-145.	0.3	25
1778	Screening Process Failures for Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 375-382.	2.3	34
1779	The biological and clinical challenge of liver cancer heterogeneity. Hepatic Oncology, 2014, 1, 349-353.	4.2	34
1780	Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 45, 2005-2012.	1.4	17
1781	TGF-Î²/Smad signaling during hepatic fibro-carcinogenesis (Review). International Journal of Oncology, 2014, 45, 1363-1371.	1.4	109
1782	Role and mechanisms of microRNA-503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. Molecular Medicine Reports, 2014, 10, 3268-3274.	1.1	26
1783	Health disparities in diagnosis and treatment of hepatocellular carcinoma. Clinical Liver Disease, 2014, 4, 143-145.	1.0	13
1784	The Association of Common Functional Polymorphisms in Mir-146a and Mir-196a2 and Hepatocellular Carcinoma Risk. Medicine (United States), 2014, 93, e252.	0.4	17
1785	Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. Ultrasound in Medicine and Biology, 2015, 41, 3070-3078.	0.7	16

#	Article	IF	Citations
1786	HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncology Reports, 2015, 34, 2238-2250.	1.2	75
1787	Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Molecular Cancer, 2015, 14, 165.	7.9	197
1788	Angiogenesis in hepatocellular carcinoma. Biology Bulletin Reviews, 2015, 5, 568-578.	0.3	4
1789	Selective Inflow Occlusion Technique Versus Intermittent Pringle Maneuver in Hepatectomy for Large Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e2250.	0.4	9
1790	Prostate Tumor Overexpressed 1 Is a Novel Prognostic Marker for Hepatocellular Carcinoma Progression and Overall Patient Survival. Medicine (United States), 2015, 94, e423.	0.4	7
1791	Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults. The Cochrane Library, 0, , .	1.5	0
1792	TRAIL expression levels in human hepatocellular carcinoma have implications for tumor growth, recurrence and survival. International Journal of Cancer, 2015, 136, E154-60.	2.3	11
1793	Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study. Liver International, 2015, 35, 2155-2166.	1.9	813
1794	Trans-Arterial Radioembolization for Hepatocellular Carcinoma. Digestive Diseases, 2015, 33, 661-667.	0.8	3
1796	Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Scientific Reports, 2015, 5, 14752.	1.6	241
1797	High-mobility group box 1 has a prognostic role and contributes to epithelial mesenchymal transition in human hepatocellular carcinoma. Molecular Medicine Reports, 2015, 12, 5997-6004.	1.1	19
1798	A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. Scientific Reports, 2015, 5, 9202.	1.6	22
1799	Screening and Identifying a Novel ssDNA Aptamer against Alpha-fetoprotein Using CE-SELEX. Scientific Reports, 2015, 5, 15552.	1.6	83
1800	Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms and their interactions in hepatocellular carcinoma: a multi-centre case-control study. Scientific Reports, 2015, 5, 16489.	1.6	35
1801	CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway. Molecular Medicine Reports, 2015, 12, 8229-8236.	1.1	20
1802	miR-615-3p expression level in bone marrow is associated with tumor recurrence in hepatocellular carcinoma. Molecular and Clinical Oncology, 2015, 3, 487-494.	0.4	16
1803	Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Molecular Medicine Reports, 2015, 11, 2334-2340.	1.1	15
1804	Fatsioside A-induced apoptotic death of HepG2 cells requires activation of AMP-activated protein kinase. Molecular Medicine Reports, 2015, 12, 5679-5684.	1.1	6

#	Article	IF	Citations
1806	Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells. Biological and Pharmaceutical Bulletin, 2015, 38, 1410-1414.	0.6	44
1807	Efficacy and Safety of Telaprevir, Pegylated Interferon α-2b and Ribavirin Triple Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b. Internal Medicine, 2015, 54, 2551-2560.	0.3	7
1808	Downregulation of MicroRNA-145 Caused by Hepatitis B Virus X Protein Promotes Expression of CUL5 and Contributes to Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2015, 37, 1547-1559.	1.1	41
1809	Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model. Scientific Reports, 2015, 4, 4324.	1.6	4
1810	TIMP-1 mediates TGF-Î²-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling. Scientific Reports, 2015, 5, 16492.	1.6	50
1811	Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Molecular Medicine Reports, 2015, 12, 6065-6071.	1.1	63
1812	Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. Cancer Biomarkers, 2015, 15, 677-683.	0.8	24
1813	Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Scientific Reports, 2015, 5, 16294.	1.6	104
1814	Glycogen synthase kinase-3Î² regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-ÎºB pathway in hepatocellular carcinoma. Oncology Letters, 2015, 10, 3557-3564.	0.8	4
1815	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 253-262.	4.2	172
1816	Prolyl-4-Hydroxylase 2 Potentially Contributes to Hepatocellular Carcinoma-Associated Erythrocytosis by Maintaining Hepatocyte Nuclear Factor-4Î± Expression. Cellular Physiology and Biochemistry, 2015, 37, 2257-2264.	1.1	3
1817	Increased glyceraldehyde-3-phosphate dehydrogenase expression indicates higher survival rates in male patients with hepatitisÂB virus-accociated hepatocellular carcinoma and cirrhosis. Experimental and Therapeutic Medicine, 2015, 9, 1597-1604.	0.8	2
1818	Mitochondrial reactive oxygen species and complex II levels are associated with the outcome of hepatocellular carcinoma. Oncology Letters, 2015, 10, 2347-2350.	0.8	5
1819	Nonalcoholic Cirrhosis Increased Risk of Digestive Tract Malignancies. Medicine (United States), 2015, 94, e2080.	0.4	11
1820	Stratified screening of hepatocellular carcinoma in high-risk populations. Radiology of Infectious Diseases, 2015, 2, 109-112.	2.4	2
1821	Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC Cancer, 2015, 15, 707.	1.1	28
1822	Niemann-Pick type C2 protein regulates liver cancer progressionviamodulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications. International Journal of Cancer, 2015, 137, 1341-1351.	2.3	37
1823	Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Molecular Carcinogenesis, 2015, 54, 959-970.	1.3	5

#	Article	IF	Citations
1824	The emerging role of positron emission tomography in hepatocellular carcinoma. Hepatic Oncology, 2015, 2, 191-200.	4.2	8
1825	Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling. BMC Cancer, 2015, 15, 821.	1.1	29
1826	Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutrition Journal, 2015, 14, 67.	1.5	37
1827	HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. Journal of Translational Medicine, 2015, 13, 379.	1.8	32
1828	Viral non-coding RNA inhibits HNF4Î± expression in HCV associated hepatocellular carcinoma. Infectious Agents and Cancer, 2015, 10, 19.	1.2	4
1829	CXCR2â€“CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 129.	3.5	83
1830	Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice. Journal of Experimental and Clinical Cancer Research, 2015, 34, 138.	3.5	22
1831	The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection. Medicine (United States), 2015, 94, e941.	0.4	33
1832	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. Journal of Medical Virology, 2015, 87, 1368-1376.	2.5	2
1833	Knockdown of Myosin VI Inhibits Proliferation of Hepatocellular Carcinoma Cells In Vitro. Chemical Biology and Drug Design, 2015, 86, 723-730.	1.5	9
1835	Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open, 2015, 3, E208-E216.	1.1	13
1836	Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Molecular Carcinogenesis, 2015, 54, 598-607.	1.3	53
1837	Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2015, 27, 853-859.	0.8	41
1838	Identification of microRNAs specific for epithelial cell adhesion moleculeâ€“positive tumor cells in hepatocellular carcinoma. Hepatology, 2015, 62, 829-840.	3.6	51
1839	The role of AEG-1 in the development of liver cancer. Hepatic Oncology, 2015, 2, 303-312.	4.2	20
1840	Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma. Molecular Carcinogenesis, 2015, 54, 853-858.	1.3	28
1841	Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drugâ€Loaded Magnetic Solid Lipid Nanoparticles. Advanced Healthcare Materials, 2015, 4, 1681-1690.	3.9	81
1842	Preoperative Enteral Nutritional Support in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e2006.	0.4	23

#	Article	IF	Citations
1843	Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells. Oncology Letters, 2015, 10, 268-272.	0.8	5
1844	Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. OncoTargets and Therapy, 2015, 8, 3193.	1.0	1
1845	Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Macedonian Journal of Medical Sciences, 2015, 3, 732-736.	0.1	118
1846	Hepatocellular carcinoma: From diagnosis to treatment. World Journal of Hepatology, 2015, 7, 1020.	0.8	137
1847	IL28B Is Associated with Outcomes of Chronic HBV Infection. Yonsei Medical Journal, 2015, 56, 625.	0.9	9
1848	Farnesoid X receptor associates with Î²-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget, 2015, 6, 4226-4238.	0.8	34
1849	Association of nonalcoholic fatty liver disease and liver cancer. World Journal of Gastroenterology, 2015, 21, 913.	1.4	20
1850	Focal liver lesions: Practical magnetic resonance imaging approach. World Journal of Hepatology, 2015, 7, 1987.	0.8	52
1851	Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori, 2015, 101, e46-e48.	0.6	7
1852	Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. OncoTargets and Therapy, 2015, 8, 3775.	1.0	5
1853	Hypoxia up-regulates SERPINB3 through HIF-2Î± in human liver cancer cells. Oncotarget, 2015, 6, 2206-2221.	0.8	59
1854	Ambovex® as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial. Journal of Hepatocellular Carcinoma, 2015, 2, 79.	1.8	1
1855	Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [18F]fluorocholine PET/CT. Diagnostics, 2015, 5, 189-199.	1.3	12
1856	Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World Journal of Gastroenterology, 2015, 21, 11552.	1.4	48
1857	miR-15b-5p induces endoplasmic reticulum stress and apoptosis in human hepatocellular carcinoma, both in vitro and in vivo, by suppressing Rab1A. Oncotarget, 2015, 6, 16227-16238.	0.8	62
1858	Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6, 114.	0.6	11
1859	Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget, 2015, 6, 12340-12356.	0.8	28
1860	CARCINOMA HEPATOCELULAR â€“ UMA REVISÃƒO BIBLIOGRÃFICA. Revista MÃ©dica Da UFPR, 2015, 2, 178.	0.0	0

#	Article	IF	Citations
1861	Co-expression of CXCL8 and HIF-1Î± is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncotarget, 2015, 6, 22880-22889.	0.8	51
1862	Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway. Oncotarget, 2015, 6, 34859-34874.	0.8	35
1863	Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways. International Journal of Molecular Sciences, 2015, 16, 16469-16482.	1.8	74
1864	The role of circulating microRNA in hepatocellular carcinoma. Frontiers in Bioscience - Landmark, 2015, 20, 78-104.	3.0	15
1865	Role of microRNAs in hepatocellular carcinoma. Frontiers in Bioscience - Landmark, 2015, 20, 1056-1067.	3.0	14
1866	Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases (Basel, Switzerland), 2015, 3, 68-77.	1.0	4
1867	Novel Radiolytic Rotenone Derivative, Rotenoisin B with Potent Anti-Carcinogenic Activity in Hepatic Cancer Cells. International Journal of Molecular Sciences, 2015, 16, 16806-16815.	1.8	17
1868	GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues. European Journal of Histochemistry, 2015, 59, 2540.	0.6	80
1869	UNC50 Prompts G1/S Transition and Proliferation in HCC by Regulation of Epidermal Growth Factor Receptor Trafficking. PLoS ONE, 2015, 10, e0119338.	1.1	5
1870	Mechanism of Arctigenin-Induced Specific Cytotoxicity against Human Hepatocellular Carcinoma Cell Lines: Hep G2 and SMMC7721. PLoS ONE, 2015, 10, e0125727.	1.1	31
1871	Relatively Small Contribution of Methylation and Genomic Copy Number Aberration to the Aberrant Expression of Inflammation-Related Genes in HBV-Related Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0126836.	1.1	1
1872	Identification of Hepatocellular Carcinoma-associated Hub Genes and Pathways by Integrated Microarray Analysis. Tumori, 2015, 101, 206-214.	0.6	35
1873	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLoS ONE, 2015, 10, e0129053.	1.1	67
1874	Risk of Developing Depressive Disorders following Hepatocellular Carcinoma: A Nationwide Population-Based Study. PLoS ONE, 2015, 10, e0135417.	1.1	17
1875	Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. PLoS ONE, 2015, 10, e0145147.	1.1	19
1876	fMiRNA-192 and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLoS Genetics, 2015, 11, e1005726.	1.5	151
1877	LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget, 2015, 6, 42813-42824.	0.8	131
1878	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arquivos De Gastroenterologia, 2015, 52, 2-14.	0.3	12

#	Article	IF	Citations
1879	Evaluation of the Selenotranscriptome Expression in Two Hepatocellular Carcinoma Cell Lines. Analytical Cellular Pathology, 2015, 2015, 1-6.	0.7	27
1880	Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	8
1881	Diagnostic Value of Semiquantitative Analysis of Dynamic Susceptibility Contrast Magnetic Resonance Imaging with GD-EOB-DTPA in Focal Liver Lesions Characterization: A Feasibility Study. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	2
1882	Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. BioMed Research International, 2015, 2015, 1-9.	0.9	12
1883	Predictors for Early Identification of Hepatitis C Virus Infection. BioMed Research International, 2015, 2015, 1-7.	0.9	8
1884	Molecular Signalling in Hepatocellular Carcinoma: Role of and Crosstalk among Wnt/Î²-Catenin, Sonic Hedgehog, Notch and Dickkopf-1. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 209-217.	0.8	46
1885	The Value of Serum Midkine Level in Diagnosis of Hepatocellular Carcinoma. International Journal of Hepatology, 2015, 2015, 1-6.	0.4	46
1886	Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma. Mediators of Inflammation, 2015, 2015, 1-7.	1.4	4
1887	Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	44
1888	Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget, 2015, 6, 4440-4450.	0.8	57
1890	Hepatocellular carcinoma in Asia: Prevention strategy and planning. World Journal of Hepatology, 2015, 7, 1708.	0.8	91
1892	Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development. Oncotarget, 2015, 6, 9355-9369.	0.8	27
1893	Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. World Journal of Gastroenterology, 2015, 21, 7375.	1.4	71
1894	Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 12022.	1.4	62
1895	Painless lump over the forehead which turned painful: an unusual presentation of hepatocellular carcinoma. BJR|case Reports, 2015, 1, 20150033.	0.1	1
1896	MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation. Oncotarget, 2015, 6, 6359-6372.	0.8	36
1897	Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience, 2015, 2, 443-456.	0.9	38
1898	Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World Journal of Hepatology, 2015, 7, 101.	0.8	124

#	Article	IF	Citations
1899	Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study. Medical Science Monitor, 2015, 21, 3209-3215.	0.5	19
1900	Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Reports, 2015, 48, 565-570.	1.1	18
1902	The hepatitis C treatment revolution: how to avoid Asia missing out. Journal of Virus Eradication, 2015, 1, 272-275.	0.3	6
1903	Is mother-to-infant transmission the most important factor for persistent HBV infection?. Emerging Microbes and Infections, 2015, 4, 1-9.	3.0	54
1904	Tumor-Suppressing Effect of MiR-4458 on Human Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2015, 35, 1797-1807.	1.1	30
1905	miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumor Biology, 2015, 36, 8309-8316.	0.8	65
1906	PTPRD is Homozygously Deleted and Epigenetically Downregulated in Human Hepatocellular Carcinomas. OMICS A Journal of Integrative Biology, 2015, 19, 220-229.	1.0	14
1907	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. Journal of Hepatology, 2015, 63, 722-732.	1.8	97
1908	Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma. Surgery, 2015, 158, 331-338.	1.0	16
1909	Pre-existing diabetes and risks of morbidity and mortality after liver transplantation: A nationwide database study in an Asian population. European Journal of Internal Medicine, 2015, 26, 433-438.	1.0	16
1910	Alcoholic Cirrhosis and Hepatocellular Carcinoma. Advances in Experimental Medicine and Biology, 2015, 815, 113-130.	0.8	37
1911	Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. Targeted Oncology, 2015, 10, 287-295.	1.7	10
1912	Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population. Tumor Biology, 2015, 36, 7807-7815.	0.8	6
1913	Translational Regenerative Medicineâ€"Hepatic Systems. , 2015, , 469-484.		0
1914	Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique. European Journal of Radiology, 2015, 84, 1029-1035.	1.2	40
1915	Association between Hypoxia-inducible Factor-1Î± gene polymorphisms and risk of chronic hepatitis b and hepatitis b virus-related liver cirrhosis in a Chinese population: A retrospective caseâ€"control study. Gene, 2015, 564, 96-100.	1.0	6
1916	Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. Cell Stem Cell, 2015, 16, 601-612.	5.2	149
1917	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology and Hepatology, 2015, 9, 603-627.	1.4	102

#	Article	IF	Citations
1918	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer, 2015, 15, 210.	1.1	87
1919	TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer, 2015, 15, 245.	1.1	45
1920	Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer, 2015, 15, 236.	1.1	16
1921	Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies. BMC Cancer, 2015, 15, 314.	1.1	23
1922	Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma. Cancer Research, 2015, 75, 3181-3191.	0.4	268
1923	Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. Molecular and Clinical Oncology, 2015, 3, 115-120.	0.4	17
1924	Association of Paraoxonase 1 Gene Polymorphisms With the Risk of Hepatitis B Virus-related Liver Diseases in a Guangxi Population. Medicine (United States), 2015, 94, e2179.	0.4	10
1925	MiRâ€940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. Cancer Science, 2015, 106, 819-824.	1.7	51
1926	The changing epidemiology of Asian digestive cancers: From etiologies and incidences to preventive strategies. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 843-853.	1.0	19
1927	Neuropilin-2 induced by transforming growth factor-Î² augments migration of hepatocellular carcinoma cells. BMC Cancer, 2015, 15, 909.	1.1	30
1928	Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1127-1138.	1.4	2
1929	Melittin induces PTCH1 expression by down-regulating MeCP2 in human hepatocellular carcinoma SMMC-7721 cells. Toxicology and Applied Pharmacology, 2015, 288, 74-83.	1.3	36
1930	The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway. Biomedicine and Pharmacotherapy, 2015, 76, 141-146.	2.5	15
1932	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. Digestive and Liver Disease, 2015, 47, 682-688.	0.4	5
1933	Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma. Chinese Journal of Cancer, 2015, 34, 254-63.	4.9	29
1934	Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. International Journal of Oncology, 2015, 46, 587-596.	1.4	177
1935	Mitochondrial dysfunction induces EMT through the TGF-Î²/Smad/Snail signaling pathway in Hep3B hepatocellular carcinoma cells. International Journal of Oncology, 2015, 47, 1845-1853.	1.4	45
1936	USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncology Reports, 2015, 34, 2917-2924.	1.2	43

#	Article	IF	Citations
1937	CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 1963-1970.	1.4	14
1938	Identification of a non-coding KLF4 transcript generated from intron retention and downregulated in human hepatocellular carcinoma. International Journal of Oncology, 2015, 47, 1554-1562.	1.4	8
1939	miR-153 inhibits epithelial-to-mesenchymal transition in hepatocellular carcinoma by targeting Snail. Oncology Reports, 2015, 34, 655-662.	1.2	44
1940	The emerging role of astrocyte-elevated gene-1 in hepatocellular carcinoma (Review). Oncology Reports, 2015, 34, 539-546.	1.2	12
1941	MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncology Letters, 2015, 10, 3779-3784.	0.8	21
1942	miR-1297 promotes apoptosis and inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting HMGA2. International Journal of Molecular Medicine, 2015, 36, 1345-1352.	1.8	38
1943	Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncology Letters, 2015, 10, 3345-3353.	0.8	24
1944	Anticancer and apoptotic activities of oleanolic acid are mediated through cell cycle arrest and disruption of mitochondrial membrane potential in HepG2 human hepatocellular carcinoma cells. Molecular Medicine Reports, 2015, 12, 5012-5018.	1.1	82
1945	A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. Oncology Letters, 2015, 10, 2787-2794.	0.8	6
1946	RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. International Journal of Oncology, 2015, 46, 1710-1720.	1.4	31
1947	Potential Role of Phosphorylation as a Regulator of Aspartyl-(asparaginyl)-Î²-hydroxylase: Relevance to Infiltrative Spread of Human Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 139-153.	4.2	9
1948	Insufficient Ablative Margin Determined by Early Computed Tomography May Predict the Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. Liver Cancer, 2015, 4, 26-38.	4.2	77
1949	Restoration of Epigenetically Silenced Sulfatase 1 Expression by 5-Aza-2â€²-Deoxycytidine Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis. Medical Epigenetics, 2015, 3, 1-18.	262.3	8
1950	Lupeol enhances radiosensitivity of human hepatocellular carcinoma cell line SMMC-7721 in vitro and in vivo. International Journal of Radiation Biology, 2015, 91, 202-208.	1.0	14
1951	Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. American Journal of Medicine, 2015, 128, 90.e1-90.e7.	0.6	128
1952	Identification of Hepatocellular Carcinomaâ€“Related Genes with a Machine Learning and Network Analysis. Journal of Computational Biology, 2015, 22, 63-71.	0.8	53
1953	MICA SNPs and the NKG2D system in virus-induced HCC. Journal of Gastroenterology, 2015, 50, 261-272.	2.3	41
1954	18-Î² Glycyrrhetinic acid alleviates 2-acetylaminofluorene-induced hepatotoxicity in Wistar rats. Human and Experimental Toxicology, 2015, 34, 628-641.	1.1	43

#	Article	IF	Citations
1955	A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis. International Journal of Biological Macromolecules, 2015, 75, 115-120.	3.6	44
1956	Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 82-89.	0.6	27
1957	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinicalâ€“pathological study. Digestive and Liver Disease, 2015, 47, 296-302.	0.4	2
1958	Synthesis and application of strawberry-like Fe 3 O 4 -Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease. Biomaterials, 2015, 51, 194-207.	5.7	93
1959	Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology, 2015, 42, 329-338.	0.8	22
1960	Axl activates autocrine transforming growth factorâ€Î² signaling in hepatocellular carcinoma. Hepatology, 2015, 61, 930-941.	3.6	127
1961	Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 342-352.	1.4	137
1962	MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumor Biology, 2015, 36, 4747-4755.	0.8	45
1963	JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: A tissue microarray-based study. Acta Histochemica, 2015, 117, 14-19.	0.9	13
1964	Aspartate-Î²-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine, 2015, 33, 1256-1266.	1.7	23
1965	Eicosapentaenoic acid (EPA) induced apoptosis in HepG2 cells through ROSâ€“Ca2+â€“JNK mitochondrial pathways. Biochemical and Biophysical Research Communications, 2015, 456, 926-932.	1.0	40
1966	Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine and Growth Factor Reviews, 2015, 26, 83-93.	3.2	33
1967	Long Noncoding RNAs and Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 291-294.	0.6	14
1968	Fish consumption and n-3 polyunsaturated fatty acids, and risk of hepatocellular carcinoma: systematic review and meta-analysis. Cancer Causes and Control, 2015, 26, 367-376.	0.8	46
1969	Overexpression of micro<scp>RNA</scp>â€30a inhibits hepatitis B virus X proteinâ€induced autophagosome formation in hepatic cells. FEBS Journal, 2015, 282, 1152-1163.	2.2	16
1970	MicroRNAs used as novel biomarkers for detecting cancer metastasis. Tumor Biology, 2015, 36, 1755-1762.	0.8	1
1972	RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing. Cancer Letters, 2015, 357, 510-519.	3.2	41
1973	CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF. Tumor Biology, 2015, 36, 737-745.	0.8	34

#	Article	IF	Citations
1974	Utility of the <scp>FIB</scp>â€4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. Journal of Viral Hepatitis, 2015, 22, 777-783.	1.0	13
1975	Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis. Oncogene, 2015, 34, 364-372.	2.6	26
1976	Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Medical Oncology, 2015, 32, 65.	1.2	3
1977	Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a <scp>E</scp>uropean population: Multicentre, prospective cohort study. International Journal of Cancer, 2015, 136, 1899-1908.	2.3	75
1978	Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. Journal of Translational Medicine, 2015, 13, 41.	1.8	27
1979	Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and 18F-FDG PET/CT. Abdominal Imaging, 2015, 40, 843-851.	2.0	98
1980	High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21â€“Mediated Matrix Metalloproteinase Activity. Cancer Research, 2015, 75, 1645-1656.	0.4	80
1981	Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. Journal of Hepatology, 2015, 63, 114-121.	1.8	189
1982	Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma. Tumor Biology, 2015, 36, 3881-3886.	0.8	25
1983	Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 600-609.	0.7	32
1984	Roles of p38Î± mitogenâ€activated protein kinase in mouse models of inflammatory diseases and cancer. FEBS Journal, 2015, 282, 1841-1857.	2.2	117
1985	Hepatitis B virus infection in children. Expert Review of Anti-Infective Therapy, 2015, 13, 1-24.	2.0	9
1986	FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1311-1319.	1.2	11
1987	First hepatitis B virus full-length genomic study among blood donors from Argentina: unexpected mutations in the circulating subgenotypesâ€™ proteins. Virus Genes, 2015, 50, 286-291.	0.7	0
1988	How cell death shapes cancer. Cell Death and Disease, 2015, 6, e1675-e1675.	2.7	205
1989	Elevated expression levels of androgen receptors and matrix metalloproteinase-2 and -9 in 30 cases of hepatocellular carcinoma compared with adjacent tissues as predictors of cancer invasion and staging. Experimental and Therapeutic Medicine, 2015, 9, 905-908.	0.8	23
1990	Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacologica Sinica, 2015, 36, 1191-1199.	2.8	144
1991	Inhibition of Hepatocellular Carcinoma by Total Alkaloids of Rubus alceifolius Poir Involves Suppression of Hedgehog Signaling. Integrative Cancer Therapies, 2015, 14, 394-401.	0.8	5

#	Article	IF	Citations
1992	Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. Journal of Integrative Medicine, 2015, 13, 142-164.	1.4	97
1993	Cell-autonomous decrease in proliferative competitiveness of the aged hepatocyte. Journal of Hepatology, 2015, 62, 1341-1348.	1.8	20
1994	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology, 2015, 277, 594-603.	3.6	31
1995	NKD1 marks intestinal and liver tumors linked to aberrant Wnt signaling. Cellular Signalling, 2015, 27, 245-256.	1.7	19
1996	Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array. Journal of Surgical Research, 2015, 195, 444-453.	0.8	10
1997	Oxygen in human health from life to death â€“ An approach to teaching redox biology and signaling to graduate and medical students. Redox Biology, 2015, 5, 124-139.	3.9	33
1998	Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncology Letters, 2015, 9, 955-963.	0.8	114
1999	Enhancing effect of natural borneol on the cellular uptake of demethoxycurcumin and their combined induction of G2/M arrest in HepG2 cells via ROS generation. Journal of Functional Foods, 2015, 17, 103-114.	1.6	9
2000	Anti-tumor effect of Cordyceps militaris in HCV-infected human hepatocarcinoma 7.5 cells. Journal of Microbiology, 2015, 53, 468-474.	1.3	9
2001	Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clinical Science, 2015, 128, 29-37.	1.8	10
2002	Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Research, 2015, 121, 69-81.	1.9	65
2003	Outcomes in liver transplantation: Does sex matter?. Journal of Hepatology, 2015, 62, 946-955.	1.8	79
2004	Chronic alcohol drinking: Liver and pancreatic cancer?. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S86-S91.	0.7	6
2005	Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy. Journal of Hepatology, 2015, 63, 1181-1189.	1.8	11
2006	Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection, 2015, 21, 969-974.	2.8	29
2007	Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy. Cell Death and Differentiation, 2015, 22, 1764-1774.	5.0	56
2008	Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Annals of Surgical Oncology, 2015, 22, 1499-1507.	0.7	25
2009	Î²-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. Nature Communications, 2015, 6, 7369.	5.8	62

#	Article	IF	Citations
2010	Combination of interventional adenovirus-p53 introduction and ultrasonic irradiation in the treatment of liver cancer. Oncology Letters, 2015, 9, 1297-1302.	0.8	5
2011	Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression. Oncology Letters, 2015, 9, 1893-1896.	0.8	29
2012	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncology Letters, 2015, 9, 1628-1632.	0.8	25
2013	Suppression of CYP2C9 by MicroRNA hsa-miR-128-3p in Human Liver Cells and Association with Hepatocellular Carcinoma. Scientific Reports, 2015, 5, 8534.	1.6	92
2014	Chemopreventive Potential of Green Tea Catechins in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2015, 16, 6124-6139.	1.8	42
2015	Oncogenic Viruses and Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 341-360.	1.0	16
2016	Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 361-379.	1.0	160
2017	Management and diagnosis of fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 671-683.	1.4	11
2018	Differences in antiproliferative effect of STAT3 inhibition in HCC cells with versus without HBV expression. Biochemical and Biophysical Research Communications, 2015, 461, 513-518.	1.0	6
2019	A cost utility analysis of simeprevir used with peginterferonâ€‰+â€‰ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. Journal of Medical Economics, 2015, 18, 838-849.	1.0	14
2020	PTEN and hTERT gene expression and the correlation with human hepatocellular carcinoma. Pathology Research and Practice, 2015, 211, 316-319.	1.0	15
2021	Replication the association of 2q32.2â€“q32.3 and 14q32.11 with hepatocellular carcinoma. Gene, 2015, 561, 63-67.	1.0	9
2022	Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN. Biomedicine and Pharmacotherapy, 2015, 72, 58-65.	2.5	43
2023	Identification of dysfunctional biological pathways and their synergistic mechanism in hepatocellular carcinoma process. Experimental and Molecular Pathology, 2015, 98, 540-545.	0.9	4
2024	Effects of 5â€²-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective. Molecular and Cellular Biochemistry, 2015, 405, 53-61.	1.4	14
2025	Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydrate Polymers, 2015, 128, 63-74.	5.1	79
2026	Oncological and surgical results of laparoscopic versus open liver resection for HCC less than 5Âcm: case-matched analysis. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 2628-2634.	1.3	56
2027	Liver Transplantation for Hepatocellular Carcinoma. Current Gastroenterology Reports, 2015, 17, 11.	1.1	7

#	Article	IF	Citations
2028	Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma. Virologica Sinica, 2015, 30, 85-91.	1.2	23
2029	Significant association between upstream transcription factor 1 rs2516839 polymorphism and hepatocellular carcinoma risk: a caseâ€“control study. Tumor Biology, 2015, 36, 2551-2558.	0.8	9
2030	Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance. Tumor Biology, 2015, 36, 4235-4241.	0.8	15
2031	Insights into the application of let-7 family as promising biomarker in cancer screening. Tumor Biology, 2015, 36, 5233-5239.	0.8	3
2032	Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC. Tumor Biology, 2015, 36, 6149-6158.	0.8	45
2033	Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?. Tumor Biology, 2015, 36, 6255-6263.	0.8	12
2034	Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma. Tumor Biology, 2015, 36, 6901-6908.	0.8	13
2035	Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population. Tumor Biology, 2015, 36, 6891-6900.	0.8	6
2036	Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. American Journal of Gastroenterology, 2015, 110, 836-844.	0.2	108
2037	EPHX1 Tyr113His polymorphism contributes to hepatocellular carcinoma risk: Evidence from a meta-analysis. Molecular Biology, 2015, 49, 312-321.	0.4	2
2038	International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer, 2015, 15, 94.	1.1	49
2039	The prognostic value of combined TGF-Î²1 and ELF in hepatocellular carcinoma. BMC Cancer, 2015, 15, 116.	1.1	41
2040	The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer, 2015, 15, 188.	1.1	55
2041	EMT and tumor metastasis. Clinical and Translational Medicine, 2015, 4, 6.	1.7	588
2042	TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression. Annals of Surgical Oncology, 2015, 22, 3121-3129.	0.7	50
2043	Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 1453-1460.	0.7	17
2044	Sex hormone affects the severity of non-alcoholic steatohepatitis through the MyD88-dependent IL-6 signaling pathway. Experimental Biology and Medicine, 2015, 240, 1279-1286.	1.1	22
2045	Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma. Tumor Biology, 2015, 36, 7007-7015.	0.8	9

#	Article	IF	Citations
2046	Hepatitis B virus replication and sex-determining region Y box 4 production are tightly controlled by a novel positive feedback mechanism. Scientific Reports, 2015, 5, 10066.	1.6	19
2047	Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2015, 36, 423-434.	1.1	167
2048	Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target. Tumor Biology, 2015, 36, 4063-4074.	0.8	32
2049	Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells. Biochimie, 2015, 112, 85-95.	1.3	29
2050	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. Hepatology Research, 2015, 45, 1331-1340.	1.8	7
2051	Inflammation and Immunity in Cancer. , 2015, , .		1
2052	Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Japanese Journal of Clinical Oncology, 2015, 45, 336-342.	0.6	12
2053	Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway. Tumor Biology, 2015, 36, 5815-5824.	0.8	18
2054	TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells. Oncogene, 2015, 34, 2566-2574.	2.6	64
2055	Clinicopathological Features and Prognostic Factors of Young Patients With Surgically Treated Liver Cancer. Medicine (United States), 2015, 94, e684.	0.4	9
2056	A Schiff base derivative for effective treatment of diethylnitrosamine-induced liver cancer in vivo. Anti-Cancer Drugs, 2015, 26, 555-564.	0.7	20
2057	Oxidative DNA damage induced by di-(2-ethylhexyl) phthalate in HEK-293 cell line. Environmental Toxicology and Pharmacology, 2015, 39, 1099-1106.	2.0	34
2058	miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Research, 2015, 75, 1859-1867.	0.4	83
2059	Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5Âyears. Hepatology International, 2015, 9, 243-250.	1.9	52
2060	Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis. OncoImmunology, 2015, 4, e1021537.	2.1	41
2061	Synergistic mediation of tumor signaling pathways in hepatocellular carcinoma therapy via dual-drug-loaded pH-responsive electrospun fibrous scaffolds. Journal of Materials Chemistry B, 2015, 3, 3436-3446.	2.9	30
2062	Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. British Journal of Cancer, 2015, 112, 1141-1156.	2.9	106
2063	HES5 promotes cell proliferation and invasion through activation of STAT3 and predicts poor survival in hepatocellular carcinoma. Experimental and Molecular Pathology, 2015, 99, 474-484.	0.9	11

#	Article	IF	Citations
2064	Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma. Cancer Gene Therapy, 2015, 22, 530-535.	2.2	43
2065	Mils for HCC: the state of art. Updates in Surgery, 2015, 67, 105-109.	0.9	7
2067	Effects of Mutations of 3 Amino Acids on Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2015, 14, 262-269.	0.8	0
2068	Gastric Metastasis of Hepatocellular Carcinoma With Gastrointestinal Bleeding After Liver Transplant: A Case Report. Transplantation Proceedings, 2015, 47, 2544-2547.	0.3	4
2070	IL-13 and TGF-Î²1: Core Mediators of Fibrosis. Current Pathobiology Reports, 2015, 3, 273-282.	1.6	11
2071	Targeting HCC Therapy: On or Off ToPiX?. Digestive Diseases and Sciences, 2015, 60, 2219-2221.	1.1	1
2072	Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats. Carcinogenesis, 2015, 36, bgv143.	1.3	33
2073	Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Cell Death and Disease, 2015, 6, e1667-e1667.	2.7	25
2074	Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Digestive Diseases and Sciences, 2015, 60, 3142-3148.	1.1	92
2075	A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging. Immunobiology, 2015, 220, 1328-1336.	0.8	26
2076	LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway. Carcinogenesis, 2015, 36, 1201-1212.	1.3	53
2077	The Ras/<scp>MAPK</scp> pathway and hepatocarcinoma: pathogenesis and therapeutic implications. European Journal of Clinical Investigation, 2015, 45, 609-623.	1.7	193
2078	Hepatocellular carcinoma based on cryptogenic liver disease: The most common nonâ€viral hepatocellular carcinoma in patients aged over 80 years. Hepatology Research, 2015, 45, 441-447.	1.8	14
2079	<scp>ANGPTL</scp>2 promotes tumor metastasis in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 396-404.	1.4	28
2080	Hepatocellular carcinoma risk in <scp>HB</scp>eAgâ€negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. Journal of Viral Hepatitis, 2015, 22, 120-127.	1.0	38
2081	The Role of Oxidative Stress in Hepatocarcinogenesis. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 479-503.	0.4	1
2082	The gene expression profiling of hepatocellular carcinoma by a network analysis approach shows a dominance of intrinsically disordered proteins (IDPs) between hub nodes. Molecular BioSystems, 2015, 11, 2933-2945.	2.9	5
2083	Detection of liver cancer cells by using ELISA and coupling of anti-glypican 3 antibody and magnetite nanoparticles. Geosystem Engineering, 2015, 18, 219-225.	0.7	7

#	Article	IF	Citations
2084	Modern multimodality diagnosis of portal vein infiltration in hepatocellular carcinoma and expected changes during current therapies. Acta Radiologica, 2015, 56, 1283-1292.	0.5	7
2085	An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cellâ€“like Behaviors Contributing to Disease Progression. Cancer Research, 2015, 75, 4985-4997.	0.4	113
2086	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in Liver Disease, 2015, 35, 270-290.	1.8	135
2087	Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma. Tumor Biology, 2015, 36, 8447-8453.	0.8	10
2088	Role of gelsolin in cell proliferation and invasion of human hepatocellular carcinoma cells. Gene, 2015, 571, 292-297.	1.0	19
2089	Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. Hepatic Oncology, 2015, 2, 291-302.	4.2	6
2090	Paclitaxel-sensitization enhanced by curcumin involves down-regulation of nuclear factor-Î¹B and Lin28 in Hep3B cells. Journal of Receptor and Signal Transduction Research, 2015, 35, 618-625.	1.3	18
2091	Low Expression of miR-448 Induces EMT and Promotes Invasion by Regulating ROCK2 in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2015, 36, 487-498.	1.1	45
2092	Quantum Dots Based Potential-Resolution Dual-Targets Electrochemiluminescent Immunosensor for Subtype of Tumor Marker and Its Serological Evaluation. Analytical Chemistry, 2015, 87, 9163-9169.	3.2	54
2093	pH-Sensitive pullulanâ€“DOX conjugate nanoparticles for co-loading PDTC to suppress growth and chemoresistance of hepatocellular carcinoma. Journal of Materials Chemistry B, 2015, 3, 8070-8078.	2.9	30
2094	Hepatitis B virus X protein induces the histone H3 lysine 9 trimethylation on the promoter of p16 gene in hepatocarcinogenesis. Experimental and Molecular Pathology, 2015, 99, 399-408.	0.9	13
2095	Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Molecular Cancer Therapeutics, 2015, 14, 2613-2622.	1.9	24
2096	Patterns of cancer recurrence in localized resected hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 269-274.	0.6	16
2097	Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway. Cell Death and Disease, 2015, 6, e1751-e1751.	2.7	42
2098	Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-AChE pathway in apoptotic hepatocellular carcinoma cells. International Journal of Biochemistry and Cell Biology, 2015, 68, 21-32.	1.2	12
2099	Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Human Pathology, 2015, 46, 1769-1775.	1.1	36
2100	Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. Journal of Vascular and Interventional Radiology, 2015, 26, 1630-1638.	0.2	9
2101	Sustained methylene blue staining toÂguide anatomic hepatectomy forÂhepatocellular carcinoma: Initial experience and technical details. Surgery, 2015, 158, 121-127.	1.0	19

#	Article	IF	Citations
2102	Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology, 2015, 11, 943-951.	1.1	24
2103	Diagnosis of Hepatobiliary Malignancies. , 2015, , 471-502.		0
2104	The collagen triple helix repeat containing 1 facilitates hepatitis B virusâ€associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades. Molecular Carcinogenesis, 2015, 54, 1554-1566.	1.3	24
2105	NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cellular and Molecular Immunology, 2015, 12, 292-302.	4.8	148
2106	miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene, 2015, 34, 965-977.	2.6	87
2107	Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis. Journal of Hepatology, 2015, 62, 879-888.	1.8	63
2108	Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging. Journal of Controlled Release, 2015, 199, 63-71.	4.8	29
2109	Cell expression patterns of CD147 in N-diethylnitrosamine/phenobarbital-induced mouse hepatocellular carcinoma. Journal of Molecular Histology, 2015, 46, 79-91.	1.0	8
2110	The efficacy of Radachlorin-mediated photodynamic therapy in human hepatocellular carcinoma cells. Journal of Photochemistry and Photobiology B: Biology, 2015, 142, 86-91.	1.7	22
2111	Alcohol and inflammatory responses: Summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol, 2015, 49, 1-6.	0.8	19
2112	Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2015, 33, 172-179.	0.8	517
2113	Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. Journal of Hepatology, 2015, 62, 599-606.	1.8	60
2114	MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Letters, 2015, 356, 809-818.	3.2	68
2115	The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. International Journal of Cardiology, 2015, 180, 185-191.	0.8	37
2116	The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers. Tumor Biology, 2015, 36, 1993-2005.	0.8	34
2117	5â€Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (Î”Î¨m)â€mediated apoptosis in hepatocellular carcinoma. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 146-153.	0.9	56
2118	Interleukinâ€1Î²/Interleukinâ€1 receptorâ€associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis. Hepatology, 2015, 61, 585-597.	3.6	56
2119	4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents. Investigational New Drugs, 2015, 33, 104-108.	1.2	5

#	Article	IF	Citations
2120	Improved Surveillance for Hepatocellular Carcinoma With a Primary Careâ€“Oriented Clinical Reminder. Clinical Gastroenterology and Hepatology, 2015, 13, 172-179.	2.4	92
2121	The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure. Liver International, 2015, 35, 999-1009.	1.9	69
2122	Review of angiogenesis in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1-9.	1.8	85
2123	Building the Multidisciplinary Team for Management of Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2015, 13, 827-835.	2.4	47
2124	Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 791-798.e1.	2.4	86
2125	Epidemiology of Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2015, 24, 1-17.	0.6	256
2126	Carnosic acid induces apoptosis associated with mitochondrial dysfunction and Akt inactivation in HepG2 cells. International Journal of Food Sciences and Nutrition, 2015, 66, 76-84.	1.3	23
2127	miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma. Tumor Biology, 2015, 36, 219-225.	0.8	49
2128	Indole-3-carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microRNA-21 and upregulation of phosphatase and tensin homolog. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 244-253.	1.9	38
2129	Golgi phosphoprotein 3 (<scp>GOLPH3</scp>) promotes hepatocellular carcinoma cell aggressiveness by activating the <scp>NF</scp>â€<scp>B</scp> pathway. Journal of Pathology, 2015, 235, 490-501.	2.1	53
2130	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut, 2015, 64, 820-829.	6.1	127
2131	Epigenetic therapy as a novel approach in hepatocellular carcinoma. , 2015, 145, 103-119.		59
2132	Genomic analysis of fibrolamellar hepatocellular carcinoma. Human Molecular Genetics, 2015, 24, 50-63.	1.4	90
2133	Cytotoxic and apoptotic effects of menadione on rat hepatocellular carcinoma cells. Cytotechnology, 2015, 67, 1003-1009.	0.7	14
2134	Staging Hepatocellular Carcinoma with Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid -Enhanced Magnetic Resonance Imaging: A Comparison with Multi-Detector Row Computed Tomography. OMICS Journal of Radiology, 2016, 5, .	0.0	0
2135	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut and Liver, 2016, 10, 332-9.	1.4	399
2136	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clinical and Molecular Hepatology, 2016, 22, 7-17.	4.5	232
2137	Trends in Health Care Utilization and Costs Attributable to Hepatocellular Carcinoma, 2002â€“2009: A Population-Based Cohort Study. Current Oncology, 2016, 23, 196-220.	0.9	9

#	Article	IF	Citations
2138	Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. OncoTargets and Therapy, 2016, Volume 9, 7141-7147.	1.0	4
2139	Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. BioScience Trends, 2016, 10, 85-91.	1.1	35
2140	Zinc Fingers and Homeoboxes 2 (Zhx2) Regulates Sexually Dimorphic Cyp Gene Expression in the Adult Mouse Liver. Gene Expression, 2016, 17, 7-17.	0.5	19
2141	Oleanolic acid induced autophagic cell death in hepatocellular carcinoma cells via PI3K/Akt/mTOR and ROS-dependent pathway. Korean Journal of Physiology and Pharmacology, 2016, 20, 237.	0.6	40
2142	Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis. OncoTargets and Therapy, 2016, 9, 1721.	1.0	8
2143	Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas. Oncotarget, 2016, 7, 53571-53582.	0.8	13
2144	Outcomes and recurrence pattern after non-anatomic liver resection for solitary hepatocellular carcinomas. Korean Journal of Hepato-biliary-pancreatic Surgery, 2016, 20, 1.	1.0	5
2145	Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World Journal of Gastroenterology, 2016, 22, 6851.	1.4	52
2146	Transarterial radioembolization for hepatocellular carcinoma: a review. Journal of Hepatocellular Carcinoma, 2016, Volume 3, 25-29.	1.8	32
2147	OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. Journal of Korean Medical Science, 2016, 31, 1215.	1.1	27
2148	Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients. OncoTargets and Therapy, 2016, Volume 9, 7425-7433.	1.0	11
2149	Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375. Theranostics, 2016, 6, 142-154.	4.6	71
2150	Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. Journal of Cancer, 2016, 7, 883-889.	1.2	4
2151	An Atypical Initial Presentation of Hepatocellular Carcinoma as Spinal Cord Compression. , 2016, 06, .		1
2152	Hepatitis B and its Relationship With Oxidative Stress. Hepatitis Monthly, 2016, 16, e37973.	0.1	21
2153	Hepatocellular carcinoma in identical twins in Chile: case report. Ecancermedicalscience, 2016, 10, 708.	0.6	4
2154	INFLUENCE OF HEPATOCELLULAR CARCINOMA ETIOLOGY IN THE SURVIVAL AFTER RESECTION. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2016, 29, 105-108.	0.5	13
2155	Bioinformatics analysis of the gene expression profile of hepatocellular carcinoma: preliminary results. Wspolczesna Onkologia, 2016, 1, 20-27.	0.7	8

#	Article	IF	Citations
2156	Hepatocellular carcinoma: Review of disease and tumor biomarkers. World Journal of Hepatology, 2016, 8, 471.	0.8	58
2157	Hsp60 exerts a tumor suppressor function by inducing cell differentiation and inhibiting invasion in hepatocellular carcinoma. Oncotarget, 2016, 7, 68976-68989.	0.8	34
2158	MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. Oncotarget, 2016, 7, 266-278.	0.8	62
2159	Hepatitis B virus molecular biology and pathogenesis. Hepatoma Research, 2016, 2, 163.	0.6	117
2160	Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget, 2016, 7, 72276-72289.	0.8	25
2161	Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Hepatitis Monthly, 2016, 16, e37584.	0.1	9
2162	Dietary Flavonoid Hyperoside Induces Apoptosis of Activated Human LX-2 Hepatic Stellate Cell by Suppressing Canonical NF-ÎB Signaling. BioMed Research International, 2016, 2016, 1-10.	0.9	28
2163	HCV-Induced Oxidative Stress: Battlefield-Winning Strategy. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-7.	1.9	17
2164	Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. ELife, 2016, 5, e10727.	2.8	79
2165	Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 8294.	1.4	81
2166	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 262.	1.4	96
2167	Alginate Containing Nanoarchitectonics for Improved Cancer Therapy. , 2016, , 565-588.		9
2168	miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular Carcinoma. BioMed Research International, 2016, 2016, 1-8.	0.9	45
2169	Targeting hepatocellular carcinoma: what did we discover so far?. Oncology Reviews, 2016, 10, 302.	0.8	30
2170	Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and Therapy, 2016, 9, 773.	1.0	21
2171	Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma. Current Oncology, 2016, 23, 472-480.	0.9	13
2172	Telomeres, NAFLD and Chronic Liver Disease. International Journal of Molecular Sciences, 2016, 17, 383.	1.8	48
2173	Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. International Journal of Molecular Sciences, 2016, 17, 2143.	1.8	28

#	Article	IF	Citations
2174	MicroRNAs in the Evaluation and Potential Treatment of Liver Diseases. Journal of Clinical Medicine, 2016, 5, 52.	1.0	20
2175	Incidence and mortality of liver cancer and their relationship with the human development index in the world. Biomedical Research and Therapy, 2016, 3, .	0.3	7
2176	Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics. Cancer Cell International, 2016, 16, 44.	1.8	8
2177	A Preliminary Communication: Ongoing Study on HOXA10 Methylation Profile of Endometriosis Patients with Infertility. Journal of Endometriosis and Pelvic Pain Disorders, 2016, 8, 106-110.	0.3	3
2178	Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model. PLoS ONE, 2016, 11, e0148695.	1.1	7
2179	SIRT6 Depletion Suppresses Tumor Growth by Promoting Cellular Senescence Induced by DNA Damage in HCC. PLoS ONE, 2016, 11, e0165835.	1.1	43
2180	Synthesis, characterization, and evaluation of mPEG–SN38 and mPEG–PLA–SN38 micelles for cancer therapy. International Journal of Nanomedicine, 2016, 11, 1677.	3.3	13
2181	Cytotoxicity of 11-epi-Sinulariolide Acetate Isolated from Cultured Soft Corals on HA22T Cells through the Endoplasmic Reticulum Stress Pathway and Mitochondrial Dysfunction. International Journal of Molecular Sciences, 2016, 17, 1787.	1.8	13
2182	Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget, 2016, 7, 81255-81267.	0.8	87
2183	14-3-3Î¶ promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1Î±. Oncotarget, 2016, 7, 15854-15867.	0.8	31
2184	TheTERTpromoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Oncotarget, 2016, 7, 684-699.	0.8	54
2185	Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. Journal of Clinical Gastroenterology, 2016, 50, 169-174.	1.1	20
2186	Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. Medicine (United States), 2016, 95, e2478.	0.4	33
2187	Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Annals of Surgery, 2016, 263, 778-786.	2.1	63
2188	Processing of miR17-92 Cluster in Hepatic Stellate Cells Promotes Hepatic Fibrogenesis During Alcohol-Induced Injury. Alcoholism: Clinical and Experimental Research, 2016, 40, 1430-1442.	1.4	43
2189	Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma. Medicine (United States), 2016, 95, e3185.	0.4	32
2190	Relevance of microRNAâ€18a and microRNAâ€199aâ€5p to hepatocellular carcinoma recurrence after living donor liver transplantation. Liver Transplantation, 2016, 22, 665-676.	1.3	26
2191	Effect of socioeconomic status on hepatocellular carcinoma incidence and stage at diagnosis, a populationâ€based cohort study. Liver International, 2016, 36, 902-910.	1.9	21

#	Article	IF	Citations
2192	Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance. Hepatology Research, 2016, 46, 1264-1274.	1.8	16
2193	Novel populationâ€based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology, 2016, 63, 1205-1212.	3.6	51
2194	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of antiâ€cancer therapy. International Journal of Cancer, 2016, 138, 1601-1608.	2.3	26
2195	Clinical characteristics and prognosis of nonâ€B nonâ€C hepatocellular carcinoma patients with modest alcohol consumption. Hepatology Research, 2016, 46, 434-442.	1.8	11
2196	Hepatocellular Carcinoma Surveillance. Journal of Clinical Gastroenterology, 2016, 50, e8-e12.	1.1	9
2197	TTF1-NPs Induce ERS-Mediated Apoptosis and Inhibit Human Hepatoma Cell Growth In Vitro and In Vivo. Oncology Research, 2016, 23, 311-320.	0.6	10
2198	Overexpression of SASH1 Inhibits the Proliferation, Invasion, and EMT in Hepatocarcinoma Cells. Oncology Research, 2016, 24, 25-32.	0.6	26
2199	NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma. Toxicology, 2016, 359-360, 47-57.	2.0	30
2200	Sexâ€specific associations between birth weight and adult primary liver cancer in a large cohort of <scp>D</scp>anish children. International Journal of Cancer, 2016, 138, 1410-1415.	2.3	14
2201	Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. Hepatology Research, 2016, 46, 1145-1151.	1.8	27
2202	Impact of aldoâ€keto reductase family 1 member B10 on the risk of hepatitis C virusâ€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1315-1322.	1.4	16
2203	High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis. BMC Cancer, 2016, 16, 880.	1.1	24
2204	Upregulation of long non coding RNA PCAT-1 contributes to cell proliferation, migration and apoptosis in hepatocellular carcinoma. Molecular Medicine Reports, 2016, 13, 4481-4486.	1.1	46
2205	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open, 2016, 6, e009889.	0.8	42
2206	Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer, 2016, 5, 221-232.	4.2	44
2209	Obesity and Liver Cancer. Recent Results in Cancer Research, 2016, 208, 177-198.	1.8	35
2210	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncology Letters, 2016, 12, 3662-3668.	0.8	14
2211	RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression. Oncology Reports, 2016, 36, 2777-2784.	1.2	37

#	Article	IF	Citations
2212	SNF2H promotes hepatocellular carcinoma proliferation by activating the Wnt/Î²-catenin signaling pathway. Oncology Letters, 2016, 12, 1329-1336.	0.8	10
2213	Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-ÎºB and Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells. Journal of Experimental and Clinical Cancer Research, 2016, 35, 172.	3.5	23
2214	Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. Oncology Research, 2016, 24, 511-519.	0.6	15
2215	ATXN7 Gene Variants and Expression Predict Post-Operative Clinical Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2016, 39, 2427-2438.	1.1	12
2216	HOX Antisense lincRNA HOXA-AS2 Promotes Tumorigenesis of Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2016, 40, 287-296.	1.1	66
2217	miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma. Journal of Biomedical Science, 2016, 23, 79.	2.6	60
2218	Knockdown of FRAT1 inhibits hypoxia-induced epithelial-to-mesenchymal transition via suppression of the Wnt/Î²-catenin pathway in hepatocellular carcinoma cells. Oncology Reports, 2016, 36, 2999-3004.	1.2	14
2219	An Indel Polymorphism within pre-miR3131 Confers Risk for Hepatocellular Carcinoma. Carcinogenesis, 2017, 38, bgw206.	1.3	10
2220	Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma. Genetical Research, 2016, 98, e14.	0.3	0
2221	Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Scientific Reports, 2016, 6, 21260.	1.6	52
2222	Loss of GATA5 expression due to gene promoter methylation induces growth and colony formation of hepatocellular carcinoma cells. Oncology Letters, 2016, 11, 861-869.	0.8	13
2223	Rosmarinic acid inhibits inflammation and angiogenesis of hepatocellular carcinoma by suppression of NF-ÎºB signaling in H22 tumor-bearing mice. Journal of Pharmacological Sciences, 2016, 132, 131-137.	1.1	80
2224	Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study. Molecular and Clinical Oncology, 2016, 4, 369-374.	0.4	21
2225	Establishment of a dual-color fluorescence tracing orthotopic transplantation model of hepatocellular carcinoma. Molecular Medicine Reports, 2016, 13, 762-768.	1.1	7
2226	Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia. BMC Public Health, 2016, 16, 769.	1.2	32
2227	HCV core protein-induced upregulation of microRNA-196a promotes aberrant proliferation in hepatocellular carcinoma by targeting FOXO1. Molecular Medicine Reports, 2016, 13, 5223-5229.	1.1	24
2228	Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study. Scientific Reports, 2016, 6, 32733.	1.6	15
2229	Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Science, 2016, 107, 1791-1799.	1.7	6

#	Article	IF	Citations
2230	MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-Î¹B signaling pathway. Scientific Reports, 2016, 6, 22328.	1.6	55
2231	Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Journal of Experimental and Clinical Cancer Research, 2016, 35, 159.	3.5	125
2232	Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiology and Oncology, 2016, 50, 418-426.	0.6	15
2233	Sustainable inflammation transforms hepatic cells by causing oxidative stress injury and potential epithelial-mesenchymal transition. International Journal of Oncology, 2016, 49, 971-980.	1.4	4
2234	Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma. Oncology Letters, 2016, 11, 3003-3008.	0.8	8
2235	Distinct set of chromosomal aberrations in childhood hepatocellular carcinoma is correlated to hepatitis B virus infection. Cancer Genetics, 2016, 209, 87-96.	0.2	6
2236	Cold-water extracts of Grifola frondosa and its purified active fraction inhibit hepatocellular carcinoma inÂvitro and inÂvivo. Experimental Biology and Medicine, 2016, 241, 1374-1385.	1.1	20
2237	Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma. Oncology Reports, 2016, 35, 2576-2582.	1.2	13
2238	Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC. Biological Chemistry, 2016, 397, 1147-1162.	1.2	3
2239	Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms. European Journal of Pharmacology, 2016, 784, 173-180.	1.7	50
2240	Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Experimental Biology and Medicine, 2016, 241, 1803-1810.	1.1	8
2241	Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma. Oncogene, 2016, 35, 6271-6280.	2.6	28
2242	Membrane IL1Î± Inhibits the Development of Hepatocellular Carcinoma via Promoting T- and NK-cell Activation. Cancer Research, 2016, 76, 3179-3188.	0.4	30
2243	Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. Molecular Medicine Reports, 2016, 13, 1541-1550.	1.1	117
2244	Pathologic response to preoperative transarterial chemoembolization for resectable hepatocellular carcinoma may not predict recurrence after liver resection. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 122-124.	0.6	1
2245	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 451-496.	9.6	449
2246	Mechanisms of HBV-induced hepatocellular carcinoma. Journal of Hepatology, 2016, 64, S84-S101.	1.8	664
2247	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology, 2016, 27, 1279-1287.	0.2	14

#	Article	IF	Citations
2248	Hypoxia-inducible factors as molecular targets for liver diseases. Journal of Molecular Medicine, 2016, 94, 613-627.	1.7	104
2249	Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nature Genetics, 2016, 48, 500-509.	9.4	596
2250	Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene, 2016, 35, 5422-5434.	2.6	160
2251	Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence. Oncology Letters, 2016, 11, 1791-1798.	0.8	87
2252	NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Current Hepatology Reports, 2016, 15, 103-112.	0.4	3
2253	MicroRNA-616 promotes the migration, invasion and epithelial-mesenchymal transition of HCC by targeting PTEN. Oncology Reports, 2016, 35, 366-374.	1.2	29
2254	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes and Development, 2016, 30, 1020-1033.	2.7	122
2255	A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells. Oncology Letters, 2016, 11, 3152-3160.	0.8	7
2256	NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5999-6004.	3.3	198
2257	Roles of long noncoding RNAs in Hepatocellular Carcinoma. Open Life Sciences, 2016, 11, 91-97.	0.6	4
2258	A â€1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression. Cancer Medicine, 2016, 5, 2942-2952.	1.3	4
2259	Chemically-Induced Hepatocarcinogenesis. , 2016, , 65-92.		0
2260	Effective Codelivery of lncRNA and pDNA by Pullulanâ€Based Nanovectors for Promising Therapy of Hepatocellular Carcinoma. Advanced Functional Materials, 2016, 26, 7314-7325.	7.8	51
2261	Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma. Oncology Letters, 2016, 12, 1971-1974.	0.8	19
2262	CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma. Immunology Letters, 2016, 178, 105-113.	1.1	10
2263	Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma. Oncology Reports, 2016, 35, 1083-1090.	1.2	22
2264	miR-612 suppresses stem cell-like property of hepatocellular carcinoma cells by modulating Sp1/Nanog signaling. Cell Death and Disease, 2016, 7, e2377-e2377.	2.7	46
2265	Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice. International Journal of Molecular Medicine, 2016, 38, 1499-1506.	1.8	30

#	Article	IF	Citations
2266	miRâ€296 inhibits proliferation and induces apoptosis by targeting <scp>FGFR</scp>1 in human hepatocellular carcinoma. FEBS Letters, 2016, 590, 4252-4262.	1.3	35
2267	Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2016, 35, 140.	3.5	15
2268	HBx-induced miR-21 suppresses cell apoptosis in hepatocellular carcinoma by targeting interleukin-12. Oncology Reports, 2016, 36, 2305-2312.	1.2	32
2269	Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy. Surgical Oncology, 2016, 25, 171-177.	0.8	10
2270	Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway. Biomedicine and Pharmacotherapy, 2016, 83, 450-455.	2.5	68
2271	Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones, 2016, 102, 151-178.	0.7	51
2272	High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. OncoImmunology, 2016, 5, e1219010.	2.1	88
2273	Hepatocellular Carcinoma: the Impact of NAFLD. Current Hepatology Reports, 2016, 15, 190-198.	0.4	2
2274	FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and Liver Disease, 2016, 48, 1492-1497.	0.4	16
2275	Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor. Journal of Surgical Research, 2016, 206, 371-379.	0.8	14
2276	Concise Review: Organoids Are a Powerful Tool for the Study of Liver Disease and Personalized Treatment Design in Humans and Animals. Stem Cells Translational Medicine, 2016, 5, 325-330.	1.6	63
2277	Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway. Cell Death and Disease, 2016, 7, e2324-e2324.	2.7	47
2278	Hepatocellular Carcinoma as a Paradigm for a Systemic Evolutionary Approach to Cancer. , 2016, , 157-161.		1
2279	Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. Journal of Hematology and Oncology, 2016, 9, 74.	6.9	146
2280	Treatment response after radioembolisation in patients with hepatocellular carcinomaâ€"An evaluation with dual energy computed-tomography. European Journal of Radiology Open, 2016, 3, 230-235.	0.7	23
2281	Downregulation of Peptidylprolyl isomerase A promotes cell death and enhances doxorubicin-induced apoptosis in hepatocellular carcinoma. Gene, 2016, 591, 236-244.	1.0	23
2282	miR-187-3p inhibits the metastasis and epithelialâ€"mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Letters, 2016, 381, 380-390.	3.2	104
2283	Liver diseases: what is known so far about the therapy with human amniotic membrane?. Cell and Tissue Banking, 2016, 17, 653-663.	0.5	7

#	Article	IF	Citations
2284	A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy. Polymer Chemistry, 2016, 7, 5805-5818.	1.9	29
2285	Hepatitis C and Hepatocellular Carcinoma. , 2016, , 261-273.		0
2286	High-throughput flow cytometry screening of human hepatocellular carcinoma reveals CD146 to be a novel marker of tumor-initiating cells. Biochemistry and Biophysics Reports, 2016, 8, 107-113.	0.7	9
2287	Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Scientific Reports, 2016, 6, 27411.	1.6	49
2288	Cytokine-induced killer cell infusion combined with conventional treatments produced better prognosis for hepatocellular carcinoma patients with barcelona clinic liver cancer B or earlier stage: A systematic review and meta-analysis. Cytotherapy, 2016, 18, 1525-1531.	0.3	14
2289	Longâ€term liverâ€related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders. Haemophilia, 2016, 22, e494-e501.	1.0	4
2290	Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression. Scientific Reports, 2016, 6, 34034.	1.6	37
2291	Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. Oncology Letters, 2016, 12, 1753-1762.	0.8	35
2292	MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. International Journal of Oncology, 2016, 48, 2425-2434.	1.4	47
2293	Gut Microbiota and HCC. , 2016, , 149-155.		0
2294	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2016, 110, hcw151.	0.2	26
2295	Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk. American Journal of Human Genetics, 2016, 99, 275-286.	2.6	31
2296	Roles of long noncoding RNAs in hepatocellular carcinoma. Virus Research, 2016, 223, 131-139.	1.1	50
2297	Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice. Immunological Investigations, 2016, 45, 553-565.	1.0	14
2298	IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. Cellular Signalling, 2016, 28, 1314-1324.	1.7	55
2299	Bridging Sunitinib Exposure to Timeâ€toâ€Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 297-304.	1.3	9
2300	Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 282-288.	0.6	4
2301	EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma. Scientific Reports, 2016, 6, 31237.	1.6	17

#	Article	IF	Citations
2302	Pterostilbene inhibits hepatocellular carcinoma through p53/SOD2/ROS-mediated mitochondrial apoptosis. Oncology Reports, 2016, 36, 3233-3240.	1.2	31
2303	An Atypical System for Studying Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Scientific Reports, 2016, 6, 26282.	1.6	8
2304	Effects of nitric oxide on the biological behavior of HepG2 human hepatocellular carcinoma cells. Experimental and Therapeutic Medicine, 2016, 11, 1875-1880.	0.8	27
2305	Melatoninâ€™s Beneficial Effects in Hepatic Injury. , 2016, , 165-175.		0
2306	MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3â€²UTR. Biochemical and Biophysical Research Communications, 2016, 480, 455-460.	1.0	44
2308	Quantitative Proteomics Analysis of Tissue Interstitial Fluid for Identification of Novel Serum Candidate Diagnostic Marker for Hepatocellular Carcinoma. Scientific Reports, 2016, 6, 26499.	1.6	22
2309	Downregulation of Î´ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU. Molecular Medicine Reports, 2016, 13, 59-66.	1.1	3
2310	Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma. Tumor Biology, 2016, 37, 16269-16274.	0.8	8
2311	HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression. Scientific Reports, 2016, 6, 35917.	1.6	8
2312	Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World Journal of Surgical Oncology, 2016, 14, 159.	0.8	13
2313	Valproic acid (VPA) promotes the epithelial mesenchymal transition of hepatocarcinoma cells via transcriptional and post-transcriptional up regulation of Snail. Biomedicine and Pharmacotherapy, 2016, 84, 1029-1035.	2.5	12
2314	Dietary fructoseâ€induced hepatocellular carcinoma development manifested in mice lacking apoptosis inhibitor of macrophage (<scp>AIM</scp>). Genes To Cells, 2016, 21, 1320-1332.	0.5	29
2315	Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma. Molecular Medicine Reports, 2016, 14, 4606-4612.	1.1	57
2316	Hepatocellular Carcinoma and Hepatitis C Virus. , 2016, , 109-136.		1
2317	Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. Scientific Reports, 2016, 6, 35378.	1.6	45
2318	Epidemiology of Hepatocellular Carcinoma. , 2016, , 3-24.		6
2319	Molecular Mechanisms of Hepatocellular Carcinoma. , 2016, , 43-63.		2
2320	Epigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis. Nature Communications, 2016, 7, 10893.	5.8	46

#	Article	IF	Citations
2321	Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma. Scientific Reports, 2016, 6, 28229.	1.6	5
2322	Clinicopathological Features and Metastatic Pattern of Hepatocellular Carcinoma: An Autopsy Study of 398 Patients. Pathobiology, 2016, 83, 301-307.	1.9	20
2323	Importance of activated hepatic stellate cells and angiopoietin-1 in the pathogenesis of hepatocellular carcinoma. Molecular Medicine Reports, 2016, 14, 1721-1725.	1.1	12
2324	A 13-Year Retrospective Study on Primary Liver Cancer in Cambodia: A Strikingly High Hepatitis C Occurrence among Hepatocellular Carcinoma Cases. Oncology, 2016, 91, 106-116.	0.9	14
2325	Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study. Journal of Nippon Medical School, 2016, 83, 248-256.	0.3	14
2326	Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area. Liver Cancer, 2016, 5, 21-36.	4.2	12
2327	miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell International, 2016, 16, 63.	1.8	74
2328	A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infectious Diseases, 2016, 16, 647.	1.3	35
2329	Quantitative assessment of washout in hepatocellular carcinoma using MRI. BMC Cancer, 2016, 16, 758.	1.1	10
2330	MicroRNA-200b inhibits the proliferation of hepatocellular carcinoma by targeting DNA methyltransferase 3a. Molecular Medicine Reports, 2016, 13, 3929-3935.	1.1	19
2331	Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterology, 2016, 3, e000107.	1.1	35
2332	Assessment of interleukin-28B (interferon Î»3) rs12979860 C/T gene polymorphism and the risk for hepatocellular carcinoma in chronic hepatitis C cirrhotic patients. Egyptian Liver Journal, 2016, 6, 48-53.	0.3	2
2333	Controversies in criteria for liver transplantation in hepatocellular carcinoma. Current Opinion in Gastroenterology, 2016, 32, 1.	1.0	9
2334	The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine (United States), 2016, 95, e4436.	0.4	66
2335	Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (United States), 2016, 95, e4602.	0.4	6
2336	Adenovirusâ€mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth. Journal of Gene Medicine, 2016, 18, 102-111.	1.4	14
2337	Clinical characteristics and survival outcomes of superâ€elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatology Research, 2016, 46, E5-E14.	1.8	5
2338	XRCC1 rs25487 genetic variant and TP53 mutation at codon 249 predict clinical outcomes of hepatitis B virusâ€related hepatocellular carcinoma after hepatectomy: A cohort study for 10Âyearsâ€™ follow up. Hepatology Research, 2016, 46, 765-774.	1.8	23

#	Article	IF	Citations
2339	Geoepidemiology of hepatocellular carcinoma in the island of Crete, Greece. A possible role of pesticides. Liver International, 2016, 36, 588-594.	1.9	7
2340	A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transplant International, 2016, 29, 369-380.	0.8	26
2341	MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and Î²-catenin pathway in Hepatocellular Carcinoma. Journal of Experimental and Clinical Cancer Research, 2016, 35, 89.	3.5	52
2342	Genetic Polymorphisms of Cytochrome P4501A1 (CYP1A1) and Glutathione S-Transferase P1 (GSTP1) and Risk of Hepatocellular Carcinoma Among Chronic Hepatitis C Patients in Egypt. Biochemical Genetics, 2016, 54, 696-713.	0.8	4
2343	An accurate assay for HCV based on real-time fluorescence detection of isothermal RNA amplification. Journal of Virological Methods, 2016, 235, 152-157.	1.0	5
2344	Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C. Infectious Agents and Cancer, 2016, 11, 9.	1.2	3
2345	Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. Cancer Gene Therapy, 2016, 23, 157-161.	2.2	8
2346	Diabetes Prevalence and Risk Factors in Four Asian American Communities. Journal of Community Health, 2016, 41, 1264-1273.	1.9	19
2347	Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 688-697.	0.7	25
2348	EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. Journal of Hepatology, 2016, 65, 888-898.	1.8	53
2349	Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 152-157.	0.6	6
2350	Women with Cirrhosis. Gastroenterology Clinics of North America, 2016, 45, 345-358.	1.0	17
2351	Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population. Biochemical and Biophysical Research Communications, 2016, 474, 482-490.	1.0	12
2352	17Î²-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochemical and Biophysical Research Communications, 2016, 473, 1247-1254.	1.0	24
2353	A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm. Medical Hypotheses, 2016, 93, 132-137.	0.8	13
2354	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer, 2016, 16, 94.	1.1	37
2355	A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI). BMC Cancer, 2016, 16, 137.	1.1	86
2356	Circulating tumor DNA in hepatocellular carcinoma: trends and challenges. Cell and Bioscience, 2016, 6, 32.	2.1	33

#	Article	IF	Citations
2357	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. BMC Gastroenterology, 2016, 16, 13.	0.8	16
2358	Doseâ€response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women. International Journal of Cancer, 2016, 139, 355-362.	2.3	23
2359	Preparation, characterization and evaluation of ¹⁸⁶Reâ€darubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 72-77.	0.5	20
2360	Regional differences in sorafenibâ€treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study. Liver International, 2016, 36, 1196-1205.	1.9	44
2361	Clinical characteristics and potential aetiologies of nonâ€B nonâ€C hepatocellular carcinoma in hepatitis B virus endemic area. Liver International, 2016, 36, 1351-1361.	1.9	19
2362	Hypermethylation reduces the expression of PNPLA7 in hepatocellular carcinoma. Oncology Letters, 2016, 12, 670-674.	0.8	9
2363	Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncology Reports, 2016, 36, 613-625.	1.2	58
2364	SNF5 is Involved in Suppression of Hepatocellular Carcinoma Progression via TGFâ€Beta 1 Signaling. Anatomical Record, 2016, 299, 869-877.	0.8	7
2365	Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. Molecular Carcinogenesis, 2016, 55, 64-76.	1.3	24
2366	The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Molecular Carcinogenesis, 2016, 55, 209-219.	1.3	126
2367	Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells. Molecular Carcinogenesis, 2016, 55, 387-396.	1.3	30
2368	Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma. Tumor Biology, 2016, 37, 9699-9707.	0.8	62
2369	Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma. Tumor Biology, 2016, 37, 9343-9355.	0.8	12
2370	Obesity and Cancer: The Oil that Feeds the Flame. Cell Metabolism, 2016, 23, 48-62.	7.2	296
2371	Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression. International Journal of Oncology, 2016, 48, 358-366.	1.4	29
2372	Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma. Tumor Biology, 2016, 37, 9745-9753.	0.8	16
2373	Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. Molecular and Translational Medicine, 2016, , 95-121.	0.4	2
2374	Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology International, 2016, 10, 632-639.	1.9	127

#	Article	IF	Citations
2375	Exploring the Potential Role of Chemopreventive Agent, Hesperetin Conjugated Pegylated Gold Nanoparticles in Diethylnitrosamine-Induced Hepatocellular Carcinoma in Male Wistar Albino Rats. Indian Journal of Clinical Biochemistry, 2016, 31, 171-184.	0.9	20
2376	Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. Gastroenterology Report, 2016, 4, 237-240.	0.6	5
2377	Infection and Cancer: The Case of Hepatitis B. Journal of Clinical Oncology, 2016, 34, 83-90.	0.8	131
2378	Double staining of Î²-galactosidase with fibrosis and cancer markers reveals the chronological appearance of senescence in liver carcinogenesis induced by diethylnitrosamine. Toxicology Letters, 2016, 241, 19-31.	0.4	17
2379	Alcoholic and Non-Alcoholic Fatty Liver Disease. , 2016, , .		5
2380	Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. Journal of Virology, 2016, 90, 1729-1740.	1.5	80
2381	Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study. Journal of Comparative Effectiveness Research, 2016, 5, 141-154.	0.6	4
2382	Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib. European Journal of Medicinal Chemistry, 2016, 120, 275-283.	2.6	9
2383	Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma. Cancer Research, 2016, 76, 2912-2920.	0.4	83
2384	The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2016, 35, 8.	3.5	59
2385	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncology, 2016, 12, 183-198.	1.1	8
2386	MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. International Journal of Oncology, 2016, 48, 965-974.	1.4	106
2387	Nine susceptibility loci for hepatitis B virus-related hepatocellular carcinoma identified by a pilot two-stage genome-wide association study. Oncology Letters, 2016, 11, 624-632.	0.8	18
2388	Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochemistry (Moscow), 2016, 81, 80-90.	0.7	95
2389	FOXR2 contributes to cell proliferation and malignancy in human hepatocellular carcinoma. Tumor Biology, 2016, 37, 10459-10467.	0.8	25
2390	The clinical and prognostic significance of CD14+HLA-DRâ^'/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumor Biology, 2016, 37, 10427-10433.	0.8	66
2391	Tumor angiogenesis-related parameters in multi-phase enhanced CT correlated with outcomes of hepatocellular carcinoma patients after radical hepatectomy. European Journal of Surgical Oncology, 2016, 42, 538-544.	0.5	3
2392	Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatology International, 2016, 10, 501-510.	1.9	32

#	Article	IF	Citations
2393	MicroRNA-7 downregulates the oncogene VDAC1 to influence hepatocellular carcinoma proliferation and metastasis. Tumor Biology, 2016, 37, 10235-10246.	0.8	38
2394	Hepatocellular carcinoma and estrogen receptors: Polymorphisms and isoforms relations and implications. Medical Hypotheses, 2016, 86, 67-70.	0.8	20
2395	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology, 2016, 5, e1129483.	2.1	125
2396	Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells. Molecular Medicine Reports, 2016, 13, 1570-1576.	1.1	32
2397	Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 418-427.	0.7	13
2398	Diagnostic criteria for hepatocellular carcinoma â©½3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. Journal of Hepatology, 2016, 64, 1099-1107.	1.8	93
2399	Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. Journal of Gastroenterology, 2016, 51, 910-922.	2.3	7
2400	New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Nutrition and Cancer, 2016, 68, 250-266.	0.9	53
2401	MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. Cancer Letters, 2016, 375, 73-83.	3.2	95
2402	The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition. Tumor Biology, 2016, 37, 11311-11320.	0.8	6
2403	AZGP1 suppresses epithelial-to-mesenchymal transition and hepatic carcinogenesis by blocking TGFÎ²1-ERK2 pathways. Cancer Letters, 2016, 374, 241-249.	3.2	35
2404	iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1303-1311.	1.7	86
2405	Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene, 2016, 35, 4155-4164.	2.6	44
2406	Phospholipidomic identification of potential serum biomarkers in dengue fever, hepatitis B and hepatitis C using liquid chromatography-electrospray ionization-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1009-1010, 44-54.	1.2	11
2407	Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression. Pathology and Oncology Research, 2016, 22, 555-565.	0.9	12
2408	MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Tumor Biology, 2016, 37, 8047-8055.	0.8	9
2409	Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. International Journal of Clinical Oncology, 2016, 21, 676-683.	1.0	4
2410	Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Acta Biomaterialia, 2016, 30, 144-154.	4.1	243

#	Article	IF	Citations
2411	The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. Journal of Gastroenterology, 2016, 51, 370-379.	2.3	41
2412	Cancer prevention in HIV-infected populations. Seminars in Oncology, 2016, 43, 173-188.	0.8	42
2413	Endogenous hepatic glucocorticoid receptor signaling coordinates sexâ€biased inflammatory gene expression. FASEB Journal, 2016, 30, 971-982.	0.2	45
2414	Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122. Journal of Hepatology, 2016, 64, 278-291.	1.8	105
2415	Radiofrequency ablation-increased CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by promoting stemness. Tumor Biology, 2016, 37, 3697-3704.	0.8	20
2416	Severity of cirrhosis should determine the operative modality for patients with early hepatocellular carcinoma and compensated liver function. Surgery, 2016, 159, 621-631.	1.0	27
2417	Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma. Tumor Biology, 2016, 37, 4295-4304.	0.8	25
2418	SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumor Biology, 2016, 37, 2379-2385.	0.8	80
2419	Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis. International Journal of Clinical Oncology, 2016, 21, 302-309.	1.0	17
2420	Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway. Tumor Biology, 2016, 37, 2023-2035.	0.8	30
2421	Upregulation of Leucine Zipper Protein mRNA in Hepatocellular Carcinoma Associated With Poor Prognosis. Technology in Cancer Research and Treatment, 2016, 15, 517-522.	0.8	1
2422	Interleukin-17A Plays a Pivotal Role in Chemically Induced Hepatocellular Carcinoma in Mice. Digestive Diseases and Sciences, 2016, 61, 474-488.	1.1	15
2423	MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor. Tumor Biology, 2016, 37, 3823-3830.	0.8	38
2424	Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma. Tumor Biology, 2016, 37, 3561-3569.	0.8	23
2425	The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene, 2016, 575, 66-70.	1.0	51
2426	Role of chemokine pathways in hepatobiliary cancer. Cancer Letters, 2016, 379, 173-183.	3.2	64
2428	Klotho: a tumor suppressor and modulator of the Wnt/Î²-catenin pathway in human hepatocellular carcinoma. Laboratory Investigation, 2016, 96, 197-205.	1.7	85
2429	Heterogeneity of liver cancer and personalized therapy. Cancer Letters, 2016, 379, 191-197.	3.2	202

#	Article	IF	Citations
2430	Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Letters, 2016, 379, 206-212.	3.2	44
2431	In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Archives of Toxicology, 2016, 90, 677-689.	1.9	24
2432	Hepatic DNA hydroxymethylation is site-specifically altered by chronic alcohol consumption and aging. European Journal of Nutrition, 2017, 56, 535-544.	1.8	9
2433	Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatrics and Gerontology International, 2017, 17, 189-201.	0.7	22
2434	Metaâ€analysis reveals an association between signal transducer and activator of transcriptionâ€4 polymorphism and hepatocellular carcinoma risk. Hepatology Research, 2017, 47, 303-311.	1.8	11
2435	Nonstructural protein 5B promotes degradation of the NORE1A tumor suppressor to facilitate hepatitis C virus replication. Hepatology, 2017, 65, 1462-1477.	3.6	5
2436	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates in Surgery, 2017, 69, 67-73.	0.9	15
2437	Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice. Journal of Biological Chemistry, 2017, 292, 3789-3799.	1.6	19
2438	Effect of Korean Red Ginseng in chronic liver disease. Journal of Ginseng Research, 2017, 41, 450-455.	3.0	47
2439	CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma. Scientific Reports, 2017, 7, 41499.	1.6	43
2440	Inhibitory effects of different substituted transition metal-based krebs-type sandwich structures on human hepatocellular carcinoma cells. Dalton Transactions, 2017, 46, 2874-2883.	1.6	24
2441	Câ€Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives. Journal of Cellular Physiology, 2017, 232, 2657-2673.	2.0	43
2442	Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2017, 36, 11.	3.5	146
2443	Hypoxia activates Wnt/Î²-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Scientific Reports, 2017, 7, 40446.	1.6	64
2444	Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma. Journal of Biological Chemistry, 2017, 292, 3186-3200.	1.6	27
2445	Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting Î±-SMA. Biomedicine and Pharmacotherapy, 2017, 87, 669-677.	2.5	16
2446	Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammationâ€based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. Journal of Surgical Oncology, 2017, 115, 718-728.	0.8	51
2447	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an inâ€field multicenter cohort study. Liver International, 2017, 37, 1184-1192.	1.9	15

#	Article	IF	Citations
2448	The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147. Cancer Cell International, 2017, 17, 17.	1.8	39
2449	Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug Delivery, 2017, 24, 20-29.	2.5	78
2450	The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2017, 21, 986-992.	1.6	50
2451	Molecular biology of liver carcinogenesis and hepatitis. , 2017, , 160-172.e3.		0
2452	Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence. Pathology Research and Practice, 2017, 213, 316-321.	1.0	64
2453	Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death and Disease, 2017, 8, e2626-e2626.	2.7	104
2454	Texture analysis of baseline multiphasic hepatic computed tomography images for the prognosis of single hepatocellular carcinoma after hepatectomy: A retrospective pilot study. European Journal of Radiology, 2017, 90, 198-204.	1.2	44
2455	Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. Oncology Reports, 2017, 37, 969-978.	1.2	23
2456	Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopfâ€3 expressing adenoviral vector for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1769-1777.	1.4	11
2457	HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. Cancer Letters, 2017, 393, 113-124.	3.2	26
2458	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. American Journal of Medicine, 2017, 130, 1099-1106.e1.	0.6	99
2459	The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transplantation, 2017, 23, 545-551.	1.3	16
2460	The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Digestive Diseases and Sciences, 2017, 62, 1180-1185.	1.1	8
2461	Deacetylation of Ku70 by SIRT6 attenuates Bax-mediated apoptosis in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2017, 485, 713-719.	1.0	30
2462	Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation. Nature Communications, 2017, 8, 14420.	5.8	97
2463	The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 311-318.	0.7	17
2464	Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. Drug Delivery, 2017, 24, 289-299.	2.5	18
2465	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Targeted Oncology, 2017, 12, 201-209.	1.7	25

#	Article	IF	Citations
2466	Tumor regulation of the tissue environment in the liver. , 2017, 173, 47-57.		68
2467	Comparison between acoustic radiation force impulse quantification data and perfusion-CT parameters in hepatocellular carcinoma. European Journal of Radiology, 2017, 89, 215-220.	1.2	2
2468	microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2. Biomedicine and Pharmacotherapy, 2017, 89, 642-650.	2.5	36
2469	Association Between High-Avidity T-Cell Receptors, Induced by Î±-Fetoproteinâ^'Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. Gastroenterology, 2017, 152, 1395-1406.e10.	0.6	61
2470	miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma. Oncology Reports, 2017, 37, 1445-1450.	1.2	14
2471	Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma. Oncology Reports, 2017, 37, 323-332.	1.2	35
2472	miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7. Oncology Research, 2017, 25, 427-435.	0.6	48
2473	Melatonin enhances the anti-tumor effect of sorafenib via AKT/p27-mediated cell cycle arrest in hepatocarcinoma cell lines. RSC Advances, 2017, 7, 21342-21351.	1.7	18
2474	Sh<scp>RNA</scp> knockâ€down of <scp>CXCR</scp>7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization. Journal of Cellular and Molecular Medicine, 2017, 21, 1989-1999.	1.6	14
2475	Pure Laparoscopic Versus Open Right Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis. Annals of Surgery, 2017, 265, 856-863.	2.1	165
2476	Application of molecular imaging technology in evaluating the inhibiting effect of apigenin inÂvivo on subcutaneous hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2017, 487, 122-127.	1.0	12
2477	Molecular Mechanisms and Targets of Therapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 949-955.	0.2	32
2478	Hepatic expression of oncogenes Bmi1 and Dkk1 is upâ€regulated in hepatitis B virus surface antigenâ€"transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro. International Journal of Cancer, 2017, 141, 354-363.	2.3	20
2479	Long noncoding <scp>RNA </scp>SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma. Cancer Science, 2017, 108, 653-662.	1.7	44
2480	Validation of <scp>PAGE</scp>â€B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver International, 2017, 37, 1788-1795.	1.9	37
2481	Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and doseâ€"response meta-analysis. BMJ Open, 2017, 7, e013739.	0.8	124
2482	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs, 2017, 22, 191-200.	1.0	3
2483	Barcelona clinic liver cancer-stage C hepatocellular carcinoma. Medicine (United States), 2017, 96, e6745.	0.4	21

#	Article	IF	Citations
2484	Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. Journal of Clinical Gastroenterology, 2017, 51, 650-655.	1.1	35
2485	Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors donâ€™t seem to matter, unless you are an immigrant. Journal of Hepatology, 2017, 67, 648-649.	1.8	14
2486	Chitosan nanoparticles from marine squid protect liver cells against N -diethylnitrosoamine-induced hepatocellular carcinoma. Carbohydrate Polymers, 2017, 171, 18-26.	5.1	19
2487	Other non-surgical treatments for liver cancer. Reports of Practical Oncology and Radiotherapy, 2017, 22, 181-192.	0.3	13
2488	Triosephosphate isomerase 1 suppresses growth, migration and invasion of hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2017, 482, 1048-1053.	1.0	44
2489	miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/Î²-catenin signaling pathway. Biomedicine and Pharmacotherapy, 2017, 85, 472-478.	2.5	45
2490	Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatology Research, 2017, 47, 957-962.	1.8	48
2491	Physician-Patient Communication is Associated With Hepatocellular Carcinoma Screening in Chronic Liver Disease Patients. Journal of Clinical Gastroenterology, 2017, 51, 454-460.	1.1	5
2492	Association between PNPLA3 gene polymorphisms and risk of hepatitis B virus-related hepatocellular carcinoma in Han population in China:a case-control study. Scandinavian Journal of Gastroenterology, 2017, 52, 1120-1127.	0.6	7
2493	Gut microbiota changes and chronic hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2017, 11, 813-819.	1.4	83
2494	MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Molecular Cancer, 2017, 16, 103.	7.9	133
2495	Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Journal of Controlled Release, 2017, 258, 130-145.	4.8	25
2496	Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging. Medicine (United States), 2017, 96, e5518.	0.4	8
2497	Knockout of the Nogo-B Gene Attenuates Tumor Growth and Metastasis in Hepatocellular Carcinoma. Neoplasia, 2017, 19, 583-593.	2.3	24
2498	Geographic epidemiology of hepatocellular carcinoma, viral hepatitis, and socioeconomic position in New York City. Cancer Causes and Control, 2017, 28, 779-789.	0.8	17
2499	MicroRNA-199b-5p attenuates TGF-Î²1-induced epithelialâ€“mesenchymal transition in hepatocellular carcinoma. British Journal of Cancer, 2017, 117, 233-244.	2.9	48
2500	MicroRNA-204 suppressed proliferation and motility capacity of human hepatocellular carcinoma via directly targeting zinc finger E-box binding homeobox 2. Oncology Letters, 2017, 13, 3823-3830.	0.8	8
2501	Genes directly regulated by NF-ÎºB in human hepatocellular carcinoma HepG2. International Journal of Biochemistry and Cell Biology, 2017, 89, 157-170.	1.2	11

#	Article	IF	Citations
2502	Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Advances in Biological Regulation, 2017, 65, 59-76.	1.4	39
2503	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. Journal of Hepatology, 2017, 67, 727-738.	1.8	525
2504	MicroRNA-592 targets IGF-1R to suppress cellular proliferation, migration and invasion in hepatocellular carcinoma. Oncology Letters, 2017, 13, 3522-3528.	0.8	19
2505	Role of CYP2B in Phenobarbital-Induced Hepatocyte Proliferation in Mice. Drug Metabolism and Disposition, 2017, 45, 977-981.	1.7	11
2506	Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. Journal of Clinical Pharmacology, 2017, 57, 1138-1147.	1.0	81
2507	Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Science China Life Sciences, 2017, 60, 575-584.	2.3	75
2508	Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Seminars in Interventional Radiology, 2017, 34, 213-219.	0.3	2
2509	Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	0.6	10
2510	In sickness and in health: The many roles of the minichromosome maintenance proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 295-308.	3.3	26
2511	Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line. Biochemical and Biophysical Research Communications, 2017, 490, 371-377.	1.0	50
2512	Breast cancer risk-associated variants at 6q25.1 influence risk of hepatocellular carcinoma in a Chinese population. Carcinogenesis, 2017, 38, 447-454.	1.3	5
2513	JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell. Biomedicine and Pharmacotherapy, 2017, 92, 989-997.	2.5	16
2515	SIRT3 functions as a tumor suppressor in hepatocellular carcinoma. Tumor Biology, 2017, 39, 101042831769117.	0.8	16
2516	Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction. Hepatology, 2017, 66, 182-197.	3.6	89
2517	Pregnancy and maternal chronic hepatitis B infectionâ€"Evidence of reproductive advantage?. American Journal of Reproductive Immunology, 2017, 77, e12667.	1.2	7
2518	Artificial Intelligence and Automatic Image Interpretation in Modern Medicine. Translational Medicine Research, 2017, , 371-407.	0.0	3
2519	Systematical analyses of variants in DNase I hypersensitive sites to identify hepatocellular carcinoma susceptibility loci in a Chinese population. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1887-1894.	1.4	2
2520	The mitochondrial hinge protein, <scp>UQCRH</scp>, is a novel prognostic factor for hepatocellular carcinoma. Cancer Medicine, 2017, 6, 749-760.	1.3	36

#	Article	IF	Citations
2521	High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. Tumor Biology, 2017, 39, 101042831769597.	0.8	26
2522	Cancer risk in patients with hepatitis C virus infection: aÂpopulationâ€based study in Sweden. Cancer Medicine, 2017, 6, 1135-1140.	1.3	22
2523	Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2017, 90, 100-108.	2.5	49
2524	Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. Journal of Controlled Release, 2017, 263, 18-28.	4.8	51
2525	Animal models as a tool in hepatocellular carcinoma research: A Review. Tumor Biology, 2017, 39, 101042831769592.	0.8	93
2526	Amphiregulin impairs apoptosis-stimulating protein 2 of p53 overexpressionâ€“induced apoptosis in hepatoma cells. Tumor Biology, 2017, 39, 101042831769502.	0.8	5
2527	B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. Tumor Biology, 2017, 39, 101042831769596.	0.8	13
2529	Molecular mechanisms of 3,3â€²4,4â€²,5-pentachlorobiphenyl-induced epithelial-mesenchymal transition in human hepatocellular carcinoma cells. Toxicology and Applied Pharmacology, 2017, 322, 75-88.	1.3	20
2530	Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. RSC Advances, 2017, 7, 16253-16263.	1.7	8
2531	Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. International Journal of Clinical Oncology, 2017, 22, 715-725.	1.0	12
2532	CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis. Oncogene, 2017, 36, 4047-4059.	2.6	36
2533	Several microRNAs could predict survival in patients with hepatitis B-related liver cancer. Scientific Reports, 2017, 7, 45195.	1.6	20
2534	Metabolomic applications in hepatocellular carcinoma: toward the exploration of therapeutics and diagnosis through small molecules. RSC Advances, 2017, 7, 17217-17226.	1.7	23
2535	Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. Gastroenterology, 2017, 152, 608-615.e4.	0.6	81
2536	Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicology and Applied Pharmacology, 2017, 315, 90-101.	1.3	50
2537	Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. Hepatology Research, 2017, 47, 1196-1205.	1.8	22
2538	Association of decreased expression of the macrophage scavenger receptor MARCO with tumor progression and poor prognosis in human hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1107-1114.	1.4	32
2539	Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis. Digestive Diseases and Sciences, 2017, 62, 808-816.	1.1	9

#	Article	IF	Citations
2540	Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia. Drug and Alcohol Dependence, 2017, 171, 132-139.	1.6	5
2541	Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2017, 224, 283-293e4.	0.2	21
2542	Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. American Journal of Pathology, 2017, 187, 228-235.	1.9	26
2543	Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Molecular Biology Reports, 2017, 44, 149-158.	1.0	7
2544	Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles. Molecular Medicine Reports, 2017, 15, 380-386.	1.1	16
2545	MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1. Oncology Reports, 2017, 38, 1569-1578.	1.2	38
2546	Resveratrol inhibits proliferation and migration through SIRT1 mediated post-translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells. Molecular Medicine Reports, 2017, 16, 8037-8044.	1.1	93
2547	FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition. Cancer Biomarkers, 2017, 19, 447-454.	0.8	14
2548	IL-17 Activates the IL-6/STAT3 Signal Pathway in the Proliferation of Hepatitis B Virus-Related Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2017, 43, 2379-2390.	1.1	58
2549	TRIP6 promotes cell proliferation in hepatocellular carcinoma via suppression of FOXO3a. Biochemical and Biophysical Research Communications, 2017, 494, 594-601.	1.0	19
2550	Overexpression of eEF1A1 regulates G1-phase progression to promote HCC proliferation through the STAT1-cyclin D1 pathway. Biochemical and Biophysical Research Communications, 2017, 494, 542-549.	1.0	37
2551	Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 1061-1069.	1.9	35
2552	Prognostic implication of NQO1 overexpression in hepatocellular carcinoma. Human Pathology, 2017, 69, 31-37.	1.1	39
2554	Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis. Oncology Reports, 2017, 38, 2607-2618.	1.2	187
2555	The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Scientific Reports, 2017, 7, 12870.	1.6	156
2556	Biocompatible silver, gold and silver/gold alloy nanoparticles for enhanced cancer therapy: in vitro and in vivo perspectives. Nanoscale, 2017, 9, 16773-16790.	2.8	62
2557	Downregulation of microRNA-196a inhibits human liver cancer cell proliferation and invasion by targeting FOXO1. Oncology Reports, 2017, 38, 2148-2154.	1.2	32
2558	Development of an Indirect Competitive Enzyme-Linked Immunosorbent Assay for Glycocholic Acid Based on Chicken Single-Chain Variable Fragment Antibodies. Analytical Chemistry, 2017, 89, 11091-11097.	3.2	31

#	Article	IF	Citations
2559	HBV suppresses thapsigargin-induced apoptosis via inhibiting CHOP expression in hepatocellular carcinoma cells. Oncology Letters, 2017, 14, 4403-4409.	0.8	3
2560	Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models. Oncology Letters, 2017, 14, 4078-4084.	0.8	30
2561	Phosphorylated <scp>ERK</scp> is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Medicine, 2017, 6, 2787-2795.	1.3	29
2562	LncRNA HANR Promotes Tumorigenesis and Increase of Chemoresistance in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2017, 43, 1926-1938.	1.1	88
2563	6â€Methoxyethylaminoâ€numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. FASEB Journal, 2017, 31, 5453-5465.	0.2	9
2564	Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers. Cancer Letters, 2017, 408, 112-120.	3.2	223
2565	Human oncogenic viruses: nature and discovery. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160264.	1.8	66
2566	Long non-coding RNA 657 suppresses hepatocellular carcinoma cell growth by acting as a molecular sponge of miR-106a-5p to regulate PTEN expression. International Journal of Biochemistry and Cell Biology, 2017, 92, 34-42.	1.2	57
2567	Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death and Disease, 2017, 8, e3043-e3043.	2.7	25
2568	The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma. Journal of Biological Chemistry, 2017, 292, 17939-17949.	1.6	49
2569	A novel prognostic indexâ€"neutrophil times Î³-glutamyl transpeptidase to lymphocyte ratio (NÎ³LR) predicts outcome for patients with hepatocellular carcinoma. Scientific Reports, 2017, 7, 9229.	1.6	15
2570	Hepatocellular carcinoma in a mouse model fed a cholineâ€deficient, Lâ€amino acidâ€defined, highâ€fat diet. International Journal of Experimental Pathology, 2017, 98, 221-233.	0.6	59
2571	p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival. Medicine (United States), 2017, 96, e8106.	0.4	21
2572	The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. Journal of Pathology, 2017, 243, 418-430.	2.1	29
2573	A novel method for identifying potential disease-related miRNAs via a diseaseâ€"miRNAâ€"target heterogeneous network. Molecular BioSystems, 2017, 13, 2328-2337.	2.9	11
2574	Transforming Growth Factor-Î² Promotes Liver Tumorigenesis inÂMice via Up-regulation of Snail. Gastroenterology, 2017, 153, 1378-1391.e6.	0.6	71
2575	Quantitative dynamic contrast-enhanced magnetic resonance imaging in a VX2 rabbit liver tumour model using different gadolinium-based contrast agents: comparison of DCE-MRI quantitative results between Magnevist and Eovist. BJR|case Reports, 2017, 3, 20160099.	0.1	2
2576	Mammalianâ€enabled (<scp>MENA</scp>) protein enhances oncogenic potential and cancer stem cellâ€like phenotype in hepatocellular carcinoma cells. FEBS Open Bio, 2017, 7, 1144-1153.	1.0	10

#	Article	IF	Citations
2577	Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. , 2017, , 149-178.		0
2578	Multi-organ Metastasis of Fibrolamellar Hepatocellular Carcinoma in a Malayan Gharial (Tomistoma) Tj ETQq1 1 0.784314 rgBT /Over	0.1	1
2579	Longâ€term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatology Communications, 2017, 1, 595-608.	2.0	19
2580	Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (United States), 2017, 96, e5904.	0.4	181
2582	Downregulated long non-coding RNA DREH promotes cell proliferation in hepatitis B virus-associated hepatocellular carcinoma. Oncology Letters, 2017, 14, 2025-2032.	0.8	33
2583	Protein glycosylation in viral hepatitis-related HCC: Characterization of heterogeneity, biological roles, and clinical implications. Cancer Letters, 2017, 406, 64-70.	3.2	16
2584	Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation. Oncology Letters, 2017, 14, 1395-1402.	0.8	0
2585	miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3. Oncology Letters, 2017, 14, 2552-2558.	0.8	29
2586	Disulfiram and disulfiram-loaded poly-[lactide-co-glycolic acid] nanoparticles modulate metastatic markers and proteasomal activity in hepatocarcinoma Hep3b cell line. European Journal of Nanomedicine, 2017, 9, .	0.6	1
2587	Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. Archives of Medical Research, 2017, 48, 553-560.	1.5	13
2588	Managing HCC in NAFLD. Current Hepatology Reports, 2017, 16, 374-381.	0.4	1
2589	Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Scientific Reports, 2017, 7, 16978.	1.6	25
2590	In vitro and in vivo antitumor effects of the diterpene-enriched extract from Taxodium ascendens through the mitochondrial-dependent apoptosis pathway. Biomedicine and Pharmacotherapy, 2017, 96, 1199-1208.	2.5	12
2591	Analysis of the mitochondrial 4977 bp deletion in patients with hepatocellular carcinoma. Balkan Journal of Medical Genetics, 2017, 20, 81-86.	0.5	22
2592	Desipramine induces apoptosis in hepatocellular carcinoma cells. Oncology Reports, 2017, 38, 1029-1034.	1.2	13
2593	Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma. Biomarkers in Cancer, 2017, 9, 1179299X1773730.	3.6	32
2594	Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis. Digestive Disease Interventions, 2017, 01, 066-073.	0.3	0
2595	Characteristics and Unmet Clinical Needs Related to Hepatocellular Carcinoma. Digestive Disease Interventions, 2017, 01, 074-082.	0.3	0

#	Article	IF	Citations
2596	Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors. Medicine (United States), 2017, 96, e7426.	0.4	25
2597	Chronic Alcohol Consumption Promotes Diethylnitrosamine-Induced Hepatocarcinogenesis via Immune Disturbances. Scientific Reports, 2017, 7, 2567.	1.6	39
2598	SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3Î²/Î²-catenin signaling in HCC cells. Tumor Biology, 2017, 39, 101042831770040.	0.8	19
2599	Fisetin inhibits liver cancer growth in a mouse model: Relation to dopamine receptor. Oncology Reports, 2017, 38, 53-62.	1.2	39
2600	Hepatitis B virus X protein promotes hepatocellular carcinoma invasion and metastasis via upregulating thioredoxin interacting protein. Oncology Letters, 2017, 14, 1323-1332.	0.8	17
2601	Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of Galectin-3 in Hepatocellular carcinoma. Scientific Reports, 2017, 7, 5189.	1.6	15
2602	A novel approach for Hepatocellular Carcinoma detection and classification based on triphasic CT Protocol. , 2017, , .		23
2604	GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma. BMC Cancer, 2017, 17, 380.	1.1	17
2605	Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinoma. BMC Cancer, 2017, 17, 409.	1.1	8
2606	MiR-542-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting UBE3C. Biomedicine and Pharmacotherapy, 2017, 93, 420-428.	2.5	37
2607	ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Scientific Reports, 2017, 7, 4412.	1.6	15
2608	Yesâ€associated protein/TEA domain family member and hepatocyte nuclear factor 4â€alpha (HNF4Î±) repress reciprocally to regulate hepatocarcinogenesis in rats and mice. Hepatology, 2017, 65, 1206-1221.	3.6	57
2609	Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: A novel link between oxidative stress and cancer. Free Radical Biology and Medicine, 2017, 102, 67-76.	1.3	93
2610	Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury. Oncogene, 2017, 36, 1978-1990.	2.6	34
2611	Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology, 2017, 52, 512-519.	2.3	275
2613	Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology and Hepatology, 2017, 15, 746-755.e4.	2.4	33
2614	Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients. Biomedical Chromatography, 2017, 31, e3893.	0.8	26
2615	METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6â€methyladenosineâ€dependent primary MicroRNA processing. Hepatology, 2017, 65, 529-543.	3.6	685

#	Article	IF	Citations
2616	Patientâ€reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology, 2017, 65, 875-884.	3.6	129
2617	Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics. Journal of Proteomics, 2017, 150, 230-241.	1.2	10
2618	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	1.9	67
2619	Arsenic trioxide intravenous infusion combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with pulmonary metastasis: Longâ€term outcome analysis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 295-300.	1.4	27
2620	Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 570-594.	0.6	21
2621	MicroRNAâ€'138 targets SP1 to inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells. Oncology Letters, 2017, 15, 1279-1286.	0.8	11
2623	2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics, 2017, 37, 1994-2017.	1.4	185
2624	MicroRNAâ€'495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulinâ€'like growth factor receptorâ€'1. Experimental and Therapeutic Medicine, 2017, 15, 1150-1158.	0.8	21
2625	Hypomethylated Ubiquitin-Conjugating Enzyme2 Q1 (UBE2Q1) Gene Promoter in the Serum Is a Promising Biomarker for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Tohoku Journal of Experimental Medicine, 2017, 242, 93-100.	0.5	22
2626	Rapid Detection of Small Molecule Metabolites in Serum of Hepatocellular Carcinoma Patients Using Ultrafast Liquid Chromatography–Ion Trap–Time of Flight Tandem Mass Spectrometry. Analytical Sciences, 2017, 33, 573-578.	0.8	8
2627	Lipid Metabolism in Liver Cancer. , 0, , .		2
2628	Gene Variations of Sixth Complement Component Affecting Tacrolimus Metabolism in Patients with Liver Transplantation for Hepatocellular Carcinoma. Chinese Medical Journal, 2017, 130, 1670-1676.	0.9	5
2629	Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Annals of Gastroenterology, 2017, 30, 357-363.	0.4	12
2631	Liver Imaging Reporting and Data System: an expert consensus statement. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 29-39.	1.8	46
2632	Oxidative Stress as a Mechanism for Hepatocellular Carcinoma. , 2017, , 279-287.		4
2633	Advantage of Sorafenib Combined with Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma. Tumori, 2017, 103, 286-291.	0.6	5
2634	Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. OncoTargets and Therapy, 2017, Volume 10, 2761-2768.	1.0	25
2635	Co-expression of Piwil2/Piwil4 in nucleus indicates poor prognosis of hepatocellular carcinoma. Oncotarget, 2017, 8, 4607-4617.	0.8	19

#	Article	IF	Citations
2636	Alcohol and Cancer: Mechanisms and Therapies. Biomolecules, 2017, 7, 61.	1.8	87
2637	National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens. Cancers, 2017, 9, 108.	1.7	68
2638	Identification of Novel A2/C2 Inter-Genotype Recombinants of Hepatitis B Virus from a Korean Chronic Patient Co-Infected with Both Genotype A2 and C2. International Journal of Molecular Sciences, 2017, 18, 737.	1.8	4
2639	Modeling Natural Killer Cell Targeted Immunotherapies. Frontiers in Immunology, 2017, 8, 370.	2.2	8
2640	Novel Immunotherapies for Autoimmune Hepatitis. Frontiers in Pediatrics, 2017, 5, 8.	0.9	17
2641	Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Disease Markers, 2017, 2017, 1-10.	0.6	6
2642	The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma. BioMed Research International, 2017, 2017, 1-11.	0.9	12
2643	MicroRNA-377 Downregulates Bcl-xL and Increases Apoptosis in Hepatocellular Carcinoma Cells. Oncology Research, 2017, 25, 29-34.	0.6	16
2644	Cytotoxicity, Oxidative Stress, Cell Cycle Arrest, and Mitochondrial Apoptosis after Combined Treatment of Hepatocarcinoma Cells with Maleic Anhydride Derivatives and Quercetin. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-16.	1.9	38
2645	Quercetin Reverses Rat Liver Preneoplastic Lesions Induced by Chemical Carcinogenesis. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-8.	1.9	20
2646	Pure hepatocellular carcinoma originates from an ectopic liver nodule located in the pancreas. Wspolczesna Onkologia, 2017, 21, 311-314.	0.7	8
2647	Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame. Cancers, 2017, 9, 130.	1.7	38
2648	The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 5363-5375.	1.0	14
2649	Hepatocellular carcinoma: a clinicopathological study of 64 cases. Pan African Medical Journal, 2017, 27, 41.	0.3	5
2650	Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition. Drug Design, Development and Therapy, 2017, Volume 11, 1789-1802.	2.0	36
2651	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS ONE, 2017, 12, e0170394.	1.1	11
2652	Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma. PLoS ONE, 2017, 12, e0182208.	1.1	35
2653	Adaptive ultrasound temperature imaging for monitoring radiofrequency ablation. PLoS ONE, 2017, 12, e0182457.	1.1	15

#	Article	IF	Citations
2654	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0184878.	1.1	5
2655	Highly tumorigenic hepatocellular carcinoma cell line with cancer stem cell-like properties. PLoS ONE, 2017, 12, e0171215.	1.1	32
2656	High cancer mortality for US-born Latinos: evidence from California and Texas. BMC Cancer, 2017, 17, 478.	1.1	60
2657	Down-regulation of the tumour suppressor Î¹-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients. BMC Cancer, 2017, 17, 553.	1.1	34
2658	Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer, 2017, 17, 610.	1.1	15
2659	Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer, 2017, 17, 896.	1.1	26
2660	Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma. Cancer Cell International, 2017, 17, 94.	1.8	4
2661	Ambient ultraviolet radiation exposure and hepatocellular carcinoma incidence in the United States. Environmental Health, 2017, 16, 89.	1.7	10
2662	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Molecular Cancer, 2017, 16, 149.	7.9	338
2663	Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Oncotarget, 2017, 8, 408-417.	0.8	10
2664	Oxidored-nitro domain-containing protein 1 promotes liver fibrosis by activating the Wnt/Î²-catenin signaling pathway in vitro. Molecular Medicine Reports, 2017, 16, 5050-5054.	1.1	12
2665	MicroRNA-302a inhibits cell proliferation and invasion, and induces cell apoptosis in hepatocellular carcinoma by directly targeting VEGFA. Molecular Medicine Reports, 2017, 16, 6360-6367.	1.1	18
2666	MicroRNA-296-5p downregulated AKT2 to inhibit hepatocellular carcinoma cell proliferation, migration and invasion. Molecular Medicine Reports, 2017, 16, 1565-1572.	1.1	15
2667	Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells. Molecular Medicine Reports, 2017, 16, 6094-6101.	1.1	11
2668	Association of FHIT expression and FHIT gene hypermethylation with liver cancer risk: a PRISMA-compliant meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 3083-3093.	1.0	4
2669	Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma. Molecular Medicine Reports, 2017, 16, 5523-5528.	1.1	8
2670	Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget, 2017, 8, 105596-105605.	0.8	45
2671	Association between the functional polymorphism Ile31Phe in theAURKAgene and susceptibility of hepatocellular carcinoma in chronic hepatitis B virus carriers. Oncotarget, 2017, 8, 54904-54912.	0.8	14

#	Article	IF	Citations
2672	Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma. Journal of Cancer, 2017, 8, 1988-1994.	1.2	12
2673	Dynamin 3 suppresses growth and induces apoptosis of hepatocellular carcinoma cells by activating inducible nitric oxide synthase production. Oncology Letters, 2017, 13, 4776-4784.	0.8	17
2674	The utility of biomarkers in hepatocellular carcinoma: review of urine-based ¹H-NMR studies – what the clinician needs to know. International Journal of General Medicine, 2017, Volume 10, 431-442.	0.8	8
2675	MicroRNA-187 inhibits tumor growth and metastasis via targeting of IGF-1R in hepatocellular carcinoma. Molecular Medicine Reports, 2017, 16, 2241-2246.	1.1	13
2676	Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation. Oncotarget, 2017, 8, 4301-4312.	0.8	21
2677	Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World Journal of Hepatology, 2017, 9, 533.	0.8	140
2678	MicroRNA-363-3p is downregulated in hepatocellular carcinoma and inhibits tumorigenesis by directly targeting specificity protein 1. Molecular Medicine Reports, 2017, 16, 1603-1611.	1.1	21
2679	Downregulation of A20 increases the cytotoxicity of IFN-γ in hepatocellular carcinoma cells. Drug Design, Development and Therapy, 2017, Volume 11, 2841-2850.	2.0	5
2680	Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget, 2017, 8, 80666-80678.	0.8	96
2681	Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 109247-109257.	0.8	22
2682	Viral hepatitis and hepatocellular carcinoma: etiology and management. Journal of Gastrointestinal Oncology, 2017, 8, 229-242.	0.6	120
2683	The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection. Current Drug Targets, 2017, 18, 756-765.	1.0	18
2684	Nrf2. , 2017, , 355-374.		8
2685	THE HERBAL MIXTURE XIAO-CHAI-HU TANG (XCHT) INDUCES APOPTOSIS OF HUMAN HEPATOCELLULAR CARCINOMA HUH7 CELLS IN VITRO AND IN VIVO. Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 231-241.	0.3	6
2686	Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. Annals of Hepatology, 2017, 16, 555-564.	0.6	18
2687	Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis. Oncotarget, 2017, 8, 63890-63900.	0.8	44
2688	Disease monitoring of hepatocellular carcinoma through metabolomics. World Journal of Hepatology, 2017, 9, 1.	0.8	26
2689	Influence of antiviral therapy on survival of patients with hepatitis B-associated hepatocellular carcinoma undergoing transarterial chemoembolization. Tropical Journal of Pharmaceutical Research, 2017, 16, 1997.	0.2	2

#	Article	IF	Citations
2690	Dietary factors can protect against liver cancer development. World Journal of Hepatology, 2017, 9, 119.	0.8	37
2691	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Annals of Palliative Medicine, 2017, 6, 26-35.	0.5	15
2692	Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electronic Physician, 2017, 9, 5646-5656.	0.2	40
2693	Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 163-172.	0.7	2
2694	Long non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell migration and invasion through the PTEN pathway in hepatocellular carcinoma. Oncotarget, 2017, 8, 107859-107869.	0.8	59
2695	Roles of p53 in extrinsic factor-induced liver carcinogenesis. Hepatoma Research, 2017, 3, 95.	0.6	18
2696	SHP2 is induced by the HBx-NF-ÎºB pathway and contributes to fibrosis during human early hepatocellular carcinoma development. Oncotarget, 2017, 8, 27263-27276.	0.8	17
2697	Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?. Translational Gastroenterology and Hepatology, 2017, 2, 68-68.	1.5	16
2698	A Deep Learning Approach for Hepatocellular Carcinoma Grading. International Journal of Computer Vision and Image Processing, 2017, 7, 1-18.	0.3	6
2699	Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules. Radiology, 2018, 287, 515-524.	3.6	17
2700	Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. Cellular Oncology (Dordrecht), 2018, 41, 283-296.	2.1	16
2701	Dual role for inositolâ€requiring enzyme 1Î± in promoting the development of hepatocellular carcinoma during dietâ€induced obesity in mice. Hepatology, 2018, 68, 533-546.	3.6	47
2702	Overexpression of RHEB is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncology Letters, 2018, 15, 3838-3845.	0.8	5
2703	MicroRNA-542-3p functions as a tumor suppressor via directly targeting survivin in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2018, 99, 817-824.	2.5	19
2704	Directâ€acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1278-1287.	1.9	61
2705	Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPRâ€“mediated direct in vivo screening. Science Advances, 2018, 4, eaao5508.	4.7	64
2706	Higher CYP2E1 Activity Correlates with Hepatocarcinogenesis Induced by Diethylnitrosamine. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 398-407.	1.3	27
2707	Hepatocellular Carcinoma in a Î²-Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin, 2018, 42, 58-60.	0.4	7

#	Article	IF	Citations
2708	Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Alimentary Pharmacology and Therapeutics, 2018, 47, 1201-1212.	1.9	14
2709	Coefficient of variation on Gd-EOB MR imaging: Correlation with the presence of early-stage hepatocellular carcinoma in patients with chronic hepatitis B. European Journal of Radiology, 2018, 102, 95-101.	1.2	4
2710	Evidences for the antitumor potentiality of Hemimycale arabica and Negombata magnifica mesohyls in hepatocellular carcinoma rat model. Medicinal Chemistry Research, 2018, 27, 1538-1548.	1.1	3
2711	Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology, 2018, 288, 300-307.	3.6	40
2712	Pharmacological inhibition of TRPV4 channel suppresses malignant biological behavior of hepatocellular carcinoma via modulation of ERK signaling pathway. Biomedicine and Pharmacotherapy, 2018, 101, 910-919.	2.5	44
2713	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis Bâ€endemic area. Alimentary Pharmacology and Therapeutics, 2018, 47, 1490-1501.	1.9	22
2714	CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Journal of Pathology, 2018, 245, 297-310.	2.1	25
2715	Striking Racial/Ethnic Disparities in Liver Cancer Incidence Rates and Temporal Trends in California, 1988â€“2012. Journal of the National Cancer Institute, 2018, 110, 1259-1269.	3.0	43
2716	Clinical significance of serum transthyretin level in patients with hepatocellular carcinoma. ANZ Journal of Surgery, 2018, 88, 1328-1332.	0.3	9
2717	Tumours and Tumour-like Lesions of the Liver. , 2018, , 780-879.		18
2718	MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma. Cancer Biomarkers, 2018, 22, 151-159.	0.8	27
2719	Preoperative Serum Insulin-Like Growth Factor 1 Level as a Prognostic Factor in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. Journal of Interferon and Cytokine Research, 2018, 38, 153-160.	0.5	2
2720	The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma. Medicine (United States), 2018, 97, e0128.	0.4	8
2721	Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle, 2018, 17, 903-916.	1.3	73
2722	No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clinical Transplantation, 2018, 32, e13246.	0.8	14
2723	miR-429 suppresses tumor migration and invasion by targeting CRKL in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and epithelial-mesenchymal transition. Scientific Reports, 2018, 8, 2375.	1.6	47
2724	Hepatocellular carcinoma surveillance with ultrasoundâ€”cost-effectiveness, high-risk populations, uptake. British Journal of Radiology, 2018, 91, 20170436.	1.0	7
2725	Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Scientific Reports, 2018, 8, 3081.	1.6	67

#	Article	IF	Citations
2726	Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review). International Journal of Molecular Medicine, 2018, 41, 1809-1816.	1.8	46
2727	99mTc-Labeled RGDâ€“Polyethylenimine Conjugates with Entrapped Gold Nanoparticles in the Cavities for Dual-Mode SPECT/CT Imaging of Hepatic Carcinoma. ACS Applied Materials & Interfaces, 2018, 10, 6146-6154.	4.0	34
2728	<scp>Wisteria floribunda</scp> agglutininâ€positive Macâ€2 binding protein predicts the development of hepatocellular carcinoma in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2018, 48, 521-528.	1.8	19
2729	Sigma-1 receptor (Ïƒ1R) is downregulated in hepatic malignant tumors and regulates HepG2 cell proliferation, migration and apoptosis. Oncology Reports, 2018, 39, 1405-1413.	1.2	6
2730	TPGLDA: Novel prediction of associations between lncRNAs and diseases via lncRNA-disease-gene tripartite graph. Scientific Reports, 2018, 8, 1065.	1.6	97
2731	Primary Liver Cancers, Part 2. Cancer Control, 2018, 25, 107327481774465.	0.7	16
2732	The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population. Digestive Diseases and Sciences, 2018, 63, 515-528.	1.1	37
2733	Telomeres in cancer. Differentiation, 2018, 99, 41-50.	1.0	20
2734	miR-124 inhibits progression of hepatocarcinoma by targeting KLF4 and promises a novel diagnostic marker. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 159-167.	1.9	13
2736	Hepatitis B virus X protein modulates cytosolic Ca2+ signaling in primary human hepatocytes. Virus Research, 2018, 246, 23-27.	1.1	13
2737	Immune Regulation in HCC and the Prospect of Immunotherapy. Molecular Pathology Library, 2018, , 175-194.	0.1	0
2738	Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1397-1406.	1.4	15
2739	Reply to: â€œâ€˜Who killed JRâ€™: Chronic hepatitis C or alcohol use disorders?â€• Journal of Hepatology, 2018, 68, 1099-1100.	1.8	1
2740	Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection. BMC Cancer, 2018, 18, 460.	1.1	11
2742	Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients. Transplantation Proceedings, 2018, 50, 623-627.	0.3	8
2743	Telomerase reverse transcriptase suppression inhibits cell proliferation and promotes cell apoptosis in hepatocellular cancer. IUBMB Life, 2018, 70, 642-648.	1.5	6
2744	Impact of miRâ€140 Deficiency on Nonâ€Alcoholic Fatty Liver Disease. Molecular Nutrition and Food Research, 2018, 62, e1800189.	1.5	9
2745	Ambient PM2.5 air pollutionÂexposure and hepatocellular carcinoma incidence in the United States. Cancer Causes and Control, 2018, 29, 563-572.	0.8	55

#	Article	IF	Citations
2746	Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Molecular Metabolism, 2018, 13, 56-66.	3.0	65
2747	Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway. Oncology Letters, 2018, 15, 5739-5743.	0.8	21
2748	Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: A retrospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 330-338.	0.7	20
2749	Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC. Bioscience Reports, 2018, 38, .	1.1	31
2750	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, The, 2018, 391, 1163-1173.	6.3	3,542
2751	The mRNA, miRNA and lncRNA networks in hepatocellular carcinoma: An integrative transcriptomic analysis from Gene Expression Omnibus. Molecular Medicine Reports, 2018, 17, 6472-6482.	1.1	21
2752	The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2018, 101, 648-655.	2.5	32
2753	Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway. Cell Death and Disease, 2018, 9, 398.	2.7	46
2754	AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of Î²-catenin activation. Journal of Hepatology, 2018, 68, 1203-1213.	1.8	78
2755	Mini-review. Liver transplantation for hepatocellular carcinoma. Revista MÃ©dica Del Hospital General De MÃ©xico, 2018, 81, 97-101.	0.0	1
2756	Lymphotoxin in physiology of lymphoid tissues â€“ Implication for antiviral defense. Cytokine, 2018, 101, 39-47.	1.4	20
2757	The Evaluation of Angiogenesis Markers in Hepatocellular Carcinoma and Precursor Lesions in Liver Explants From a Single Institution. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 330-336.	0.6	6
2758	RACK1 Silencing Induces Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma MHCC97-H Cells. Pathology and Oncology Research, 2018, 24, 101-107.	0.9	10
2759	Fasting inhibits hepatic stellate cells activation and potentiates antiâ€cancer activity of Sorafenib in hepatocellular cancer cells. Journal of Cellular Physiology, 2018, 233, 1202-1212.	2.0	38
2760	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver International, 2018, 38, 136-143.	1.9	58
2761	Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2018, 437, 13-36.	1.4	29
2762	Obesity is Independently Associated With Increased Risk of Hepatocellular Cancerâ€related Mortality. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 874-881.	0.6	164
2763	Targeting histone deacetylase 4/ubiquitinâ€conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. Hepatology, 2018, 67, 586-599.	3.6	29

#	Article	IF	Citations
2764	Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdominal Radiology, 2018, 43, 13-25.	1.0	338
2765	Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS. Acta Radiologica, 2018, 59, 140-146.	0.5	30
2766	Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis. Carcinogenesis, 2018, 39, 28-35.	1.3	25
2767	Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma. Hepatology, 2018, 67, 1378-1391.	3.6	42
2768	Liver Reptin/RUVBL2 controls glucose and lipid metabolism with opposite actions on mTORC1 and mTORC2 signalling. Gut, 2018, 67, 2192-2203.	6.1	17
2769	Integrated Proteomic and Transcriptomic Analysis Reveals Long Noncoding RNA HOX Transcript Antisense Intergenic RNA (HOTAIR) Promotes Hepatocellular Carcinoma Cell Proliferation by Regulating Opioid Growth Factor Receptor (OGFr). Molecular and Cellular Proteomics, 2018, 17, 146-159.	2.5	33
2770	Clinical characteristics of hepatocellular carcinoma patients with normal serum alphaâ€fetoprotein level: A study of 112 consecutive cases. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e336-e340.	0.7	3
2771	A Largeâ€scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology, 2018, 67, 662-675.	3.6	268
2772	Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology, 2018, 67, 914-923.	3.6	52
2773	High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Laboratory Investigation, 2018, 98, 95-105.	1.7	41
2774	Ultra-fast and sensitive silicon nanobelt field-effect transistor for high-throughput screening of alpha-fetoprotein. Sensors and Actuators B: Chemical, 2018, 256, 1114-1121.	4.0	11
2775	Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity. Redox Biology, 2018, 14, 237-249.	3.9	47
2776	Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases. Clinical and Experimental Medicine, 2018, 18, 79-87.	1.9	27
2777	Recent developments of câ€Met as a therapeutic target in hepatocellular carcinoma. Hepatology, 2018, 67, 1132-1149.	3.6	190
2778	Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 2018, 67, 600-611.	3.6	219
2779	Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI. Acta Radiologica, 2018, 59, 639-648.	0.5	14
2780	Nanomedicines: a theranostic approach for hepatocellular carcinoma. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 680-690.	1.9	37
2781	A novel and validated prognostic nomogram based on liver fibrosis and tumor burden for patients with hepatocellular carcinoma after curative resection. Journal of Surgical Oncology, 2018, 117, 625-633.	0.8	16

#	Article	IF	Citations
2782	Evaluation of alternative serum biomarkers to monitor the progression of chronic HBV and HCV infection. Infection, Genetics and Evolution, 2018, 58, 17-22.	1.0	1
2783	Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004â€“2014. Irish Journal of Medical Science, 2018, 187, 803-811.	0.8	1
2785	Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. International Journal of Infectious Diseases, 2018, 67, 92-97.	1.5	66
2786	Rs4705342 polymorphism is involved in the tumorigenesis of HBV positive HCC by altering the binding affinity of HBV induced NFâ€kB with the promoter region of microRNAâ€143. Journal of Cellular Biochemistry, 2018, 119, 5233-5242.	1.2	13
2787	Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease, 2018, 22, 201-211.	1.0	65
2788	Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2018, 30, 60-70.	0.8	24
2789	Nootkatone confers hepatoprotective and antiâ€fibrotic actions in a murine model of liver fibrosis by suppressing oxidative stress, inflammation, and apoptosis. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22017.	1.4	26
2790	lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. American Journal of Physiology - Renal Physiology, 2018, 314, G559-G565.	1.6	88
2791	Direct-acting antiviral agents in the treatment of chronic Hepatitis C â€“ â€œReal-lifeâ€•experience from an academic centre and two specialized clinical practices. Zeitschrift Fur Gastroenterologie, 2018, 56, 351-360.	0.2	3
2792	Endogenous Molecular-Cellular Network Cancer Theory: A Systems Biology Approach. Methods in Molecular Biology, 2018, 1702, 215-245.	0.4	5
2793	LigaSure versus CUSA for parenchymal transection during laparoscopic hepatectomy in hepatocellular carcinoma patients with cirrhosis: a propensity score-matched analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 2454-2465.	1.3	28
2794	LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2. Journal of Cellular Physiology, 2018, 233, 4726-4734.	2.0	55
2795	Bleeding Recurrence and Mortality Following Interventional Management of Spontaneous HCC Rupture: Results of a Multicenter European Study. World Journal of Surgery, 2018, 42, 225-232.	0.8	33
2796	Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget, 2018, 9, 37721-37732.	0.8	16
2797	Remaining clinical issues in hepatitis C treatment. Canadian Liver Journal, 2018, 1, 66-77.	0.3	1
2798	Luteolin sensitizes human liver cancer cells to TRAILâ€induced apoptosis via autophagy and JNKâ€mediated death receptor 5 upregulation. International Journal of Oncology, 2019, 54, 665-672.	1.4	20
2799	Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Hepatobiliary Surgery and Nutrition, 2018, 7, 429-439.	0.7	16
2800	MicroRNAâ€363â€3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage. Molecular Medicine Reports, 2019, 19, 935-942.	1.1	7

#	Article	IF	Citations
2801	miRâ€'378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRÎ² and câ€'Raf. Molecular Medicine Reports, 2018, 17, 4581-4588.	1.1	14
2802	Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2018, 24, 3426-3439.	1.4	90
2803	Immunohistochemical Expression of Epidermal Growth Factor Receptor in Hepatocellular Carcinoma. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2018, 39, 21-28.	0.2	4
2804	The biological and diagnostic role of miRNA rsquo s in hepatocellular carcinoma. Frontiers in Bioscience - Landmark, 2018, 23, 1701-1720.	3.0	29
2805	Evaluation of the anticancer activity of sprout extract-loaded nanoemulsion of N. sativa against hepatocellular carcinoma. Journal of Microencapsulation, 2018, 35, 643-656.	1.2	8
2806	Interaction of Mitochondrial and Epigenetic Regulation in Hepatocellular Carcinoma. , 0, , .		2
2807	Epidemiology and Pathogenesis of Alcoholic Liver Disease. , 2018, , 334-344.e3.		3
2808	FOXC1, the new player in the cancer sandbox. Oncotarget, 2018, 9, 8165-8178.	0.8	53
2809	Introductory Chapter: Etiology and Pathogenesis of Hepatocellular Carcinoma. , 2018, , .		1
2810	HCC in Elderly Patients. Curative Intraoperative Strategies and Management in Recurrences. , 2018, , .		2
2811	Role of Dietary Carotenoids in Different Etiologies of Chronic Liver Diseases. , 2018, , .		1
2813	Low expression of miRâ€'199 in hepatocellular carcinoma contributes to tumor cell hyperâ€'proliferation by negatively suppressing XBP1. Oncology Letters, 2018, 16, 6531-6539.	0.8	22
2814	Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration. OncoTargets and Therapy, 2018, Volume 11, 7143-7153.	1.0	6
2815	Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication. International Journal of Molecular Sciences, 2018, 19, 3742.	1.8	48
2816	Upregulation of microRNAâ€'300 induces the proliferation of liver cancer by downregulating transcription factor FOXO1. Oncology Reports, 2018, 40, 3561-3572.	1.2	6
2817	Nongenotoxic Carcinogenesis. , 2018, , 36-46.		0
2818	Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis. Surgical Oncology, 2018, 27, 751-758.	0.8	34
2819	Loss of paraspinal muscle mass is a genderâ€specific consequence of cirrhosis that predicts complications and death. Alimentary Pharmacology and Therapeutics, 2018, 48, 1271-1281.	1.9	29

#	Article	IF	Citations
2820	lncRNA FEZF1â€‘AS1 contributes to cell proliferation, migration and invasion by sponging miRâ€‘4443 in hepatocellular carcinoma. Molecular Medicine Reports, 2018, 18, 5614-5620.	1.1	25
2821	Early heme oxygenase 1 induction delays tumour initiation and enhances DNA damage repair in liver macrophages of Mdr2â^'/â^' mice. Scientific Reports, 2018, 8, 16238.	1.6	8
2822	miR-185 inhibits cell migration and invasion of hepatocellular carcinoma through CDC42. Oncology Letters, 2018, 16, 3101-3107.	0.8	14
2823	MicroRNAâ€‘577 inhibits the migration and invasion of hepatocellular carcinoma cells by targeting homeobox A1. Oncology Reports, 2018, 39, 2987-2995.	1.2	5
2825	Revealing Different Lung Metastatic Potentials Induced Metabolic Alterations of Hepatocellular Carcinoma Cells via Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Cancer, 2018, 9, 4696-4705.	1.2	2
2826	Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. Cancer Management and Research, 2019, Volume 11, 63-79.	0.9	12
2827	Tomato lycopene prevention of alcoholic fatty liver disease andÂhepatocellular carcinoma development. Chronic Diseases and Translational Medicine, 2018, 4, 211-224.	0.9	26
2828	Hepatocellular Carcinoma in Î²-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. International Journal of Molecular Sciences, 2018, 19, 4070.	1.8	25
2829	Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. Cancer Management and Research, 2018, Volume 10, 5545-5552.	0.9	7
2830	Gamma linolic acid regulates PHD2 mediated hypoxia and mitochondrial apoptosis in DEN induced Hepatocellular carcinoma. Drug Design, Development and Therapy, 2018, Volume 12, 4241-4252.	2.0	17
2831	Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma?. Radiation Oncology Journal, 2018, 36, 129-138.	0.7	17
2832	Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. World Journal of Hepatology, 2018, 10, 785-789.	0.8	13
2833	15 Hepatocellular Carcinoma: Staging and Clinical Management. , 2018, , .		0
2834	Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers, 2018, 10, 481.	1.7	135
2835	Advances in genomic hepatocellular carcinoma research. GigaScience, 2018, 7, .	3.3	25
2836	Prognostic Significance of 14-3-3Îµ, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma. Anticancer Research, 2018, 38, 6855-6863.	0.5	6
2837	Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6. Journal of Experimental and Clinical Cancer Research, 2018, 37, 290.	3.5	24
2838	Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World Journal of Gastroenterology, 2018, 24, 4436-4447.	1.4	105

#	Article	IF	Citations
2839	Helicobacter pylori Infection as a Risk Factor for Hepatocellular Carcinoma: A Case-Control Study in Ethiopia. International Journal of Hepatology, 2018, 2018, 1-7.	0.4	10
2840	PI3KÎ´ Is a Therapeutic Target in Hepatocellular Carcinoma. Hepatology, 2018, 68, 2285-2300.	3.6	35
2841	Follistatinâ€like protein 5 inhibits hepatocellular carcinoma progression by inducing caspaseâ€dependent apoptosis and regulating Bclâ€2 family proteins. Journal of Cellular and Molecular Medicine, 2018, 22, 6190-6201.	1.6	17
2842	Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis. Biomedicine and Pharmacotherapy, 2018, 107, 1692-1704.	2.5	28
2843	Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes. Clinical Cancer Research, 2019, 25, 463-472.	3.2	41
2844	Study of liver in HBV-related hepatocellular carcinoma: Stereology shows quantitative differences in liver structure. European Journal of Histochemistry, 2018, 62, .	0.6	4
2845	Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC. Biomedicine and Pharmacotherapy, 2018, 107, 1682-1691.	2.5	27
2846	Long Non-Coding MALAT1 Functions as a Competing Endogenous RNA to Regulate Vimentin Expression by Sponging miR-30a-5p in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2018, 50, 108-120.	1.1	46
2847	Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9879-E9888.	3.3	67
2848	Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World Journal of Gastroenterology, 2018, 24, 3695-3708.	1.4	52
2849	Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE, 2018, 13, e0205277.	1.1	47
2850	MicroRNAâ€‘205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A. Oncology Letters, 2018, 16, 2207-2214.	0.8	14
2851	Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes, 2018, 9, 483.	1.0	13
2852	Synthesis, crystal structures and anti-inflammatory activity of four 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidone derivatives. Acta Crystallographica Section C, Structural Chemistry, 2018, 74, 1171-1179.	0.2	12
2853	The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: A meta-analysis of observational studies. PLoS ONE, 2018, 13, e0202987.	1.1	32
2854	Single nucleotide polymorphisms of XRCC3 gene in hepatocellular carcinoma â€“ relationship with clinicopathological features. Polish Journal of Pathology, 2018, 69, 73-81.	0.1	9
2855	Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice. PLoS ONE, 2018, 13, e0204909.	1.1	12
2856	Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. Cell, 2018, 175, 679-694.e22.	13.5	344

#	Article	IF	Citations
2857	LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 228.	3.5	30
2858	The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. Internal Medicine, 2018, 57, 1345-1353.	0.3	29
2859	Hepatitis B Virus Infection Dampens CtIP Expression in Hepatoma Cell. Journal of Cancer, 2018, 9, 1182-1187.	1.2	3
2860	Activation of hepatic stem cells compartment during hepatocarcinogenesis in a HBsAg HBV-transgenic mouse model. Scientific Reports, 2018, 8, 13168.	1.6	11
2861	Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression. Journal of Experimental and Clinical Cancer Research, 2018, 37, 214.	3.5	94
2862	Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?. Yonsei Medical Journal, 2018, 59, 912.	0.9	14
2863	Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics, 2018, 8, 4649-4663.	4.6	120
2864	The long noncoding RNA GAS8-AS1 suppresses hepatocarcinogenesis by epigenetically activating the tumor suppressor GAS8. Journal of Biological Chemistry, 2018, 293, 17154-17165.	1.6	47
2865	The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors. Science Signaling, 2018, 11, .	1.6	68
2866	The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Scientific Reports, 2018, 8, 13143.	1.6	27
2867	Novel biomarkers in hepatocellular carcinoma. Digestive and Liver Disease, 2018, 50, 1115-1123.	0.4	104
2868	Hepatic leptin receptor expression can partiallyÂcompensate for IL-6RÎ± deficiency inÂDEN-induced hepatocellular carcinoma. Molecular Metabolism, 2018, 17, 122-133.	3.0	14
2869	IRE1Î±â€˜XBP1 signaling pathway regulates ILâ€˜6 expression and promotes progression of hepatocellular carcinoma. Oncology Letters, 2018, 16, 4729-4736.	0.8	25
2870	miR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression. Oncology Research, 2018, 26, 1073-1081.	0.6	22
2871	Epigenetic basis of hepatocellular carcinoma: A network-based integrative meta-analysis. World Journal of Hepatology, 2018, 10, 155-165.	0.8	13
2872	Tumor-suppressing effects of autophagy on hepatocellular carcinoma. Liver Research, 2018, 2, 157-160.	0.5	6
2873	Coordination of FOXA2 and SIRT6 suppresses the hepatocellular carcinoma progression through ZEB2 inhibition. Cancer Management and Research, 2018, Volume 10, 391-402.	0.9	15
2874	AngII induces HepG2 cells to activate epithelialâ€‘mesenchymal transition. Experimental and Therapeutic Medicine, 2018, 16, 3471-3477.	0.8	6

#	Article	IF	Citations
2875	The Paradoxical Role of NKG2D in Cancer Immunity. Frontiers in Immunology, 2018, 9, 1808.	2.2	47
2876	Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 1399-1410.	1.4	35
2877	Pten Haplodeficiency Accelerates Liver Tumor Growth in miR-122aâ€“Null Mice via Expansion of Periportal Hepatocyte-Like Cells. American Journal of Pathology, 2018, 188, 2688-2702.	1.9	6
2878	JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca2+/caspase-mediated mitochondrial pathway in HepG2 cells. Biomedicine and Pharmacotherapy, 2018, 107, 1385-1392.	2.5	18
2879	Gastrointestinal Cancersâ€”Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. International Journal of Radiation Oncology Biology Physics, 2018, 102, 233-242.	0.4	0
2880	Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3Î² signal pathway. Cell Death and Disease, 2018, 9, 888.	2.7	105
2881	Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 203.	3.5	77
2882	Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2009-2021.	1.7	27
2883	Aldehyde dehydrogenase 2 activation ameliorates <scp>CC</scp>l₄â€induced chronic liver fibrosis in mice by upâ€regulating Nrf2/<scp>HO</scp>â€1 antioxidant pathway. Journal of Cellular and Molecular Medicine, 2018, 22, 3965-3978.	1.6	40
2884	MicroRNA-493 suppresses cell proliferation and invasion by targeting ZFX in human hepatocellular carcinoma. Cancer Biomarkers, 2018, 22, 427-434.	0.8	13
2885	Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased?. United European Gastroenterology Journal, 2018, 6, 413-421.	1.6	6
2886	Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area. European Journal of Gastroenterology and Hepatology, 2018, 30, 1090-1096.	0.8	9
2887	Systematic analyses of a novel lncRNA-associated signature as the prognostic biomarker for Hepatocellular Carcinoma. Cancer Medicine, 2018, 7, 3240-3256.	1.3	35
2888	Study of promoter hypomethylation profiles of RAS oncogenes in hepatocellular carcinoma derived from hepatitis C virus genotype 3a in Pakistani population. Journal of Medical Virology, 2018, 90, 1516-1523.	2.5	8
2889	Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. Molecular Therapy, 2018, 26, 1840-1854.	3.7	51
2890	Structural characteristics and bioactive properties of a novel polysaccharide from Flammulina velutipes. Carbohydrate Polymers, 2018, 197, 147-156.	5.1	85
2891	EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. Anticancer Research, 2018, 38, 4101-4109.	0.5	19
2892	MiRâ€106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domainâ€containing protein 7A (Zbtb7a). Journal of Biochemical and Molecular Toxicology, 2018, 32, e22169.	1.4	28

#	Article	IF	Citations
2893	Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 906-909.	0.7	3
2894	Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population. Gene, 2018, 674, 188-194.	1.0	32
2895	Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 69, 927-947.	1.8	569
2896	Biophotonic detection of high order chromatin alterations in field carcinogenesis predicts risk of future hepatocellular carcinoma: A pilot study. PLoS ONE, 2018, 13, e0197427.	1.1	1
2897	T cell receptor repertoire profiling predicts the prognosis of <scp>HBV</scp>â€associated hepatocellular carcinoma. Cancer Medicine, 2018, 7, 3755-3762.	1.3	18
2898	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology, 2018, 155, 443-457.e17.	0.6	536
2899	Transforming growth factorâ€Î²1 and lysophosphatidic acid activate integrin Î²6 gene promoter in Hepâ€3B cells. Oncology Letters, 2018, 16, 439-446.	0.8	2
2900	Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. International Journal of Surgery, 2018, 56, 256-263.	1.1	12
2901	Bardoxolone Methyl Suppresses Hepatitis B Virus Large Surface Protein Variant W4P-Related Carcinogenesis and Hepatocellular Carcinoma Cell Proliferation Via the Inhibition of Signal Transducer and Activator of Transcription 3 Signaling. Pharmacology, 2018, 102, 105-113.	0.9	7
2902	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. Advances in Experimental Medicine and Biology, 2018, 1061, 3-18.	0.8	22
2903	lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARÎ³ pathway in hepatocellular carcinoma. International Journal of Oncology, 2018, 53, 551-566.	1.4	43
2904	Genetic variants in the exon region of versican predict survival of patients with resected early-stage hepatitis B virus-associated hepatocellular carcinoma. Cancer Management and Research, 2018, Volume 10, 1027-1036.	0.9	7
2905	The functional role of exosome in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2085-2095.	1.2	32
2906	Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country. Cancer Management and Research, 2018, Volume 10, 977-988.	0.9	23
2907	MiRâ€205 suppresses tumor growth, invasion, and epithelialâ€mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma. FASEB Journal, 2018, 32, 6123-6134.	0.2	27
2908	SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression. Frontiers in Pharmacology, 2018, 9, 194.	1.6	9
2909	AP-2Î² inhibits hepatocellular carcinoma invasion and metastasis through Slug and Snail to suppress epithelial-mesenchymal transition. Theranostics, 2018, 8, 3707-3721.	4.6	25
2910	Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma. Journal of Cancer, 2018, 9, 2357-2373.	1.2	59

#	Article	IF	Citations
2911	Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy. International Journal of Nanomedicine, 2018, Volume 13, 1265-1280.	3.3	20
2912	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-20.	0.8	13
2913	Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study. Annals of Surgical Oncology, 2018, 25, 3316-3323.	0.7	85
2914	The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis. Carcinogenesis, 2018, 39, 1497-1505.	1.3	26
2915	The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It. Cancers, 2018, 10, 83.	1.7	83
2916	Obesity-associated miR-27a upregulation promotes hepatocellular carcinoma metastasis through suppressing SFRP1. OncoTargets and Therapy, 2018, Volume 11, 3281-3292.	1.0	10
2917	When Hepatitis B Virus Meets Interferons. Frontiers in Microbiology, 2018, 9, 1611.	1.5	71
2918	Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook. Frontiers in Medicine, 2018, 5, 78.	1.2	38
2919	Different Sex-Based Responses of Gut Microbiota During the Development of Hepatocellular Carcinoma in Liver-Specific Tsc1-Knockout Mice. Frontiers in Microbiology, 2018, 9, 1008.	1.5	52
2920	A Review of Circulating Tumor DNA in Hepatobiliary Malignancies. Frontiers in Oncology, 2018, 8, 212.	1.3	10
2921	HIF-1Î± promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8â€“NF-ÎºB axis. Cellular and Molecular Biology Letters, 2018, 23, 26.	2.7	37
2922	Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1991-1999.	1.2	13
2923	Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis. Bioscience Reports, 2018, 38, .	1.1	9
2924	Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 555.	1.8	26
2925	Antioxidant Activity of Zein Hydrolysates from Zea Species and Their Cytotoxic Effects in a Hepatic Cell Culture. Molecules, 2018, 23, 312.	1.7	23
2926	Multiple Mycotoxins in Rice: Occurrence and Health Risk Assessment in Children and Adults of Punjab, Pakistan. Toxins, 2018, 10, 77.	1.5	56
2927	CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients. Cellular Physiology and Biochemistry, 2018, 47, 2602-2612.	1.1	23
2928	Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1. Cellular Physiology and Biochemistry, 2018, 47, 2340-2349.	1.1	8

#	Article	IF	Citations
2929	Cancer Siteâ€“Specific Disparities in New York, Including the 1945â€“1965 Birth Cohort's Impact on Liver Cancer Patterns. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 917-927.	1.1	20
2930	Dichotomous associations of liver pathology with hepatocellular carcinoma morphology in Middle Africa: the situation in Cameroon. BMC Research Notes, 2018, 11, 451.	0.6	3
2931	Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS ONE, 2018, 13, e0194922.	1.1	13
2932	Roles of microRNA in liver cancer. Liver Research, 2018, 2, 61-72.	0.5	15
2933	Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review. Current Pharmaceutical Biotechnology, 2018, 19, 43-67.	0.9	21
2934	Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. Oncology Letters, 2018, 15, 6857-6864.	0.8	7
2935	Diabetes With or Without Hypertension Does Not Affect Graft Survival and All-cause Mortality After Liver Transplant: A Propensity Score Matching Analysis. Transplantation Proceedings, 2018, 50, 1123-1128.	0.3	2
2936	The curcumin derivative WZ35 activates ROS-dependent JNK to suppress hepatocellular carcinoma metastasis. Food and Function, 2018, 9, 2970-2978.	2.1	26
2937	Role of nonresolving inflammation in hepatocellular carcinoma development and progression. Npj Precision Oncology, 2018, 2, 6.	2.3	199
2938	Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer, 2018, 18, 101.	1.1	11
2940	Decreased expression of microRNA-223 promotes cell proliferation in hepatocellular carcinoma cells via the insulin-like growth factor-1 signaling pathway. Experimental and Therapeutic Medicine, 2018, 15, 4325-4331.	0.8	6
2941	Lack of reduction in serum alphaâ€fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virusâ€related cirrhosis. Journal of Viral Hepatitis, 2018, 25, 1493-1500.	1.0	6
2942	Beneficial effects of naringenin in liver diseases: Molecular mechanisms. World Journal of Gastroenterology, 2018, 24, 1679-1707.	1.4	233
2943	Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues. Medical Oncology, 2018, 35, 127.	1.2	13
2944	LINC00052/miR-101-3p axis inhibits cell proliferation and metastasis by targeting SOX9 in hepatocellular carcinoma. Gene, 2018, 679, 138-149.	1.0	48
2945	Can fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography detect hepatocellular carcinoma and its extrahepatic metastases?. Egyptian Journal of Radiology and Nuclear Medicine, 2018, 49, 196-201.	0.3	3
2946	Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity. European Journal of Histochemistry, 2018, 62, 2859.	0.6	21
2947	Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signaling. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3150-3154.	1.0	25

#	Article	IF	Citations
2948	In silico and in vivo characterization of cabralealactone, solasodin and salvadorin in a rat model: potential anti-inflammatory agents. Drug Design, Development and Therapy, 2018, Volume 12, 1431-1443.	2.0	11
2950	Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways associated with TP53 expression status in HBV-related hepatocellular carcinoma. Cancer Management and Research, 2018, Volume 10, 953-967.	0.9	10
2951	Blocking CDK1/PDK1/Î²-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics, 2018, 8, 3737-3750.	4.6	145
2952	The tumor suppressive miR-302c-3p inhibits migration and invasion of hepatocellular carcinoma cells by targeting TRAF4. Journal of Cancer, 2018, 9, 2693-2701.	1.2	25
2953	AIM2 deficiency reduces the development of hepatocellular carcinoma in mice. International Journal of Cancer, 2018, 143, 2997-3007.	2.3	30
2954	Adherence to the Chinese or American Dietary Guidelines is Associated with a Lower Risk of Primary Liver Cancer in China: A Case-Control Study. Nutrients, 2018, 10, 1113.	1.7	20
2955	Comparative analysis of tumorâ€'associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study. Oncology Letters, 2018, 16, 3690-3698.	0.8	11
2956	Systems analysis of key genes and pathways in the progression of hepatocellular carcinoma. Medicine (United States), 2018, 97, e10892.	0.4	5
2957	MicroRNAâ€'424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncology Letters, 2018, 15, 9126-9132.	0.8	9
2958	Antitumor mechanisms of bifidobacteria (Review). Oncology Letters, 2018, 16, 3-8.	0.8	120
2959	Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell, 2018, 33, 1061-1077.e6.	7.7	151
2960	N-phenylsulfonyl-3,5-bis(arylidene)-4-piperidone derivatives as activation NF-ÎºB inhibitors in hepatic carcinoma cell lines. European Journal of Medicinal Chemistry, 2018, 155, 531-544.	2.6	43
2961	High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis. Cancer Biomarkers, 2018, 22, 611-619.	0.8	9
2962	Knockdown of SUMO1P3 represses tumor growth and invasion and enhances radiosensitivity in hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2019, 450, 125-134.	1.4	22
2963	Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacologica Sinica, 2019, 40, 122-132.	2.8	47
2964	Does persistent anti-HBc positivity influence the prognosis of HBsAg-negative hepatocellular carcinoma? comparative outcomes of anti-Hbc positive versus anti-Hbc negative non-B non-C HCC. Hpb, 2019, 21, 242-248.	0.1	2
2965	Gallstones and cholecystectomy in relation to risk of liver cancer. European Journal of Cancer Prevention, 2019, 28, 61-67.	0.6	10
2966	Clinicopathologic significance of LAIR-1 expression in hepatocellular carcinoma. Current Problems in Cancer, 2019, 43, 18-26.	1.0	24

#	Article	IF	Citations
2967	Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 293-316.	0.4	4
2968	Visual simultaneous detection of single nucleotide polymorphism of tumor susceptibility gene and marker alpha-fetoprotein based on double-labeled colloidal gold probe with lateral ï¬‚ow strip biosensor. Sensors and Actuators B: Chemical, 2019, 298, 126819.	4.0	22
2969	Induction of ROS and DNA damage-dependent senescence by icaritin contributes to its antitumor activity in hepatocellular carcinoma cells. Pharmaceutical Biology, 2019, 57, 424-431.	1.3	23
2970	Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes, 2019, 10, 630.	1.0	38
2971	A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 589-604.	8.2	2,482
2972	Unsuspected primary malignancy in the setting of elevated serum alpha-fetoprotein. Baylor University Medical Center Proceedings, 2019, 32, 268-270.	0.2	1
2974	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Childâ€“Pugh A Liver Function: A Proof-Of-Concept Study. Cancers, 2019, 11, 1084.	1.7	200
2976	Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma. Journal of Translational Medicine, 2019, 17, 273.	1.8	23
2977	Tropomodulin 3 modulates EGFRâ€PI3Kâ€AKT signaling to drive hepatocellular carcinoma metastasis. Molecular Carcinogenesis, 2019, 58, 1897-1907.	1.3	27
2978	Viral hijacking of cellular metabolism. BMC Biology, 2019, 17, 59.	1.7	318
2979	Current Research Progress on Long Noncoding RNAs Associated with Hepatocellular Carcinoma. Analytical Cellular Pathology, 2019, 2019, 1-8.	0.7	13
2980	High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. Journal of Cancer, 2019, 10, 3494-3500.	1.2	12
2981	LncRNA SNHG15 promotes hepatocellular carcinoma progression by sponging miRâ€141â€3p. Journal of Cellular Biochemistry, 2019, 120, 19775-19783.	1.2	29
2982	Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 307-318.	0.4	53
2983	Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers, 2019, 11, 952.	1.7	114
2984	Association of lncRNA H19 Gene Polymorphisms with the Occurrence of Hepatocellular Carcinoma. Genes, 2019, 10, 506.	1.0	27
2985	Accumulation of Tumor-Infiltrating CD49a+ NK Cells Correlates with Poor Prognosis for Human Hepatocellular Carcinoma. Cancer Immunology Research, 2019, 7, 1535-1546.	1.6	66
2986	SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis. Journal of Cancer, 2019, 10, 3871-3882.	1.2	37

#	Article	IF	Citations
2987	Sleeping Beauty Mouse Models of Cancer: Microenvironmental Influences on Cancer Genetics. Frontiers in Oncology, 2019, 9, 611.	1.3	5
2988	The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 3067-3071.	1.9	13
2989	A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform. Translational Oncology, 2019, 12, 1345-1356.	1.7	5
2990	microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA . Cancer Management and Research, 2019, Volume 11, 5821-5834.	0.9	10
2991	Meeting report: 32nd International Conference on Antiviral Research. Antiviral Research, 2019, 169, 104550.	1.9	6
2992	High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway. Life Sciences, 2019, 232, 116602.	2.0	21
2993	MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells. Physiological Genomics, 2019, 51, 500-505.	1.0	20
2994	Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages. Pharmacology Research and Perspectives, 2019, 7, e00486.	1.1	13
2995	The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for Overall Survival of Hepatocellular Carcinoma Patients Treated with palliative Treatments. Journal of Cancer, 2019, 10, 2299-2311.	1.2	33
2996	A novel â€œAIE + ESIPTâ€•near-infrared nanoprobe for the imaging of Î³-glutamyl transpeptidase in living cells and the application in precision medicine. Analyst, The, 2019, 144, 5136-5142.	1.7	31
2997	2,3â€²4,4â€²,5-Pentachlorobiphenyl induces hepatocellular carcinoma cell proliferation through pyruvate kinase M2-dependent glycolysis. Toxicology Letters, 2019, 313, 108-119.	0.4	22
2998	PCLâ€“DOX microdroplets: an evaluation of the enhanced intracellular delivery of doxorubicin in metastatic cancer cells via in silico and in vitro approaches. New Journal of Chemistry, 2019, 43, 12241-12256.	1.4	4
2999	CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis. Journal of Experimental and Clinical Cancer Research, 2019, 38, 286.	3.5	23
3000	Hepatitis C virus infection in children and adolescents. The Lancet Gastroenterology and Hepatology, 2019, 4, 477-487.	3.7	117
3001	A Novel AURKA Mutant-Induced Early-Onset Severe Hepatocarcinogenesis Greater than Wild-Type via Activating Different Pathways in Zebrafish. Cancers, 2019, 11, 927.	1.7	15
3002	Human amniotic membrane conditioned medium inhibits proliferation and modulates related microRNAs expression in hepatocarcinoma cells. Scientific Reports, 2019, 9, 14193.	1.6	20
3003	Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma. Scientific Reports, 2019, 9, 14738.	1.6	18
3004	Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. Journal of Clinical Medicine, 2019, 8, 1676.	1.0	20

#	Article	IF	Citations
3005	NF-Î²B-Dependent IFIT3 Induction by HBx Promotes Hepatitis B Virus Replication. Frontiers in Microbiology, 2019, 10, 2382.	1.5	15
3006	Enlightening the oceanâ€™s twilight zone. ICES Journal of Marine Science, 2019, 76, 803-812.	1.2	29
3007	Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine. International Journal of Biological Sciences, 2019, 15, 1771-1786.	2.6	34
3008	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers, 2019, 11, 1721.	1.7	8
3010	Survival, tumour response and safety of 70â€“150 Î¼m versus 100â€“300 Î¼m doxorubicin drugâ€eluting beads in transarterial chemoembolisation for hepatocellular carcinoma. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 802-811.	0.9	17
3011	Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. Journal of Experimental and Clinical Cancer Research, 2019, 38, 458.	3.5	49
3012	Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases. Journal of Cancer, 2019, 10, 5007-5014.	1.2	3
3013	Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Advances in Experimental Medicine and Biology, 2019, 1237, 97-119.	0.8	5
3014	Overexpression of lncRNA PIK3CD-AS1 promotes expression of LATS1 by competitive binding with microRNA-566 to inhibit the growth, invasion and metastasis of hepatocellular carcinoma cells. Cancer Cell International, 2019, 19, 150.	1.8	19
3015	Effect of prophylactic TACE on 5â€‘year survival of patients with hepatocellular carcinoma after hepatectomy. Oncology Letters, 2019, 18, 1824-1830.	0.8	8
3016	Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma. Molecules, 2019, 24, 3080.	1.7	16
3018	Long-term survival after anterior approach right hepatectomy combined with inferior vena cava thrombectomy using trans-diaphragmatic intrapericardial inferior vena cava occlusion: a case report and review of the literature. BMC Surgery, 2019, 19, 122.	0.6	4
3019	Anti-cancer effects of ethanol extract of Reynoutria japonica Houtt. radix in human hepatocellular carcinoma cells via inhibition of MAPK and PI3K/Akt signaling pathways. Journal of Ethnopharmacology, 2019, 245, 112179.	2.0	10
3020	The Relevance of Gender in Tumor-Influencing Epigenetic Traits. Epigenomes, 2019, 3, 6.	0.8	3
3021	Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Molecular Medicine Reports, 2019, 20, 3773-3781.	1.1	38
3022	MAT2B mediates invasion and metastasis by regulating EGFR signaling pathway in hepatocellular carcinoma. Clinical and Experimental Medicine, 2019, 19, 535-546.	1.9	10
3023	Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. Journal of Interferon and Cytokine Research, 2019, 39, 780-785.	0.5	7
3024	Compound Analytics using Combinatorics for Feature Selection: A Case Study in Biomarker Detection. , 2019, , .		0

#	Article	IF	Citations
3025	A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo, 2019, 33, 1411-1420.	0.6	45
3026	Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS ONE, 2019, 14, e0221958.	1.1	2
3027	Stimulated phospholipid synthesis is key for hepatitis B virus replications. Scientific Reports, 2019, 9, 12989.	1.6	8
3028	Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. Hepatology International, 2019, 13, 715-725.	1.9	4
3029	MicroRNAâ€‘300 inhibits the growth of hepatocellular carcinoma cells by downregulating CREPT/Wnt/Î²â€‘catenin signaling. Oncology Letters, 2019, 18, 3743-3753.	0.8	14
3030	Dysregulation of the miR-325â€“3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochemical and Biophysical Research Communications, 2019, 519, 358-365.	1.0	17
3032	Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. Journal of Translational Medicine, 2019, 17, 328.	1.8	51
3033	LINC00473 promotes hepatocellular carcinoma progression via acting as a ceRNA for microRNA-195 and increasing HMGA2 expression. Biomedicine and Pharmacotherapy, 2019, 120, 109403.	2.5	22
3034	Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Seminars in Liver Disease, 2019, 39, 026-042.	1.8	257
3035	Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery. Pharmaceutics, 2019, 11, 50.	2.0	59
3036	Distinct role of 4E-BP1 and S6K1 in regulating autophagy and hepatitis B virus (HBV) replication. Life Sciences, 2019, 220, 1-7.	2.0	13
3037	In vivo induction of hepatocellular carcinoma by diethylnitrosoamine and pharmacological intervention in Balb C mice using Bergenia ciliata extracts. Brazilian Journal of Biology, 2019, 79, 629-638.	0.4	43
3038	MicroRNAâ€‘3653 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting ITGB1. Oncology Reports, 2019, 41, 1669-1677.	1.2	14
3039	Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates hostâ€“virus interactions. Nucleic Acids Research, 2019, 47, 2455-2471.	6.5	7
3040	How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1213-1224.	1.8	79
3041	Synthesis of new derivatives of boehmeriasin A and their biological evaluation in liver cancer. European Journal of Medicinal Chemistry, 2019, 166, 243-255.	2.6	7
3042	Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma. Bioscience Reports, 2019, 39, .	1.1	6
3043	Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virusâ€“Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation. Transplantation Proceedings, 2019, 51, 1157-1161.	0.3	15

#	Article	IF	Citations
3044	Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis. International Journal of Molecular Sciences, 2019, 20, 2507.	1.8	45
3045	Prognostic value of preoperative computed tomography in HBV-related hepatocellular carcinoma patients after curative resection . OncoTargets and Therapy, 2019, Volume 12, 3791-3804.	1.0	4
3046	MiR-221 Promotes Hepatocellular Carcinoma Cells Migration via Targeting PHF2. BioMed Research International, 2019, 2019, 1-11.	0.9	31
3047	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. Journal of Translational Medicine, 2019, 17, 203.	1.8	18
3048	Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genetics, 2019, 15, e1008181.	1.5	109
3049	Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers, 2019, 11, 841.	1.7	68
3050	A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 2246-2255.	1.9	14
3051	There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 347-363.	2.3	35
3052	The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. Translational Oncology, 2019, 12, 1092-1107.	1.7	31
3053	Metadherin: A Therapeutic Target in Multiple Cancers. Frontiers in Oncology, 2019, 9, 349.	1.3	55
3054	Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3â€“Targeted Chimeric Antigen Receptorâ€“Engineered T Cells in Hepatocellular Carcinoma. Journal of Immunology, 2019, 203, 198-207.	0.4	95
3055	Characterization of Lipid and Lipid Droplet Metabolism in Human HCC. Cells, 2019, 8, 512.	1.8	60
3056	Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. Journal of Hematology and Oncology, 2019, 12, 53.	6.9	163
3057	The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. Journal of Oncology, 2019, 2019, 1-13.	0.6	21
3058	Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Review of Proteomics, 2019, 16, 553-568.	1.3	5
3059	The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology, 2019, 54, 746-752.	0.6	5
3060	Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon. Journal of Viral Hepatitis, 2019, 26, 1086-1093.	1.0	10
3061	An Optimized HCC Recurrence Prediction Using APO Algorithm Multiple Time Series Clinical Liver Cancer Dataset. Journal of Medical Systems, 2019, 43, 193.	2.2	7

#	Article	IF	Citations
3062	MTA2 promotes HCC progression through repressing FRMD6, a key upstream component of hippo signaling pathway. Biochemical and Biophysical Research Communications, 2019, 515, 112-118.	1.0	14
3063	SERPINA3 is a key modulator of HNRNP-K transcriptional activity against oxidative stress in HCC. Redox Biology, 2019, 24, 101217.	3.9	31
3064	Differences in the prognostic value of tumor size on hepatocellular cancerâ€specific survival stratified by gender in a SEER populationâ€based study. United European Gastroenterology Journal, 2019, 7, 933-941.	1.6	13
3065	Avicularin ameliorates human hepatocellular carcinoma via the regulation of NFâ€ΊB/COXâ€2/PPARâ€Î³ activities. Molecular Medicine Reports, 2019, 19, 5417-5423.	1.1	18
3066	PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 204.	3.5	66
3067	Inhibition of CTRP6 prevented survival and migration in hepatocellular carcinoma through inactivating the AKT signaling pathway. Journal of Cellular Biochemistry, 2019, 120, 17059-17066.	1.2	15
3068	Human Liver Regeneration: An Etiology Dependent Process. International Journal of Molecular Sciences, 2019, 20, 2332.	1.8	31
3069	FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma. Molecular Therapy - Nucleic Acids, 2019, 16, 576-588.	2.3	41
3070	miR-494 induces EndMT and promotes the development of HCC (Hepatocellular Carcinoma) by targeting SIRT3/TGF-Î²/SMAD signaling pathway. Scientific Reports, 2019, 9, 7213.	1.6	29
3071	LncRNA CRNDE promotes hepatocellular carcinoma progression by upregulating SIX1 through modulating miRâ€337â€3p. Journal of Cellular Biochemistry, 2019, 120, 16128-16142.	1.2	24
3072	Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 534-542.	1.8	36
3073	Hesperidinâ€CAMKIV interaction and its impact on cell proliferation and apoptosis in the human hepatic carcinoma and neuroblastoma cells. Journal of Cellular Biochemistry, 2019, 120, 15119-15130.	1.2	33
3074	Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI. European Radiology, 2019, 29, 3338-3347.	2.3	204
3075	Change in Perfusion Angiography During Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Predicts Short-Term Outcomes. American Journal of Roentgenology, 2019, 213, 746-754.	1.0	5
3076	A Prospective Study of Nut Consumption and Risk of Primary Hepatocellular Carcinoma in the U.S. Women and Men. Cancer Prevention Research, 2019, 12, 367-374.	0.7	16
3078	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 385.	1.0	21
3079	Significant effects of late evening snack on liver functions in patients with liver cirrhosis: A metaâ€analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1143-1152.	1.4	44
3080	ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells. Cells, 2019, 8, 210.	1.8	10

#	Article	IF	Citations
3081	Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer. Digestive Diseases and Sciences, 2019, 64, 976-984.	1.1	2
3082	Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea . Cancer Management and Research, 2019, Volume 11, 1373-1382.	0.9	8
3083	Inhibition of NETâ€'1 suppresses proliferation and promotes apoptosis of hepatocellular carcinoma cells by activating the PI3K/AKT signaling pathway. Experimental and Therapeutic Medicine, 2019, 17, 2334-2340.	0.8	8
3084	Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma. Advanced Healthcare Materials, 2019, 8, e1801318.	3.9	24
3085	The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progress and is negatively regulated by miR-101. Experimental Cell Research, 2019, 379, 1-10.	1.2	24
3086	LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Bioscience Reports, 2019, 39, .	1.1	17
3087	Association of metabolic syndrome with the risk of developing liver disease in chronic hepatitis B patients. African Journal of Biochemistry Research, 2019, 13, 23-29.	0.2	0
3088	LncRNA MAGI2â€AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miRâ€374bâ€5p/SMG1 signaling pathway. Journal of Cellular Physiology, 2019, 234, 18825-18836.	2.0	58
3089	Overexpression of CLN3 contributes to tumour progression and predicts poor prognosis in hepatocellular carcinoma. Surgical Oncology, 2019, 28, 180-189.	0.8	6
3090	The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 957-967.	1.2	31
3091	Hepatocellular carcinoma in a rapidly growing community: Epidemiology, clinico-pathology and predictors of extrahepatic metastasis. Arab Journal of Gastroenterology, 2019, 20, 38-43.	0.4	11
3092	Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA. European Journal of Gastroenterology and Hepatology, 2019, 31, 24-28.	0.8	8
3093	Oncoprotein LAMTOR5 activates GLUT1 via upregulating NF-Î°B in liver cancer. Open Medicine (Poland), 2019, 14, 264-270.	0.6	13
3094	Inflammatory cytokineâ€'induced expression of MASTL is involved in hepatocarcinogenesis by regulating cell cycle progression. Oncology Letters, 2019, 17, 3163-3172.	0.8	6
3095	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. Carcinogenesis, 2019, 40, 1077-1085.	1.3	34
3096	SNP rs2596542G>A in MICA is associated with risk of hepatocellular carcinoma: a meta-analysis. Bioscience Reports, 2019, 39, .	1.1	12
3097	Effects of sex hormones on liver tumor progression and regression in Myc/xmrk double oncogene transgenic zebrafish. General and Comparative Endocrinology, 2019, 277, 112-121.	0.8	14
3098	Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms. Seminars in Liver Disease, 2019, 39, 141-152.	1.8	16

#	Article	IF	Citations
3099	Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. BMC Cancer, 2019, 19, 276.	1.1	11
3100	Detection of Solid Tumor Molecular Residual DiseaseÂ(MRD) Using Circulating Tumor DNA (ctDNA). Molecular Diagnosis and Therapy, 2019, 23, 311-331.	1.6	123
3101	Different anti-inflammatory effects of Lactobacillus acidophilus and Bifidobactrum bifidioum in hepatocellular carcinoma cancer mouse through impact on microRNAs and their target genes. Journal of Nutrition & Intermediary Metabolism, 2019, 16, 100096.	1.7	20
3102	Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types. Acta Biochimica Et Biophysica Sinica, 2019, 51, 285-292.	0.9	29
3103	Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of Î²â€¢catenin/TCF/LEF signalling. Cell Proliferation, 2019, 52, e12583.	2.4	18
3104	Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. Journal of the Formosan Medical Association, 2019, 118, 1239-1246.	0.8	4
3105	Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites, 2019, 9, 36.	1.3	90
3106	Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 2354-2361.	0.9	36
3107	Aberrantly DNA Methylated-Differentially Expressed Genes and Pathways in Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 355-366.	1.2	50
3108	COMMD7 Regulates NF-ÎºB Signaling Pathway in Hepatocellular Carcinoma Stem-like Cells. Molecular Therapy - Oncolytics, 2019, 12, 112-123.	2.0	26
3109	Elevated Expressions of Survivin and Endoglin in Patients with Hepatic Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 7-12.	0.7	5
3110	Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-ÎºB pathway activation. European Journal of Medicinal Chemistry, 2019, 167, 187-199.	2.6	45
3111	SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production. Journal of Experimental and Clinical Cancer Research, 2019, 38, 70.	3.5	44
3112	GAS5 Regulates RECK Expression and Inhibits Invasion Potential of HCC Cells by Sponging miR-135b. BioMed Research International, 2019, 2019, 1-11.	0.9	24
3113	Bioactive glycoalkaloides isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells. Scientific Reports, 2019, 9, 1746.	1.6	58
3114	Glycine decarboxylase induces autophagy and is downregulated by miRNA-30d-5p in hepatocellular carcinoma. Cell Death and Disease, 2019, 10, 192.	2.7	33
3115	Targeted and Multifunctional Technology for Identification between Hepatocellular Carcinoma and Liver Cirrhosis. ACS Applied Materials & Interfaces, 2019, 11, 14526-14537.	4.0	20
3116	MicroRNA-1277 Inhibits Proliferation and Migration of Hepatocellular Carcinoma HepG2 Cells by Targeting and Suppressing BMP4 Expression and Reflects the Significant Indicative Role in Hepatocellular Carcinoma Pathology and Diagnosis After Magnetic Resonance Imaging Assessment. Oncology Research, 2019, 27, 301-309.	0.6	9

#	Article	IF	Citations
3117	Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation. Cellular Oncology (Dordrecht), 2019, 42, 369-380.	2.1	12
3118	Environmental Risk Factors for Liver Cancer and Nonalcoholic Fatty Liver Disease. Current Epidemiology Reports, 2019, 6, 50-66.	1.1	48
3120	The role and mechanisms of action of microRNAs in cancer drug resistance. Clinical Epigenetics, 2019, 11, 25.	1.8	468
3121	Image-guided doxorubicin delivery with ultrasound and microbubbles in a mouse model of hepatocellular carcinoma using a diagnostic ultrasound system. , 2019, , .		0
3122	GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer. Analytical Cellular Pathology, 2019, 2019, 1-13.	0.7	19
3123	Hepatocellular carcinoma â€“ clinicopathological characteristics, survival, and expression of various histologic molecular markers. Polish Journal of Pathology, 2019, 70, 269-276.	0.1	2
3124	Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study. BMJ Open, 2019, 9, e028571.	0.8	14
3125	7. Maligne Erkrankungen Des Gastrointestinaltrakts. , 2019, , 145-192.		0
3126	A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol. Future Oncology, 2019, 15, 3547-3554.	1.1	11
3127	Liver stiffness measurement changes following hepatocellular carcinoma treatment with percutaneous microwave ablation or transarterial chemoembolization: a cohort study. European Journal of Gastroenterology and Hepatology, 2019, 31, 685-691.	0.8	5
3128	Poor expression of long-chain noncoding RNA GAPLINC inhibits epithelialâ€“mesenchymal transition, and invasion and migration of hepatocellular carcinoma cells. Anti-Cancer Drugs, 2019, 30, 784-794.	0.7	4
3129	The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis. Cells, 2019, 8, 1504.	1.8	63
3130	The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2019, 18, 371-382.	0.4	0
3131	Liver Transplant for Patients with HepatoÂcellular Carcinoma and Child-Pugh C Liver Function Should Be Mentioned in Guidelines. Liver Cancer, 2019, 8, 522-523.	4.2	1
3132	Omics-based Investigation of Diet-induced Obesity Synergized with HBx, Src, and p53 Mutation Accelerating Hepatocarcinogenesis in Zebrafish Model. Cancers, 2019, 11, 1899.	1.7	18
3133	The signaling axis of Rac1-TFEB regulates autophagy and tumorigenesis. Anti-Cancer Drugs, 2019, 30, 1031-1037.	0.7	10
3134	Prediction of Association Between lncRNAs and Diseases Based on Experimental Evidence. , 2019, , .		0
3135	NAFLD in Women: Unique Pathways, Biomarkers, and Therapeutic Opportunities. Current Hepatology Reports, 2019, 18, 425-432.	0.4	8

#	Article	IF	Citations
3136	Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma. Medicine (United States), 2019, 98, e17680.	0.4	8
3137	Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. Medicine (United States), 2019, 98, e18020.	0.4	3
3138	Type 2 Diabetes Prevention Diet and Hepatocellular Carcinoma Risk in US Men and Women. American Journal of Gastroenterology, 2019, 114, 1870-1877.	0.2	35
3139	Socioeconomic And Survival Differences Among Minorities With Hepatocellular Carcinoma In Florida . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 167-181.	1.8	19
3140	Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis. Journal of Clinical Gastroenterology, 2019, 53, 236-241.	1.1	6
3141	Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study. Oncologist, 2019, 24, e730-e739.	1.9	8
3142	Upregulation of musashi1 increases malignancy of hepatocellular carcinoma via the Wnt/Î²-catenin signaling pathway and predicts a poor prognosis. BMC Gastroenterology, 2019, 19, 230.	0.8	8
3143	Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. Journal of Cellular Biochemistry, 2019, 120, 135-142.	1.2	72
3144	Long non-coding RNA LINC00472 suppresses hepatocellular carcinoma cell proliferation, migration and invasion through miR-93-5p/PDCD4 pathway. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 436-445.	0.7	32
3145	Genetic polymorphisms in complement receptor 1 gene and its association with HBV-related liver disease: A case-control study. Gene, 2019, 688, 107-118.	1.0	7
3146	Utilizing Contrast-Enhanced Ultrasound Imaging for Evaluating Fatty Liver Disease Progression in Pre-clinical Mouse Models. Ultrasound in Medicine and Biology, 2019, 45, 549-557.	0.7	14
3147	AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop. Biochemical and Biophysical Research Communications, 2019, 509, 535-540.	1.0	8
3148	Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Clinica Chimica Acta, 2019, 488, 68-75.	0.5	34
3149	Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine, 2019, 124, 154569.	1.4	47
3150	Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2019, 28, 7-18.	1.9	18
3151	Mortality from liver angiosarcoma, hepatocellular carcinoma, and cirrhosis among vinyl chloride workers. American Journal of Industrial Medicine, 2019, 62, 14-20.	1.0	17
3152	Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma. JAMA Surgery, 2019, 154, 209.	2.2	319
3153	Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage Bâ€“C hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2019, 195, 254-264.	1.0	18

#	Article	IF	Citations
3154	Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and Î²-catenin pathways. Carcinogenesis, 2019, 40, 461-473.	1.3	25
3155	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. Archives of Biochemistry and Biophysics, 2019, 661, 97-106.	1.4	5
3157	The Role of microRNAs in the Gut-Liver Axis. , 2019, , 207-234.		0
3158	Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sciences, 2019, 216, 200-206.	2.0	12
3159	Glutathione-sensitive PEGylated curcumin prodrug nanomicelles: Preparation, characterization, cellular uptake and bioavailability evaluation. International Journal of Pharmaceutics, 2019, 555, 270-279.	2.6	53
3160	Mechanisms involved in the activation of C/EBPÎ± by small activating RNA in hepatocellular carcinoma. Oncogene, 2019, 38, 3446-3457.	2.6	24
3161	Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. Archives of Pharmacal Research, 2019, 42, 48-62.	2.7	50
3162	IL-22 in hepatocyteâ€™s survival of Pakistani patients with end stage liver disease: an insight into IL 22 mediated hepato-regenerative pathway. Molecular Biology Reports, 2019, 46, 1127-1138.	1.0	2
3163	Ultrasound guidance in minimally invasive robotic procedures. Medical Image Analysis, 2019, 54, 149-167.	7.0	38
3164	Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation. Toxicology and Applied Pharmacology, 2019, 365, 51-60.	1.3	14
3165	The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis. Nature Communications, 2019, 10, 83.	5.8	38
3166	Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2019, 13, 179-187.	1.4	51
3167	Profilin 1, negatively regulated by microRNA-19a-3p, serves as a tumor suppressor in human hepatocellular carcinoma. Pathology Research and Practice, 2019, 215, 499-505.	1.0	19
3168	Sex difference in recurrence and survival after liver resection for hepatocellular carcinoma: A multicenter study. Surgery, 2019, 165, 516-524.	1.0	28
3169	Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. American Journal of Gastroenterology, 2019, 114, 80-88.	0.2	28
3170	The master regulator FUBP1: its emerging role in normal cell function and malignant development. Cellular and Molecular Life Sciences, 2019, 76, 259-281.	2.4	46
3171	Synthesis of new thiazolo-pyrrolidineâ€“(spirooxindole) tethered to 3-acylindole as anticancer agents. Bioorganic Chemistry, 2019, 82, 423-430.	2.0	66
3172	Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. European Radiology, 2019, 29, 3287-3295.	2.3	42

#	Article	IF	Citations
3173	Role of HSD17B13 in the liver physiology and pathophysiology. Molecular and Cellular Endocrinology, 2019, 489, 119-125.	1.6	41
3174	The effect of high intensity focused ultrasound on the treatment of liver cancer and patientsâ€™ immunity. Cancer Biomarkers, 2019, 24, 85-90.	0.8	14
3175	Identification of Protein Abundance Changes in Hepatocellular Carcinoma Tissues Using PCTâ€“SWATH. Proteomics - Clinical Applications, 2019, 13, e1700179.	0.8	32
3176	Clinical Epidemiology of Chronic Liver Diseases. , 2019, , .		2
3177	Clinical Epidemiology of Chronic Liver Disease: Hepatocellular Carcinoma. , 2019, , 229-249.		2
3178	Delivery of Superparamagnetic Polymeric Micelles Loaded With Quercetin to Hepatocellular Carcinoma Cells. Journal of Pharmaceutical Sciences, 2019, 108, 996-1006.	1.6	29
3179	STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. Cytokine, 2019, 124, 154573.	1.4	14
3180	Diet-induced hepatic steatosis activates Ras to promote hepatocarcinogenesis via CPT1Î±. Cancer Letters, 2019, 442, 40-52.	3.2	13
3181	Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades. Digestive Diseases and Sciences, 2019, 64, 585-590.	1.1	17
3182	Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy. Human Pathology, 2019, 86, 193-202.	1.1	9
3183	AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Experimental Animals, 2019, 68, 147-158.	0.7	8
3184	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011â€“2015 update. Journal of Gastroenterology, 2019, 54, 367-376.	2.3	156
3185	RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. Experimental Cell Research, 2019, 374, 152-161.	1.2	22
3186	Tumor markers: myths and facts unfolded. Abdominal Radiology, 2019, 44, 1575-1600.	1.0	28
3187	Vitamin D and Gastrointestinal Cancers: A Narrative Review. Digestive Diseases and Sciences, 2019, 64, 1098-1109.	1.1	21
3188	Survival outcomes of liver transplantation versus liver resection among patients with hepatocellular carcinoma: A SEER-based longitudinal study. Journal of the Formosan Medical Association, 2019, 118, 790-796.	0.8	14
3189	Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway. Oncogene, 2019, 38, 1239-1255.	2.6	108
3190	Fibrosisâ€matched outcomes between chronic hepatitis B patients with drugâ€induced virological response and inactive carriers. Liver International, 2019, 39, 81-89.	1.9	4

#	Article	IF	Citations
3191	Chemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves. Arabian Journal of Chemistry, 2019, 12, 3652-3666.	2.3	20
3192	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. Genes and Immunity, 2019, 20, 1-9.	2.2	13
3193	Type III interferon-induced CBFÎ² inhibits HBV replication by hijacking HBx. Cellular and Molecular Immunology, 2019, 16, 357-366.	4.8	33
3194	Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis. Journal of Investigative Surgery, 2019, 32, 632-641.	0.6	19
3195	Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Typeâ€A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology, 2019, 69, 573-586.	3.6	12
3196	Liver function and dysfunction â€“ a unique window into the physiological reach of <scp>ER</scp> stress and the unfolded protein response. FEBS Journal, 2019, 286, 356-378.	2.2	43
3197	Overexpression of miRâ€623 suppresses progression of hepatocellular carcinoma via regulating the PI3K/Akt signaling pathway by targeting XRCC5. Journal of Cellular Biochemistry, 2020, 121, 213-223.	1.2	11
3198	Cerium Oxide Nanoparticles Attenuate Oxidative Stress and Inflammation in the Liver of Diethylnitrosamine-Treated Mice. Biological Trace Element Research, 2020, 193, 214-225.	1.9	49
3199	Schistosoma mansoni Eggâ€“Secreted Antigens Activate Hepatocellular Carcinomaâ€“Associated Transcription Factors câ€Jun and STAT3 in Hamster and Human Hepatocytes. Hepatology, 2020, 72, 626-641.	3.6	39
3200	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.	1.3	6
3201	LINC00346 promotes hepatocellular carcinoma progression via activating the JAKâ€STAT3 signaling pathway. Journal of Cellular Biochemistry, 2020, 121, 735-742.	1.2	18
3202	Waist Circumference and Risk of Liver Cancer: A Systematic Review and Meta-Analysis of over 2 Million Cohort Study Participants. Liver Cancer, 2020, 9, 6-14.	4.2	21
3203	Free radicals, antioxidants, nuclear factorâ€E2â€related factorâ€2 and liver damage. Journal of Applied Toxicology, 2020, 40, 151-168.	1.4	59
3204	Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minimally Invasive Therapy and Allied Technologies, 2020, 29, 344-352.	0.6	5
3205	Epidemiological and etiological variations in hepatocellular carcinoma. Infection, 2020, 48, 7-17.	2.3	133
3206	Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 807-815.	3.3	12
3207	Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. European Radiology, 2020, 30, 558-570.	2.3	118
3208	REFLECTâ€”a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. Journal of Gastroenterology, 2020, 55, 113-122.	2.3	123

#	Article	IF	Citations
3209	HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal of the National Cancer Institute, 2020, 112, 747-755.	3.0	15
3210	ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling. Oncogene, 2020, 39, 1665-1680.	2.6	10
3211	Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naÃ¯ve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut, 2020, 69, 1301-1308.	6.1	101
3212	Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression. International Journal of Cancer, 2020, 146, 3410-3422.	2.3	18
3213	LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma. Journal of Gene Medicine, 2020, 22, e3134.	1.4	30
3214	Hepatocellular carcinoma in non-alcohol fatty liver disease â€“ changing trends and specific challenges. Current Medical Research and Opinion, 2020, 36, 235-243.	0.9	18
3215	Comparison of the prognostic value of inflammationâ€based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver International, 2020, 40, 229-239.	1.9	48
3216	Knockdown of CTCF reduces the binding of EZH2 and affects the methylation of the SOCS3 promoter in hepatocellular carcinoma. International Journal of Biochemistry and Cell Biology, 2020, 120, 105685.	1.2	8
3217	Identifying critical states of hepatocellular carcinoma based on landscape dynamic network biomarkers. Computational Biology and Chemistry, 2020, 85, 107202.	1.1	9
3218	Pharmacological Activities of Novel Chromene Derivatives as Calcium/Calmodulin Dependent Protein Kinase IV (CAMKIV) Inhibitors. ChemistrySelect, 2020, 5, 498-505.	0.7	4
3219	The significance of exosomes in the development and treatment of hepatocellular carcinoma. Molecular Cancer, 2020, 19, 1.	7.9	387
3220	Cell-free DNA in hepatocellular carcinoma. , 2020, , 199-209.		1
3221	Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma. Medicine (United States), 2020, 99, e18571.	0.4	45
3222	Extracellular ATP and Purinergic P2Y2 Receptor Signaling Promote Liver Tumorigenesis in Mice by Exacerbating DNA Damage. Cancer Research, 2020, 80, 699-708.	0.4	29
3223	Astaxanthin Encapsulated in Biodegradable Calcium Alginate Microspheres for the Treatment of Hepatocellular Carcinoma In Vitro. Applied Biochemistry and Biotechnology, 2020, 191, 511-527.	1.4	13
3224	Association of TNFRSF12A Methylation With Prognosis in Hepatocellular Carcinoma With History of Alcohol Consumption. Frontiers in Genetics, 2019, 10, 1299.	1.1	11
3225	Candidate lncRNAâ€“miRNAâ€“mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 87-96.	1.2	33
3226	A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI. European Journal of Gastroenterology and Hepatology, 2020, 32, 74-79.	0.8	2

#	Article	IF	Citations
3227	Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma. Nanomedicine, 2020, 15, 145-161.	1.7	21
3228	Role of SNHG16 in human cancer. Clinica Chimica Acta, 2020, 503, 175-180.	0.5	32
3229	Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma. Frontiers in Medicine, 2020, 7, 556.	1.2	12
3230	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers, 2020, 12, 2859.	1.7	92
3231	Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases. Cancers, 2020, 12, 2932.	1.7	12
3232	BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Medicine, 2020, 9, 8159-8172.	1.3	39
3233	A Diamine-PEGylated Oleanolic Acid Derivative Induced Efficient Apoptosis through a Death Receptor and Mitochondrial Apoptotic Pathway in HepG2 Human Hepatoma Cells. Biomolecules, 2020, 10, 1375.	1.8	18
3234	Long noncoding RNA PICSAR/miRâ€588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway. Cancer Science, 2020, 111, 4118-4128.	1.7	26
3235	Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. Current Medical Research and Opinion, 2020, 36, 1813-1823.	0.9	0
3236	The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 535-547.	1.0	41
3237	Mycotoxins in Ethiopia: A Review on Prevalence, Economic and Health Impacts. Toxins, 2020, 12, 648.	1.5	33
3238	Towards precision public health: Geospatial analytics and sensitivity/specificity assessments to inform liver cancer prevention. SSM - Population Health, 2020, 12, 100640.	1.3	12
3239	Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma. Theranostics, 2020, 10, 10957-10972.	4.6	31
3240	Hepatocellular Carcinoma Within the Milan Criteria: A Novel Inflammation-Based Nomogram System to Assess the Outcomes of Ablation. Frontiers in Oncology, 2020, 10, 1764.	1.3	9
3241	Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma. Disease Markers, 2020, 2020, 1-7.	0.6	8
3242	L-lysine-structure-directed MIL-88A and its application in electrochemical sensing of cholylglycine via molecular imprinting technique. Microchemical Journal, 2020, 158, 105249.	2.3	7
3243	Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro. BioMed Research International, 2020, 2020, 1-12.	0.9	12
3244	Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-Î²B Signaling Pathway. BioMed Research International, 2020, 2020, 1-9.	0.9	8

#	Article	IF	Citations
3245	Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. Journal of Viral Hepatitis, 2020, 27, 671-679.	1.0	41
3246	Major Hepatectomy in Elderly Patients with Large Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study . Cancer Management and Research, 2020, Volume 12, 5607-5618.	0.9	10
3247	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers, 2020, 12, 1867.	1.7	56
3248	Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators. European Journal of Medicinal Chemistry, 2020, 204, 112608.	2.6	16
3249	Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 1840.	1.7	4
3250	hsa_circ_0006916 promotes hepatocellular carcinoma progression by activating the miR-337-3p/STAT3 axis. Cellular and Molecular Biology Letters, 2020, 25, 47.	2.7	14
3251	Prognostic significance of controlling nutritional status score- based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. Journal of Gastrointestinal Oncology, 2020, 11, 1024-1039.	0.6	10
3252	Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models. Frontiers in Oncology, 2020, 10, 572861.	1.3	3
3253	Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Frontiers in Cellular and Infection Microbiology, 2020, 10, 587628.	1.8	19
3254	Oral microbial community analysis of the patients in the progression of liver cancer. Microbial Pathogenesis, 2020, 149, 104479.	1.3	28
3255	Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer, 2020, 20, 1136.	1.1	16
3256	CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2020, 39, 259.	3.5	54
3257	Glycogen Phosphorylase B Is Regulated by miR101-3p and Promotes Hepatocellular Carcinoma Tumorigenesis. Frontiers in Cell and Developmental Biology, 2020, 8, 566494.	1.8	16
3258	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis Bâ€related hepatocellular carcinoma. Molecular Carcinogenesis, 2020, 59, 1269-1279.	1.3	10
3259	Hepatic SIRT6 deficit promotes liver tumorigenesis in the mice models. Genes and Diseases, 2022, 9, 789-796.	1.5	3
3260	The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 8894.	1.8	30
3261	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. Journal of Clinical Medicine, 2020, 9, 3817.	1.0	27
3262	Conjoint analysis for hepatic carcinoma with hub genes and multi-slice spiral CT. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	4

#	Article	IF	Citations
3263	Molecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma. Cells, 2020, 9, 2540.	1.8	19
3264	Pro-Resolving Lipid Mediator Resolvin E1 Mitigates the Progress of Diethylnitrosamine-Induced Liver Fibrosis in Sprague-Dawley Rats by Attenuating Fibrogenesis and Restricting Proliferation. International Journal of Molecular Sciences, 2020, 21, 8827.	1.8	8
3265	Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinomaâ€"A Review. International Journal of Molecular Sciences, 2020, 21, 8362.	1.8	80
3266	Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma. Cancers, 2020, 12, 3318.	1.7	3
3267	A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging, 2020, 20, 82.	1.2	33
3268	Screening and Identification of Potential Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis. Frontiers in Genetics, 2020, 11, 555537.	1.1	11
3269	RhoA and Rac1 in Liver Cancer Cells: Induction of Overexpression Using Mechanical Stimulation. Micromachines, 2020, 11, 729.	1.4	16
3270	The roles of exosomal circularRNAsin cancer. IUBMB Life, 2020, 72, 1909-1919.	1.5	2
3271	The impact of sex on hepatotoxic, inflammatory and proliferative responses in mouse models of liver carcinogenesis. Toxicology, 2020, 442, 152546.	2.0	7
3272	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2020, 54, 675-681.	1.1	10
3273	Biocompatibility, Cytotoxicity, Antimicrobial and Epigenetic Effects of Novel Chitosan-Based Quercetin Nanohydrogel in Human Cancer Cells . International Journal of Nanomedicine, 2020, Volume 15, 5963-5975.	3.3	27
3274	The clinical application of mesenchymal stem cells in liver disease: the current situation and potential future. Annals of Translational Medicine, 2020, 8, 565-565.	0.7	30
3275	Enhanced CT Textures Derived From Computer Mathematic Distribution Analysis Enables Arterial Enhancement Fraction Being an Imaging Biomarker Option of Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1337.	1.3	2
3276	Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. Npj Precision Oncology, 2020, 4, 17.	2.3	15
3277	LncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases. Liver International, 2020, 40, 2612-2626.	1.9	46
3278	HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt. FASEB Journal, 2020, 34, 12255-12268.	0.2	16
3279	ABO blood group genotypes and risk of hepatocellular carcinoma in a cohort of Egyptian patients. Gene Reports, 2020, 21, 100760.	0.4	0
3280	miR-425-5p Acts as a Molecular Marker and Promoted Proliferation, Migration by Targeting RNF11 in Hepatocellular Carcinoma. BioMed Research International, 2020, 2020, 1-11.	0.9	12

#	Article	IF	Citations
3281	Enhanced In Vitro Magnetic Cell Targeting of Doxorubicin-Loaded Magnetic Liposomes for Localized Cancer Therapy. Nanomaterials, 2020, 10, 2104.	1.9	11
3282	Image-Guided Treatment of Primary Liver Cancer in Mice Leads to Vascular Disruption and Increased Drug Penetration. Frontiers in Pharmacology, 2020, 11, 584344.	1.6	11
3283	Competing Endogenous RNA (ceRNA) Network Analysis of Autophagy-Related Genes in Hepatocellular Carcinoma . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 445-462.	0.4	5
3284	The prognostic value of aspartate aminotransferaseâ€toâ€lymphocyte ratio index in earlyâ€stage hepatocellular carcinoma after hepatectomy: A propensityâ€score matched analysis. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e238-e248.	0.7	3
3285	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PDâ˜1/PD-L1 Checkpoint Blockade. Cancers, 2020, 12, 3048.	1.7	37
3286	Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma. In Vivo, 2020, 34, 2631-2640.	0.6	8
3287	iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine. International Journal of Molecular Sciences, 2020, 21, 6215.	1.8	49
3288	A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients. Archives of Medical Science, 2020, 16, 1104-1110.	0.4	8
3289	Contrast-Enhanced Ultrasonography for Screening and Diagnosis of Hepatocellular Carcinoma: A Case Series and Review of the Literature. Medicines (Basel, Switzerland), 2020, 7, 51.	0.7	4
3290	A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients. Journal of Translational Medicine, 2020, 18, 342.	1.8	104
3291	Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma. PLoS ONE, 2020, 15, e0239386.	1.1	11
3292	Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis. Disease Markers, 2020, 2020, 1-8.	0.6	11
3293	PIGU promotes hepatocellular carcinoma progression through activating NF-Î²B pathway and increasing immune escape. Life Sciences, 2020, 260, 118476.	2.0	7
3294	Deterioration in liver function after liverâ€directed therapy for hepatocellular carcinoma measured by cholate clearance. GastroHep, 2020, 2, 232-239.	0.3	1
3295	A Caseâ€“Control Study of ADCY9 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in the Chinese Han Population. Frontiers in Oncology, 2020, 10, 1450.	1.3	3
3296	Transcription Factors in Cancer Development and Therapy. Cancers, 2020, 12, 2296.	1.7	72
3297	LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX. Cancer Biology and Therapy, 2020, 21, 927-936.	1.5	10
3298	Development and validation of a novel pseudogene pair-based prognostic signature for prediction of overall survival in patients with hepatocellular carcinoma. BMC Cancer, 2020, 20, 887.	1.1	6

#	Article	IF	Citations
3299	mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer. International Journal of Molecular Sciences, 2020, 21, 6648.	1.8	19
3300	Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1203-1214.	1.4	16
3301	Lysine Acetylome Study of Human Hepatocellular Carcinoma Tissues for Biomarkers and Therapeutic Targets Discovery. Frontiers in Genetics, 2020, 11, 572663.	1.1	14
3302	Hepatocellular Carcinomaâ€"The Influence of Immunoanatomy and the Role of Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 6757.	1.8	9
3303	ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-Î²B signaling pathway. BMC Cancer, 2020, 20, 853.	1.1	14
3304	The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World Journal of Surgical Oncology, 2020, 18, 243.	0.8	18
3305	Transcriptome-Wide 5-Methylcytosine Functional Profiling of Long Non-Coding RNA in Hepatocellular Carcinoma . Cancer Management and Research, 2020, Volume 12, 6877-6885.	0.9	19
3306	LncRNA SNAI3-AS1 promotes PEG10-mediated proliferation and metastasis via decoying of miR-27a-3p and miR-34a-5p in hepatocellular carcinoma. Cell Death and Disease, 2020, 11, 685.	2.7	31
3307	LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway . Cancer Management and Research, 2020, Volume 12, 6585-6595.	0.9	26
3308	HSP70â€"eIF4G Interaction Promotes Protein Synthesis and Cell Proliferation in Hepatocellular Carcinoma. Cancers, 2020, 12, 2262.	1.7	7
3309	A non-synonymous variant rs12614 of complement factor B associated with risk of chronic hepatitis B in a Korean population. BMC Medical Genetics, 2020, 21, 241.	2.1	0
3310	Prognostic nomogram for hepatocellular carcinoma with fibrosis of varying degrees: a retrospective cohort study. Annals of Translational Medicine, 2020, 8, 1429-1429.	0.7	5
3311	Biochemical and molecular study of long non-coding RNAs (HOTTIP, ZEB-AS1 and MEG-3) in hepatocellular carcinoma. Meta Gene, 2020, 26, 100808.	0.3	1
3312	Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma. Bioscience Reports, 2020, 40, .	1.1	6
3313	Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway. Diagnostic Pathology, 2020, 15, 141.	0.9	18
3314	The Mutational and Transcriptional Landscapes of Hepatocarcinogenesis in a Rat Model. IScience, 2020, 23, 101690.	1.9	12
3315	Multicenter analysis of long-term oncologic outcomes of hepatectomy for elderly patients with hepatocellular carcinoma. Hpb, 2020, 22, 1314-1323.	0.1	8
3316	Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis â€" epidemiology, risk factors, clinical implications and treatment. Clinical and Experimental Hepatology, 2020, 6, 170-175.	0.6	6

#	Article	IF	Citations
3317	Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2020, 21, 8303.	1.8	16
3318	Accuracy of contrast-enhanced ultrasound liver imaging reporting and data system: a systematic review and meta-analysis. Hepatology International, 2020, 14, 1104-1113.	1.9	8
3319	Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma. International Journal of Medical Sciences, 2020, 17, 3190-3199.	1.1	0
3320	Long noncoding RNA metastasisâ€associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNAâ€22/Snail family transcriptional repressor 1 axis. Cancer Science, 2020, 111, 1582-1595.	1.7	22
3321	Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. International Journal of Molecular Sciences, 2020, 21, 3057.	1.8	45
3322	Tumour budding and tumourâ€“stroma ratio in hepatocellular carcinoma. British Journal of Cancer, 2020, 123, 38-45.	2.9	16
3323	Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials, 2020, 10, 870.	1.9	33
3324	Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cancer Biomarkers, 2020, 28, 221-230.	0.8	12
3325	Nine hub genes related to the prognosis of HBV-positive hepatocellular carcinoma identified by protein interaction analysis. Annals of Translational Medicine, 2020, 8, 478-478.	0.7	13
3326	Phosphoglycerate kinase 1 (PGK1) in cancer: A promising target for diagnosis and therapy. Life Sciences, 2020, 256, 117863.	2.0	45
3327	CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics, 2020, 10, 5790-5801.	4.6	41
3328	The role of vesicular overexpressed in cancer pro-survival protein 1 in hepatocellular carcinoma proliferation. Cancer Biomarkers, 2020, 28, 9-20.	0.8	6
3329	Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell International, 2020, 20, 165.	1.8	48
3330	Long non-coding RNAs in hepatocellular carcinoma: Ordering of the complicated lncRNA regulatory network and novel strategies for HCC clinical diagnosis and treatment. Pharmacological Research, 2020, 158, 104848.	3.1	30
3332	MiR-224 Executes a Tumor Accelerative Role during Hepatocellular Carcinoma Malignancy by Targeting Cytoplasmic Polyadenylation Element-Binding Protein 3. Pharmacology, 2020, 105, 477-487.	0.9	8
3333	Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist, 2020, 25, e1541-e1551.	1.9	66
3334	Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics, 2020, 10, 338.	1.3	14
3335	Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines, 2020, 8, 247.	2.1	9

#	Article	IF	Citations
3336	A method to establish a c-Myc transgenic mouse model of hepatocellular carcinoma. MethodsX, 2020, 7, 100921.	0.7	3
3337	Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma. Biochemical Pharmacology, 2020, 178, 114089.	2.0	33
3338	Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. Cancer Genetics, 2020, 245, 27-34.	0.2	8
3339	Detection of Hepatocellular Carcinoma in Contrast-Enhanced Magnetic Resonance Imaging Using Deep Learning Classifier: A Multi-Center Retrospective Study. Scientific Reports, 2020, 10, 9458.	1.6	33
3340	Lipid-based nanoparticle technologies for liver targeting. Advanced Drug Delivery Reviews, 2020, 154-155, 79-101.	6.6	103
3341	Extract of Stellera Chamaejasme L. Inhibits the Progression of Hepatocellular Carcinoma by Regulating miR-134-5p and JAK1/STAT3 Pathway. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 586-595.	0.7	3
3342	Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study. World Journal of Surgical Oncology, 2020, 18, 121.	0.8	10
3343	Preemptive Homology-Directed DNA Repair Fosters Complex Genomic Rearrangements in Hepatocellular Carcinoma. Translational Oncology, 2020, 13, 100796.	1.7	6
3344	Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway. International Journal of Medical Sciences, 2020, 17, 1224-1234.	1.1	13
3345	Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis. Technology in Cancer Research and Treatment, 2020, 19, 153303382093488.	0.8	14
3346	ZKSCAN3 drives tumor metastasis via integrin Î²4/FAK/AKT mediated epithelialâ€“mesenchymal transition in hepatocellular carcinoma. Cancer Cell International, 2020, 20, 216.	1.8	21
3347	Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open, 2020, 4, 351-359.	0.7	25
3348	STAT3 and AKT signaling pathways mediate oncogenic role of NRSF in hepatocellular carcinoma. Acta Biochimica Et Biophysica Sinica, 2020, 52, 1063-1070.	0.9	7
3349	The Changing Epidemiology of Hepatocellular Carcinomaâ€‰:â€‰ Experience of a Single Center. BioMed Research International, 2020, 2020, 1-9.	0.9	15
3350	Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Ageâ€“Periodâ€“Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 88-94.	1.1	27
3351	Nonalcoholic Fatty Liver Disease. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	6
3352	MicroRNAâ€34c suppresses proliferation of vascular smooth muscle cell via modulating high mobility group box protein 1. Journal of Clinical Laboratory Analysis, 2020, 34, e23293.	0.9	4
3353	Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma. Stem Cell Reports, 2020, 14, 462-477.	2.3	18

#	Article	IF	Citations
3354	Olaparib and enzalutamide synergistically suppress HCC progression via the ARâ€mediated miRâ€146aâ€5p/BRCA1 signaling. FASEB Journal, 2020, 34, 5877-5891.	0.2	9
3355	The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers, 2020, 12, 684.	1.7	34
3356	Effect of remote ischemic preConditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial. Hpb, 2020, 22, 1250-1257.	0.1	11
3357	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. Journal of Cancer, 2020, 11, 2442-2452.	1.2	4
3358	Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers, 2020, 12, 562.	1.7	56
3359	PKCÎ»/Î¹ Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell, 2020, 38, 247-262.e11.	7.7	73
3360	Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-8.	0.5	8
3361	RNA-binding motif protein 43 (RBM43) suppresses hepatocellular carcinoma progression through modulation of cyclin B1 expression. Oncogene, 2020, 39, 5495-5506.	2.6	18
3363	Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188391.	3.3	96
3364	Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced Drug Delivery Reviews, 2020, 159, 344-363.	6.6	187
3365	Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. Journal of Vascular and Interventional Radiology, 2020, 31, 401-408.e1.	0.2	6
3366	Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease. Cancer Biomarkers, 2020, 29, 69-78.	0.8	12
3367	Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 71-78.	1.1	4
3368	The Biofunctional Effects of Mesima as a Radiosensitizer for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 871.	1.8	8
3369	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP17.	4.2	46
3370	Circâ€HOMER1 enhances the inhibition of miRâ€1322 on CXCL6 to regulate the growth and aggressiveness of hepatocellular carcinoma cells. Journal of Cellular Biochemistry, 2020, 121, 4440-4449.	1.2	34
3371	Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels. Frontiers in Oncology, 2019, 9, 1478.	1.3	11
3372	Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. Journal of the Egyptian National Cancer Institute, 2020, 32, 5.	0.6	135

#	Article	IF	Citations
3373	Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Annals of Gastroenterological Surgery, 2020, 4, 208-215.	1.2	9
3374	Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. Molecules, 2020, 25, 770.	1.7	31
3375	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a caseâ€“control study. Cancer Causes and Control, 2020, 31, 321-332.	0.8	20
3376	DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma. Oncogene, 2020, 39, 3229-3244.	2.6	27
3377	Function of BMP4 in the Formation of Vasculogenic Mimicry in Hepatocellular Carcinoma. Journal of Cancer, 2020, 11, 2560-2571.	1.2	15
3378	Mechanistic study of interaction between IL-22 and HCV core protein in the development of hepatocellular carcinoma among liver transplant recipients. Microbial Pathogenesis, 2020, 142, 104071.	1.3	7
3379	Using a single abdominal computed tomography image to differentiate five contrast-enhancement phases: A machine-learning algorithm for radiomics-based precision medicine. European Journal of Radiology, 2020, 125, 108850.	1.2	13
3380	Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy. Infectious Agents and Cancer, 2020, 15, 8.	1.2	12
3381	Transmembrane protein 106C promotes the development of hepatocellular carcinoma. Journal of Cellular Biochemistry, 2020, 121, 4484-4495.	1.2	8
3382	The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0228857.	1.1	120
3383	The potential mechanism of miR-130b on promotion of the invasion and metastasis of hepatocellular carcinoma by inhibiting Notch-Dll1. Journal of Receptor and Signal Transduction Research, 2020, 40, 157-165.	1.3	6
3384	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. Digestive Diseases, 2020, 38, 522-533.	0.8	7
3385	An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma. Frontiers in Genetics, 2019, 10, 1323.	1.1	46
3386	CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN Î²-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020006.	0.5	18
3387	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1595-1601.	1.4	18
3388	PIAS4, upregulated in hepatocellular carcinoma, promotes tumorigenicityÂand metastasis. Journal of Cellular Biochemistry, 2020, 121, 3372-3381.	1.2	9
3389	Crosstalk between NLRP12 and JNK during Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 496.	1.8	12
3390	Fibrotic liver has prompt recovery after ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2020, 318, G390-G400.	1.6	18

#	Article	IF	Citations
3391	Interreader Agreement of Liver Imaging Reporting and Data System on MRI: A Systematic Review and Metaâ€Analysis. Journal of Magnetic Resonance Imaging, 2020, 52, 795-804.	1.9	24
3392	Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC). International Immunopharmacology, 2020, 81, 106222.	1.7	43
3393	Folate functionalized pH-sensitive photothermal therapy traceable hollow mesoporous silica nanoparticles as a targeted drug carrier to improve the antitumor effect of doxorubicin in the hepatoma cell line SMMC-7721. Drug Delivery, 2020, 27, 258-268.	2.5	27
3394	Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact. Surgery Today, 2020, 50, 1560-1577.	0.7	20
3395	Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh. PLoS ONE, 2020, 15, e0232121.	1.1	6
3396	Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. Journal of Cellular Biochemistry, 2020, 122, 983.	1.2	5
3397	Circ_0001178 regulates miR-382/VEGFA axis to facilitate hepatocellular carcinoma progression. Cellular Signalling, 2020, 72, 109621.	1.7	17
3398	Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway. Cell Death Discovery, 2020, 6, 17.	2.0	19
3399	Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p/PDGFRA axis. Gene Therapy, 2021, 28, 634-645.	2.3	19
3400	A novel lncRNA PLK4 upâ€regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAPâ€mediated cell senescence. Journal of Cellular and Molecular Medicine, 2020, 24, 5304-5316.	1.6	14
3401	Exosomal miRNAs in hepatitis B virus related liver disease: a new hope for biomarker. Gut Pathogens, 2020, 12, 23.	1.6	30
3402	Impact of osteopontin on the development of nonâ€alcoholic liver disease and related hepatocellular carcinoma. Liver International, 2020, 40, 1620-1633.	1.9	20
3403	Hepatocellular Carcinoma Brain Metastases: A Single-Institution Experience. World Neurosurgery, 2020, 140, e27-e32.	0.7	4
3404	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. , 2020, 8, e000394.		39
3405	Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer, 2020, 20, 313.	1.1	13
3406	Long Noncoding RNA RMRP Suppresses the Tumorigenesis of Hepatocellular Carcinoma Through Targeting microRNA-766 . OncoTargets and Therapy, 2020, Volume 13, 3013-3024.	1.0	7
3407	Overweight and Obesity as Independent Factors for Increased Risk of Hepatocellular Cancer-Related Mortality: A Meta-Analysis. Journal of the American College of Nutrition, 2021, 40, 287-293.	1.1	7
3408	Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2021, 52, 201-206.	0.6	4

#	Article	IF	Citations
3409	Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 137-141.	0.6	3
3410	Hepatoprotective effect and possible mechanism of phytoestrogen calycosin on carbon tetrachlorideâ€“induced liver fibrosis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 189-204.	1.4	13
3411	Automated detection and delineation of hepatocellular carcinoma on multiphasic contrast-enhanced MRI using deep learning. Abdominal Radiology, 2021, 46, 216-225.	1.0	47
3412	MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology, 2021, 162, 252-261.	2.0	24
3413	Hepatocellular carcinoma in patients with no identifiable risk factors. Hpb, 2021, 23, 118-126.	0.1	4
3414	Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. Digestive Diseases and Sciences, 2021, 66, 308-314.	1.1	25
3415	Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation. Molecular Therapy - Nucleic Acids, 2021, 23, 154-168.	2.3	14
3416	Characterization and evaluation of inclusion complexes between astaxanthin esters with different molecular structures and hydroxypropyl-Î²-cyclodextrin. Food Hydrocolloids, 2021, 110, 106208.	5.6	28
3417	Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. Journal of the Formosan Medical Association, 2021, 120, 621-628.	0.8	1
3418	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Modern Pathology, 2021, 34, 823-833.	2.9	6
3419	Stroma-derived ANGPTL2 establishes an anti-tumor microenvironment during intestinal tumorigenesis. Oncogene, 2021, 40, 55-67.	2.6	9
3420	Metabolic heterogeneity of human hepatocellular carcinoma: implications for personalized pharmacological treatment. FEBS Journal, 2021, 288, 2332-2346.	2.2	12
3421	Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Advances in Cancer Research, 2021, 149, 1-61.	1.9	330
3422	Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis. Food and Chemical Toxicology, 2021, 147, 111912.	1.8	14
3423	Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. European Radiology, 2021, 31, 3053-3064.	2.3	32
3424	Composite Score of Healthy Lifestyle Factors and Risk of Hepatocellular Carcinoma: Findings from a Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 380-387.	1.1	13
3425	The 14-3-3Ïƒ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway. Theranostics, 2021, 11, 996-1015.	4.6	43
3426	Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics, 2021, 11, 209-221.	4.6	27

#	Article	IF	Citations
3427	Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2021, 476, 1195-1209.	1.4	10
3428	Long noncoding RNA LINC01189 is associated with HCV-hepatocellular carcinoma and regulates cancer cell proliferation and chemoresistance through hsa-miR-155-5p. Annals of Hepatology, 2021, 22, 100269.	0.6	9
3429	The Changing Liver Transplant Recipient. Clinics in Liver Disease, 2021, 25, 137-155.	1.0	3
3430	Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis. Cancer Gene Therapy, 2021, 28, 486-501.	2.2	20
3431	Wnt8B, transcriptionally regulated by ZNF191, promotes cell proliferation of hepatocellular carcinoma via Wnt signaling. Cancer Science, 2021, 112, 629-640.	1.7	13
3432	Metabolomics approach to understand the hepatitis C virus induced hepatocellular carcinoma using LC-ESI-MS/MS. Arabian Journal of Chemistry, 2021, 14, 102907.	2.3	8
3433	33-kDa ANXA3 isoform contributes to hepatocarcinogenesis via modulating ERK, PI3K/Akt-HIF and intrinsic apoptosis pathways. Journal of Advanced Research, 2021, 30, 85-102.	4.4	12
3434	Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. Journal of Hepatology, 2021, 74, 638-648.	1.8	84
3435	The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sciences, 2021, 264, 118615.	2.0	2
3436	Identification and validation of a new gene signature predicting prognosis of hepatocellular carcinoma patients by network analysis of stemness indices. Expert Review of Gastroenterology and Hepatology, 2021, 15, 699-709.	1.4	9
3437	Quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. International Journal of Cancer, 2021, 148, 2102-2114.	2.3	13
3438	Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Modern Pathology, 2021, 34, 417-425.	2.9	61
3439	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Journal of the National Cancer Institute, 2021, 113, 123-136.	3.0	28
3440	HBsAg-specific CD8+ T cells as an indispensable trigger to induce murine hepatocellular carcinoma. Cellular and Molecular Immunology, 2021, 18, 128-137.	4.8	21
3441	Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chinese Clinical Oncology, 2021, 10, 2-2.	0.4	9
3442	Integrative analysis of layers of data in hepatocellular carcinoma reveals pathway dependencies. World Journal of Hepatology, 2021, 13, 94-108.	0.8	0
3443	Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1). Bioengineered, 2021, 12, 6713-6723.	1.4	12
3444	Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization. PLoS ONE, 2021, 16, e0245911.	1.1	3

#	Article	IF	Citations
3445	Calmodulin/CaMKIIâ€Î³ mediates prosurvival capability in apicidinâ€persistent hepatocellular carcinoma cells via ERK1/2/CREB/câ€fos signaling pathway. Journal of Cellular Biochemistry, 2021, 122, 612-625.	1.2	8
3446	Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma. Japanese Journal of Radiology, 2021, 39, 494-502.	1.0	3
3447	CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis. Scientific Reports, 2021, 11, 386.	1.6	20
3448	Predicting Symptoms from Multiphasic MRI via Multi-instance Attention Learning for Hepatocellular Carcinoma Grading. Lecture Notes in Computer Science, 2021, , 439-448.	1.0	1
3449	An Overview of Hepatocellular Carcinoma (HCC) in Lebanon: A Focus on Hepatitis B- and Thalassemia-Related HCC. , 2021, , 375-386.		0
3450	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. Journal of Gastroenterology, 2021, 56, 261-273.	2.3	28
3451	Manganese Breaks the Immune Tolerance of HBs-Ag. Open Forum Infectious Diseases, 2021, 8, ofab028.	0.4	7
3452	Automatic Detection and Classification of Focal Liver Lesions Based on Deep Convolutional Neural Networks: A Preliminary Study. Frontiers in Oncology, 2020, 10, 581210.	1.3	36
3453	Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Childâ€“Pugh Grade A Liver Function. Annals of Surgical Oncology, 2021, 28, 4227-4235.	0.7	11
3454	A Preliminary Study on the Diagnostic Efficacy of Proton Magnetic Resonance Spectroscopy at 3.0T in Rabbit With VX2 Liver Tumor. Technology in Cancer Research and Treatment, 2021, 20, 153303382110368.	0.8	2
3455	LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis. ACS Omega, 2021, 6, 1160-1170.	1.6	18
3456	UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway. International Journal of Medical Sciences, 2021, 18, 3097-3105.	1.1	6
3457	Age, Gender Pattern and Liver Function Markers in Hepatitis B and C Seropositive Participants Attending a Health Facility in Yaba-Lagos, Nigeria. Journal of Biosciences and Medicines, 2021, 09, 44-58.	0.1	2
3458	Hepatocellular carcinoma in non-alcoholic fatty liver diseaseâ€"a review of an emerging challenge facing clinicians. Hepatobiliary Surgery and Nutrition, 2021, 10, 59-75.	0.7	34
3459	CRKL promotes hepatocarcinoma through enhancing glucose metabolism of cancer cells via activating PI3K/Akt. Journal of Cellular and Molecular Medicine, 2021, 25, 2714-2724.	1.6	6
3460	Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop. Digestive Diseases and Sciences, 2022, 67, 569-584.	1.1	10
3461	Identifying Apoptosis-Related Transcriptomic Aberrations and Revealing Clinical Relevance as Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 519180.	1.3	16
3462	TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging, 2021, 13, 5585-5606.	1.4	15

#	Article	IF	Citations
3463	Comparison of the Phytochemical Properties, Antioxidant Activity and Cytotoxic Effect on HepG2 Cells in Mongolian and Taiwanese Rhubarb Species. Molecules, 2021, 26, 1217.	1.7	7
3464	Exosomes: A new frontier under the spotlight for diagnosis and treatment of gastrointestinal diseases. World Journal of Meta-analysis, 2021, 9, 12-28.	0.1	0
3465	Hepatitis Câ€positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer, 2021, 127, 1395-1406.	2.0	16
3466	A radiomics nomogram based on contrast-enhanced MRI for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 3139-3148.	1.0	25
3467	The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 335-347.	8.2	167
3468	Prognostic Value of Preoperative Prognostic Nutritional Index and Body Mass Index Combination in Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization. Cancer Management and Research, 2021, Volume 13, 1637-1650.	0.9	6
3469	Distinct functions of transforming growth factor-Î² signaling in c-MYC driven hepatocellular carcinoma initiation and progression. Cell Death and Disease, 2021, 12, 200.	2.7	16
3470	â€œComplimenting the Complementâ€• Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 627701.	1.3	22
3471	Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. Journal of Clinical Medicine, 2021, 10, 551.	1.0	17
3472	Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Frontiers in Molecular Biosciences, 2020, 7, 599142.	1.6	23
3473	Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines, 2021, 9, 159.	1.4	20
3474	Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. International Journal of Molecular Sciences, 2021, 22, 2163.	1.8	36
3475	A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. PLoS ONE, 2021, 16, e0249003.	1.1	2
3476	Narrative review of hepatocellular carcinoma: from molecular bases to therapeutic approach. Digestive Medicine Research, 0, 4, 15-15.	0.2	1
3477	Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1. Aging, 2021, 13, 12207-12223.	1.4	5
3478	NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis. Oncology Letters, 2021, 21, 390.	0.8	7
3479	Analysis of transcriptome in the relationship between expression of PRC1 protein and prognosis of patients with cholangiocarcinoma. Journal of International Medical Research, 2021, 49, 030006052198920.	0.4	1
3480	Identifying SLC27A5 as a potential prognostic marker of hepatocellular carcinoma by weighted gene co-expression network analysis and in vitro assays. Cancer Cell International, 2021, 21, 174.	1.8	10

#	Article	IF	Citations
3481	Comparison of 10-Year Survival Outcomes for Early Single Hepatocellular Carcinoma following Different Treatments. BioMed Research International, 2021, 2021, 1-8.	0.9	5
3482	DeepVISP: Deep Learning for Virus Site Integration Prediction and Motif Discovery. Advanced Science, 2021, 8, 2004958.	5.6	9
3483	MicroRNA signature in liver cancer. Pathology Research and Practice, 2021, 219, 153369.	1.0	24
3484	Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 145-154.	1.8	12
3485	Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells. PLoS ONE, 2021, 16, e0248521.	1.1	25
3486	MicroRNAâ€'1271â€'5p alleviates the malignant development of hepatitis B virusâ€'mediated liver cancer via binding to AQP5. Molecular Medicine Reports, 2021, 23, .	1.1	7
3487	LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101490.	0.7	11
3488	Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells. Archives of Biochemistry and Biophysics, 2021, 699, 108754.	1.4	12
3489	Huanglian decoction suppresses the growth of hepatocellular carcinoma cells by reducing CCNB1 expression. World Journal of Gastroenterology, 2021, 27, 939-958.	1.4	13
3490	Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepatic Oncology, 2021, 8, HEP35.	4.2	4
3491	The Bibliometric Analysis of Top 100 Cited Articles in Environmental Epidemiology. Journal of Basic and Clinical Health Sciences, 2021, 5, 54-59.	0.2	0
3492	Identification and Validation of a Prognostic Model Based on Three Autophagy-Related Genes in Hepatocellular Carcinoma. BioMed Research International, 2021, 2021, 1-15.	0.9	3
3493	GPER-Induced ERK Signaling Decreases Cell Viability of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 638171.	1.3	11
3494	Gene Expression Profile and Prognostic Value of m6A RNA Methylation Regulators in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 85-101.	1.8	6
3495	The effect of Telomere Lengthening on Genetic Diseases. Journal of Contemporary Medicine, 2021, 11, 254-261.	0.1	0
3496	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells, 2021, 10, 521.	1.8	13
3497	Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. Journal of Clinical Medicine, 2021, 10, 1840.	1.0	11
3498	Interplay of autophagy and cancer stem cells in hepatocellular carcinoma. Molecular Biology Reports, 2021, 48, 3695-3717.	1.0	12

#	Article	IF	Citations
3499	Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. European Radiology, 2021, 31, 7500-7511.	2.3	58
3500	LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c. World Journal of Surgical Oncology, 2021, 19, 121.	0.8	11
3501	Dual Role of TNF and LTÎ± in Carcinogenesis as Implicated by Studies in Mice. Cancers, 2021, 13, 1775.	1.7	12
3502	Role of G Protein-Coupled Estrogen Receptor in Digestive System Carcinomas: A Minireview. OncoTargets and Therapy, 2021, Volume 14, 2611-2622.	1.0	6
3503	The evaluation of the therapeutic potential of hesperetin on diethylnitrosamine and phenobarbital induced liver injury in rats. Ankara Universitesi Veteriner Fakultesi Dergisi, 0, , .	0.4	1
3504	Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center. PLoS ONE, 2021, 16, e0250347.	1.1	9
3505	Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma. Hpb, 2021, 23, 1595-1606.	0.1	9
3506	LncRNA SUMO1P3 acts as a prognostic biomarker and promotes hepatocellular carcinoma growth and metastasis. Aging, 2021, 13, 12479-12492.	1.4	7
3507	NAFLD-Associated HCC: Progress and Opportunities. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 223-239.	1.8	33
3508	Differential Mutation Detection Capability Through Capture-Based Targeted Sequencing in Plasma Samples in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 596789.	1.3	8
3509	The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 649107.	1.3	25
3510	Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade. Public Health Reports, 2021, , 003335492110058.	1.3	3
3511	Prognostic significance of systemic immune-inflammation index- based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. Journal of Gastrointestinal Oncology, 2021, 12, 735-750.	0.6	9
3512	DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 1637.	1.7	9
3513	LncRNA influence sequential steps of hepatocellular carcinoma metastasis. Biomedicine and Pharmacotherapy, 2021, 136, 111224.	2.5	24
3514	Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 642443.	1.8	13
3515	Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis. Medical Oncology, 2021, 38, 63.	1.2	19
3516	Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells. Aging, 2021, 13, 12046-12057.	1.4	6

#	Article	IF	Citations
3517	Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget, 2021, 12, 756-766.	0.8	2
3518	Combined Inhibition of TGF-Î²1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. Journal of Clinical Medicine, 2021, 10, 1889.	1.0	25
3519	Regulation and functional roles of chemokines in liver diseases. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 630-647.	8.2	46
3520	Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma. Cells, 2021, 10, 1294.	1.8	11
3521	A novel fiveâ€gene signature predicts overall survival of patients with hepatocellular carcinoma. Cancer Medicine, 2021, 10, 3808-3821.	1.3	26
3522	Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study. European Journal of Radiology, 2021, 138, 109623.	1.2	16
3523	High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma. OncoTargets and Therapy, 2021, Volume 14, 2975-2988.	1.0	5
3524	A TGFÎ² Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFÎ²-independent Manner. Anticancer Research, 2021, 41, 2431-2440.	0.5	1
3525	A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Mining, 2021, 14, 29.	2.2	7
3526	SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-ÎºB and ERK Signaling. Biomolecules and Therapeutics, 2021, 29, 331-341.	1.1	5
3527	Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients. Bioscience Reports, 2021, 41, .	1.1	4
3528	Rosmarinic Acid Induces Proliferation Suppression of Hepatoma Cells Associated with NF-ÎºB Signaling Pathway. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1623-1632.	0.5	10
3529	Viral hepatitis in haemophilia: historical perspective and current management. British Journal of Haematology, 2021, 195, 174-185.	1.2	15
3530	Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center. Abdominal Radiology, 2021, 46, 4170-4177.	1.0	3
3531	MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Cellular Oncology (Dordrecht), 2021, 44, 821-834.	2.1	34
3532	Preoperative MR imaging for predicting early recurrence of solitary hepatocellular carcinoma without microvascular invasion. European Journal of Radiology, 2021, 138, 109663.	1.2	16
3533	Food Environments and Hepatocellular Carcinoma Incidence. International Journal of Environmental Research and Public Health, 2021, 18, 5740.	1.2	1
3534	Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancers, 2021, 13, 2648.	1.7	29

#	Article	IF	Citations
3535	Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway. Cell Calcium, 2021, 95, 102367.	1.1	36
3536	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. Frontiers in Oncology, 2021, 11, 696183.	1.3	17
3537	Comprehensive Analysis of Competing Endogenous RNA Network Focusing on Long Noncoding RNA Involved in Cirrhotic Hepatocellular Carcinoma. Analytical Cellular Pathology, 2021, 2021, 1-12.	0.7	3
3538	Pathogens and Carcinogenesis: A Review. Biology, 2021, 10, 533.	1.3	32
3539	Y disruption, autosomal hypomethylation and poor male lung cancer survival. Scientific Reports, 2021, 11, 12453.	1.6	15
3540	Curcumin restrains hepatocellular carcinoma progression depending on the regulation of the circ_0078710/miR-378b/PRIM2 axis. Journal of Receptor and Signal Transduction Research, 2022, 42, 313-324.	1.3	15
3541	Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. BioScience Trends, 2021, 15, 142-147.	1.1	36
3542	Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in <scp>US</scp> women and men. International Journal of Cancer, 2021, 149, 1529-1535.	2.3	0
3543	Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. BioScience Trends, 2021, 15, 155-160.	1.1	48
3544	PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors. ACS Applied Bio Materials, 2021, 4, 4789-4799.	2.3	2
3545	Treatment trends and outcomes of hepatocellular carcinoma in a single center for 35 years. Minerva Surgery, 2021, 76, 252-263.	0.1	1
3546	Impact of bromodomainâ€containing protein 4 (BRD4) and intestineâ€specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity. Cancer Medicine, 2021, 10, 5545-5556.	1.3	6
3547	<scp>FDA</scp> Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist, 2021, 26, 797-806.	1.9	61
3549	Screening the genome for HCC-specific CpG methylation signatures as biomarkers for diagnosis and prognosis evaluation. BMC Medical Genomics, 2021, 14, 163.	0.7	2
3550	Realâ€world evidence in hepatocellular carcinoma. Liver International, 2021, 41, 61-67.	1.9	6
3551	Emerging Role and Clinicopathological Significance of AEG-1 in Different Cancer Types: A Concise Review. Cells, 2021, 10, 1497.	1.8	12
3553	Nrf2 Down-Regulation by Camptothecin Favors Inhibiting Invasion, Metastasis and Angiogenesis in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 661157.	1.3	12
3554	Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 657051.	1.1	12

#	Article	IF	Citations
3555	TP53 rs28934571 polymorphism increases the prognostic risk in hepatocellular carcinoma. Biomarkers in Medicine, 2021, 15, 615-622.	0.6	2
3556	Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness. Cancers, 2021, 13, 2755.	1.7	11
3557	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine, 2021, 10, 5395-5404.	1.3	0
3558	Identification of SRGAP2 as a potential oncogene and a prognostic biomarker in hepatocellular carcinoma. Life Sciences, 2021, 277, 119592.	2.0	9
3559	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World Journal of Gastroenterology, 2021, 27, 4104-4142.	1.4	15
3560	Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 837-850.	1.8	2
3561	A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open, 2021, 5, 1015-1018.	0.7	4
3562	Clinical Features and Overall Survival of Females with Hepatocellular Carcinoma: A Retrospective Study and Review of the Literature in the Association of Southeast Asian Nations. International Journal of Women's Health, 2021, Volume 13, 717-725.	1.1	2
3563	Dietary fructose promotes liver carcinogenesis by inducing the malignant transformation of hepatic progenitor cells. Journal of Functional Foods, 2021, 82, 104489.	1.6	1
3564	Bie Jia Jian pill enhances the amelioration of bone mesenchymal stem cells on hepatocellular carcinoma progression. Journal of Natural Medicines, 2021, , 1.	1.1	3
3565	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterology, 2021, 21, 306.	0.8	17
3566	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 559-568.	3.7	121
3567	Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment. Life Sciences, 2021, 277, 119612.	2.0	14
3568	Long Noncoding RNAs and Human Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 1-21.	9.6	25
3569	Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride production. Cancer Medicine, 2021, 10, 6795-6806.	1.3	5
3570	The DEN and CCl₄â€Induced Mouse Model of Fibrosis and Inflammationâ€Associated Hepatocellular Carcinoma. Current Protocols, 2021, 1, e211.	1.3	7
3571	Efficacy of voxel-based dosimetry map for predicting response to trans-arterial radioembolization therapy for hepatocellular carcinoma. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 1396-1403.	0.5	0
3572	Retrospective evaluation of the effect of Ninjinâ€™yoeito in hepatocellular carcinoma patients treated with lenvatinib. Surgery Today, 2022, 52, 441-448.	0.7	4

#	Article	IF	Citations
3573	Exosome-derived SNHG16 sponging miR-4500 activates HUVEC angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Journal of Physiology and Biochemistry, 2021, 77, 667-682.	1.3	23
3574	Does Schistosoma Mansoni Facilitate Carcinogenesis?. Cells, 2021, 10, 1982.	1.8	12
3575	The growth rate of hepatocellular carcinoma is different with different TNM stages at diagnosis. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 330-336.	0.6	4
3576	A Potentially Misleading Hepatocellular Carcinoma. Medicina (Lithuania), 2021, 57, 850.	0.8	1
3577	Identification of Key Functional Modules and Immunomodulatory Regulators of Hepatocellular Carcinoma. Journal of Immunology Research, 2021, 2021, 1-21.	0.9	2
3578	Deep learning applied to the imaging diagnosis of hepatocellular carcinoma. Artificial Intelligence in Gastrointestinal Endoscopy, 2021, 2, 127-135.	0.2	2
3579	Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma. Cancers, 2021, 13, 4237.	1.7	10
3580	<scp>RNA</scp> methyltransferase <scp>NSUN2</scp> promotes growth of hepatocellular carcinoma cells by regulating fizzyâ€relatedâ€1 in vitro and in vivo. Kaohsiung Journal of Medical Sciences, 2021, 37, 991-999.	0.8	5
3581	Human Serum Albumin Nanoparticles as a Carrier for On-Demand Sorafenib Delivery. Current Pharmaceutical Biotechnology, 2022, 23, 1214-1225.	0.9	3
3582	Liver transplantation in malignant disease. World Journal of Clinical Oncology, 2021, 12, 623-645.	0.9	7
3583	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Hepatology Communications, 2021, 5, 1939-1952.	2.0	8
3584	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precision Oncology, 2021, 5, 1285-1296.	1.5	8
3585	Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. Journal of Hematology and Oncology, 2021, 14, 134.	6.9	70
3586	Purple Sweet Potato Phytochemicals: Potential Chemo-preventive and Anticancer Activities. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 288-298.	0.1	1
3587	Hepatic sexual dimorphism â€" implications for non-alcoholic fatty liver disease. Nature Reviews Endocrinology, 2021, 17, 662-670.	4.3	41
3588	Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Scientific Reports, 2021, 11, 16343.	1.6	20
3589	Iron-sulphur cluster biogenesis factor LYRM4 is a novel prognostic biomarker associated with immune infiltrates in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 463.	1.8	6
3590	RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma. Scientific Reports, 2021, 11, 17797.	1.6	16

#	Article	IF	Citations
3591	lncRNA TPT1â€‘AS1 knockdown inhibits liver cancer cell proliferation, migration and invasion. Molecular Medicine Reports, 2021, 24, .	1.1	6
3592	Examination of the effect of curcumin in experimental liver damage created by diethylnitrosamine in Swiss albino mice to superoxide dismutase and catalase activities and glutathione, malondialdehyde, and advanced oxidation protein products levels. Biotechnology and Applied Biochemistry, 2022, 69, 1217-1225.	1.4	4
3593	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 1132-1143.	0.8	2
3594	Characterization of Androgen Receptor Complex Associated Protein (ARCAP) in Hepatocellular Carcinoma and Liver. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	0.6	2
3595	Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective. Cancers, 2021, 13, 4732.	1.7	12
3596	m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression. Molecular Therapy - Nucleic Acids, 2021, 26, 637-648.	2.3	53
3597	Pharmacological Evaluation of Novel 1,2,4-triazine Derivatives Containing Thiazole Ring Against Hepatocellular Carcinoma. Current Bioactive Compounds, 2021, 17, .	0.2	3
3598	Association of Polymorphism in Survivin Gene and the Risk of Liver Cancer Resulting from Hepatitis C Virus Among Egyptian Patients. Current Cancer Drug Targets, 2021, 21, 536-543.	0.8	2
3599	Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 475.	1.8	8
3600	Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. Anticancer Research, 2021, 41, 4555-4562.	0.5	7
3601	Systematic Characterization of Novel Immune Gene Signatures Predicts Prognostic Factors in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 686664.	1.8	5
3602	A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 706915.	1.3	8
3603	The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers, 2021, 13, 4876.	1.7	27
3605	Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis. Hepatology International, 2021, 15, 1413-1420.	1.9	4
3606	Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052110445.	0.4	2
3607	Seroprevalence, genotyping and monitoring of hepatitis C viral loads in patients on antivirals in Burkina Faso. Intervirology, 2021, , .	1.2	1
3608	Targeting Drug Chemo-Resistance in Cancer Using Natural Products. Biomedicines, 2021, 9, 1353.	1.4	50
3609	Occult hepatitis B virus infection and the risk of hepatocellular carcinoma: a systematic review and meta-analysis. Digestive Medicine Research, 0, 4, 46-46.	0.2	2

#	Article	IF	Citations
3610	Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival. Journal of Gastrointestinal Cancer, 2022, 53, 921-929.	0.6	3
3611	Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002.	0.8	5
3612	Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Medicine, 2021, 10, 7308-7319.	1.3	6
3613	A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. CardioVascular and Interventional Radiology, 2022, 45, 43-53.	0.9	11
3614	Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein responseâ€'induced upregulation of CHAC1 expression. Oncology Reports, 2021, 46, .	1.2	39
3615	Triformyl cholic acid and folic acid functionalized magnetic graphene oxide nanocomposites: Multiple-targeted dual-modal synergistic chemotherapy/photothermal therapy for liver cancer. Journal of Inorganic Biochemistry, 2021, 223, 111558.	1.5	20
3616	Global analysis of DNA methylation in hepatocellular carcinoma via a whole-genome bisulfite sequencing approach. Genomics, 2021, 113, 3618-3634.	1.3	4
3617	Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis. Clinical Imaging, 2021, 79, 251-258.	0.8	6
3618	Non-coding RNAs as biomarkers for hepatocellular carcinomaâ€"A systematic review. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101736.	0.7	6
3619	Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Translational Oncology, 2021, 14, 101201.	1.7	4
3620	Bioinformatics Analyses of Potential miRNA-mRNA Regulatory Axis in HBV-related Hepatocellular Carcinoma. International Journal of Medical Sciences, 2021, 18, 335-346.	1.1	14
3621	Ursolic acid reverses liver fibrosis by inhibiting NOX4/NLRP3 inflammasome pathways and bacterial dysbiosis. Gut Microbes, 2021, 13, 1972746.	4.3	29
3622	Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-Î²1/Smad3 and p38/PPARÎ± Pathways. PPAR Research, 2021, 2021, 1-15.	1.1	17
3623	Prognostic Nutritional Index Considering Resection Range Is Useful for Predicting Postoperative Morbidity of Hepatectomy. Journal of Gastrointestinal Surgery, 2021, 25, 2788-2795.	0.9	10
3624	A case report on a large, peduncular intraâ€abdominal hepatocellular carcinoma extending into the retroperitoneum. Clinical Case Reports (discontinued), 2021, 9, 1288-1291.	0.2	0
3626	Analysis of Prognostic Associated Alternative Splicing Signatures in Breast Cancer. Statistics and Applications, 2021, 10, 355-364.	0.0	0
3627	A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. Translational Cancer Research, 2021, 10, 3979-3992.	0.4	3
3628	Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. International Journal of Molecular Sciences, 2021, 22, 436.	1.8	40

#	Article	IF	Citations
3629	ZEB1 serves an oncogenic role in the tumourigenesis of HCC by promoting cell proliferation, migration, and inhibiting apoptosis via Wnt/Î²-catenin signaling pathway. Acta Pharmacologica Sinica, 2021, 42, 1676-1689.	2.8	20
3630	Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean Journal of Radiology, 2021, 22, 1822-1833.	1.5	9
3633	The exosome encapsulated <scp>microRNAs</scp> as circulating diagnostic marker for hepatocellular carcinoma with low alphaâ€fetoprotein. International Journal of Cancer, 2020, 147, 2934-2947.	2.3	81
3634	Cancer-Associated Infectious Agents and Epigenetic Regulation. Methods in Molecular Biology, 2015, 1238, 333-354.	0.4	13
3635	Helicobacter -Based Mouse Models of Digestive System Carcinogenesis. Methods in Molecular Biology, 2009, 511, 267-295.	0.4	46
3636	Hepatitis C and Hepatocellular Carcinoma. , 2009, , 259-281.		4
3637	Epidemiology and Pathogenesis of Hepatocellular Carcinoma. , 2011, , 1-19.		4
3638	Hepatocellular Carcinoma: Etiology and Natural History. , 2012, , 1-16.		2
3639	Ethanol and Hepatocarcinogenesis. , 2013, , 411-427.		2
3640	Viral Hepatitides, Inflammation and Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1263, 25-43.	0.8	11
3641	MicroRNAs Linking Cancer and Inflammation: Focus on Liver Cancer. , 2014, , 183-208.		3
3642	Hepatocellular Carcinoma and Patient Assessment. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 21-32.	0.6	1
3643	Mouse Models to Study Metformin Effects in Carcinogenesis. Energy Balance and Cancer, 2015, , 271-292.	0.2	1
3645	Liver Cancer. , 2011, , 225-249.		1
3646	Transarterial Therapies for Hepatocellular Carcinoma. Recent Results in Cancer Research, 2013, 190, 195-206.	1.8	14
3647	Imaging of Hepatocellular Carcinoma: Current Concepts. Recent Results in Cancer Research, 2013, 190, 33-55.	1.8	5
3648	Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results in Cancer Research, 2014, 193, 113-133.	1.8	16
3649	The woodchuck model of hepadnavirus infection. , 2008, , 271-301.		1

#	Article	IF	Citations
3650	Possible Involvement of Signal Transducer and Activator of Transcription-3 (STAT3) Signaling Pathway in the Initiation and Progression of Hepatocellular Carcinoma. , 2014, , 73-87.		2
3651	Chronic Viral Hepatitis. , 2010, , 1593-1617.		9
3652	Neoplasms and Nodules. , 2010, , 181-231.		6
3653	A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2020, 526, 1150-1156.	1.0	5
3654	Two purified proteins from royal jelly with in vitro dual anti-hepatic damage potency: Major royal jelly protein 2 and its novel isoform X1. International Journal of Biological Macromolecules, 2019, 128, 782-795.	3.6	32
3655	Effect of talin1 on apoptosis in hepatoma carcinoma cells via the PI3K/Akt/NF-Î²B signaling pathway. RSC Advances, 2017, 7, 40179-40188.	1.7	5
3656	Mass spectrometry-based metabolomics in health and medical science: a systematic review. RSC Advances, 2020, 10, 3092-3104.	1.7	117
3657	Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clinical Science, 2019, 133, 2245-2264.	1.8	13
3658	A Panoramic Review on Lepidium sativum L. Bioactives as Prospective Therapeutics. Drug Research, 2021, 71, 233-242.	0.7	5
3659	Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma. OncoImmunology, 2018, 7, e1502129.	2.1	7
3660	Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis, 2017, 38, 231-240.	1.3	125
3661	The association of nonalcoholic steatohepatitis and hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2020, 32, 1566-1570.	0.8	10
3662	Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation, 2018, 102, 1710-1716.	0.5	103
3663	Synthesis, crystal structures and anti-inflammatory activity of fluorine-substituted 1,4,5,6-tetrahydrobenzo[h]quinazolin-2-amine derivatives. Acta Crystallographica Section C, Structural Chemistry, 2019, 75, 1157-1165.	0.2	26
3664	Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma. Cancer Science, 2020, 111, 1228-1240.	1.7	26
3665	Hepatocellular carcinoma in China. BMJ, The, 0, , c1026.	3.0	15
3666	TLR4 Influences Hepatitis B Virus Related Hepatocellular Carcinoma by Regulating the Wnt/Î²-Catenin Pathway. Cellular Physiology and Biochemistry, 2017, 42, 469-479.	1.1	19
3667	Heavy Metal Pollution in the Birim River of Ghana. International Journal of Environmental Monitoring and Analysis, 2016, 4, 65.	0.2	11

#	Article	IF	Citations
3668	Degradation of splicing factor SRSF3 contributes to progressive liver disease. Journal of Clinical Investigation, 2019, 129, 4477-4491.	3.9	69
3669	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. Journal of Clinical Investigation, 2020, 130, 2509-2526.	3.9	29
3670	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. Journal of Clinical Investigation, 2009, 119, 465-477.	3.9	298
3671	CD13 is a therapeutic target in human liver cancer stem cells. Journal of Clinical Investigation, 2010, 120, 3326-3339.	3.9	536
3672	Oncogenic Î²-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. Journal of Clinical Investigation, 2012, 122, 586-599.	3.9	155
3673	Cell cycleâ€“related kinase is a direct androgen receptorâ€“regulated gene that drives Î²-catenin/T cell factorâ€“dependent hepatocarcinogenesis. Journal of Clinical Investigation, 2011, 121, 3159-3175.	3.9	121
3674	CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. Journal of Clinical Investigation, 2012, 122, 2165-2175.	3.9	100
3675	MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. Journal of Clinical Investigation, 2012, 122, 2884-2897.	3.9	726
3676	JUNB/AP-1 controls IFN-Î³ during inflammatory liver disease. Journal of Clinical Investigation, 2013, 123, 5258-5268.	3.9	44
3677	Risk Factors for Hepatocellular Carcinoma: A Case-Control Study in Belgrade (Serbia). Tumori, 2010, 96, 911-917.	0.6	35
3678	Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1Î±/PPAR-Î³/PKM2-mediated glycolysis. Journal of Experimental and Clinical Cancer Research, 2020, 39, 24.	3.5	126
3679	Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences, 2020, 11, 29.	1.8	832
3680	How Do Mechanisms of Hepatocarcinogenesis (HBV, HCV, and NASH) Affect Our Understanding and Approach to HCC?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e132-e136.	1.8	6
3682	The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Medical Science Monitor, 2011, 17, PH7-PH11.	0.5	16
3683	Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Medical Science Monitor, 2013, 19, 742-750.	0.5	12
3684	IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. Medical Science Monitor, 2014, 20, 247-254.	0.5	10
3685	Associations between Pre-S Deletion Mutation of Hepatitis B Virus and Risk of Hepatocellular Carcinoma in the Asian Population: A Meta-Analysis. Medical Science Monitor, 2015, 21, 1072-1077.	0.5	14
3686	Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. Medical Science Monitor, 2016, 22, 3694-3704.	0.5	26

#	Article	IF	Citations
3687	miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells. Medical Science Monitor, 2017, 23, 1741-1750.	0.5	30
3688	Application Value of Mass Spectrometry in the Differentiation of Benign and Malignant Liver Tumors. Medical Science Monitor, 2017, 23, 1636-1644.	0.5	12
3689	Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Medical Science Monitor, 2019, 25, 6615-6623.	0.5	9
3690	Anticancer Action of Psilostachyin-A in 5-Fluorouracil-Resistant Human Liver Carcinoma are Mediated Through Autophagy Induction, G2/M Phase Cell Cycle Arrest and Inhibiting Extracellular-Signal-Regulated Kinase/Mitogen Activated Protein Kinase (ERK/MAPK) Signaling Pathway. Medical Science Monitor, 2019, 25, 6711-6718.	0.5	3
3691	Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy. Medical Science Monitor, 2020, 26, e924040.	0.5	5
3692	Glycoregulatory Enzymes as Early Diagnostic Markers during Premalignant Stage in Hepatocellular Carcinoma. American Journal of Cancer Prevention, 2013, 1, 14-19.	0.3	18
3693	KIR and HLA Loci Are Associated with Hepatocellular Carcinoma Development in Patients with Hepatitis B Virus Infection: A Case-Control Study. PLoS ONE, 2011, 6, e25682.	1.1	38
3694	The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e27362.	1.1	31
3695	ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B. PLoS ONE, 2012, 7, e29928.	1.1	36
3696	Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1Î±/VEGFA. PLoS ONE, 2012, 7, e37266.	1.1	111
3697	Loss of the SxxSS Motif in a Human T-Cell Factor-4 Isoform Confers Hypoxia Resistance to Liver Cancer: An Oncogenic Switch in Wnt Signaling. PLoS ONE, 2012, 7, e39981.	1.1	15
3698	Molecular Profiles of HCV Cirrhotic Tissues Derived in a Panel of Markers with Clinical Utility for Hepatocellular Carcinoma Surveillance. PLoS ONE, 2012, 7, e40275.	1.1	6
3699	Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells. PLoS ONE, 2012, 7, e44147.	1.1	23
3700	Effects of NFKB1 and NFKBIA Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathological Features. PLoS ONE, 2013, 8, e56130.	1.1	37
3701	Klotho Endows Hepatoma Cells with Resistance to Anoikis via VEGFR2/PAK1 Activation in Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e58413.	1.1	37
3702	Lack of Association of MiR-34b/c Polymorphism (rs4938723) with Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2013, 8, e68588.	1.1	12
3703	Transcript Profiling Identifies Iqgap2â^'/â^' Mouse as a Model for Advanced Human Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e71826.	1.1	22
3704	Overexpression of Endothelin 1 Triggers Hepatocarcinogenesis in Zebrafish and Promotes Cell Proliferation and Migration through the AKT Pathway. PLoS ONE, 2014, 9, e85318.	1.1	64

#	Article	IF	Citations
3705	Licochalcone A Suppresses Migration and Invasion of Human Hepatocellular Carcinoma Cells through Downregulation of MKK4/JNK via NF-Î¹B Mediated Urokinase Plasminogen Activator Expression. PLoS ONE, 2014, 9, e86537.	1.1	66
3706	Over-Expressed Testis-Specific Protein Y-Encoded 1 as a Novel Biomarker for Male Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e89219.	1.1	10
3707	A Genetic Variant in Primary miR-378 Is Associated with Risk and Prognosis of Hepatocellular Carcinoma in a Chinese Population. PLoS ONE, 2014, 9, e93707.	1.1	24
3708	Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation. PLoS ONE, 2014, 9, e95307.	1.1	47
3709	Melittin Restores PTEN Expression by Down-Regulating HDAC2 in Human Hepatocelluar Carcinoma HepG2 Cells. PLoS ONE, 2014, 9, e95520.	1.1	29
3710	Development of a Highly Sensitive Glycan Microarray for Quantifying AFP-L3 for Early Prediction of Hepatitis B Virusâ€"Related Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e99959.	1.1	22
3711	The Long Noncoding RNA Expression Profile of Hepatocellular Carcinoma Identified by Microarray Analysis. PLoS ONE, 2014, 9, e101707.	1.1	59
3712	Endoplasmic Reticulum Stress Activates the Hepatic Activator Protein 1 Complex via Mitogen Activated Protein Kinase-Dependent Signaling Pathways. PLoS ONE, 2014, 9, e103828.	1.1	13
3713	Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray. PLoS ONE, 2014, 9, e106314.	1.1	74
3714	HBx Inhibits CYP2E1 Gene Expression via Downregulating HNF4Î± in Human Hepatoma Cells. PLoS ONE, 2014, 9, e107913.	1.1	19
3715	Circulating AIM as an Indicator of Liver Damage and Hepatocellular Carcinoma in Humans. PLoS ONE, 2014, 9, e109123.	1.1	37
3716	Leukocyte Telomere Length-Related rs621559 and rs398652 Genetic Variants Influence Risk of HBV-Related Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e110863.	1.1	7
3717	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. PLoS ONE, 2014, 9, e112184.	1.1	49
3718	Telomerase Inhibition Decreases Alpha-Fetoprotein Expression and Secretion by Hepatocellular Carcinoma Cell Lines: In Vitro and In Vivo Study. PLoS ONE, 2015, 10, e0119512.	1.1	17
3719	Analysis of Prognostic Factors for Survival after Hepatectomy for Hepatocellular Carcinoma Based on a Bayesian Network. PLoS ONE, 2015, 10, e0120805.	1.1	28
3720	Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Gd-EOB-DTPA for the Evaluation of Liver Fibrosis Induced by Carbon Tetrachloride in Rats. PLoS ONE, 2015, 10, e0129621.	1.1	16
3721	Potential Role of Circulating microRNA-21 for Hepatocellular Carcinoma Diagnosis: A Meta-Analysis. PLoS ONE, 2015, 10, e0130677.	1.1	39
3722	The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. PLoS ONE, 2015, 10, e0134594.	1.1	21

#	Article	IF	Citations
3723	Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS ONE, 2015, 10, e0138907.	1.1	22
3724	Rb and p53 Liver Functions Are Essential for Xenobiotic Metabolism and Tumor Suppression. PLoS ONE, 2016, 11, e0150064.	1.1	5
3725	Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages. PLoS ONE, 2016, 11, e0158286.	1.1	5
3726	Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. PLoS ONE, 2016, 11, e0160979.	1.1	13
3727	Integrated Multiple â€œ-omicsâ€•Data Reveal Subtypes of Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0165457.	1.1	28
3728	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS ONE, 2016, 11, e0165722.	1.1	33
3729	Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS ONE, 2017, 12, e0172412.	1.1	16
3730	Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. PLoS ONE, 2017, 12, e0174326.	1.1	6
3731	No contribution of lifestyle and environmental exposures to gender discrepancy of liver disease severity in chronic hepatitis b infection: Observations from the Haimen City cohort. PLoS ONE, 2017, 12, e0175482.	1.1	9
3732	BRG1 promotes hepatocarcinogenesis by regulating proliferation and invasiveness. PLoS ONE, 2017, 12, e0180225.	1.1	17
3733	Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. PLoS Pathogens, 2017, 13, e1006735.	2.1	66
3734	The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical Practice. journal of applied laboratory medicine, The, 2017, 1, 720-728.	0.6	8
3735	Resveratrol suppresses hyperglycemia-induced activation of NF-Î¹B and AP-1 via c-Jun and RelA gene regulation. Medical Journal of the Islamic Republic of Iran, 2018, 32, 51-56.	0.9	4
3736	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. Journal of Clinical and Translational Hepatology, 2016, 1, 131-7.	0.7	42
3737	Environmental Exposures and Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2016, 1, 138-43.	0.7	10
3738	Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. Journal of Clinical and Translational Hepatology, 2015, 3, 182-188.	0.7	23
3739	Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	0.7	9
3740	Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. Journal of Clinical and Translational Hepatology, 2019, 7, 1-14.	0.7	28

#	Article	IF	Citations
3741	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography, 2019, 38, 191-199.	1.0	13
3742	Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases. Histology and Histopathology, 2014, 29, 33-44.	0.5	37
3743	Autophagy Related-Protein 16-1 Up-Regulated in Hepatitis B Virus-Related Hepatocellular Carcinoma and Impaired Apoptosis. Gastroenterology Research, 2018, 11, 404-410.	0.4	7
3744	Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. Journal of Clinical Medicine Research, 2018, 10, 765-771.	0.6	16
3745	Emerging roles for non-selenium containing ER-resident glutathione peroxidases in cell signaling and disease. Biological Chemistry, 2021, 402, 271-287.	1.2	26
3746	Citotoxyc and apoptotic activity of extracts from leaves and juice of passiflora edulis. Journal of Liver Research, Disorders & Therapy, 2018, 4, .	0.1	6
3747	Drug targeting strategies for liver cancer and other liver diseases. MOJ Drug Design Development & Therapy, 2018, 2, .	0.1	5
3750	The long non-coding RNA H19 â€“ a new player in hepatocellular carcinoma. Cell Stress, 2017, 1, 4-6.	1.4	4
3751	The long non-coding RNA H19 suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma. Cell Stress, 2017, 1, 37-54.	1.4	50
3752	A review of the impact of obesity on common gastrointestinal malignancies. Integrative Cancer Science and Therapeutics, 2017, 4, .	0.1	6
3753	Plasma osteopontin level as a diagnostic marker of hepatocellular carcinoma in patients with radiological evidence of focal hepatic lesions. Tumori, 2013, 99, 100-7.	0.6	9
3754	Effect of Adjuvant Interferon Therapy on Hepatitis B/C Virus-Related Hepatocellular Carcinoma After Curative Therapy - Meta-Analysis. Advances in Clinical and Experimental Medicine, 2015, 24, 331-340.	0.6	21
3755	Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. Journal of Liver Cancer, 2020, 20, 135-147.	0.3	15
3756	HBx and SP1 upregulate DKK1 expression.. Acta Biochimica Polonica, 2017, 64, 35-39.	0.3	7
3757	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011, 3, 192-222.	1.4	520
3758	Beneficial effects of Cripto-1 for transarterial chemoembolization in hepatocellular carcinoma. Aging, 2019, 11, 2998-3011.	1.4	4
3759	miR-125a-5p inhibits tumorigenesis in hepatocellular carcinoma. Aging, 2019, 11, 7639-7662.	1.4	28
3760	CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging, 2020, 12, 784-807.	1.4	82

#	Article	IF	Citations
3761	New landscapes and horizons in hepatocellular carcinoma therapy. Aging, 2020, 12, 3053-3094.	1.4	37
3762	Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Aging, 2020, 12, 7848-7873.	1.4	9
3763	Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma. Aging, 2020, 12, 23849-23871.	1.4	17
3764	Plasma metabolomic analysis of human hepatocellular carcinoma: Diagnostic and therapeutic study. Oncotarget, 2016, 7, 47332-47342.	0.8	22
3765	Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma. Oncotarget, 2016, 7, 49888-49901.	0.8	30
3766	Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget, 2016, 7, 54650-54661.	0.8	63
3767	Clinical utility of microRNA-378 as early diagnostic biomarker of human cancers: a meta-analysis of diagnostic test. Oncotarget, 2016, 7, 58569-58578.	0.8	22
3768	Association of the GLB1 rs4678680 genetic variant with risk of HBV-related hepatocellular carcinoma. Oncotarget, 2016, 7, 56501-56507.	0.8	6
3769	eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget, 2016, 7, 62327-62339.	0.8	24
3770	Paradoxical overexpression of MBNL2 in hepatocellular carcinoma inhibits tumor growth and invasion. Oncotarget, 2016, 7, 65589-65601.	0.8	14
3771	Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget, 2016, 7, 71036-71051.	0.8	44
3772	Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population. Oncotarget, 2016, 7, 73754-73768.	0.8	15
3773	miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/Î²-catenin signaling pathway. Oncotarget, 2016, 7, 75038-75051.	0.8	38
3774	FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells. Oncotarget, 2016, 7, 77495-77507.	0.8	15
3775	Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. Oncotarget, 2016, 7, 77622-77634.	0.8	33
3776	The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget, 2016, 7, 86791-86802.	0.8	16
3777	CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 18872-18884.	0.8	42
3778	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 15846-15857.	0.8	40

#	Article	IF	Citations
3779	Screening effective differential expression genes for hepatic carcinoma with metastasis in the peripheral blood mononuclear cells by RNA-seq. Oncotarget, 2017, 8, 27976-27989.	0.8	13
3780	Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells. Oncotarget, 2017, 8, 37278-37290.	0.8	33
3781	PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy. Oncotarget, 2017, 8, 29202-29219.	0.8	9
3782	Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget, 2017, 8, 39323-39344.	0.8	34
3783	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget, 2017, 8, 41242-41255.	0.8	89
3784	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget, 2017, 8, 46234-46248.	0.8	49
3785	MiR-199a/b-5p inhibits hepatocellular carcinoma progression by post-transcriptionally suppressing ROCK1. Oncotarget, 2017, 8, 67169-67180.	0.8	42
3786	Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget, 2014, 5, 3662-3672.	0.8	40
3787	Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma. Oncotarget, 2014, 5, 3685-3696.	0.8	25
3788	Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI. Oncotarget, 2017, 8, 72959-72971.	0.8	12
3789	Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis. Oncotarget, 2017, 8, 66328-66342.	0.8	26
3790	Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget, 2017, 8, 91328-91342.	0.8	9
3791	Association of ACYP2 and MPHOSPH6 genetic polymorphisms with the risk of hepatocellular carcinoma in chronic hepatitis B virus carriers. Oncotarget, 2017, 8, 86011-86019.	0.8	1
3792	Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-Î²B signaling pathway. Oncotarget, 2014, 5, 8330-8340.	0.8	70
3793	CTHRC1 activates pro-tumorigenic signaling pathways in hepatocellular carcinoma. Oncotarget, 2017, 8, 105238-105250.	0.8	13
3794	Agrin para-secreted by PDGF-activated human hepatic stellate cells promotes hepatocarcinogenesis in vitro and in vivo. Oncotarget, 2017, 8, 105340-105355.	0.8	30
3795	Metformin reverses bFGF-induced epithelial-mesenchymal transition in HCC cells. Oncotarget, 2017, 8, 104247-104257.	0.8	18
3796	Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice. Oncotarget, 2017, 8, 104315-104329.	0.8	7

#	Article	IF	Citations
3797	Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and in vitro investigation. Oncotarget, 2017, 8, 108333-108354.	0.8	14
3798	High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma. Oncotarget, 2017, 8, 111623-111630.	0.8	12
3799	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget, 2017, 8, 115667-115680.	0.8	16
3800	Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget, 2014, 5, 9425-9443.	0.8	78
3801	Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget, 2018, 9, 16988-16995.	0.8	19
3802	Prognostic value of LINE-1 methylation level in 321 patients with primary liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget, 2018, 9, 20795-20806.	0.8	14
3803	Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma. Oncotarget, 2018, 9, 26868-26883.	0.8	51
3804	PLAGL1 gene function during hepatoma cells proliferation. Oncotarget, 2018, 9, 32775-32794.	0.8	4
3805	Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. Oncotarget, 2015, 6, 633-641.	0.8	38
3806	CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. Oncotarget, 2015, 6, 4733-4744.	0.8	22
3807	MicroRNA-153 promotes Wnt/Î²-catenin activation in hepatocellular carcinoma through suppression of WWOX. Oncotarget, 2015, 6, 3840-3847.	0.8	48
3808	MicroRNA-135b, a HSF1 target, promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma. Oncotarget, 2015, 6, 2421-2433.	0.8	64
3809	Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget, 2015, 6, 2539-2548.	0.8	50
3810	Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma. Oncotarget, 2015, 6, 16507-16516.	0.8	29
3811	Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma. Oncotarget, 2015, 6, 21193-21207.	0.8	9
3812	Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget, 2015, 6, 19217-19227.	0.8	33
3813	HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. Oncotarget, 2015, 6, 29048-29059.	0.8	35
3814	Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition. Oncotarget, 2015, 6, 30130-30148.	0.8	25

#	Article	IF	Citations
3815	Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk. Oncotarget, 2015, 6, 42952-42962.	0.8	19
3816	A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget, 2015, 6, 31927-31943.	0.8	98
3817	GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS Axis in hepatocellular carcinoma. Oncotarget, 2015, 6, 33658-33674.	0.8	21
3818	P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget, 2015, 6, 41162-41179.	0.8	34
3819	Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice. Oncotarget, 2016, 7, 10448-10458.	0.8	22
3820	MicroRNA-150 suppresses cell proliferation and metastasis in hepatocellular carcinoma by inhibiting the GAB1-ERK axis. Oncotarget, 2016, 7, 11595-11608.	0.8	43
3821	Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1. Oncotarget, 2016, 7, 14336-14349.	0.8	28
3822	MEK1 signaling promotes self-renewal and tumorigenicity of liver cancer stem cells via maintaining SIRT1 protein stabilization. Oncotarget, 2016, 7, 20597-20611.	0.8	33
3823	EVI1 promotes cell proliferation in HBx-induced hepatocarcinogenesis as a critical transcription factor regulating lncRNAs. Oncotarget, 2016, 7, 21887-21899.	0.8	9
3824	Cellular apoptosis susceptibility (CAS) is linked to integrin Î²1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC). Oncotarget, 2016, 7, 22883-22892.	0.8	18
3825	Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget, 2016, 7, 27838-27847.	0.8	25
3826	SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1Î±-mediated mitochondrial biogenesis. Oncotarget, 2016, 7, 29255-29274.	0.8	89
3827	Hepatitis B virus X protein amplifies TGF-Î² promotion on HCC motility through down-regulating PPM1a. Oncotarget, 2016, 7, 33125-33135.	0.8	27
3828	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	0.8	45
3829	Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo. Oncotarget, 2016, 7, 32607-32616.	0.8	58
3830	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget, 2016, 7, 39609-39626.	0.8	25
3831	Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma. Electronic Physician, 2017, 9, 3492-3498.	0.2	29
3832	Evaluation of CD44 and CD133 as markers of liver cancer stem cells in Egyptian patients with HCV-induced chronic liver diseases versus hepatocellular carcinoma. Electronic Physician, 2017, 9, 4708-4717.	0.2	13

#	Article	IF	Citations
3834	Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies. Hepatoma Research, 2016, 2, 151.	0.6	12
3835	The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Research, 2020, 2020, .	0.6	21
3836	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Annals of Gastroenterology, 2017, 30, 327-343.	0.4	6
3837	Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis. Cancer Biology and Medicine, 2020, 17, 478-491.	1.4	13
3838	Selenium concentration, dietary intake and risk of hepatocellular carcinoma â€“ A systematic review with meta-analysis. Nutricion Hospitalaria, 2019, 36, 1430-1437.	0.2	3
3839	MARVELD1 attenuates arsenic trioxide-induced apoptosis in liver cancer cells by inhibiting reactive oxygen species production. Annals of Translational Medicine, 2019, 7, 200-200.	0.7	5
3840	Magnesium and liver disease. Annals of Translational Medicine, 2019, 7, 578-578.	0.7	49
3841	The clinical value of total plasma cell-free DNA in hepatitis B virus-related hepatocellular carcinoma. Annals of Translational Medicine, 2019, 7, 650-650.	0.7	14
3842	Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 24-24.	1.5	38
3843	Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 364-372.	0.7	26
3844	LONG NON-CODING RNA H19 AS POTENTIAL BIOMARKER FOR HCV GENOTYPE 4 INDUCED HEPATOCELLULAR CARCINOMA PATIENTS. Al-Azhar Journal of Pharmaceutical Sciences, 2019, 60, 76-94.	0.1	2
3845	MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules. Current Medicinal Chemistry, 2013, 20, 3629-3640.	1.2	32
3846	Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. Current Drug Metabolism, 2019, 20, 283-291.	0.7	4
3847	Has Selenium a Chemopreventive Effect on Hepatocellular Carcinoma?. Mini-Reviews in Medicinal Chemistry, 2011, 11, 599-610.	1.1	5
3848	Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Current Drug Delivery, 2020, 17, 826-844.	0.8	13
3849	Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?. Current Cancer Drug Targets, 2018, 19, 26-40.	0.8	31
3850	The Influence of Diabetes in the Pathogenesis and the Clinical Course of Hepatocellular Carcinoma: Recent Findings and New Perspectives. Current Diabetes Reviews, 2013, 9, 382-386.	0.6	49
3851	Liver Stem Cells: From Preface to Advancements. Current Stem Cell Research and Therapy, 2013, 9, 10-21.	0.6	14

#	Article	IF	Citations
3852	Statins and Protein Prenylation in Cancer Cell Biology and Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 303-315.	0.9	49
3853	Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1575-1581.	0.9	48
3854	Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 484-492.	0.9	22
3855	Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. Anticancer Research, 2016, 36, 4639-4646.	0.5	7
3856	Puerarin Induces Hepatocellular Carcinoma Cell Apoptosis Modulated by MAPK Signaling Pathways in a Dose-dependent Manner. Anticancer Research, 2017, 37, 4425-4431.	0.5	15
3857	miR-223 and Stathmin-1 Expression in Non-tumor Liver Tissue of Patients with Hepatocellular Carcinoma. , 2017, 37, 5877-5883.		8
3858	Cytokeratin-18 in Diagnosis of HCC in Patients with Liver Cirrhosis. Asian Pacific Journal of Cancer Prevention, 2017, 18, 1105-1111.	0.5	10
3859	Effect of a Copper (II) Complex on The Induction of Apoptosis in Human Hepatocellular Carcinoma Cells. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2877-2884.	0.5	12
3860	Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1503-1508.	0.5	12
3861	Characterization and Validation of Hepatocellular Carcinoma (HCC) Xenograft tumor as a Suitable Liver Cancer Model for Preclinical Mesenchymal Stem Cell Studies. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1627-1631.	0.5	11
3862	Prevention of Hepatocellular Carcinoma. , 2009, , 36-61.		2
3863	Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC). Asian Pacific Journal of Cancer Prevention, 2019, 20, 2515-2522.	0.5	9
3864	The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cellular Oncology, 2010, 32, 285-300.	1.9	38
3865	Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C VirusAssociated Hepatocellular Carcinomas. Acta Naturae, 2017, 9, 108-114.	1.7	4
3866	Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization. Journal of Korean Medical Science, 2019, 34, e208.	1.1	6
3867	Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clinical and Molecular Hepatology, 2012, 18, 219.	4.5	24
3868	Current status of laparoscopic liver resection for hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 212-218.	4.5	57
3869	Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma. Clinical and Molecular Hepatology, 2017, 23, 138-146.	4.5	3

#	Article	IF	Citations
3870	Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clinical and Molecular Hepatology, 2020, 26, 196-208.	4.5	15
3871	Molecular targeting for treatment of advanced hepatocellular carcinoma. The Korean Journal of Hepatology, 2009, 15, 299.	1.5	8
3872	Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. The Korean Journal of Hepatology, 2010, 16, 308.	1.5	8
3873	Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy. Frontiers in Oncology, 2020, 10, 574668.	1.3	5
3874	Milk Fat Globule-EGF Factor 8 Contributes to Progression of Hepatocellular Carcinoma. Cancers, 2020, 12, 403.	1.7	16
3875	Exploration of Deregulated Long Non-Coding RNAs in Association with Hepatocarcinogenesis and Survival. Cancers, 2015, 7, 1847-1862.	1.7	16
3876	Sex-dependent differences in DNA copy number alterations in hepatocellular carcinoma. Academic Journal of Second Military Medical University, 2012, 32, 5-9.	0.0	1
3877	Novel therapeutic approaches for hepatocellulcar carcinoma: Fact and fiction. World Journal of Gastroenterology, 2008, 14, 1641.	1.4	8
3878	Natural history of hepatitis-related hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1652.	1.4	203
3879	Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World Journal of Gastroenterology, 2008, 14, 1664.	1.4	96
3880	Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1670.	1.4	33
3881	Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1690.	1.4	67
3882	Activins and activin antagonists in hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1699.	1.4	56
3883	Occult persistence and lymphotropism of hepatitis C virus infection. World Journal of Gastroenterology, 2008, 14, 2789.	1.4	33
3884	Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 5945.	1.4	130
3885	Clinical relevance and public health signifcance of hepatitisB virus genomic variations. World Journal of Gastroenterology, 2009, 15, 5761.	1.4	132
3886	Melatonin and Doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World Journal of Gastroenterology, 2010, 16, 1473.	1.4	92
3887	Impairment of pre-mRNA splicing in liver disease: Mechanisms and consequences. World Journal of Gastroenterology, 2010, 16, 3091.	1.4	40

#	Article	IF	Citations
3888	Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World Journal of Gastroenterology, 2010, 16, 3592.	1.4	7
3889	Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. World Journal of Gastroenterology, 2010, 16, 5257.	1.4	17
3890	DEC1 nuclear expression: A marker of differentiation grade in hepatocellular carcinoma. World Journal of Gastroenterology, 2011, 17, 2037.	1.4	39
3891	Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma: A meta-analysis. World Journal of Gastroenterology, 2011, 17, 2248.	1.4	20
3892	Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World Journal of Gastroenterology, 2011, 17, 3922.	1.4	77
3893	Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World Journal of Gastroenterology, 2011, 17, 4206.	1.4	35
3894	Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World Journal of Gastroenterology, 2011, 17, 914.	1.4	21
3895	Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 1806.	1.4	74
3896	Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 1926.	1.4	19
3897	Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?. World Journal of Gastroenterology, 2012, 18, 1933.	1.4	11
3898	Aberrant methylation ofSPARCin human hepatocellular carcinoma and its clinical implication. World Journal of Gastroenterology, 2012, 18, 2043.	1.4	22
3899	Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World Journal of Gastroenterology, 2012, 18, 2408.	1.4	45
3900	Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World Journal of Gastroenterology, 2012, 18, 3389.	1.4	29
3901	Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World Journal of Gastroenterology, 2012, 18, 4071.	1.4	115
3902	Role of innate immunity in the development of hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 7500.	1.4	47
3903	Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World Journal of Gastroenterology, 2013, 19, 8895.	1.4	22
3904	Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World Journal of Gastroenterology, 2013, 19, 1359.	1.4	18
3905	Occult hepatitis B virus and hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 5951.	1.4	53

#	Article	IF	Citations
3906	Challenges in transplantation for alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 8033.	1.4	32
3907	Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?. World Journal of Gastroenterology, 2014, 20, 9217-28.	1.4	59
3908	Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression. World Journal of Gastroenterology, 2014, 20, 10082.	1.4	43
3909	Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World Journal of Gastroenterology, 2014, 20, 795.	1.4	30
3910	Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World Journal of Gastroenterology, 2014, 20, 17141.	1.4	44
3911	Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 17541.	1.4	29
3912	Effect of microRNA-1 on hepatocellular carcinoma tumor endothelial cells. World Journal of Gastroenterology, 2015, 21, 5884-5892.	1.4	11
3913	Telomere shortening as genetic risk factor of liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 379.	1.4	14
3914	Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 6317.	1.4	32
3915	Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World Journal of Gastroenterology, 2015, 21, 6518.	1.4	49
3916	Long noncoding RNAs in hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 7208-7217.	1.4	25
3917	Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 8249.	1.4	24
3918	Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 8994.	1.4	22
3919	Efficiency and safety of radiofrequency-assisted hepatectomy for hepatocellular carcinoma with cirrhosis: A single-center retrospective cohort study. World Journal of Gastroenterology, 2015, 21, 10159-10165.	1.4	9
3920	Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World Journal of Gastroenterology, 2015, 21, 11185.	1.4	135
3921	Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. World Journal of Gastroenterology, 2015, 21, 13225.	1.4	63
3922	Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 205.	1.4	28
3923	Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World Journal of Gastroenterology, 2016, 22, 394.	1.4	12

#	Article	IF	Citations
3924	Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World Journal of Gastroenterology, 2016, 22, 407.	1.4	61
3925	High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World Journal of Gastroenterology, 2016, 22, 3803.	1.4	7
3926	Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World Journal of Gastroenterology, 2016, 22, 5384.	1.4	40
3927	Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World Journal of Gastroenterology, 2016, 22, 7569.	1.4	18
3928	Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 1497.	1.4	47
3929	Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 2286.	1.4	23
3930	Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma. World Journal of Gastroenterology, 2018, 24, 1152-1166.	1.4	24
3931	Hepatocellular carcinoma surveillance: An evidence-based approach. World Journal of Gastroenterology, 2019, 25, 1550-1559.	1.4	144
3932	Organoids of liver diseases: From bench to bedside. World Journal of Gastroenterology, 2019, 25, 1913-1927.	1.4	12
3933	Occupational exposure to vinyl chloride and liver diseases. World Journal of Gastroenterology, 2019, 25, 4885-4891.	1.4	18
3934	Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 2012-2029.	1.4	4
3935	Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 5759-5783.	1.4	128
3936	Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 6599-6613.	1.4	11
3937	Role of alcohol in pathogenesis of hepatitis B virus infection. World Journal of Gastroenterology, 2020, 26, 883-903.	1.4	24
3939	The response of thrombosis in the portal vein or hepatic vein in hepatocellular carcinoma to radiation therapy. Radiation Oncology Journal, 2016, 34, 168-176.	0.7	10
3940	Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1668-1673.	0.1	8
3941	Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and metaâ€'analysis. Molecular and Clinical Oncology, 2020, 12, 15-22.	0.4	11
3942	ZEB1 promotes tumorigenesis and metastasis in hepatocellular carcinoma by regulating the expression of vimentin. Molecular Medicine Reports, 2019, 19, 2297-2306.	1.1	15

#	Article	IF	Citations
3943	Long nonâ€'coding RNAâ€'based risk scoring system predicts prognosis of alcoholâ€'related hepatocellular carcinoma. Molecular Medicine Reports, 2020, 22, 997-1007.	1.1	10
3944	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by directâ€'acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncology Letters, 2020, 19, 2205-2212.	0.8	26
3945	High KIAA1522 expression predicts a poor prognosis in patients with hepatocellular carcinoma. Oncology Letters, 2020, 20, 509-516.	0.8	8
3946	Low HOXC10 expression in liver cancer regulates proliferation via a mechanism involving miRâ€'221 and the MAPK signaling pathway. Oncology Letters, 2020, 20, 1-1.	0.8	7
3947	Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virusâ€'associated early stage hepatocellular carcinoma based on RNAâ€'sequencing data. Oncology Letters, 2020, 20, 1-1.	0.8	4
3948	Preoperative plus postoperative neutrophilâ€'lymphocyte ratio for predicting overall survival following partial hepatectomy for hepatocellular carcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	12
3949	Hypoxia-induced circular RNA hsa_circ_0008450 accelerates hepatocellular cancer progression via the miR-431/AKAP1 axis. Oncology Letters, 2020, 20, 1-1.	0.8	17
3950	ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma. Oncology Reports, 2017, 38, 1451-1463.	1.2	13
3951	Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database. Oncology Reports, 2020, 43, 1771-1784.	1.2	17
3952	Long nonâ€'coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miRâ€'675. Oncology Reports, 2020, 44, 165-173.	1.2	41
3953	Risk of hepatitis B virus-related hepatocellular carcinoma development is much higher in Koreans than in Taiwanese. Korean Journal of Internal Medicine, 2017, 32, 940-942.	0.7	1
3954	A Case of Hepatocellular Carcinoma in a Patient with Crohn's Disease. Korean Journal of Medicine, 2015, 88, 424.	0.1	1
3955	Chemoprotective Effects of Resveratrol Against Diethylnitrosamine Induced Hepatocellular Carcinoma in Wistar Rats. International Journal of Pharmacology, 2019, 15, 549-559.	0.1	7
3956	Resveratrol Inhibits MMP-2 Expression of Hepatoma in Nude Mice. Journal of Animal and Veterinary Advances, 2011, 10, 33-37.	0.1	2
3957	Hepatocellular carcinoma: Options for diagnosing and managing a deadly disease. Cleveland Clinic Journal of Medicine, 2013, 80, 645-653.	0.6	1
3958	C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients. Quantitative Imaging in Medicine and Surgery, 2013, 3, 196-9.	1.1	13
3959	Therapeutic actions of melatonin on gastrointestinal cancer development and progression. Translational Gastrointestinal Cancer, 2013, 2, .	3.0	8
3960	Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma. Chinese Clinical Oncology, 2013, 2, 32.	0.4	14

#	Article	IF	Citations
3961	Hepatitis B virus and host factors. Hepatobiliary Surgery and Nutrition, 2013, 2, 121-3.	0.7	12
3962	In vitro anti-proliferative effect of Tephrosia purpurea on human hepatocellular carcinoma cells. Pharmacognosy Magazine, 2017, 13, 16.	0.3	10
3963	Cyclooxygenase-2 gene polymorphisms and susceptibility to hepatocellular carcinoma: A meta-analysis based on 10 case-control studies. Journal of Cancer Research and Therapeutics, 2018, 14, 105.	0.3	9
3964	Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line. International Journal of Preventive Medicine, 2015, 6, 54.	0.2	29
3965	Aberrant p16INK4A methylation: Relation to viral related chronic liver disease and hepatocellular carcinoma. South Asian Journal of Cancer, 2014, 03, 001-004.	0.2	4
3966	Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. Journal of Carcinogenesis, 2017, 16, 1.	2.5	551
3967	US-guided percutanous microwave ablation for early-stage hepatocellular carcinoma in elderly patients is as effective as in younger patients: A 10-year experience. Journal of Cancer Research and Therapeutics, 2020, 16, 292.	0.3	4
3968	The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis. Cancer Research and Treatment, 2016, 48, 1065-1073.	1.3	15
3969	Prognostic Value ofâ€‚TP53â€‚Mutationâ€‚for Transcatheter Arterial Chemoembolizationâ€‚Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma. Cancer Research and Treatment, 2020, 52, 925-937.	1.3	9
3970	Integrated analysis of the RNA-Seq data of liver hepatocellular carcinoma. Neoplasma, 2018, 65, 97-103.	0.7	5
3971	Extracts of Five Medicinal Herbs Induced Cytotoxicity in Both Hepatoma and Myeloma Cell Lines. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	5
3972	Angioprevention is Implicated in Resveratrol Chemoprevention of Experimental Hepatocarcinogenesis. Journal of Carcinogenesis & Mutagenesis, 2010, 01, .	0.3	13
3973	Expressions of Orphan Nuclear Receptor TR3/Nur77 in Chronic Hepatopathy and Its Clinical Significance. Journal of Clinical & Experimental Oncology, 2017, 06, .	0.1	2
3974	Effect of zinc supplementation in patients with type C liver cirrhosis. Open Journal of Gastroenterology, 2011, 01, 28-34.	0.1	10
3975	Meta-analysis demonstrates lack of a relationship between XRCC1-399 gene polymorphisms and susceptibility to hepatocellular carcinoma. Genetics and Molecular Research, 2013, 12, 1916-1923.	0.3	9
3976	Association between the c.1564A>T genetic polymorphism of the MDR1 gene and hepatocellular carcinoma in Chinese population. Genetics and Molecular Research, 2014, 13, 6820-6826.	0.3	2
3977	Association between a single nucleotide polymorphism of the XRCC1 gene and hepatocellular carcinoma susceptibility in the Chinese Han population. Genetics and Molecular Research, 2014, 13, 160-166.	0.3	1
3978	Perspective of laparoscopic liver resection for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2015, 7, 102.	0.8	11

#	Article	IF	Citations
3979	From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways. World Journal of Gastrointestinal Oncology, 2010, 2, 259.	0.8	11
3980	Primary hepatocellular carcinoma and metabolic syndrome: An update. World Journal of Gastrointestinal Oncology, 2013, 5, 186.	0.8	63
3981	Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity. World Journal of Stem Cells, 2017, 9, 159-168.	1.3	11
3982	Hepatic flow is an intraoperative predictor of early allograft dysfunction in whole-graft deceased donor liver transplantation: An observational cohort study. World Journal of Hepatology, 2019, 11, 663-677.	0.8	9
3983	Cirrhotic patients and older people. World Journal of Hepatology, 2019, 11, 678-688.	0.8	22
3984	Biomarkers for hepatocellular cancer. World Journal of Hepatology, 2020, 12, 558-573.	0.8	30
3985	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World Journal of Hepatology, 2010, 2, 114.	0.8	42
3986	Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World Journal of Hepatology, 2010, 2, 91.	0.8	7
3987	Pure laparoscopic hepatectomy for hepatocellular carcinoma with chronic liver disease. World Journal of Hepatology, 2013, 5, 487.	0.8	28
3988	Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI. World Journal of Hepatology, 2014, 6, 930.	0.8	6
3989	Hagen-Poiseuilleâ€™s law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation. World Journal of Hepatology, 2015, 7, 28.	0.8	9
3990	Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World Journal of Hepatology, 2015, 7, 1460.	0.8	16
3991	Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1875.	0.8	26
3992	Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism. World Journal of Hepatology, 2015, 7, 2781.	0.8	44
3993	Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?. World Journal of Hepatology, 2015, 7, 521.	0.8	8
3994	Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World Journal of Hepatology, 2015, 7, 1097.	0.8	17
3995	Quantitative morphometric analysis of hepatocellular carcinoma: programmed algorithm development and preliminary application. Diagnostic and Interventional Radiology, 2012, 19, 97-105.	0.7	12
3996	UBD (ubiquitin D). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	1

#	Article	IF	Citations
3997	Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Medical Weekly, 2011, 141, w13197.	0.8	48
3998	Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Medical Weekly, 2012, 142, w13651.	0.8	11
3999	A large cohort of patients with hepatocellular carcinoma in a single European centre: aetiology and prognosis now and in a historical cohort. Swiss Medical Weekly, 2014, 144, w13900.	0.8	8
4000	Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian Journal of Hepato-gastroenterology, 2019, 9, 27-33.	0.1	23
4001	Metadherin Is a Prognostic Predictor of Hepatocellular Carcinoma after Curative Hepatectomy. Gut and Liver, 2013, 7, 206-212.	1.4	26
4002	Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut and Liver, 2018, 12, 94-101.	1.4	14
4003	Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays. Gut and Liver, 2018, 12, 306-315.	1.4	5
4004	Therapeutic Effects of Korean Red Ginseng Extract in Egyptian Patients with Chronic Liver Diseases. Journal of Ginseng Research, 2011, 35, 69-79.	3.0	21
4005	Evolving role of Sorafenib in the management of hepatocellular carcinoma. World Journal of Clinical Oncology, 2017, 8, 203.	0.9	32
4006	Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. Journal of the Belgian Society of Radiology, 2019, 103, 47.	0.1	11
4007	Free radical scavenging and hepatoprotective activity of HD-03/ES in experimental models. Journal of Experimental and Integrative Medicine, 2012, 2, 161.	0.1	6
4008	Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment. Toxicological Research, 2011, 27, 247-251.	1.1	1
4009	Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World Journal of Pharmacology, 2015, 4, 96.	1.3	4
4010	LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chinese Journal of Cancer, 2012, 31, 223-232.	4.9	15
4011	The Association of Ala133Ser Polymorphism and Methylation in Ras Association Domain Family 1A Gene With Unfavorable Prognosis of Hepatocellular Carcinoma. Hepatitis Monthly, 2015, 15, e32145.	0.1	6
4012	Histologic Grade and Mitotic Index as Predictors of Microvascular Invasion in Hepatocellular Carcinoma. Experimental and Clinical Transplantation, 2015, 13, 421-5.	0.2	5
4013	Hepatitis C Virus Mediated Hepatocellular Carcinoma: A Focused Review for a Time of Changing Therapeutic Options. North American Journal of Medicine & Science, 2014, 07, 008.	3.8	4
4014	Sex-related Differences in DNA Copy Number Alterations in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2012, 13, 225-229.	0.5	14

#	Article	IF	Citations
4015	Molecular Prognostic Profile of Egyptian HCC Cases Infected with Hepatitis C Virus. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5433-5438.	0.5	26
4016	Preparation of Microspheres Encapsulating a Recombinant TIMP-1 Adenovirus and their Inhibition of Proliferation of Hepatocellular Carcinoma Cells. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6363-6368.	0.5	3
4017	Risk Factors of Hepatocellular Carcinoma - Current Status and Perspectives. Asian Pacific Journal of Cancer Prevention, 2012, 13, 743-752.	0.5	124
4018	Treatment of Malignant Melanoma by Downregulation of XIAP and Overexpression of TRAIL with a Conditionally Replicating Oncolytic Adenovirus. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1471-1476.	0.5	6
4019	Associations Between Three Common MicroRNA Polymorphisms and Hepatocellular Carcinoma Risk in Chinese. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6601-6604.	0.5	30
4020	Epidemiology and Survival of Hepatocellular Carcinoma in North-east Peninsular Malaysia. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6955-6959.	0.5	32
4021	Prevalence of Aflatoxin Induced p53 Mutation at Codon 249 (R249s) in Hepatocellular Carcinoma Patients with and without Hepatitis B Surface Antigen (HBsAg). Asian Pacific Journal of Cancer Prevention, 2013, 14, 7675-7679.	0.5	21
4022	The KIF1B (rs17401966) Single Nucleotide Polymorphism is not Associated with the Development of HBV-related Hepatocellular Carcinoma in Thai Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2865-2869.	0.5	33
4023	Serum Talin-1 is a Potential Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3819-3823.	0.5	30
4024	Association Between the c.3751G>A Genetic Variant of MDR1 and Hepatocellular Carcinoma Risk in a Chinese Han Population. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5361-5365.	0.5	6
4025	Hepatitis C Virus Prevalence and Genotyping among Hepatocellular Carcinoma Patients in Baghdad. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7725-7730.	0.5	9
4026	Polymorphisms of TERT and CLPTM1L and the Risk of Hepatocellular Carcinoma in Chinese Males. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8197-8201.	0.5	13
4027	Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma. Asian Pacific Journal of Cancer Prevention, 2014, 15, 647-650.	0.5	13
4028	Low Counts of Î³Î´ T Cells in Peritumoral Liver Tissue are Related to More Frequent Recurrence in Patients with Hepatocellular Carcinoma after Curative Resection. Asian Pacific Journal of Cancer Prevention, 2014, 15, 775-780.	0.5	29
4029	Iso-suillin Isolated from Suillus luteus, Induces G₁Phase Arrest and Apoptosis in Human Hepatoma SMMC-7721 Cells. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1423-1428.	0.5	7
4030	Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1539-1544.	0.5	37
4031	Talin-1 Correlates with Reduced Invasion and Migration in Human Hepatocellular Carcinoma Cells. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2655-2661.	0.5	27
4032	Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3151-3156.	0.5	5

#	Article	IF	Citations
4033	Burden of Virus-associated Liver Cancer in the Arab World, 1990-2010. Asian Pacific Journal of Cancer Prevention, 2015, 16, 265-270.	0.5	21
4034	Significance of Rumex Vesicarius as Anticancer Remedy Against Hepatocellular Carcinoma: a Proposal-Based on Experimental Animal Studies. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4303-4310.	0.5	20
4035	Molecular Links between Alcohol and Tobacco Induced DNA Damage, Gene Polymorphisms and Patho-physiological Consequences: A Systematic Review of Hepatic Carcinogenesis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4803-4812.	0.5	18
4036	Role of IL-18 Gene Promoter Polymorphisms, Serum IL-18 Levels, and Risk of Hepatitis B Virus-related Liver Disease in the Guangxi Zhuang Population: a Retrospective Case-Control Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6019-6026.	0.5	11
4037	Single Nucleotide Polymorphisms in miR-149 (rs2292832) and miR-101-1 (rs7536540) Are Not Associated with Hepatocellular Carcinoma in Thai Patients with Hepatitis B Virus Infection. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6457-6461.	0.5	10
4038	Phytochemical Analysis and Anti-cancer Investigation of Boswellia Serrata Bioactive Constituents In Vitro. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7179-7188.	0.5	49
4039	Association between the NQO1 C609T Polymorphism with Hepatocellular Carcinoma Risk in the Chinese Population. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1821-1825.	0.5	5
4040	Association between the Epidermal Growth Factor 61*A/G Polymorphism and Hepatocellular Carcinoma Risk: a Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3009-3014.	0.5	4
4041	NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte. ELife, 2019, 8, .	2.8	29
4042	Identification of crucial genes based on expression profiles of hepatocellular carcinomas by bioinformatics analysis. PeerJ, 2019, 7, e7436.	0.9	48
4043	Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases. Cureus, 2020, 12, e11150.	0.2	16
4044	Tissue Biomarkers in the Early Detection of Hepatocellular Carcinoma among Egyptian Patients with Chronic Hepatitis C: A Possible Genetic Profile. British Journal of Medicine and Medical Research, 2013, 3, 1858-1870.	0.2	4
4045	Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study. Hepatobiliary Surgery and Nutrition, 2023, 12, 155-168.	0.7	5
4046	Relationship between Protein kinase C isoforms, Telomerase and Alpha- fetoprotein through PI3K/AKT/mTOR pathway in Hepatocellular carcinoma. Y Hoc Thanh Pho Ho Chi Minh, 2021, 5, 12-26.	0.1	0
4047	Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Journal of Oncology, 2021, 2021, 1-10.	0.6	8
4048	Screening Hub Genes of Hepatocellular Carcinoma Based on Public Databases. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-15.	0.7	5
4049	Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis. Life, 2021, 11, 1066.	1.1	2
4050	HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Frontiers in Medicine, 2021, 8, 713981.	1.2	20

#	Article	IF	Citations
4051	Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens, 2021, 10, 1366.	1.2	10
4052	High Red Cell Distribution Width and Low Absolute Lymphocyte Count Associate With Subsequent Mortality in HCV Infection. Pathogens and Immunity, 2021, 6, 90-104.	1.4	4
4053	Automated segmentation of lung, liver, and liver tumors from Tcâ€99m MAA SPECT/CT images for Yâ€90 radioembolization using convolutional neural networks. Medical Physics, 2021, 48, 7877-7890.	1.6	8
4054	Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 1245-1257.	0.8	2
4055	Hepatocellular Carcinoma Tumor Microenvironment and Its Implications in Terms of Anti-tumor Immunity: Future Perspectives for New Therapeutics. Journal of Gastrointestinal Cancer, 2021, 52, 1198-1205.	0.6	8
4056	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers, 2021, 13, 5018.	1.7	16
4057	A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling. Toxicology and Applied Pharmacology, 2021, 431, 115739.	1.3	15
4058	Molecular Biology of Liver Carcinogenesis and Hepatitis. , 2007, , 153-163.		0
4060	Prognostic Prediction in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2008, 42, 221-223.	1.1	1
4063	Radiofrequency Ablation of Hepatocellular Carcinoma. , 2009, , 421-451.		1
4064	Screening and Biomarkers for Hepatocellular Carcinoma. , 2009, , 327-348.		0
4065	Molecular Mechanisms of Hepatocellular Carcinoma: Insights to Therapy. , 2009, , 109-130.		0
4066	Primary Liver Cancer: Chemical Carcinogenesis. , 2009, , 55-107.		1
4067	Epidemiology of the Hepatocellular Carcinoma. , 2009, , 1-8.		1
4068	Molecular Pathogenesis. , 2009, , 9-25.		1
4069	HBV Signaling. , 2010, , 465-481.		0
4070	Obesity and Cancer in Asia. , 2010, , 65-86.		0
4071	Molecular Pathogenesis of Hepatocellular Carcinoma. , 2010, , 373-396.		0

#	Article	IF	Citations
4072	Nongenotoxic Carcinogenesis. , 2010, , 35-48.		0
4073	Transgenic and Knockout Mouse Models of Liver Cancer. , 2010, , 163-188.		0
4074	Role of Epigenetic Machinery and MicRNAs in Diet-Induced Hepatocarcinogenesis. , 2010, , 158-201.		0
4077	Orthotopic Liver Transplantation in Patients with Mixed Hepatocellular Carcinoma-Cholangiocarcinoma. Journal of Transplantation Technologies & Research, 2011, 01, .	0.1	7
4078	Morphometric analysis of various types of autophagy in hepatocellular carcinoma tissues. Academic Journal of Second Military Medical University, 2011, 31, 238-242.	0.0	0
4079	Proton Therapy for Thoracoabdominal Tumors. Biological and Medical Physics Series, 2012, , 207-222.	0.3	0
4080	Sex and Gender Differences in Gastroenterology and Hepatology. , 2012, , 65-82.		1
4081	The Molecular Pathogenesis of Aflatoxin with Hepatitis B Virus-Infection in Hepatocellular Carcinoma. , 0, , .		0
4086	Overview of Hepatitis Viruses and Cancer. , 2012, , 509-529.		0
4088	Percutaneous Local Injection of Ethanol and Mitoxantrone in Treatment of Hepatocellular Carcinoma. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2011, 1, 28-36.	0.1	1
4089	THE EXPRESSION PATTERN OF GALECTIN-3 IN THE RAT HEPATOCELLULAR CARCINOMA. Bulletin of Pharmaceutical Sciences, 2011, 34, 181-187.	0.0	1
4090	Genomics of Hepatocellular Carcinoma. , 2012, , 45-78.		0
4091	Metabonomics of Hepatocellular Carcinoma. , 2012, , 155-177.		0
4092	Clinical Characteristics of 130 Patients With Hepatocellular Carcinoma Followed at a Tertiary Hospital From Brazil. World Journal of Oncology, 2012, 3, 165-172.	0.6	4
4093	NS-398 induces caspase-dependent, mitochondria-mediated intrinsic apoptosis of hepatoma cells. Advances in Bioscience and Biotechnology (Print), 2012, 03, 649-656.	0.3	0
4095	Molecular Genetics and Genomics of Hepatocellular Carcinoma. , 0, , .		0
4096	Liver Transplantation for Hepatocellular Carcinoma (Hcc). , 0, , .		0
4098	Application of obstruction of Glission pedicle combined with partial occlusion obstruction of inferior vena cava in regional liver resection. African Journal of Pharmacy and Pharmacology, 2012, 6, .	0.2	0

#	Article	IF	Citations
4099	The Relationship Between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. , 0, , .		0
4100	Sorafenib Use in Hepatocellular Carcinoma in Japan: Early Experience and Impact on Clinical Practice. Clinical Drug Investigation, 2012, 32, 1-2.	1.1	2
4101	Liver Cancer. , 2013, , 167-175.		0
4102	Robotic Radiosurgery for Liver Metastases. Cureus, 2012, , .	0.2	1
4103	Screening and Identification of Polypeptides Specifically Binding to Hepatoma Carcinoma Cells. Journal of Animal and Veterinary Advances, 2012, 11, 2166-2175.	0.1	0
4105	Prognostic Factors for Hepatocellular Carcinoma: Is it ready for Primetime?. Journal of Liver, 2013, 02, .	0.3	1
4106	Characteristics Features of Hepatocellular Carcinoma in Bangladesh and their Public Health Implications. Euroasian Journal of Hepato-gastroenterology, 2013, 3, 28-30.	0.1	1
4107	Adult Liver Stem Cells. Pancreatic Islet Biology, 2014, , 319-338.	0.1	0
4108	Expression of Matrix Metalloproteinase 1(MMP1) in Hepatocellular Carcinoma (HCC) : Immunohistochemical and Biochemical Studies. The Egyptian Journal of Hospital Medicine, 2013, 51, 289-299.	0.0	0
4109	Sorafenib-Inhibited Signaling: Emerging Evidence of RAFIndependent Pathways as Potential Therapeutic Targets in Hepatocellular Carcinoma. , 0, , .		0
4110	Early Chronic Inflammation and Subsequent Somatic Mutations Shift Phospho-Smad3 Signaling from Tumor- Suppression to Fibro-Carcinogenesis in Human Chronic Liver Diseases. , 0, , .		0
4111	MicroRNA SNPs in Cancer. , 2014, , 149-163.		0
4112	Radioembolization of Yttrium-90 Microspheres for Clinical Treatment of Hepatic Malignancy. Journal of Nuclear Medicine & Radiation Therapy, 2014, 05, .	0.2	0
4113	Complete Response of Hepatocellular Carcinoma to Sorafenib: A Case Report and Review of Literatures. Journal of Liver, 2014, 03, .	0.3	0
4114	Prevalence of HCV in apparently healthy voluntary blood donors. IOSR Journal of Dental and Medical Sciences, 2014, 13, 01-04.	0.0	0
4115	Pathophysiology of HCC. , 2014, , 15-32.		0
4116	Long-term interferon therapies improved hepatic fibrosis and prevented the recurrence of hepatocellular carcinoma in a patient with hepatitis C virus infection. Acta Hepatologica Japonica, 2014, 55, 399-404.	0.0	0
4117	Etiology. , 2014, , 3-6.		0

#	Article	IF	Citations
4118	Comparative Observational Study of Two Ethnic Population Groups of Patients with Hepatocellular Carcinoma. Journal of Clinical & Experimental Oncology, 2014, 03, .	0.1	0
4119	Sorafenib Combined with Transarterial-Chemoembolization in Child-Pugh Class B Patients with Hepatocellular Carcinoma. Journal of Liver Cancer, 2014, 14, 31-36.	0.3	0
4120	Liver cirrhosis and hepatocellular carcinoma in patients with chronic viral hepatitis c: some epidemiologic and molecular-genetic aspects. Epidemiology and Infectious Diseases (Russian Journal), 2014, 19, 40-51.	0.1	0
4121	Association of the Cellular Apoptosis Susceptibility Protein with HBV Infection in Hepatocellular Carcinoma. Infection International, 2014, 3, 77-81.	0.1	0
4122	Correlation Study of (CMV) in the Presence of (HCV) and / or (HBV) in Hepatocellular Carcinoma () Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	0
4123	Laparoscopic liver resection for the treatment of hepatocellular carcinoma. World Journal of Surgical Procedures, 2015, 5, 137.	0.1	0
4124	Laparoscopic Liver Resection for Hepatocellular Carcinoma. , 2015, , 457-463.		0
4125	Computed Tomography Assessment of the Vascularization Degree of Hepatocellular Carcinoma in the Noncirrhotic Liver. American Journal of Clinical and Experimental Medicine, 2015, 3, 24.	0.1	0
4126	A Novel Prognostic Score based on Serum Alpha-Fetoprotein, Number of Nodules, and MYC Gene Status Predicts Prognosis of Patients after Liver Resection for Hepatocellular Carcinoma. Journal of Integrative Oncology, 2015, 05, .	0.3	0
4127	Indications for Liver Transplantation. , 2015, , 97-125.		1
4128	Lebertumoren. , 2015, , 1-10.		0
4129	Evaluation of the Results of Radical Management of a Cohort of 107 Patients with Hepatocellular Carcinoma in Colombia. Journal of Cancer Therapy, 2015, 06, 1137-1144.	0.1	0
4131	Role of MicroRNA in the Diagnosis and Therapy of Hepatocellular Carcinoma: A New Frontier. MicroRNA (Shariqah, United Arab Emirates), 2015, 3, 137-143.	0.6	2
4132	Clinical, laboratory, and virological characteristics of patients with positive hepatitis B surface antigen in Upper Egypt. The Egyptian Journal of Internal Medicine, 2015, 27, 32-37.	0.3	1
4133	Rezeke hepatosellÃ¼ler karsinomalÄ± sirotik hastada nadir Ã¼st GÄ°S kanama sebebi: TÃ¼mÃ¶r nÃ¼ksÃ¼ne baÄŸlÄ± duodenum invazyonu. Endoskopi Gastrointestinal, 2011, 19, .	0.0	0
4134	A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2015, 33, 4088-4088.	0.8	0
4135	Researches on the Pharmacological Effects of Eicosapentaenoic Acid. American Journal of Medicine Studies, 2015, 3, 4-7.	0.0	0
4137	Image-Guided Therapy of Liver Malignancy. , 2015, , 551-587.		0

#	Article	IF	Citations
4139	Sinulariolide suppress human hepatocellular carcinoma cell migration and invasion by inhibiting matrix metalloproteinase-2/-9 through MAPKs and PI3K/Akt signaling pathways. Planta Medica, 2015, 81, .	0.7	1
4140	Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. Annals of Gastroenterology, 2016, 30, 101-105.	0.4	4
4141	Biomarkers of the Antioxidant Response: A Focus on Liver Carcinogenesis. Exposure and Health, 2016, , 1-24.	2.8	0
4142	Biomarkers Associated with Adiposity and Metabolic Dysfunction in Hepatobiliary Tract Cancer. Exposure and Health, 2016, , 1-29.	2.8	0
4143	Hepatic and Extrahepatic Malignancies in Alcoholic Liver Disease. , 2016, , 249-269.		0
4144	Correlation of magnetic resonance signal characteristics and perfusion parameters assessed by volume perfusion computed tomography in hepatocellular carcinoma: Impact on lesion characterization. World Journal of Radiology, 2016, 8, 683.	0.5	0
4146	The Disrupted Steady-State: Tipping the Balance in Favour of Cancer. , 2016, , 1-37.		0
4147	Treatment of Hepatic Malignances and Disorders: The Role of Liver Bioengineering. Pancreatic Islet Biology, 2017, , 249-276.	0.1	0
4148	THE ROLE OF BCL-2 ONCOPROTEIN IN HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA. Research Journal of Applied Biotechnology, 2016, 2, 101-110.	0.1	0
4149	Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. Journal of the Advanced Practitioner in Oncology, 2016, 7, 764-778.	0.2	1
4150	Nongenotoxic Carcinogenesis. , 2017, , .		0
4151	NF-Î²B and Its Implication in Liver Health and Cancer Development. , 2017, , 87-114.		0
4152	Primary Liver Cancer: Background and Clinical Evidence. , 2017, , 103-117.		0
4153	Biomarkers of the Antioxidant Response: A Focus on Liver Carcinogenesis. Biomarkers in Disease, 2017, , 785-808.	0.0	0
4154	Biomarkers Associated with Adiposity and Metabolic Dysfunction in Hepatobiliary Tract Cancer. Biomarkers in Disease, 2017, , 755-783.	0.0	0
4155	Gastroenterologie. , 2017, , 185-264.		0
4156	Malignant Tumors of the Liver and Intrahepatic Bile Ducts. , 2017, , 145-281.		1
4157	A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepatology, 2017, XX, 1-7.	0.7	4

#	Article	IF	Citations
4158	Serum Golgi protein-73 in combination with Î±-fetoprotein for diagnosing hepatocellular carcinoma in Egyptian patients. The Egyptian Journal of Internal Medicine, 2017, 29, 40-46.	0.3	1
4159	Anti-tumour Activity of Aqueous Wheat Grass Extracts against Chemically Induced Carcinogenesis. IOSR Journal of Pharmacy and Biological Sciences, 2017, 12, 24-28.	0.1	1
4163	ANTI HBS TITRE; AMONG OUTGOING FINAL YEAR MBBS STUDENTS. The Professional Medical Journal, 2017, 24, 1167-1169.	0.0	0
4164	The Difference Analysis of Histone Modifications in Cancer Cell Line HepG2 and Normal Cell Line Hepatocyte. Hans Journal of Computational Biology, 2018, 08, 49-57.	0.0	0
4166	Profile and Risk Factor of Hepatocellular Carcinoma Patients. , 2018, , .		0
4168	Prediction of Biomarkers for Hepatocellular Carcinoma Through Microarray-Based DNA Methylation Analysis. Iranian Red Crescent Medical Journal, 2018, 20, .	0.5	0
4169	RGD peptide-targeted polyethylenimine-entrapped gold nanoparticles for targeted CT imaging of an orthotopic model of human hepatocellular carcinoma. , 2018, , .		0
4170	Assessment of Alpha-1-Acid Glycoprotein as a new Biomarker for Hepatocellular Carcinoma. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018, 8, 55-61.	0.1	0
4172	Arginase - 1 - Based Diagnosis as Indicator of the Risk of HBV - Related HCC. Gene, Cell and Tissue, 2018, In Press, .	0.2	0
4173	Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents. Hepatitis Monthly, 2018, 18, .	0.1	1
4174	Abnormal platelet count correlates with poor survival in hepatocellular carcinoma. Infection International, 2018, 6, 93-102.	0.1	0
4175	Comparison between the effect of Two Regimens for Hepatitis C Treatment (Qurevo and Ribavirin) and (Sofosbuvir, Daclatsvir and Ribavirin) on Patients above and below the Age of 60 Years. The Egyptian Journal of Hospital Medicine, 2018, 72, 5385-5390.	0.0	2
4176	Clinical Implications of Shear Wave Elastography in Patients with Chronic Hepatitis B. Journal of Clinical Ultrasound, 2018, 3, 45-49.	0.0	0
4177	è‚‡“å–ç§‘ã«ãŠã‘ã‚‹é•·å•™,æ³•. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2018, 52, 301-305.	0.1	0
4178	Effects of Mitochondrial DNA Deletion and OSW-1 on PI3K-AKT Signaling Pathway PCR Array in SK-Hep1 Cells. Chinese Medicine, 2019, 10, 107-119.	1.0	1
4179	Prognostic Biomarkers for Hepatocellular Carcinoma. , 2019, , 1-8.		0
4180	Prevention of Hepatocarcinogenesis in Liver Cirrhosis. , 2019, , 159-166.		0
4181	Vitamin D Receptor Fok I Polymorphism and Risk of Hepatocellular Carcinoma in HBV-Infected Patients. Hepatitis Monthly, 2019, In Press, .	0.1	0

#	Article	IF	Citations
4182	Effect of IRAK1 on Apoptosis and Necroptosis of Hepatoma Cell Line SK-Hep1. Chinese Medicine, 2019, 10, 19-29.	1.0	0
4183	Staging Study of Hepatocellular Carcinoma Based on Network Analysis and Random Forest Method. Statistics and Applications, 2019, 08, 95-107.	0.0	1
4185	Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes. Medical Science Monitor, 2019, 25, 1301-1306.	0.5	4
4186	Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-analysis, 2019, 7, 80-95.	0.1	2
4187	Association of serum growth differentiation factor 15 and hepatocellular carcinoma in Egyptian patients. The Egyptian Journal of Internal Medicine, 2019, 31, 57-63.	0.3	0
4188	CRISPR/Cas9 gene editing in Huh7 and Hepa RG cell lines. Romanian Biotechnological Letters, 2019, 24, 216-228.	0.5	0
4189	MicroRNAâ€'584 prohibits hepatocellular carcinoma cell proliferation and invasion by directly targeting BDNF. Molecular Medicine Reports, 2019, 20, 1994-2001.	1.1	4
4190	miR-515-5p and Notch1 as New Diagnostic Markers of Hepatocellular Carcinoma. Avicenna Journal of Medical Biochemistry, 2019, 7, 4-8.	0.5	0
4191	Implication of hepatocyte dedifferentiation in pathogenesis and treatment of hepatocellular carcinoma. Precision and Future Medicine, 2019, 3, 37-42.	0.5	1
4192	Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer. Molecular Medicine Reports, 2019, 20, 2493-2499.	1.1	5
4193	Integrated tumor stromal features of hepatocellular carcinoma reveals two distinct subtypes with prognostic/predictive significance. Aging, 2019, 11, 4478-4509.	1.4	6
4195	Treatment and outcomes of multinodular hepatocellular carcinoma: a systematic review and meta-analysis. International Surgery Journal, 2019, 6, 3460.	0.0	0
4196	Alpha-actinin 4 and tumorigenesis of hepatocellular carcinoma. Translational Cancer Research, 2019, 8, 1374-1380.	0.4	0
4198	FIB-4 Is a Potential Tool for Hepatocellular Carcinoma Risk Stratification in Ethnically Diverse Chronic Hepatitis B Patients When Using Specific Cutoff Values. Hepatitis Monthly, 2019, In Press, .	0.1	0
4199	Liver Magnetic Resonance Elastography: Clinical Use and Interpretation. , 2020, , 69-93.		2
4200	A Deep Learning Approach for Hepatocellular Carcinoma Grading. , 2020, , 353-371.		0
4201	Hepatobiliary Tumors: Immunopathology and Immunotherapy. , 2020, , 241-259.		0
4202	Use of the LI-RADS classification in patients with cirrhosis due to infection with hepatitis B, C, or D, or infected with hepatitis B and D. Radiologia Brasileira, 2020, 53, 14-20.	0.3	2

#	Article	IF	Citations
4204	High expression of lncRNA-SNHG7 is associated with poor prognosis in hepatocellular carcinoma. Oncology Letters, 2020, 19, 3959-3963.	0.8	13
4205	Diagnostic and Therapeutic Challenges in Hepatocellular Carcinoma. ARS Medica Tomitana, 2020, 26, 76-79.	0.0	0
4207	Potential dual functional roles of the Yâ€linked RBMY in hepatocarcinogenesis. Cancer Science, 2020, 111, 2987-2999.	1.7	9
4208	Hemoperitoneum caused by spontaneous rupture of hepatocellular carcinoma in noncirrhotic liver. A case report and systematic review. Open Medicine (Poland), 2020, 15, 739-744.	0.6	11
4209	Risk Factors for Hepatocellular Carcinoma: A Historical Perspective. Clinical Liver Disease, 2021, 18, 1-13.	1.0	0
4210	Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis. Annals of Hepatology, 2022, 27, 100571.	0.6	2
4211	Aloin decelerates the progression of hepatocellular carcinoma through circ_0011385/miR-149-5p/WT1 axis. Cell Cycle, 2021, 20, 2476-2493.	1.3	10
4212	Glia Maturation Factor Beta as a Novel Biomarker and Therapeutic Target for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 744331.	1.3	5
4213	Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.2	4
4214	Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells. Scientific Reports, 2020, 10, 21926.	1.6	16
4215	SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma. Aging, 2021, 13, 2803-2821.	1.4	10
4216	Liver Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 227-241.	0.8	8
4217	Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation. Immune Network, 2021, 21, e37.	1.6	18
4218	Cone-Beam Computed Tomography-Hepatic Arteriography as a Diagnostic Tool for Small Hypervascular Hepatocellular Carcinomas: Method and Clinical Implications. Korean Journal of Radiology, 2020, 21, 306.	1.5	1
4219	Incorporation of apolipoprotein E into HBVâ€“HCV subviral envelope particles to improve the hepatitis vaccine strategy. Scientific Reports, 2021, 11, 21856.	1.6	7
4220	An SNP reducing SNORD105 and PPAN expression decreases the risk of hepatocellular carcinoma in a Chinese population. Journal of Clinical Laboratory Analysis, 2021, 35, e24095.	0.9	7
4221	An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system. Global Health & Medicine, 2020, 2, 312-318.	0.6	6
4222	Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World Journal of Hepatology, 2020, 12, 766-774.	0.8	10

#	Article	IF	Citations
4223	External beam radiation therapy in a centenarian with primary liver cancer. Medicine (United States), 2020, 99, e22473.	0.4	0
4224	Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Caseâ€“Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 388-395.	1.1	8
4225	Systemic therapy for hepatocellular carcinoma. Chinese Clinical Oncology, 2013, 2, 37.	0.4	6
4226	Accomplishments in 2007 in the management of hepatobiliary cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, S25-31.	0.8	5
4227	Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointestinal Cancer Research: GCR, 2009, 3, S28-36.	0.8	3
4228	A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterology and Hepatology, 2010, 6, 1-16.	0.2	8
4229	Screening for hepatocellular carcinoma. Gastroenterology and Hepatology, 2008, 4, 201-8.	0.2	5
4230	Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. World Journal of Gastroenterology, 2011, 17, 3075-81.	1.4	18
4231	Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepatitis Monthly, 2011, 11, 86-91.	0.1	30
4232	Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepatitis Monthly, 2011, 11, 195-9.	0.1	25
4233	Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma?. Gastrointestinal Cancer Research: GCR, 2012, 5, 13-7.	0.8	6
4234	The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. American Journal of Cancer Research, 2012, 2, 269-85.	1.4	23
4235	Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis. Journal of Gastrointestinal Oncology, 2011, 2, 223-31.	0.6	10
4236	Suppression of Human Liver Cancer Cell Migration and Invasion via the GABAA Receptor. Cancer Biology and Medicine, 2012, 9, 90-8.	1.4	12
4237	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current Cancer Drug Targets, 2012, 12, 1129-59.	0.8	55
4238	Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization. International Journal of Clinical and Experimental Pathology, 2014, 7, 1114-23.	0.5	18
4239	Tumor factors associated with clinical outcomes in patients with hepatitis B virus infection and hepatocellular carcinoma. Gastroenterology and Hepatology, 2012, 8, 808-19.	0.2	5
4240	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2013, 9, 1-24.	0.2	5

#	Article	IF	Citations
4241	Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential. International Journal of Clinical and Experimental Pathology, 2014, 7, 2527-35.	0.5	10
4242	Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 2079-90.	0.5	30
4243	Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 4303-9.	0.5	108
4244	Can TIE-2 expressing monocytes represent a novel marker for hepatocellular carcinoma?. Hepatobiliary Surgery and Nutrition, 2014, 3, 175-8.	0.7	2
4245	Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis. Indian Journal of Medical Research, 2014, 140, 160-2.	0.4	1
4246	Hepatic stellate cells secretes type I collagen to trigger epithelial mesenchymal transition of hepatoma cells. American Journal of Cancer Research, 2014, 4, 751-63.	1.4	23
4247	Cytotoxic and apoptotic activities of Amorphophallus campanulatus tuber extracts against human hepatoma cell line. Research in Pharmaceutical Sciences, 2014, 9, 269-77.	0.6	10
4248	Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. International Journal of Clinical and Experimental Medicine, 2015, 8, 1205-12.	1.3	14
4250	LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. International Journal of Clinical and Experimental Pathology, 2015, 8, 1690-7.	0.5	22
4251	Role of ursolic acid chalcone, a synthetic analogue of ursolic acid, in inhibiting the properties of CD133(+) sphere-forming cells in liver stem cells. International Journal of Clinical and Experimental Pathology, 2015, 8, 1427-34.	0.5	2
4252	Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 1705-11.	0.5	25
4253	FoxM1 influences mouse hepatocellular carcinoma metastasis in vitro. International Journal of Clinical and Experimental Pathology, 2015, 8, 2771-8.	0.5	8
4254	Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/Î²-catenin signaling in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 3386-94.	0.5	15
4256	Regulation of Aspartyl-(Asparaginyl)-Î²-Hydroxylase Protein Expression and Function by Phosphorylation in Hepatocellular Carcinoma Cells. Journal of Nature and Science, 2015, 1, .	1.1	2
4258	Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/Î²-catenin pathway. American Journal of Cancer Research, 2015, 5, 1089-100.	1.4	15
4259	LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. International Journal of Clinical and Experimental Pathology, 2015, 8, 3892-900.	0.5	9
4260	Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 4126-31.	0.5	45
4261	Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Annals of Gastroenterology, 2015, 28, 323-330.	0.4	30

#	Article	IF	Citations
4262	Interferon-Î³ polymorphism and hepatocellular carcinoma susceptibility: a meta analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 5667-74.	1.3	2
4263	MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2. International Journal of Clinical and Experimental Pathology, 2015, 8, 4782-90.	0.5	23
4264	Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 4963-71.	0.5	9
4265	Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. International Journal of Clinical and Experimental Pathology, 2015, 8, 5395-402.	0.5	93
4266	Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 6638-49.	1.3	4
4267	Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 7234-8.	0.5	42
4268	Relevance between HLA-DP gene rs2281388 polymorphism and hepatocellular carcinoma risk. International Journal of Clinical and Experimental Pathology, 2015, 8, 7431-5.	0.5	2
4269	Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 10235-47.	1.3	47
4270	Fish consumption doesn't reduce the risk of hepatocellular carcinoma. International Journal of Clinical and Experimental Medicine, 2015, 8, 10825-34.	1.3	0
4271	The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 548-60.	1.0	32
4272	Up-regulation of AKAP13 and MAGT1 on cytoplasmic membrane in progressive hepatocellular carcinoma: a novel target for prognosis. International Journal of Clinical and Experimental Pathology, 2015, 8, 9796-811.	0.5	13
4273	Laparoscopic liver resection for hepatocellular carcinoma with cirrhosis in a single institution. Hepatobiliary Surgery and Nutrition, 2015, 4, 398-405.	0.7	9
4274	Exosomes as potent regulators of HCC malignancy and potential bio-tools in clinical application. International Journal of Clinical and Experimental Medicine, 2015, 8, 17088-95.	1.3	9
4275	miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7. International Journal of Clinical and Experimental Medicine, 2015, 8, 18469-75.	1.3	25
4276	Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 611-26.	0.7	0
4277	High expression of N-acetyltransferase 10: a novel independent prognostic marker of worse outcome in patients with hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 14765-71.	0.5	17
4278	Genetic polymorphisms of C-reactive protein increase susceptibility to HBV-related hepatocellular carcinoma in a Guangxi male population. International Journal of Clinical and Experimental Pathology, 2015, 8, 16055-63.	0.5	4
4279	Preventive Effect of Geraniol on Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats. Yonago Acta Medica, 2016, 59, 37-43.	0.3	9

#	Article	IF	Citations
4280	Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi. American Journal of Translational Research (discontinued), 2016, 8, 1799-812.	0.0	8
4281	The hepatitis C treatment revolution: how to avoid Asia missing out. Journal of Virus Eradication, 2015, 1, 272-5.	0.3	4
4282	Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterology and Hepatology From Bed To Bench, 2016, 9, 158-73.	0.6	51
4283	MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6. American Journal of Cancer Research, 2016, 6, 2502-2513.	1.4	14
4284	ÂIncreased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Annals of Hepatology, 2016, 15, 545-9.	0.6	3
4285	Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway. American Journal of Cancer Research, 2017, 7, 433-447.	1.4	6
4286	NVM-1 predicts prognosis and contributes to growth and metastasis in hepatocellular carcinoma. American Journal of Cancer Research, 2017, 7, 554-564.	1.4	2
4287	MiR-155 up-regulated by TGF-Î² promotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells. American Journal of Translational Research (discontinued), 2017, 9, 2956-2965.	0.0	26
4290	Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas. Acta Naturae, 2017, 9, 108-114.	1.7	1
4291	MiR-488 suppresses cell proliferation and invasion by targeting ADAM9 and lncRNA HULC in hepatocellular carcinoma. American Journal of Cancer Research, 2017, 7, 2070-2080.	1.4	24
4292	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. American Journal of Cancer Research, 2017, 7, 2465-2477.	1.4	5
4294	Inverse Association between Glucoseâ€'6â€'Phosphate Dehydrogenase Deficiency and Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1069-1073.	0.5	3
4295	KLF4 suppresses the migration of hepatocellular carcinoma by transcriptionally upregulating monoglyceride lipase. American Journal of Cancer Research, 2018, 8, 1019-1029.	1.4	15
4296	Circ5379-6, a circular form of tumor suppressor , participates in the inhibition of hepatocellular carcinoma tumorigenesis and metastasis. American Journal of Translational Research (discontinued), 2018, 10, 3493-3503.	0.0	5
4297	Vimentin acetylation is involved in SIRT5-mediated hepatocellular carcinoma migration. American Journal of Cancer Research, 2018, 8, 2453-2466.	1.4	12
4298	Strategies to Improve Hepatocellular Carcinoma Surveillance in Veterans With Hepatitis B Infection. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, S30-S39.	0.6	0
4299	Liver Imaging Reporting and Data System in Patients at High Risk for Hepatocellular Carcinoma in the Memphis Veterans Affairs Population. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S47-S52.	0.6	1
4300	ZNF503 accelerates aggressiveness of hepatocellular carcinoma cells by down-regulation of GATA3 expression and regulated by microRNA-495. American Journal of Translational Research (discontinued), 2019, 11, 3426-3437.	0.0	9

#	Article	IF	Citations
4301	Long non-coding RNA DSCAM-AS1 accelerates the progression of hepatocellular carcinoma via sponging miR-338-3p. American Journal of Translational Research (discontinued), 2019, 11, 4290-4302.	0.0	18
4303	The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 6462-6474.	0.0	14
4304	miR-224 suppresses HBV replication posttranscriptionally through inhibiting SIRT1-mediated autophagy. International Journal of Clinical and Experimental Pathology, 2018, 11, 189-198.	0.5	6
4305	The functions and properties of cullin-5, a potential therapeutic target for cancers. American Journal of Translational Research (discontinued), 2020, 12, 618-632.	0.0	5
4306	Nicotinamide nucleotide transhydrogenase acts as a new prognosis biomarker in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 972-978.	0.5	1
4307	Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC). American Journal of Translational Research (discontinued), 2020, 12, 5108-5130.	0.0	5
4308	ATOH8 overexpression inhibits the tumor progression and monocyte chemotaxis in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 2534-2543.	0.5	1
4309	Liver cancer incidence and mortality: Disparities based on age, ethnicity, health and nutrition, molecular factors, and geography. Cancer Health Disparities, 2020, 4, e1-e10.	0.5	0
4310	A novel recurrence associated immune gene signature and its clinical significance in liver cancer. American Journal of Translational Research (discontinued), 2021, 13, 8766-8776.	0.0	0
4311	Experimental and clinical evidence suggests that GRPEL2 plays an oncogenic role in HCC development. American Journal of Cancer Research, 2021, 11, 4175-4198.	1.4	2
4312	Does Fibrosis Influence Survival after Liver Transplantation? Evidence from the SEER Database. Advances in Clinical Medicine, 2021, 11, 5594-5605.	0.0	0
4313	The Interdependence of Inflammation and ROS in Cancer. , 2021, , 1-17.		1
4314	Bioanalysis: methods, techniques, and applications. , 2022, , 1-24.		0
4315	Characterisation of Preformulation Parameters to Design, Develop and Formulate Silymarin loaded PLGA Nanoparticles for Liver Targeted Drug Delivery. Research Journal of Pharmacy and Technology, 2021, , 5508-5514.	0.2	1
4316	Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma. Translational Cancer Research, 2021, 10, 4636-4651.	0.4	1
4317	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo. Frontiers in Pharmacology, 2021, 12, 774231.	1.6	9
4318	Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis. Cells, 2021, 10, 3325.	1.8	2
4319	Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. Digestive Diseases and Sciences, 2022, 67, 3831-3841.	1.1	3

#	Article	IF	Citations
4320	Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection. Hepatology Research, 2022, 52, 210-220.	1.8	6
4321	Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in highâ€risk patients. Liver International, 2022, 42, 2080-2092.	1.9	28
4322	A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 761839.	1.8	24
4323	Role of hsa_circ_0066966 in proliferation and migration of hepatitis B virusâ€related liver cancer cells. Experimental and Therapeutic Medicine, 2021, 23, 87.	0.8	1
4324	HBV HBx-Downregulated lncRNA LINC01010 Attenuates Cell Proliferation by Interacting with Vimentin. International Journal of Molecular Sciences, 2021, 22, 12497.	1.8	5
4325	Estrogen Receptor 1ÂInhibition ofÂWnt/Î²-Catenin SignalingÂContributes toÂSex Differences in Hepatocarcinogenesis. Frontiers in Oncology, 2021, 11, 777834.	1.3	12
4326	Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101835.	0.7	5
4327	Molecular Alterations of Circulating Cell-Free DNA in the Pathological Progression of Hepatocellular Carcinoma. Journal of Oncology, 2021, 2021, 1-8.	0.6	2
4328	The Combined Diagnostic Accuracy of Serum Alpha Fetoprotein and Des-Gamma Carboxyprothrombin in Hepatocellular Carcinoma among Chronic Liver Disease Patients in Ilorin. Open Journal of Gastroenterology, 2021, 11, 255-274.	0.1	0
4330	Reducing the Risk of and Screening for Liver Cancer. , 2021, , 1-20.		0
4331	The Combined Diagnostic Accuracy of Serum Alpha Fetoprotein and Des-Gamma Carboxyprothrombin in Hepatocellular Carcinoma among Chronic Liver Disease Patients in Ilorin. Open Journal of Gastroenterology, 2021, 11, 255-274.	0.1	0
4332	Comparing the Effectiveness and Safety of Sorafenib Plus TACE with Apatinib Plus Tace for Treating Patients with Unresectable Hepatocellular Carcinoma: A Multicentre Propensity Score Matching Study. SSRN Electronic Journal, 0, , .	0.4	0
4333	The lncRNAs at X Chromosome Inactivation Center: Not Just a Matter of Sex Dosage Compensation. International Journal of Molecular Sciences, 2022, 23, 611.	1.8	12
4334	Inclusion complex of emodin and glycyrrhetinic acid-conjugated-Î²-cyclodextrin to target liver cells: synthesis, characterization, and bioactivity in vitro and in vivo. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2022, 102, 339-346.	0.9	2
4335	A Primary Screening Method for Liver Cancer in Chronic Hepatitis B Carriers: A Prospective Community-Based Cohort Study. Frontiers in Oncology, 2021, 11, 762662.	1.3	1
4336	Induction of lipid metabolism dysfunction, oxidative stress and inflammation response by tris(1-chloro-2-propyl)phosphate in larval/adult zebrafish. Environment International, 2022, 160, 107081.	4.8	13
4337	Cell Signaling in Hepatocellular Carcinoma. American Research Journal of Biosciences, 2020, 6, 1-6.	0.0	0
4338	Transplantation in hepatocellular carcinoma - controversies and recommendations: A review of current literature. International Journal of Advanced Medical and Health Research, 2021, 8, 49.	0.1	0

#	Article	IF	Citations
4339	Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy. Chinese Medical Journal, 2022, 135, 301-308.	0.9	17
4340	Identification and Validation of DEPDC1B as an Independent Early Diagnostic and Prognostic Biomarker in Liver Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 681809.	1.1	4
4341	A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma. British Journal of Cancer, 2022, 126, 1196-1204.	2.9	3
4342	Clinical application of radioiodinated antibodies: where are we?. Clinical and Translational Imaging, 2022, 10, 123-162.	1.1	3
4343	Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene, 2022, 41, 1410-1420.	2.6	16
4344	CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex. Cancer Gene Therapy, 2022, 29, 1217-1227.	2.2	2
4345	Profiling and Integrated Analysis of Differentially Expressed MicroRNAs as Novel Biomarkers of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 770918.	1.3	3
4346	Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study. BJS Open, 2022, 6, .	0.7	4
4347	Upregulating microRNA-373-3p promotes apoptosis and inhibits metastasis of hepatocellular carcinoma cells. Bioengineered, 2022, 13, 1304-1319.	1.4	13
4349	Spindle and Kinetochore-associated Family Genes are Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	0
4350	Associations between diabetes mellitus and the risk of hepatocellular carcinoma in Asian individuals with hepatitis B and C infection: systematic review and a meta-analysis of cohort studies. European Journal of Cancer Prevention, 2022, 31, 107-116.	0.6	7
4351	The Interdependence of Inflammation and ROS in Cancer. , 2022, , 1135-1151.		0
4352	Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Frontiers in Oncology, 2022, 12, 822449.	1.3	12
4353	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. Cancers, 2022, 14, 768.	1.7	1
4354	Induction of apoptosis by Oleracein A and Oleracein B in HepG2 cancerous cells is mediated by ceramide generation, caspase-9/caspase-3 pathway activation, and oxidative damage. Pharmacological Research Modern Chinese Medicine, 2022, 2, 100047.	0.5	3
4355	Le carcinome hÃ©patocellulaireÂ: profil Ã©pidÃ©miologique, clinique et thÃ©rapeutique au CHU de Marrakech (Ã propos de 76 cas). HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2017, NÂ° 3, 195-200.	0.0	0
4356	E2F1â€‘induced microRNAâ€‘224â€‘5p expression is associated with hepatocellular carcinoma cell migration, invasion and epithelialâ€‘mesenchymal transition via MREG. Oncology Letters, 2022, 23, 82.	0.8	5
4357	Aberrant regulation of LncRNA TUG1-microRNA-328-3p-SRSF9 mRNA Axis in hepatocellular carcinoma: a promising target for prognosis and therapy. Molecular Cancer, 2022, 21, 36.	7.9	15

#	Article	IF	Citations
4358	Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis. Disease Markers, 2022, 2022, 1-9.	0.6	2
4359	Increased risk of hepatocellular carcinoma in patients with traumatic liver injury. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	3
4360	Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. International Journal of Molecular Sciences, 2021, 22, 13627.	1.8	16
4361	Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2021, .	0.7	0
4362	Proliferative signaling pathways in hepatocellular carcinoma. , 2022, , 255-271.		0
4363	Impact of the Liver Imaging Reporting and Data System on Research Studies of Diagnosing Hepatocellular Carcinoma Using MRI. Korean Journal of Radiology, 2022, 23, 529.	1.5	7
4364	Updates on the staging and treatment of hepatocellular carcinoma. , 2022, , 307-319.		0
4365	Effect of cirrhosis and hepatitis on the prognosis of liver cancer. , 2022, , 51-72.		0
4366	Predictive value of collagen in cancer. Advances in Cancer Research, 2022, 154, 15-45.	1.9	11
4367	Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma. , 2022, , 21-34.		0
4368	MiR-597-5p suppresses the progression of hepatocellular carcinoma via targeting transcriptional enhancer associate domain transcription factor 1 (TEAD1). In Vitro Cellular and Developmental Biology - Animal, 2022, 58, 96-108.	0.7	2
4369	Biological Activities, Pharmacokinetics and Toxicity of Nootkatone: A Review. Mini-Reviews in Medicinal Chemistry, 2022, 22, 2244-2259.	1.1	5
4370	PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. Future Oncology, 2022, 18, 1691-1703.	1.1	4
4371	Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. Scientific Reports, 2022, 12, 2538.	1.6	3
4372	Scoring systems for the management of oncological hepato-pancreato-biliary patients. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, 17-30.	0.1	3
4373	Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression. British Journal of Cancer, 2022, 127, 202-210.	2.9	8
4374	Australian consensus recommendations for the management of hepatitis B. Medical Journal of Australia, 2022, 216, 478-486.	0.8	15
4375	Citrate transporter inhibitors: possible new anticancer agents. Future Medicinal Chemistry, 2022, 14, 665-679.	1.1	3

#	Article	IF	Citations
4376	Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation. International Journal of Molecular Sciences, 2022, 23, 3868.	1.8	50
4377	Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. International Journal of Molecular Sciences, 2022, 23, 3778.	1.8	45
4378	An MRI-Based Radiomic Model for Individualized Prediction of Hepatocellular Carcinoma in Patients With Hepatitis B Virus-Related Cirrhosis. Frontiers in Oncology, 2022, 12, 800787.	1.3	1
4379	A Rapid LC-MS/MS-PRM Assay for Serologic Quantification of Sialylated O-HPX Glycoforms in Patients with Liver Fibrosis. Molecules, 2022, 27, 2213.	1.7	2
4380	Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition. Cancers, 2022, 14, 1714.	1.7	3
4381	Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 834859.	1.8	9
4382	Asari Radix et Rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: A retrospective cohort study. Chinese Herbal Medicines, 2022, 14, 470-475.	1.2	2
4383	Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clinical Infectious Diseases, 2022, 75, 1529-1536.	2.9	3
4384	Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation. International Journal of Hyperthermia, 2022, 39, 437-445.	1.1	4
4385	Circ_0011232 contributes to hepatocellular carcinoma progression through miRâ€503â€5p/AKT3 axis. Hepatology Research, 2022, 52, 532-545.	1.8	2
4386	Transcriptome Analysis of Liver Cancer Cell Huh-7 Treated With Metformin. Frontiers in Pharmacology, 2022, 13, 822023.	1.6	2
4387	The Role of Exosomes in Inflammatory Diseases and Tumor-Related Inflammation. Cells, 2022, 11, 1005.	1.8	19
4388	Signaling Pathways Involved in 5-FU Drug Resistance in Cancer. Cancer Investigation, 2022, 40, 516-543.	0.6	3
4389	Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. Frontiers in Pharmacology, 2022, 13, 838079.	1.6	20
4390	Borealin Promotes Tumor Growth and Metastasis by Activating the Wnt/Î²-Catenin Signaling Pathway in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 171-188.	1.8	3
4391	In vitro galactose-targeted study of RSPP050-loaded micelles against liver hepatocellular carcinoma. Pharmaceutical Development and Technology, 2022, 27, 379-388.	1.1	7
4392	A Prognostic Model for Patients with Hepatocellular Carcinoma Based on Hypoxia-Related Long Noncoding RNAs. Journal of Nanomaterials, 2022, 2022, 1-10.	1.5	0
4393	Emerging roles of the Hippo signaling pathway in modulating immune response and inflammationâ€driven tissue repair and remodeling. FEBS Journal, 2022, 289, 4061-4081.	2.2	11

#	Article	IF	Citations
4394	Overview of SIRT5 as a potential therapeutic target: Structure, function and inhibitors. European Journal of Medicinal Chemistry, 2022, 236, 114363.	2.6	14
4395	A motion compensated approach to quantitative digital subtraction angiography. , 2022, , .		4
4396	Hepatoprotective effect of Baicalin against thioacetamide-induced cirrhosis in rats: Targeting NOX4/NF-Î²B/NLRP3 inflammasome signaling pathways. Life Sciences, 2022, 295, 120410.	2.0	17
4397	IGF-1 contributes to liver cancer development in diabetes patients by promoting autophagy. Annals of Hepatology, 2022, 27, 100697.	0.6	7
4398	The Metabolic Relationship Between Viral Infection and Cancer. Annual Review of Cancer Biology, 2022, 6, 1-15.	2.3	6
4399	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	1.1	8
4401	Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 8302-8322.	1.4	12
4402	Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response. Anticancer Research, 2022, 42, 245-251.	0.5	1
4403	Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 767644.	1.3	16
4404	miR-515-3p, miR-623, miR-1272 and Notch3 protein as new biomarkers of Hepatocellular carcinoma. Hormone Molecular Biology and Clinical Investigation, 2021, .	0.3	0
4405	Hepatitis C Virus Core Protein Down-Regulates Expression of Src-Homology 2 Domain Containing Protein Tyrosine Phosphatase by Modulating Promoter DNA Methylation. Viruses, 2021, 13, 2514.	1.5	5
4406	Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World Journal of Gastrointestinal Oncology, 2021, 13, 1919-1938.	0.8	15
4407	Liver resection vs radiofrequency ablation in single hepatocellular carcinoma of posterosuperior segments in elderly patients. World Journal of Gastrointestinal Surgery, 2021, 13, 1696-1707.	0.8	4
4408	Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials. Cancer Control, 2022, 29, 107327482210929.	0.7	4
4409	Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance. Korean Journal of Radiology, 2022, 23, 598.	1.5	6
4410	Examining the Influencing Factors of Chronic Hepatitis B Monitoring Behaviors among Asian Americans: Application of the Information-Motivation-Behavioral Model. International Journal of Environmental Research and Public Health, 2022, 19, 4642.	1.2	3
4411	MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal of Vascular and Interventional Radiology, 2022, 33, 814-824.e3.	0.2	7
4412	Combined evaluation of Fibrosisâ€4 index and fatty liver for stratifying the risk for diabetes mellitus. Journal of Diabetes Investigation, 2022, , .	1.1	0

#	Article	IF	Citations
4413	Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors. International Journal of Clinical Oncology, 2022, 27, 1164-1172.	1.0	5
4414	CCDC88A Post-Transcriptionally Regulates VEGF via miR-101 and Subsequently Regulates Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 859331.	2.2	3
4415	Neoplasms and tumor-like conditions of the liver. , 0, , 2110-2145.		0
4447	Screening for Hepatocellular Carcinoma in Viral Liver Disease: Is Ultrasound Enough?. , 0, , 9-12.		0
4448	Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2021, 53, 1166-1182.	1.9	6
4449	Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histology and Histopathology, 2009, 24, 493-502.	0.5	6
4450	Nuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinoma. Histology and Histopathology, 2010, 25, 1269-75.	0.5	19
4451	Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Medica Okayama, 2009, 63, 299-304.	0.1	14
4460	Vitamin intake and risk of liver cancer: potential for prevention?. Chinese Clinical Oncology, 2012, 1, 7.	0.4	0
4463	Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases.. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, S10-S23.	0.6	0
4464	Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4/NF-Î°B/STAT3 signaling pathway.. American Journal of Translational Research (discontinued), 2022, 14, 1551-1566.	0.0	1
4465	DNA Methylation in Noncancerous Liver Tissues as Biomarker for Multicentric Occurrence of Hepatitis C Virusâ€“Related Hepatocellular Carcinoma. , 2022, 1, 555-562.		0
4466	Recent perspectives on therapeutic significance of microRNAs in hepatocellular carcinoma. , 2022, , 377-400.		0
4467	Chemotherapy for hepatocellular carcinomaâ€”an updated review. , 2022, , 351-363.		0
4468	Plant therapeutics for hepatocellular carcinoma. , 2022, , 93-108.		0
4469	Resveratrol for hepatocellular carcinoma therapy. , 2022, , 133-139.		0
4470	Exosomes and MicroRNAs in Biomedical Science. Synthesis Lectures on Biomedical Engineering, 2022, 17, 1-175.	0.1	0
4471	The Role of SNHG15 in the Pathogenesis of Hepatocellular Carcinoma. Journal of Personalized Medicine, 2022, 12, 753.	1.1	3

#	Article	IF	Citations
4472	The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. Frontiers in Oncology, 2022, 12, .	1.3	1
4473	Computational Analysis of Single Nucleotide Polymorphisms Associated with MicroRNA Affecting Hepatitis B Infection. MicroRNA (Shariqah, United Arab Emirates), 2022, 11, .	0.6	0
4474	Identification of a new five-gene risk score for risk stratification and prognosis prediction in HCC. Nucleosides, Nucleotides and Nucleic Acids, 2022, , 1-19.	0.4	1
4475	Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	1.1	1
4476	Performance evaluation of the Elecsys <scp>PIVKAâ€Ⅱ</scp> and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open, 2022, 6, 292-300.	0.7	10
4477	Single-Cell Transcriptomics of Liver Cancer: Hype or Insights?. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 513-525.	2.3	6
4478	Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 1079-1086.	0.7	6
4479	Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States. Liver Transplantation, 2022, 28, 1857-1864.	1.3	11
4480	Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-Î³-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related. Cancer Informatics, 2022, 21, 117693512211007.	0.9	5
4481	Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography. World Journal of Hepatology, 2022, 14, 911-922.	0.8	2
4482	Safety and Feasibility of Microwave Ablation for Hepatocellular Carcinomas in the Elderly: A Systematic Review. Frontiers in Oncology, 2022, 12, .	1.3	2
4483	An exploratory clinical trial of apatinib combined with intensityâ€modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Medicine, 0, , .	1.3	5
4484	Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA. World Journal of Hepatology, 2022, 14, 866-884.	0.8	4
4485	RAB42 is a Potential Biomarker that Correlates With Immune Infiltration in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	2
4486	Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses. Gastroenterology, 2022, 163, 671-684.	0.6	21
4487	No significant relationship exists between tumor size and prognosis in distant metastatic hepatocellular carcinoma: a propensity score matching analysis based on SEER database. BMC Gastroenterology, 2022, 22, .	0.8	3
4488	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma, 0, Volume 9, 477-496.	1.8	13
4489	Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study. Journal of Pediatric Gastroenterology and Nutrition, 2022, 75, e2-e7.	0.9	3

#	Article	IF	Citations
4492	MicroRNAs in Cancer. Synthesis Lectures on Biomedical Engineering, 2022, , 11-40.	0.1	2
4493	Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA. Cells, 2022, 11, 1930.	1.8	17
4494	The Critical Role of Ferroptosis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	10
4495	In-depth Profiling and Quantification of the Lysine Acetylome in Hepatocellular Carcinoma with a Trapped Ion Mobility Mass Spectrometer. Molecular and Cellular Proteomics, 2022, 21, 100255.	2.5	7
4496	Outcomes of adolescent and young patients with hepatocellular carcinoma after curative liver resection: a retrospective study. World Journal of Surgical Oncology, 2022, 20, .	0.8	6
4497	Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF-Î², IL-1, and IL-6). Hormone Molecular Biology and Clinical Investigation, 2022, 43, 389-396.	0.3	0
4498	4-Hydroxycoumarin Effects on Both Cellular and Genetic Characteristics of Hepatocellular Carcinoma Cells. Cytology and Genetics, 2022, 56, 292-300.	0.2	0
4499	Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer, 2023, 54, 325-331.	0.6	2
4500	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World Journal of Clinical Oncology, 2022, 13, 448-472.	0.9	6
4501	Management of ruptured hepatocellular carcinoma invading the gastrointestinal tract: A case report. International Journal of Surgery Case Reports, 2022, , 107330.	0.2	0
4502	N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth. Redox Biology, 2022, 54, 102366.	3.9	18
4503	Hepatocellular Carcinoma Presenting Simultaneously with Echinococcal Cyst Mimicking a Single Liver Lesion in a Non-Cirrhotic Patient: A Case Report and Review of the Literature. Diagnostics, 2022, 12, 1583.	1.3	1
4504	Prognostic Value of Stem Cell Index-Related Characteristics in Primary Hepatocellular Carcinoma. Contrast Media and Molecular Imaging, 2022, 2022, 1-11.	0.4	3
4505	Potential of Apolipoprotein A1 (ApoA1) for Detecting Liver Cirrhosis and Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2001-2008.	0.5	6
4506	Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
4507	Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	6
4508	Identifying potential prognosis markers in hepatocellular carcinoma via integrated bioinformatics analysis and biological experiments. Frontiers in Genetics, 0, 13, .	1.1	4
4509	Revisiting Epithelial Carcinogenesis. International Journal of Molecular Sciences, 2022, 23, 7437.	1.8	6

#	Article	IF	Citations
4510	Screening of Prognostic Markers for Hepatocellular Carcinoma Patients Based on Multichip Combined Analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-12.	0.7	0
4511	A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
4512	INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma. Bioscience Reports, 2022, 42, .	1.1	2
4513	Implementation of a Hepatocellular Carcinoma Screening Program for At-risk Patients Safety-Net Hospital: A Model for National Dissemination. Annals of Surgery, 2022, 276, 545-553.	2.1	3
4514	Cross-regulation between microRNAs and key proteins of signaling pathways in hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2022, 16, 753-765.	1.4	0
4515	Identification of MiRNAâ€“Disease Associations Based on Information of Multi-Module and Meta-Path. Molecules, 2022, 27, 4443.	1.7	1
4516	Validation of New York/California Score in the Preoperative Period of Liver Transplant for Hepatocellular Carcinoma at University of Campinas's Hospital. Transplantation Proceedings, 2022, 54, 1300-1303.	0.3	0
4517	Hepatitis B Virus Surface Antigen Promotes Stemness of Hepatocellular Carcinoma through Regulating MicroRNA-203a. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	1
4518	Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. Frontiers in Oncology, 0, 12, .	1.3	5
4519	Identification of a Two-lncRNA Signature with Prognostic and Diagnostic Value for Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-19.	0.6	0
4520	Fangchinoline abrogates growth and survival of hepatocellular carcinoma by negative regulation of câ€‘met/HGF and its associated downstream signaling pathways. Phytotherapy Research, 2022, 36, 4542-4557.	2.8	5
4521	The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma. Annals of Translational Medicine, 2022, 10, 766-766.	0.7	4
4522	Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers. Journal of Clinical Medicine, 2022, 11, 4183.	1.0	2
4523	Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5â€‰cm. Journal of International Medical Research, 2022, 50, 030006052211112.	0.4	4
4524	Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma. Science Advances, 2022, 8, .	4.7	18
4525	Comprehensive analysis of full-length transcripts reveals novel splicing abnormalities and oncogenic transcripts in liver cancer. PLoS Genetics, 2022, 18, e1010342.	1.5	12
4526	Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors. Journal of Immunology Research, 2022, 2022, 1-9.	0.9	9
4527	Risk Factors for Cancer Mortality in Spain: Population-Based Cohort Study. International Journal of Environmental Research and Public Health, 2022, 19, 9852.	1.2	0

#	Article	IF	Citations
4528	Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinomaâ€"A Single-Center Study. International Journal of Molecular Sciences, 2022, 23, 9430.	1.8	5
4529	The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2023, 22, 54-63.	0.6	12
4531	During HCV DAA Therapy Plasma Mip1B, IP10, and miRNA Profile Are Distinctly Associated with Subsequent Diagnosis of Hepatocellular Carcinoma: A Pilot Study. Biology, 2022, 11, 1262.	1.3	0
4532	Gender differences in esophageal variceal bleeding in the United States. Annals of Medicine, 2022, 54, 2115-2122.	1.5	4
4533	Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 3917-3933.	1.4	6
4534	Prognostic impact of vessels encapsulating tumor clusters and macrotrabecular patterns in hepatocellular carcinoma. Pathology Research and Practice, 2022, 238, 154084.	1.0	3
4535	Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials. Bioengineering, 2022, 9, 406.	1.6	2
4536	A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-19.	0.7	4
4537	Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms. Biomolecules, 2022, 12, 1173.	1.8	14
4538	Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies. International Journal of Surgery, 2022, 105, 106821.	1.1	12
4539	Construction and application of liver cancer models in vitro. Engineered Regeneration, 2022, 3, 310-322.	3.0	3
4540	Micro-Players of Great Significanceâ€"Host microRNA Signature in Viral Infections in Humans and Animals. International Journal of Molecular Sciences, 2022, 23, 10536.	1.8	7
4541	Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study. Journal of Liver Cancer, 2022, 22, 136-145.	0.3	5
4542	Trends in hepatocellular carcinoma in Louisiana, 2005â€"2015. , 2022, 1, 100041.		0
4543	Long non-coding RNA HOXB-AS1 is a prognostic marker and promotes hepatocellular carcinoma cellsâ€™ proliferation and invasion. Open Life Sciences, 2022, 17, 944-951.	0.6	2
4544	Polypharmacology in Clinical Applicationsâ€"Anticancer Polypharmacology. , 2022, , 73-132.		0
4545	Metabolic Syndrome and Liver Cancer. , 2022, , 87-104.		0
4546	Reducing the Risk of and Screening for Liver Cancer. , 2022, , 105-123.		0

#	Article	IF	Citations
4547	Numerical modeling in support of locoregional drug delivery during transarterial therapies for liver cancer. , 2022, , 259-286.		0
4548	CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2
4549	A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area. Journal of Gastrointestinal Surgery, 2022, 26, 2082-2092.	0.9	1
4550	Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease. International Journal of Molecular Sciences, 2022, 23, 8749.	1.8	13
4551	Spliceâ€switch oligonucleotideâ€based combinatorial platform prioritizes synthetic lethal targets <scp>CHK1</scp> and <scp>BRD4</scp> against <scp>MYC</scp>â€driven hepatocellular carcinoma. Bioengineering and Translational Medicine, 2023, 8, .	3.9	4
4552	Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival. Frontiers in Oncology, 0, 12, .	1.3	1
4553	Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?. Nutrients, 2022, 14, 3875.	1.7	3
4554	Association between serum midkine levels and tumor size in Indonesian hepatocellular carcinoma patients: a cross-sectional study. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2022, .	0.3	1
4555	Risk prediction model for early postoperative death in patients with hepatocellular carcinoma: a retrospective study based on random forest algorithm and logistic regression. European Journal of Gastroenterology and Hepatology, 0, Publish Ahead of Print, .	0.8	1
4556	Dietary Manganese Intake and Risk of Liver Cancer in Japanese Men and Women: The JACC Study. Nutrition and Cancer, 2023, 75, 154-163.	0.9	1
4557	Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential. Journal of Medicinal Chemistry, 2022, 65, 12546-12561.	2.9	7
4558	Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma. Cancers, 2022, 14, 4512.	1.7	3
4559	Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. Cancers, 2022, 14, 4387.	1.7	5
4560	Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patientsâ€"A Retrospective Observational Study. Cancers, 2022, 14, 4422.	1.7	4
4562	HCV and tumor-initiating stem-like cells. Frontiers in Physiology, 0, 13, .	1.3	1
4563	Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	9
4565	Enhancement of molecular characterization for antitumor activity on HepG2 cell lines by using some nano-polyphenolic compounds with gamma radiation. Journal of Radiation Research and Applied Sciences, 2022, 15, 100462.	0.7	0
4566	Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World Journal of Hepatology, 0, 14, 1862-1874.	0.8	5

#	Article	IF	Citations
4567	Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience. Diagnostics, 2022, 12, 2517.	1.3	5
4568	LncRNA TCTN2 promotes malignant development of hepatocellular carcinoma via regulating miR-1285-3p/ARF6 Axis. Recent Patents on Anti-Cancer Drug Discovery, 2022, 18, .	0.8	0
4569	HLGNN-MDA: Heuristic Learning Based on Graph Neural Networks for miRNAâ€“Disease Association Prediction. International Journal of Molecular Sciences, 2022, 23, 13155.	1.8	3
4571	Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future. Current Oncology, 2022, 29, 7537-7551.	0.9	5
4572	Aging of Liver in Its Different Diseases. International Journal of Molecular Sciences, 2022, 23, 13085.	1.8	13
4573	Thymosin Î²4, a potential marker of malignancy and prognosis in hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 0, , 1-12.	0.6	0
4574	Diagnostic performance of circulating tumor DNA as a minimally invasive biomarker for hepatocellular carcinoma: a systematic review and meta-analysis. PeerJ, 0, 10, e14303.	0.9	2
4575	Multiple <scp>Arterialâ€Phase MRI</scp> With Gadoxetic Acid Improves Diagnosis of Hepatocellular Carcinoma â‰¤â€‰3.0 cm. Liver International, 0, , .	1.9	1
4576	FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma. Livers, 2022, 2, 361-371.	0.8	1
4577	Multi-input dense convolutional network for classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Biomedical Signal Processing and Control, 2023, 80, 104226.	3.5	3
4578	Regularized Ultrasound Phantom-Free Local Attenuation Coefficient Slope (ACS) Imaging in Homogeneous and Heterogeneous Tissues. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2022, 69, 3338-3352.	1.7	4
4579	Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. Anticancer Research, 2022, 42, 5479-5486.	0.5	2
4580	Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection. Acta Chirurgica Belgica, 0, , 1-7.	0.2	0
4581	Molecular diversity of hepatitis B virus among pregnant women in Amhara National Regional State, Ethiopia. PLoS ONE, 2022, 17, e0276687.	1.1	0
4582	iPLA2Î²-Null Mice Show HCC Protection by an Induction of Cell-Cycle Arrest after Diethylnitrosamine Treatment. International Journal of Molecular Sciences, 2022, 23, 13760.	1.8	2
4583	Comorbidities and Outcomes among Females with Non-Alcoholic Fatty Liver Disease Compared to Males. Biomedicines, 2022, 10, 2908.	1.4	6
4586	Preoperative Prognostic Nutritional Index (PNI) and Retinol Binding Protein (RBP) in the Research Progress of HCC. Advances in Clinical Medicine, 2022, 12, 11019-11022.	0.0	0
4587	Characterization, selenylation, and antineoplastic effects on HepG2 cells in vitro and in vivo of an arabinofuranan from the fruits of Akebia quinata. Arabian Journal of Chemistry, 2023, 16, 104448.	2.3	1

#	Article	IF	Citations
4588	Sex steroid axes in determining male predominance in hepatocellular carcinoma. Cancer Letters, 2023, 555, 216037.	3.2	5
4589	Artificial Intelligence and Precision Medicine for Hepatocellular Carcinoma Therapy. Critical Reviews in Immunology, 2022, , .	1.0	1
4590	HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses, 2022, 14, 2671.	1.5	2
4591	Efficacy evaluation and prognostic risk factors analysis of precise hepatectomy in the treatment of intermediate and advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2023, 35, 120-126.	0.8	2
4592	Targeted xCTâ€mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Antiâ€PDâ€1/L1 Response. Advanced Science, 2023, 10, .	5.6	43
4593	LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance. Genes and Diseases, 2023, 10, 2082-2096.	1.5	15
4594	The effect of SNPs in lncRNA as ceRNA on the risk and prognosis of hepatocellular carcinoma. BMC Genomics, 2022, 23, .	1.2	1
4595	Screening of Hub Genes in Hepatocellular Carcinoma Based on Network Analysis and Machine Learning. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-32.	0.7	0
4596	A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC. Journal of Inflammation Research, 0, Volume 15, 6729-6743.	1.6	6
4597	TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure. Frontiers in Pharmacology, 0, 13, .	1.6	1
4598	Hypomethylation of Thyroid Peroxidase as a Biomarker for Hepatocellular Carcinoma with Tumor Thrombosis. Current Medical Science, 0, , .	0.7	0
4599	Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology. Medicina (Lithuania), 2022, 58, 1803.	0.8	0
4600	Nanomedicineâ€boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma. Military Medical Research, 2022, 9, .	1.9	7
4601	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines, 2022, 10, 3202.	1.4	26
4602	Augmenter of Liver Regeneration Monoclonal Antibody Promotes Apoptosis of Hepatocellular Carcinoma Cells. Journal of Clinical and Translational Hepatology, 2023, 000, 000-000.	0.7	1
4603	Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice. Proteomes, 2023, 11, 2.	1.7	3
4604	A multiplexed microflow LCâ€“MS/MS-PRM assay for serologic quantification of IgG N- and HPX O-glycoforms in liver fibrosis. Scientific Reports, 2023, 13, .	1.6	0
4605	P-21 Activated Kinases in Liver Disorders. Cancers, 2023, 15, 551.	1.7	2

#	Article	IF	Citations
4606	Ciclopirox Olamine Induces Proliferation Inhibition and Protective Autophagy in Hepatocellular Carcinoma. Pharmaceuticals, 2023, 16, 113.	1.7	4
4607	Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination. Cancer Cell International, 2023, 23, .	1.8	2
4608	Molecular mechanism of the miR-7/BCL2L1/P53 signaling axis regulating the progression of hepatocellular carcinoma. Annals of Translational Medicine, 2023, 11, 12-12.	0.7	3
4609	The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6035-6048.	1.2	2
4610	Microbiota and hepatitis C virus in the era of direct-acting antiviral agents. Microbial Pathogenesis, 2023, 175, 105968.	1.3	1
4611	Efficacy and safety of single- and multiple-antenna microwave ablation for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and network meta-analysis. Medicine (United States), 2022, 101, e32304.	0.4	3
4612	Clinicopathological Features and Survival of Patients with Hepatocellular Carcinoma in Ethiopia: A Multicenter Study. Cancers, 2023, 15, 193.	1.7	1
4613	Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR. Journal of Gastroenterology, 0, , .	2.3	1
4614	Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress. Oncology Research, 2022, 30, 201-210.	0.6	4
4615	Long Noncoding RNA Cytoskeleton Regulator RNA Suppresses Apoptosis in Hepatoma Cells by Modulating the miR-125a-5p/HS1-Associated Protein X-1 Axis to Induce Caspase-9 Inactivation. Gut and Liver, 2023, , .	1.4	1
4616	Exosomal miRNA in early-stage hepatocellular carcinoma. World Journal of Clinical Cases, 0, 11, 528-533.	0.3	1
4617	Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review). Oncology Reports, 2023, 49, .	1.2	5
4618	Hypo-osmolarity induces apoptosis resistance via TRPV2-mediated AKT-Bcl-2 pathway. American Journal of Physiology - Renal Physiology, 0, , .	1.6	0
4619	Hepatitis C: epidemiology, natural history, and diagnosis. , 2023, , 229-250.		0
4620	The combination of hand grip strength and modified Glasgow prognostic score predicts clinical outcomes in patients with liver cancer. Frontiers in Nutrition, 0, 10, .	1.6	1
4622	mlf-core: a framework for deterministic machine learning. Bioinformatics, 2023, 39, .	1.8	0
4623	A lipid metabolismâ€“based prognostic risk model for HBVâ€“related hepatocellular carcinoma. Lipids in Health and Disease, 2023, 22, .	1.2	1
4624	Multifaceted role of NF-ÎºB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches. Environmental Research, 2023, 228, 115767.	3.7	4

#	Article	IF	Citations
4625	Burden of liver cancer: From epidemiology to prevention. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 554-566.	0.7	16
4626	Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters, 2023, 556, 216063.	3.2	2
4627	Evaluation of transcriptomic molecular classification, biological behavior, and clinicopathological features in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2023, 23, 71-84.	1.5	0
4628	Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma. Cancers, 2023, 15, 931.	1.7	3
4629	Transcriptome analysis creates a new era of precision medicine for managing recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 780-799.	1.4	1
4630	Single-Cell Analysis of Primary Liver Cancer in Mouse Models. Cells, 2023, 12, 477.	1.8	0
4631	Pediatric combined hepatocellular-cholangiocarcinoma (cHCC-CC) with neuroendocrine features: distinguishing genetic alterations detected by chromosomal microarray. Diagnostic Pathology, 2023, 18, .	0.9	0
4632	ExposiciÃ³n a aflatoxina: un problema de salud pÃºblica. Iatreia, 2013, 27, .	0.1	0
4633	Deciphering the underlying mechanism of liver diseases through utilization of multicellular hepatic spheroid models. BMB Reports, 2023, 56, 225-233.	1.1	1
4634	Antiangiogenic drugs in combination with seaweed fucoidan: A mechanistic in vitro and in vivo study exploring the VEGF receptor and its downstream signaling molecules in hepatic cancer. Frontiers in Pharmacology, 0, 14, .	1.6	5
4635	Current Trends In Development Of Egfr Inhibitors As A Promising Anticancer Agents: Sar And Synthetic Studies From (2010-2020). Current Organic Chemistry, 2023, 27, .	0.9	0
4636	Comparison of anti-tumor activities and underlying mechanisms of glucuronomannan oligosaccharides and its sulfated derivatives on the hepatocarcinoma Huh7.5 cells. Biochemical and Biophysical Research Communications, 2023, 652, 103-111.	1.0	1
4637	Decreased DIO3OS Expression Predicts Poor Prognosis in Hepatocellular Carcinoma and is Associated with Immune Infiltration. Biochemical Genetics, 2023, 61, 1791-1806.	0.8	1
4638	Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C. BMC Cancer, 2023, 23, .	1.1	6
4639	Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation. Journal of Clinical and Experimental Hepatology, 2023, 13, 804-812.	0.4	0
4640	Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database. Journal of Gastrointestinal Oncology, 2023, 14, 312-324.	0.6	2
4641	CCBE1 promotes mitochondrial fusion by inhibiting the TGFÎ²-DRP1 axis to prevent the progression of hepatocellular carcinoma. Matrix Biology, 2023, 117, 31-45.	1.5	3
4642	A decade of liver organoids: Advances in disease modeling. Clinical and Molecular Hepatology, 2023, 29, 643-669.	4.5	1

#	Article	IF	Citations
4643	Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma. Micromachines, 2023, 14, 613.	1.4	0
4644	The role of viruses in cancer development versus cancer therapy: An oncological perspective. Cancer Medicine, 2023, 12, 11127-11148.	1.3	4
4645	Role of wnt ligand secretion mediator signaling in cancer development. Journal of Cancer Research and Practice, 2023, 10, 1.	0.2	0
4646	Innate-like T lymphocytes in chronic liver disease. Frontiers in Immunology, 0, 14, .	2.2	2
4647	BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelialâ€mesenchymal transition and hepatic stellate cells. Molecular Carcinogenesis, 2023, 62, 731-742.	1.3	2
4648	Dietary inflammatory and insulinemic potential, risk of hepatocellular carcinoma, and chronic liver disease mortality. JNCI Cancer Spectrum, 2023, 7, .	1.4	1
4649	<scp>RHBDF2</scp> is correlated with immune infiltrates in hepatocellular carcinoma and may have potential as a biomarker. FEBS Open Bio, 2023, 13, 881-897.	1.0	0
4650	High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16, 63-81.	2.3	1
4652	Role of palliative SBRT in barcelona clinic liver cancer-stageÂC hepatocellular carcinoma patients. Strahlentherapie Und Onkologie, 2023, 199, 838-846.	1.0	4
4653	Soluble CD137 and risk of hepatocellular carcinoma: nested caseâ€“control studies in cohorts in Shanghai and Singapore. British Journal of Cancer, 2023, 128, 2081-2088.	2.9	1
4654	HepatosellÃ¼ler karsinomda miR-4746'nÄ±n klinik Ã¶nemi, kestirim deÄŸeri ve ifadesi iÃ§in veri tabanÄ± madenciliÄŸi. Sakarya Medical Journal, 0, , .	0.1	0
4655	Tumours and Tumour-Like Lesions. , 2024, , 842-946.		1
4656	Bench-to-bedside development of multifunctional flexible embolic agents. Theranostics, 2023, 13, 2114-2139.	4.6	0
4657	Acoustic radiation force impulse predicts long-term outcomes in a large-scale cohort: High liver cancer, low comorbidity in hepatitis B virus. World Journal of Gastroenterology, 0, 29, 2188-2201.	1.4	0
4658	The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma. Environmental Research, 2023, 228, 115914.	3.7	5
4659	Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study. Hepatology International, 2023, 17, 1251-1264.	1.9	2
4660	OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma. Hepatology International, 0, , .	1.9	1
4661	Ephrin-A4 Ligand (EFNA4) Predicts Poor Prognosis of Hepatocellular Carcinoma and Promotes Tumor Proliferation. Journal of Clinical and Experimental Hepatology, 2023, 13, 767-773.	0.4	0

#	Article	IF	Citations
4662	Deep learning techniques for hepatocellular carcinoma diagnosis. , 2023, , 317-336.		0
4663	Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective. Nutrients, 2023, 15, 1992.	1.7	3
4686	Interventions to Improve Surveillance for Hepatocellular Carcinoma in High-Risk Patients: A Scoping Review. Journal of Gastrointestinal Cancer, 0, , .	0.6	3
4708	Advanced therapeutics avenues in hepatocellular carcinoma: a novel paradigm. , 2023, 40, .		1
4713	Hepatocellular carcinoma surveillance â€" utilization, barriers and the impact of changing aetiology. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 797-809.	8.2	12
4724	Molecular Mechanisms of Environmental Oncogenesis. , 2023, , 3-60.		0
4733	Involvement of CCCTC-binding factor in epigenetic regulation of cancer. Molecular Biology Reports, 2023, 50, 10383-10398.	1.0	1
4742	Metabolomics of Gastrointestinal Cancers. , 2023, , .		0
4752	Automatic recognition of tumor region in multiphoton images of hepatocellular carcinoma using a convolutional neural network. , 2023, , .		0
4756	Mitochondria and Alcohol. , 2023, , 1043-1073.		0
4787	FGFR and inhibitors. , 2024, , 787-908.		0
4799	Multifunctional nanocrystals for liver cancer. , 2024, , 213-232.		2